cancer_type qtl_type tag_SNP LD SNP_id gene_id gene_symbol t-stat p-value FDR beta r Traits SNP_position Gene_position MESO cis rs858239 0.6 rs13438188 ENSG00000230658.1 KLHL7-AS1 -12.81 2.74e-18 4.39e-11 -1.23 -0.86 Cerebrospinal fluid biomarker levels; chr7:23104578 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs7805206 ENSG00000230658.1 KLHL7-AS1 12.46 8.88e-18 4.39e-11 1.23 0.86 Cerebrospinal fluid biomarker levels; chr7:23120591 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7787110 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23098855 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs6461691 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23099726 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs28646184 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23099976 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs6461692 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23100076 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs10235786 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23100321 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7785842 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23102087 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs4628176 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23102947 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7456915 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23103430 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs10233039 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23103494 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs13438179 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23104232 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs10488077 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23104563 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs10241208 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23105295 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs10256524 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23105328 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs2072368 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23106493 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs2072369 ENSG00000230658.1 KLHL7-AS1 12.08 3.1e-17 4.39e-11 1.24 0.85 Cerebrospinal fluid biomarker levels; chr7:23106570 chr7:23101228~23105703:- MESO cis rs858239 0.57 rs10271613 ENSG00000230658.1 KLHL7-AS1 12.02 3.86e-17 4.39e-11 1.19 0.85 Cerebrospinal fluid biomarker levels; chr7:23122967 chr7:23101228~23105703:- MESO cis rs858239 0.57 rs10242166 ENSG00000230658.1 KLHL7-AS1 12.02 3.86e-17 4.39e-11 1.19 0.85 Cerebrospinal fluid biomarker levels; chr7:23123180 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs11982002 ENSG00000230658.1 KLHL7-AS1 12.02 3.86e-17 4.39e-11 1.19 0.85 Cerebrospinal fluid biomarker levels; chr7:23123651 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs15775 ENSG00000230658.1 KLHL7-AS1 12.02 3.86e-17 4.39e-11 1.19 0.85 Cerebrospinal fluid biomarker levels; chr7:23125082 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs929507 ENSG00000230658.1 KLHL7-AS1 12.02 3.86e-17 4.39e-11 1.19 0.85 Cerebrospinal fluid biomarker levels; chr7:23127045 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs929508 ENSG00000230658.1 KLHL7-AS1 12.02 3.86e-17 4.39e-11 1.19 0.85 Cerebrospinal fluid biomarker levels; chr7:23127090 chr7:23101228~23105703:- MESO cis rs858239 0.57 rs6968242 ENSG00000230658.1 KLHL7-AS1 12.02 3.86e-17 4.39e-11 1.19 0.85 Cerebrospinal fluid biomarker levels; chr7:23127792 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs1981665 ENSG00000230658.1 KLHL7-AS1 12.02 3.86e-17 4.39e-11 1.19 0.85 Cerebrospinal fluid biomarker levels; chr7:23128350 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs3735228 ENSG00000230658.1 KLHL7-AS1 12.02 3.86e-17 4.39e-11 1.19 0.85 Cerebrospinal fluid biomarker levels; chr7:23130808 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs1468592 ENSG00000230658.1 KLHL7-AS1 -11.98 4.39e-17 4.84e-11 -1.26 -0.85 Cerebrospinal fluid biomarker levels; chr7:23101028 chr7:23101228~23105703:- MESO cis rs858239 0.511 rs10256996 ENSG00000230658.1 KLHL7-AS1 -11.53 2.03e-16 1.34e-10 -1.12 -0.84 Cerebrospinal fluid biomarker levels; chr7:23105676 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs6971002 ENSG00000230658.1 KLHL7-AS1 11.46 2.63e-16 1.38e-10 1.27 0.84 Cerebrospinal fluid biomarker levels; chr7:23132685 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs987257 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23108221 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs1034963 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23108854 chr7:23101228~23105703:- MESO cis rs858239 0.57 rs10235467 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23109189 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs6980224 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23109518 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs10239760 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23110331 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs12539331 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23111711 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs73272048 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23113034 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs11984129 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23113058 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs764533 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23114256 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs764534 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23114316 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs2068459 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23114694 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs73272053 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23115906 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs1558313 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23116460 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs6962526 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23118614 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs10255228 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23119244 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs6971673 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23119904 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs6969733 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23128758 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs4440529 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23129132 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs4599714 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23129182 chr7:23101228~23105703:- MESO cis rs858239 0.541 rs4624924 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23129224 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs10278776 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23130140 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs4140959 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23131157 chr7:23101228~23105703:- MESO cis rs858239 0.571 rs6953020 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23132513 chr7:23101228~23105703:- MESO cis rs858239 0.632 rs13438452 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23134563 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs6948469 ENSG00000230658.1 KLHL7-AS1 11.39 3.29e-16 1.38e-10 1.23 0.84 Cerebrospinal fluid biomarker levels; chr7:23135147 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs6461693 ENSG00000230658.1 KLHL7-AS1 -11.39 3.29e-16 1.38e-10 -1.23 -0.84 Cerebrospinal fluid biomarker levels; chr7:23120514 chr7:23101228~23105703:- MESO cis rs858239 0.632 rs6952947 ENSG00000230658.1 KLHL7-AS1 -11.29 4.7e-16 1.38e-10 -1.21 -0.83 Cerebrospinal fluid biomarker levels; chr7:23081423 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7341483 ENSG00000230658.1 KLHL7-AS1 -11.29 4.7e-16 1.38e-10 -1.21 -0.83 Cerebrospinal fluid biomarker levels; chr7:23088038 chr7:23101228~23105703:- MESO cis rs858239 0.669 rs12539467 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23076240 chr7:23101228~23105703:- MESO cis rs858239 0.632 rs7811903 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23079437 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7776644 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23079688 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7776649 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23079698 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs2014768 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23082821 chr7:23101228~23105703:- MESO cis rs858239 0.632 rs1985769 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23082887 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs2003555 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23083296 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs10256359 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23084258 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs10256361 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23084266 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs28499396 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23084479 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7784929 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23084658 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7789237 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23085094 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs6978827 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23085925 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs9691762 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23086303 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7790157 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23087379 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs4409314 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23088333 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs4321896 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23088437 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7799422 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23088794 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs6960001 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23091257 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs10237755 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23091945 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs28483572 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23092166 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs61292332 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23092243 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs59073109 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23093607 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs7788821 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23094026 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs6956595 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23094637 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs6961131 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23095171 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs6961406 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23095272 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs6461690 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23095915 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs6967419 ENSG00000230658.1 KLHL7-AS1 11.29 4.7e-16 1.38e-10 1.21 0.83 Cerebrospinal fluid biomarker levels; chr7:23096691 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs10278700 ENSG00000230658.1 KLHL7-AS1 11.11 8.85e-16 2.51e-10 1.23 0.83 Cerebrospinal fluid biomarker levels; chr7:23120910 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs10263110 ENSG00000230658.1 KLHL7-AS1 11.11 8.85e-16 2.51e-10 1.23 0.83 Cerebrospinal fluid biomarker levels; chr7:23120932 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs10224327 ENSG00000230658.1 KLHL7-AS1 11.11 8.85e-16 2.51e-10 1.23 0.83 Cerebrospinal fluid biomarker levels; chr7:23122201 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs10266123 ENSG00000230658.1 KLHL7-AS1 11 1.31e-15 3.67e-10 1.2 0.83 Cerebrospinal fluid biomarker levels; chr7:23096868 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs1115941 ENSG00000230658.1 KLHL7-AS1 11 1.31e-15 3.67e-10 1.2 0.83 Cerebrospinal fluid biomarker levels; chr7:23097569 chr7:23101228~23105703:- MESO cis rs858239 0.6 rs6967475 ENSG00000230658.1 KLHL7-AS1 10.8 2.57e-15 6.87e-10 1.24 0.82 Cerebrospinal fluid biomarker levels; chr7:23089363 chr7:23101228~23105703:- MESO cis rs916888 0.773 rs1378358 ENSG00000262539.1 RP11-259G18.3 10.69 3.8e-15 9.34e-10 1.12 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs538628 ENSG00000262539.1 RP11-259G18.3 10.69 3.8e-15 9.34e-10 1.12 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs169201 ENSG00000262539.1 RP11-259G18.3 10.69 3.8e-15 9.34e-10 1.12 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs199439 ENSG00000262539.1 RP11-259G18.3 10.69 3.8e-15 9.34e-10 1.12 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs199457 ENSG00000262539.1 RP11-259G18.3 10.69 3.8e-15 9.34e-10 1.12 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:46259551~46260606:- MESO cis rs916888 0.687 rs199456 ENSG00000262539.1 RP11-259G18.3 10.69 3.8e-15 9.34e-10 1.12 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs199451 ENSG00000262539.1 RP11-259G18.3 10.69 3.8e-15 9.34e-10 1.12 0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs199513 ENSG00000262539.1 RP11-259G18.3 -10.69 3.8e-15 9.34e-10 -1.12 -0.82 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:46259551~46260606:- MESO cis rs858239 0.601 rs2141307 ENSG00000230658.1 KLHL7-AS1 10.67 4.13e-15 1.01e-09 1.21 0.82 Cerebrospinal fluid biomarker levels; chr7:23151805 chr7:23101228~23105703:- MESO cis rs9326248 0.817 rs1242127 ENSG00000254851.1 RP11-109L13.1 10.57 6e-15 1.45e-09 1.12 0.82 Blood protein levels; chr11:117205848 chr11:117135528~117138582:+ MESO cis rs916888 0.773 rs199535 ENSG00000262539.1 RP11-259G18.3 10.51 7.26e-15 1.74e-09 1.1 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:46259551~46260606:- MESO cis rs4853012 0.941 rs78128123 ENSG00000217702.2 RP11-287D1.4 10.47 8.36e-15 1.94e-09 1.44 0.81 Gestational age at birth (maternal effect); chr2:74120398 chr2:74130583~74135395:+ MESO cis rs916888 0.738 rs199515 ENSG00000262539.1 RP11-259G18.3 -10.4 1.08e-14 2.34e-09 -1.06 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:46259551~46260606:- MESO cis rs916888 0.697 rs199516 ENSG00000262539.1 RP11-259G18.3 -10.32 1.42e-14 2.61e-09 -1.05 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs199514 ENSG00000262539.1 RP11-259G18.3 -10.32 1.42e-14 2.61e-09 -1.05 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs199512 ENSG00000262539.1 RP11-259G18.3 -10.32 1.42e-14 2.61e-09 -1.05 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs199509 ENSG00000262539.1 RP11-259G18.3 -10.32 1.42e-14 2.61e-09 -1.05 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs199507 ENSG00000262539.1 RP11-259G18.3 -10.32 1.42e-14 2.61e-09 -1.05 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs415430 ENSG00000262539.1 RP11-259G18.3 -10.32 1.42e-14 2.61e-09 -1.05 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:46259551~46260606:- MESO cis rs916888 0.779 rs430685 ENSG00000262539.1 RP11-259G18.3 -10.32 1.42e-14 2.61e-09 -1.05 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs199505 ENSG00000262539.1 RP11-259G18.3 -10.32 1.42e-14 2.61e-09 -1.05 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs70602 ENSG00000262539.1 RP11-259G18.3 -10.32 1.42e-14 2.61e-09 -1.05 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs199448 ENSG00000262539.1 RP11-259G18.3 10.32 1.42e-14 2.61e-09 1.05 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs199447 ENSG00000262539.1 RP11-259G18.3 10.32 1.42e-14 2.61e-09 1.05 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs199445 ENSG00000262539.1 RP11-259G18.3 10.32 1.42e-14 2.61e-09 1.05 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs199443 ENSG00000262539.1 RP11-259G18.3 10.32 1.42e-14 2.61e-09 1.05 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs199534 ENSG00000262539.1 RP11-259G18.3 10.32 1.42e-14 2.61e-09 1.05 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs9896243 ENSG00000262539.1 RP11-259G18.3 10.32 1.42e-14 2.61e-09 1.05 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs199533 ENSG00000262539.1 RP11-259G18.3 10.32 1.42e-14 2.61e-09 1.05 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:46259551~46260606:- MESO cis rs916888 0.779 rs199528 ENSG00000262539.1 RP11-259G18.3 10.32 1.42e-14 2.61e-09 1.05 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs199525 ENSG00000262539.1 RP11-259G18.3 10.32 1.42e-14 2.61e-09 1.05 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs70600 ENSG00000262539.1 RP11-259G18.3 10.32 1.42e-14 2.61e-09 1.05 0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:46259551~46260606:- MESO cis rs916888 0.821 rs199504 ENSG00000262539.1 RP11-259G18.3 -10.3 1.58e-14 2.88e-09 -1.05 -0.81 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:46259551~46260606:- MESO cis rs4853012 0.838 rs4429500 ENSG00000217702.2 RP11-287D1.4 10.14 2.78e-14 4.59e-09 1.44 0.8 Gestational age at birth (maternal effect); chr2:74118209 chr2:74130583~74135395:+ MESO cis rs4853012 0.941 rs4852329 ENSG00000217702.2 RP11-287D1.4 10.09 3.36e-14 4.82e-09 1.43 0.8 Gestational age at birth (maternal effect); chr2:74127417 chr2:74130583~74135395:+ MESO cis rs916888 0.821 rs199506 ENSG00000262539.1 RP11-259G18.3 -10 4.51e-14 5.53e-09 -1.06 -0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:46259551~46260606:- MESO cis rs4853012 0.941 rs7571083 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74115133 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs60964317 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74116296 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs72911122 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74116992 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs59570457 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74117155 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs6707729 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74117558 chr2:74130583~74135395:+ MESO cis rs4853012 0.941 rs60291089 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74117763 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs58759652 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74117775 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs4452177 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74118079 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs60705299 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74118243 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs6715351 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74118992 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs61521879 ENSG00000217702.2 RP11-287D1.4 10 4.6e-14 5.53e-09 1.45 0.8 Gestational age at birth (maternal effect); chr2:74119081 chr2:74130583~74135395:+ MESO cis rs4853012 0.775 rs12465641 ENSG00000217702.2 RP11-287D1.4 -9.91 6.41e-14 7.69e-09 -1.45 -0.8 Gestational age at birth (maternal effect); chr2:74110588 chr2:74130583~74135395:+ MESO cis rs916888 0.61 rs199529 ENSG00000262539.1 RP11-259G18.3 9.9 6.65e-14 7.82e-09 1.04 0.8 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:46259551~46260606:- MESO cis rs9326248 1 rs585849 ENSG00000254851.1 RP11-109L13.1 -9.9 6.67e-14 7.82e-09 -1.17 -0.8 Blood protein levels; chr11:117198345 chr11:117135528~117138582:+ MESO cis rs9326248 1 rs664922 ENSG00000254851.1 RP11-109L13.1 -9.9 6.67e-14 7.82e-09 -1.17 -0.8 Blood protein levels; chr11:117200179 chr11:117135528~117138582:+ MESO cis rs9326248 1 rs664082 ENSG00000254851.1 RP11-109L13.1 -9.9 6.67e-14 7.82e-09 -1.17 -0.8 Blood protein levels; chr11:117200354 chr11:117135528~117138582:+ MESO cis rs9326248 0.953 rs488962 ENSG00000254851.1 RP11-109L13.1 9.9 6.67e-14 7.82e-09 1.17 0.8 Blood protein levels; chr11:117201809 chr11:117135528~117138582:+ MESO cis rs2739330 0.892 rs4822455 ENSG00000218537.1 MIF-AS1 9.89 6.72e-14 7.85e-09 0.99 0.8 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23894426~23898930:- MESO cis rs858239 0.665 rs858306 ENSG00000230658.1 KLHL7-AS1 9.86 7.71e-14 8.81e-09 1.21 0.8 Cerebrospinal fluid biomarker levels; chr7:23203135 chr7:23101228~23105703:- MESO cis rs858239 0.633 rs858300 ENSG00000230658.1 KLHL7-AS1 9.86 7.71e-14 8.81e-09 1.21 0.8 Cerebrospinal fluid biomarker levels; chr7:23205012 chr7:23101228~23105703:- MESO cis rs858239 0.698 rs858295 ENSG00000230658.1 KLHL7-AS1 9.86 7.71e-14 8.81e-09 1.21 0.8 Cerebrospinal fluid biomarker levels; chr7:23205950 chr7:23101228~23105703:- MESO cis rs858239 0.73 rs858290 ENSG00000230658.1 KLHL7-AS1 9.86 7.71e-14 8.81e-09 1.21 0.8 Cerebrospinal fluid biomarker levels; chr7:23208417 chr7:23101228~23105703:- MESO cis rs858239 0.73 rs858289 ENSG00000230658.1 KLHL7-AS1 9.86 7.71e-14 8.81e-09 1.21 0.8 Cerebrospinal fluid biomarker levels; chr7:23208539 chr7:23101228~23105703:- MESO cis rs4853012 0.838 rs4563249 ENSG00000217702.2 RP11-287D1.4 9.74 1.18e-13 1.26e-08 1.44 0.79 Gestational age at birth (maternal effect); chr2:74126889 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs12619982 ENSG00000217702.2 RP11-287D1.4 9.74 1.18e-13 1.26e-08 1.44 0.79 Gestational age at birth (maternal effect); chr2:74128895 chr2:74130583~74135395:+ MESO cis rs4853012 0.838 rs72915068 ENSG00000217702.2 RP11-287D1.4 9.74 1.18e-13 1.26e-08 1.44 0.79 Gestational age at birth (maternal effect); chr2:74129058 chr2:74130583~74135395:+ MESO cis rs9326248 0.953 rs634960 ENSG00000254851.1 RP11-109L13.1 9.73 1.22e-13 1.3e-08 1.15 0.79 Blood protein levels; chr11:117202247 chr11:117135528~117138582:+ MESO cis rs4853012 0.887 rs7570950 ENSG00000217702.2 RP11-287D1.4 9.71 1.29e-13 1.38e-08 1.49 0.79 Gestational age at birth (maternal effect); chr2:74111815 chr2:74130583~74135395:+ MESO cis rs9326248 1 rs4938354 ENSG00000254851.1 RP11-109L13.1 -9.7 1.36e-13 1.44e-08 -1.22 -0.79 Blood protein levels; chr11:117180449 chr11:117135528~117138582:+ MESO cis rs4853012 0.887 rs77148265 ENSG00000217702.2 RP11-287D1.4 9.65 1.62e-13 1.67e-08 1.46 0.79 Gestational age at birth (maternal effect); chr2:74112392 chr2:74130583~74135395:+ MESO cis rs4853012 0.887 rs6737314 ENSG00000217702.2 RP11-287D1.4 9.65 1.62e-13 1.67e-08 1.46 0.79 Gestational age at birth (maternal effect); chr2:74112459 chr2:74130583~74135395:+ MESO cis rs4853012 0.941 rs2421752 ENSG00000217702.2 RP11-287D1.4 9.65 1.62e-13 1.67e-08 1.46 0.79 Gestational age at birth (maternal effect); chr2:74114488 chr2:74130583~74135395:+ MESO cis rs9326248 0.906 rs171052 ENSG00000254851.1 RP11-109L13.1 9.58 2.11e-13 2.16e-08 1.14 0.79 Blood protein levels; chr11:117211047 chr11:117135528~117138582:+ MESO cis rs858239 0.73 rs858279 ENSG00000230658.1 KLHL7-AS1 9.56 2.24e-13 2.28e-08 1.19 0.79 Cerebrospinal fluid biomarker levels; chr7:23211386 chr7:23101228~23105703:- MESO cis rs4853012 0.793 rs6707619 ENSG00000217702.2 RP11-287D1.4 9.55 2.33e-13 2.36e-08 1.44 0.79 Gestational age at birth (maternal effect); chr2:74117529 chr2:74130583~74135395:+ MESO cis rs2882667 0.69 rs288033 ENSG00000253404.1 AC034243.1 9.53 2.54e-13 2.57e-08 1.06 0.79 Age-related hearing impairment (SNP x SNP interaction); chr5:138878405 chr5:138744434~138753309:- MESO cis rs858239 0.602 rs6953996 ENSG00000230658.1 KLHL7-AS1 9.51 2.69e-13 2.71e-08 1.16 0.79 Cerebrospinal fluid biomarker levels; chr7:23136327 chr7:23101228~23105703:- MESO cis rs1799949 0.965 rs6503726 ENSG00000198496.9 NBR2 -9.43 3.62e-13 3.61e-08 -0.97 -0.78 Menopause (age at onset); chr17:43132725 chr17:43125610~43153671:+ MESO cis rs916888 0.602 rs199508 ENSG00000262539.1 RP11-259G18.3 -9.42 3.79e-13 3.74e-08 -1 -0.78 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781472 chr17:46259551~46260606:- MESO cis rs9326248 0.911 rs11216284 ENSG00000254851.1 RP11-109L13.1 -9.4 4.11e-13 3.98e-08 -1.13 -0.78 Blood protein levels; chr11:117132344 chr11:117135528~117138582:+ MESO cis rs9326248 1 rs9326248 ENSG00000254851.1 RP11-109L13.1 -9.37 4.51e-13 4.32e-08 -1.1 -0.78 Blood protein levels; chr11:117128509 chr11:117135528~117138582:+ MESO cis rs4853012 0.752 rs13413795 ENSG00000217702.2 RP11-287D1.4 9.35 4.93e-13 4.71e-08 1.41 0.78 Gestational age at birth (maternal effect); chr2:74122712 chr2:74130583~74135395:+ MESO cis rs1799949 0.896 rs8176086 ENSG00000198496.9 NBR2 -9.34 5.03e-13 4.8e-08 -0.98 -0.78 Menopause (age at onset); chr17:43122761 chr17:43125610~43153671:+ MESO cis rs9326248 0.954 rs10790177 ENSG00000254851.1 RP11-109L13.1 -9.33 5.23e-13 4.96e-08 -1.19 -0.78 Blood protein levels; chr11:117177701 chr11:117135528~117138582:+ MESO cis rs1799949 0.93 rs34210004 ENSG00000198496.9 NBR2 -9.31 5.75e-13 5.36e-08 -0.98 -0.78 Menopause (age at onset); chr17:43218318 chr17:43125610~43153671:+ MESO cis rs858239 0.699 rs955187 ENSG00000230658.1 KLHL7-AS1 -9.29 6.23e-13 5.78e-08 -1.18 -0.78 Cerebrospinal fluid biomarker levels; chr7:23154986 chr7:23101228~23105703:- MESO cis rs858239 0.669 rs10950940 ENSG00000230658.1 KLHL7-AS1 -9.29 6.23e-13 5.78e-08 -1.18 -0.78 Cerebrospinal fluid biomarker levels; chr7:23157197 chr7:23101228~23105703:- MESO cis rs9326248 0.954 rs4938349 ENSG00000254851.1 RP11-109L13.1 -9.26 6.86e-13 6.24e-08 -1.14 -0.78 Blood protein levels; chr11:117151207 chr11:117135528~117138582:+ MESO cis rs2739330 0.892 rs4822455 ENSG00000273295.1 AP000350.5 9.26 6.95e-13 6.24e-08 0.88 0.78 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23901432~23907068:- MESO cis rs2882667 0.69 rs160399 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138727552 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288018 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138856727 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288017 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138857826 chr5:138744434~138753309:- MESO cis rs2882667 0.587 rs288015 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138859528 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288014 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138860104 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288013 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138860128 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288012 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138860584 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs176381 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138861042 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288011 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138864250 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288010 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138864340 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs167009 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138864768 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs495638 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138865253 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288042 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138867345 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288041 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138868322 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288040 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138869205 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288039 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138870511 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288038 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138871844 chr5:138744434~138753309:- MESO cis rs2882667 0.659 rs288037 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138872752 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288036 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138875206 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288035 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138876728 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288032 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138879639 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288031 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138880377 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288030 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138880594 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10515504 ENSG00000253404.1 AC034243.1 -9.24 7.4e-13 6.24e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138887305 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288025 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138887944 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288023 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138888359 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288022 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138888586 chr5:138744434~138753309:- MESO cis rs2882667 0.598 rs288020 ENSG00000253404.1 AC034243.1 9.24 7.4e-13 6.24e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138888609 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs288019 ENSG00000253404.1 AC034243.1 -9.19 8.89e-13 7.32e-08 -1.07 -0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138855704 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs160398 ENSG00000253404.1 AC034243.1 9.19 8.89e-13 7.32e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138727750 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs274119 ENSG00000253404.1 AC034243.1 9.19 8.89e-13 7.32e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138728530 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs274118 ENSG00000253404.1 AC034243.1 9.19 8.89e-13 7.32e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138729198 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs274117 ENSG00000253404.1 AC034243.1 9.19 8.89e-13 7.32e-08 1.07 0.78 Age-related hearing impairment (SNP x SNP interaction); chr5:138729359 chr5:138744434~138753309:- MESO cis rs9326248 1 rs3736120 ENSG00000254851.1 RP11-109L13.1 -9.18 9.15e-13 7.52e-08 -1.17 -0.78 Blood protein levels; chr11:117161409 chr11:117135528~117138582:+ MESO cis rs2882667 0.69 rs160400 ENSG00000253404.1 AC034243.1 -9.15 1.04e-12 7.94e-08 -1.08 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138727330 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs12186373 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138912885 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs13177415 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138914251 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs13181762 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138914417 chr5:138744434~138753309:- MESO cis rs2882667 0.628 rs10076629 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138920272 chr5:138744434~138753309:- MESO cis rs2882667 0.659 rs10056014 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138920329 chr5:138744434~138753309:- MESO cis rs2882667 0.598 rs10078179 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138920410 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10078079 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138920450 chr5:138744434~138753309:- MESO cis rs2882667 0.659 rs11750067 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138920589 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs13174008 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138922220 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs13158360 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138922488 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs2351463 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138923113 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10054682 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138923754 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs11953339 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138923853 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs9327828 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138925859 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10155636 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138926301 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs11749163 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138926981 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10463975 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138927560 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs2016720 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138928369 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs891996 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138932127 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs3763016 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138935043 chr5:138744434~138753309:- MESO cis rs2882667 0.628 rs3749663 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138935498 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs3749664 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138935732 chr5:138744434~138753309:- MESO cis rs2882667 0.658 rs10076442 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138941090 chr5:138744434~138753309:- MESO cis rs2882667 0.728 rs10068766 ENSG00000253404.1 AC034243.1 9.15 1.04e-12 7.94e-08 1.08 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138941095 chr5:138744434~138753309:- MESO cis rs916888 0.773 rs1378358 ENSG00000214401.4 KANSL1-AS1 9.13 1.1e-12 8.22e-08 1.05 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs538628 ENSG00000214401.4 KANSL1-AS1 9.13 1.1e-12 8.22e-08 1.05 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs169201 ENSG00000214401.4 KANSL1-AS1 9.13 1.1e-12 8.22e-08 1.05 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs199439 ENSG00000214401.4 KANSL1-AS1 9.13 1.1e-12 8.22e-08 1.05 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs199457 ENSG00000214401.4 KANSL1-AS1 9.13 1.1e-12 8.22e-08 1.05 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:46193576~46196723:+ MESO cis rs916888 0.687 rs199456 ENSG00000214401.4 KANSL1-AS1 9.13 1.1e-12 8.22e-08 1.05 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs199451 ENSG00000214401.4 KANSL1-AS1 9.13 1.1e-12 8.22e-08 1.05 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:46193576~46196723:+ MESO cis rs916888 0.821 rs199513 ENSG00000214401.4 KANSL1-AS1 -9.13 1.1e-12 8.22e-08 -1.05 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:46193576~46196723:+ MESO cis rs858239 0.665 rs6964665 ENSG00000230658.1 KLHL7-AS1 9.12 1.15e-12 8.53e-08 1.17 0.77 Cerebrospinal fluid biomarker levels; chr7:23171733 chr7:23101228~23105703:- MESO cis rs858239 0.699 rs858260 ENSG00000230658.1 KLHL7-AS1 9.12 1.15e-12 8.53e-08 1.17 0.77 Cerebrospinal fluid biomarker levels; chr7:23173315 chr7:23101228~23105703:- MESO cis rs858239 0.636 rs7808488 ENSG00000230658.1 KLHL7-AS1 9.12 1.15e-12 8.53e-08 1.17 0.77 Cerebrospinal fluid biomarker levels; chr7:23182251 chr7:23101228~23105703:- MESO cis rs858239 0.669 rs1618339 ENSG00000230658.1 KLHL7-AS1 9.12 1.15e-12 8.53e-08 1.17 0.77 Cerebrospinal fluid biomarker levels; chr7:23190155 chr7:23101228~23105703:- MESO cis rs858239 0.699 rs1881200 ENSG00000230658.1 KLHL7-AS1 -9.12 1.15e-12 8.53e-08 -1.17 -0.77 Cerebrospinal fluid biomarker levels; chr7:23162018 chr7:23101228~23105703:- MESO cis rs916888 0.61 rs142167 ENSG00000262539.1 RP11-259G18.3 -9.12 1.16e-12 8.59e-08 -0.92 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46259551~46260606:- MESO cis rs9326248 1 rs10790175 ENSG00000254851.1 RP11-109L13.1 -9.08 1.34e-12 9.83e-08 -1.1 -0.77 Blood protein levels; chr11:117164013 chr11:117135528~117138582:+ MESO cis rs858239 0.932 rs1728313 ENSG00000230658.1 KLHL7-AS1 9.08 1.36e-12 9.95e-08 1.22 0.77 Cerebrospinal fluid biomarker levels; chr7:23231412 chr7:23101228~23105703:- MESO cis rs916888 0.821 rs199506 ENSG00000214401.4 KANSL1-AS1 -9.07 1.38e-12 1e-07 -1.01 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:46193576~46196723:+ MESO cis rs2882667 0.69 rs10038162 ENSG00000253404.1 AC034243.1 -9.05 1.48e-12 1.07e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138901066 chr5:138744434~138753309:- MESO cis rs2882667 0.728 rs10037071 ENSG00000253404.1 AC034243.1 9.04 1.53e-12 1.09e-07 1.04 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138942158 chr5:138744434~138753309:- MESO cis rs2882667 0.728 rs7722413 ENSG00000253404.1 AC034243.1 9.04 1.53e-12 1.09e-07 1.04 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138942562 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs7446631 ENSG00000253404.1 AC034243.1 9.02 1.65e-12 1.15e-07 1.07 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138891376 chr5:138744434~138753309:- MESO cis rs2882667 0.599 rs288008 ENSG00000253404.1 AC034243.1 9.02 1.65e-12 1.15e-07 1.07 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138893632 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288004 ENSG00000253404.1 AC034243.1 9.02 1.65e-12 1.15e-07 1.07 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138895956 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs423469 ENSG00000253404.1 AC034243.1 9.02 1.65e-12 1.15e-07 1.07 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138898427 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs2662543 ENSG00000253404.1 AC034243.1 9.02 1.65e-12 1.15e-07 1.07 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138898441 chr5:138744434~138753309:- MESO cis rs858239 0.896 rs1637193 ENSG00000230658.1 KLHL7-AS1 9 1.79e-12 1.17e-07 1.21 0.77 Cerebrospinal fluid biomarker levels; chr7:23220632 chr7:23101228~23105703:- MESO cis rs858239 0.896 rs1637192 ENSG00000230658.1 KLHL7-AS1 9 1.79e-12 1.17e-07 1.21 0.77 Cerebrospinal fluid biomarker levels; chr7:23220895 chr7:23101228~23105703:- MESO cis rs858239 0.932 rs1637190 ENSG00000230658.1 KLHL7-AS1 9 1.79e-12 1.17e-07 1.21 0.77 Cerebrospinal fluid biomarker levels; chr7:23229446 chr7:23101228~23105703:- MESO cis rs916888 0.697 rs199516 ENSG00000214401.4 KANSL1-AS1 -8.99 1.87e-12 1.17e-07 -0.99 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:46193576~46196723:+ MESO cis rs916888 0.821 rs199514 ENSG00000214401.4 KANSL1-AS1 -8.99 1.87e-12 1.17e-07 -0.99 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:46193576~46196723:+ MESO cis rs916888 0.821 rs199512 ENSG00000214401.4 KANSL1-AS1 -8.99 1.87e-12 1.17e-07 -0.99 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:46193576~46196723:+ MESO cis rs916888 0.821 rs199509 ENSG00000214401.4 KANSL1-AS1 -8.99 1.87e-12 1.17e-07 -0.99 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:46193576~46196723:+ MESO cis rs916888 0.821 rs199507 ENSG00000214401.4 KANSL1-AS1 -8.99 1.87e-12 1.17e-07 -0.99 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:46193576~46196723:+ MESO cis rs916888 0.821 rs415430 ENSG00000214401.4 KANSL1-AS1 -8.99 1.87e-12 1.17e-07 -0.99 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:46193576~46196723:+ MESO cis rs916888 0.779 rs430685 ENSG00000214401.4 KANSL1-AS1 -8.99 1.87e-12 1.17e-07 -0.99 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:46193576~46196723:+ MESO cis rs916888 0.821 rs199505 ENSG00000214401.4 KANSL1-AS1 -8.99 1.87e-12 1.17e-07 -0.99 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:46193576~46196723:+ MESO cis rs916888 0.821 rs70602 ENSG00000214401.4 KANSL1-AS1 -8.99 1.87e-12 1.17e-07 -0.99 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs199448 ENSG00000214401.4 KANSL1-AS1 8.99 1.87e-12 1.17e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs199447 ENSG00000214401.4 KANSL1-AS1 8.99 1.87e-12 1.17e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs199445 ENSG00000214401.4 KANSL1-AS1 8.99 1.87e-12 1.17e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs199443 ENSG00000214401.4 KANSL1-AS1 8.99 1.87e-12 1.17e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs199534 ENSG00000214401.4 KANSL1-AS1 8.99 1.87e-12 1.17e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs9896243 ENSG00000214401.4 KANSL1-AS1 8.99 1.87e-12 1.17e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:46193576~46196723:+ MESO cis rs916888 0.773 rs199533 ENSG00000214401.4 KANSL1-AS1 8.99 1.87e-12 1.17e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:46193576~46196723:+ MESO cis rs916888 0.779 rs199528 ENSG00000214401.4 KANSL1-AS1 8.99 1.87e-12 1.17e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:46193576~46196723:+ MESO cis rs916888 0.821 rs199525 ENSG00000214401.4 KANSL1-AS1 8.99 1.87e-12 1.17e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:46193576~46196723:+ MESO cis rs916888 0.821 rs70600 ENSG00000214401.4 KANSL1-AS1 8.99 1.87e-12 1.17e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:46193576~46196723:+ MESO cis rs858239 0.539 rs6949363 ENSG00000230658.1 KLHL7-AS1 8.96 2.12e-12 1.17e-07 1.11 0.77 Cerebrospinal fluid biomarker levels; chr7:23152775 chr7:23101228~23105703:- MESO cis rs916888 0.61 rs199452 ENSG00000262539.1 RP11-259G18.3 8.94 2.23e-12 1.17e-07 0.97 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:46259551~46260606:- MESO cis rs916888 0.61 rs199530 ENSG00000262539.1 RP11-259G18.3 -8.94 2.23e-12 1.17e-07 -0.97 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:46259551~46260606:- MESO cis rs2882667 0.658 rs311592 ENSG00000253404.1 AC034243.1 8.94 2.28e-12 1.17e-07 1.05 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138734506 chr5:138744434~138753309:- MESO cis rs2882667 0.659 rs311595 ENSG00000253404.1 AC034243.1 8.94 2.28e-12 1.17e-07 1.05 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138736183 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs906695 ENSG00000253404.1 AC034243.1 8.94 2.28e-12 1.17e-07 1.05 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138803588 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10043478 ENSG00000253404.1 AC034243.1 8.94 2.28e-12 1.17e-07 1.05 0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138853022 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs311596 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138736393 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs1095374 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138759517 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs700620 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138762247 chr5:138744434~138753309:- MESO cis rs2882667 0.659 rs700621 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138762741 chr5:138744434~138753309:- MESO cis rs2882667 0.652 rs700622 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138762862 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs700623 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138762993 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs700624 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138763332 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs700625 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138763908 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs7722965 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138764766 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs2940595 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138765348 chr5:138744434~138753309:- MESO cis rs2882667 0.587 rs2174972 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138766229 chr5:138744434~138753309:- MESO cis rs2882667 0.587 rs825674 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138767031 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs851278 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138767577 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825677 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138769081 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs2693963 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138770637 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1976562 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138774905 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1567313 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138775013 chr5:138744434~138753309:- MESO cis rs2882667 0.589 rs825770 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138779530 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825769 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138779666 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs700626 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138782249 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs700627 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138783711 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs700629 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138788305 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825759 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138790250 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825758 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138791288 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825754 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138796200 chr5:138744434~138753309:- MESO cis rs2882667 0.722 rs825751 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138798180 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825749 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138800232 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825748 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138800378 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825746 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138800930 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825762 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138801981 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825761 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138802318 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs825760 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138804285 chr5:138744434~138753309:- MESO cis rs2882667 0.62 rs3789151 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138809771 chr5:138744434~138753309:- MESO cis rs2882667 0.722 rs4835649 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138810534 chr5:138744434~138753309:- MESO cis rs2882667 0.587 rs6596450 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138810831 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs7709770 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138813650 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs12517514 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138814430 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs4835703 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138815048 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs4835704 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138815636 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6596453 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138816202 chr5:138744434~138753309:- MESO cis rs2882667 0.622 rs34645817 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138816944 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs7736925 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138818841 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6873425 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138819556 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs883333 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138819781 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs884470 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138820236 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs884469 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138820270 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6877187 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138823655 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6860780 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138824367 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs3804199 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138826440 chr5:138744434~138753309:- MESO cis rs2882667 0.722 rs2011462 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138827083 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs4835705 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138827887 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6884198 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138828618 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs4835706 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138829037 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6596455 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138831416 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6421921 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138831581 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6596456 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138831808 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs995177 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138833874 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs7710300 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138834793 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1039789 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138835734 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1039788 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138835812 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1828188 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138836307 chr5:138744434~138753309:- MESO cis rs2882667 0.591 rs56322405 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138837693 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs4835707 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138838831 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6887841 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138840221 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs12656942 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138840769 chr5:138744434~138753309:- MESO cis rs2882667 0.686 rs62381196 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138841000 chr5:138744434~138753309:- MESO cis rs2882667 0.72 rs56044552 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138841265 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs7710288 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138844049 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs4835708 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138844204 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1976568 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138844627 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6880786 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138845874 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs9327826 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138846318 chr5:138744434~138753309:- MESO cis rs2882667 0.587 rs1848506 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138846768 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1848505 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138846841 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs2351247 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138849456 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs1972072 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138849604 chr5:138744434~138753309:- MESO cis rs2882667 0.619 rs6861556 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138852351 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs6863054 ENSG00000253404.1 AC034243.1 -8.94 2.28e-12 1.17e-07 -1.05 -0.77 Age-related hearing impairment (SNP x SNP interaction); chr5:138853166 chr5:138744434~138753309:- MESO cis rs916888 0.821 rs199504 ENSG00000214401.4 KANSL1-AS1 -8.94 2.29e-12 1.17e-07 -0.99 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:46193576~46196723:+ MESO cis rs916888 0.779 rs199526 ENSG00000214401.4 KANSL1-AS1 -8.93 2.35e-12 1.2e-07 -0.91 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770341 chr17:46193576~46196723:+ MESO cis rs9326248 1 rs4938344 ENSG00000254851.1 RP11-109L13.1 -8.92 2.43e-12 1.24e-07 -1.12 -0.77 Blood protein levels; chr11:117133033 chr11:117135528~117138582:+ MESO cis rs916888 0.61 rs199529 ENSG00000214401.4 KANSL1-AS1 8.91 2.48e-12 1.26e-07 0.99 0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:46193576~46196723:+ MESO cis rs9326248 0.911 rs474339 ENSG00000254851.1 RP11-109L13.1 -8.91 2.57e-12 1.3e-07 -1.07 -0.77 Blood protein levels; chr11:117188836 chr11:117135528~117138582:+ MESO cis rs858239 0.669 rs1006709 ENSG00000230658.1 KLHL7-AS1 8.9 2.65e-12 1.34e-07 1.14 0.77 Cerebrospinal fluid biomarker levels; chr7:23100480 chr7:23101228~23105703:- MESO cis rs2882667 0.69 rs288026 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138886905 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288024 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138888103 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288021 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138888594 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288009 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138892973 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs185956 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138894574 chr5:138744434~138753309:- MESO cis rs2882667 0.658 rs288003 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138896266 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288002 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138896398 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10044401 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138901868 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10067361 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138905185 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6890932 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138910639 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs6872423 ENSG00000253404.1 AC034243.1 8.88 2.77e-12 1.38e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138911089 chr5:138744434~138753309:- MESO cis rs916888 0.61 rs199436 ENSG00000262539.1 RP11-259G18.3 -8.87 2.88e-12 1.41e-07 -0.93 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:46259551~46260606:- MESO cis rs916888 0.61 rs199454 ENSG00000262539.1 RP11-259G18.3 -8.87 2.88e-12 1.41e-07 -0.93 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:46259551~46260606:- MESO cis rs916888 0.531 rs183211 ENSG00000262539.1 RP11-259G18.3 8.87 2.88e-12 1.41e-07 0.93 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:46259551~46260606:- MESO cis rs916888 0.61 rs199438 ENSG00000262539.1 RP11-259G18.3 8.87 2.88e-12 1.41e-07 0.93 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:46259551~46260606:- MESO cis rs916888 0.61 rs199453 ENSG00000262539.1 RP11-259G18.3 8.87 2.88e-12 1.41e-07 0.93 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:46259551~46260606:- MESO cis rs858239 0.665 rs858305 ENSG00000230658.1 KLHL7-AS1 -8.86 2.99e-12 1.46e-07 -1.19 -0.76 Cerebrospinal fluid biomarker levels; chr7:23203211 chr7:23101228~23105703:- MESO cis rs916888 0.779 rs199526 ENSG00000262539.1 RP11-259G18.3 -8.86 2.99e-12 1.46e-07 -0.92 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770341 chr17:46259551~46260606:- MESO cis rs916888 0.773 rs199535 ENSG00000214401.4 KANSL1-AS1 8.85 3.18e-12 1.55e-07 1.02 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:46193576~46196723:+ MESO cis rs858239 0.601 rs6461702 ENSG00000230658.1 KLHL7-AS1 8.85 3.21e-12 1.55e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23209654 chr7:23101228~23105703:- MESO cis rs858239 0.568 rs6970694 ENSG00000230658.1 KLHL7-AS1 8.85 3.21e-12 1.55e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23211209 chr7:23101228~23105703:- MESO cis rs858239 0.601 rs28673077 ENSG00000230658.1 KLHL7-AS1 8.85 3.21e-12 1.55e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23211235 chr7:23101228~23105703:- MESO cis rs858239 0.536 rs6961109 ENSG00000230658.1 KLHL7-AS1 8.85 3.21e-12 1.55e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23212794 chr7:23101228~23105703:- MESO cis rs858239 0.536 rs6956974 ENSG00000230658.1 KLHL7-AS1 -8.85 3.21e-12 1.55e-07 -1.14 -0.76 Cerebrospinal fluid biomarker levels; chr7:23212699 chr7:23101228~23105703:- MESO cis rs2882667 0.69 rs1725335 ENSG00000253404.1 AC034243.1 -8.82 3.51e-12 1.68e-07 -1.06 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138745541 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs160406 ENSG00000253404.1 AC034243.1 -8.82 3.51e-12 1.68e-07 -1.06 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138748032 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs9327829 ENSG00000253404.1 AC034243.1 -8.82 3.51e-12 1.68e-07 -1.06 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138925982 chr5:138744434~138753309:- MESO cis rs2882667 0.893 rs10044672 ENSG00000253404.1 AC034243.1 8.8 3.83e-12 1.81e-07 1.09 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138954790 chr5:138744434~138753309:- MESO cis rs2882667 0.893 rs13180851 ENSG00000253404.1 AC034243.1 8.8 3.83e-12 1.81e-07 1.09 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138954918 chr5:138744434~138753309:- MESO cis rs2882667 0.893 rs7717375 ENSG00000253404.1 AC034243.1 8.8 3.83e-12 1.81e-07 1.09 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138955716 chr5:138744434~138753309:- MESO cis rs916888 0.738 rs199515 ENSG00000214401.4 KANSL1-AS1 -8.8 3.86e-12 1.82e-07 -0.99 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:46193576~46196723:+ MESO cis rs858239 0.899 rs858271 ENSG00000230658.1 KLHL7-AS1 8.79 3.95e-12 1.86e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23238664 chr7:23101228~23105703:- MESO cis rs858239 1 rs858240 ENSG00000230658.1 KLHL7-AS1 8.79 3.95e-12 1.86e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23244618 chr7:23101228~23105703:- MESO cis rs916888 0.647 rs199524 ENSG00000262539.1 RP11-259G18.3 -8.79 4e-12 1.87e-07 -0.91 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:46259551~46260606:- MESO cis rs916888 0.647 rs199523 ENSG00000262539.1 RP11-259G18.3 -8.79 4e-12 1.87e-07 -0.91 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:46259551~46260606:- MESO cis rs916888 0.647 rs199520 ENSG00000262539.1 RP11-259G18.3 -8.79 4e-12 1.87e-07 -0.91 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776506 chr17:46259551~46260606:- MESO cis rs916888 0.647 rs199519 ENSG00000262539.1 RP11-259G18.3 -8.79 4e-12 1.87e-07 -0.91 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776558 chr17:46259551~46260606:- MESO cis rs7224296 0.709 rs199518 ENSG00000262539.1 RP11-259G18.3 -8.79 4e-12 1.87e-07 -0.91 -0.76 Intelligence (multi-trait analysis); chr17:46777214 chr17:46259551~46260606:- MESO cis rs916888 0.647 rs199517 ENSG00000262539.1 RP11-259G18.3 -8.79 4e-12 1.87e-07 -0.91 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46777221 chr17:46259551~46260606:- MESO cis rs2882667 0.69 rs288016 ENSG00000253404.1 AC034243.1 -8.79 4.02e-12 1.87e-07 -1.07 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138859299 chr5:138744434~138753309:- MESO cis rs916888 0.647 rs199524 ENSG00000214401.4 KANSL1-AS1 -8.78 4.1e-12 1.89e-07 -0.9 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:46193576~46196723:+ MESO cis rs916888 0.647 rs199523 ENSG00000214401.4 KANSL1-AS1 -8.78 4.1e-12 1.89e-07 -0.9 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:46193576~46196723:+ MESO cis rs916888 0.647 rs199520 ENSG00000214401.4 KANSL1-AS1 -8.78 4.1e-12 1.89e-07 -0.9 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776506 chr17:46193576~46196723:+ MESO cis rs916888 0.647 rs199519 ENSG00000214401.4 KANSL1-AS1 -8.78 4.1e-12 1.89e-07 -0.9 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776558 chr17:46193576~46196723:+ MESO cis rs7224296 0.709 rs199518 ENSG00000214401.4 KANSL1-AS1 -8.78 4.1e-12 1.89e-07 -0.9 -0.76 Intelligence (multi-trait analysis); chr17:46777214 chr17:46193576~46196723:+ MESO cis rs916888 0.647 rs199517 ENSG00000214401.4 KANSL1-AS1 -8.78 4.1e-12 1.89e-07 -0.9 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46777221 chr17:46193576~46196723:+ MESO cis rs1799949 1 rs16940 ENSG00000198496.9 NBR2 -8.77 4.27e-12 1.97e-07 -0.97 -0.76 Menopause (age at onset); chr17:43093220 chr17:43125610~43153671:+ MESO cis rs858239 0.863 rs466225 ENSG00000230658.1 KLHL7-AS1 8.76 4.47e-12 2.05e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23292784 chr7:23101228~23105703:- MESO cis rs858239 0.699 rs1881201 ENSG00000230658.1 KLHL7-AS1 -8.75 4.54e-12 2.07e-07 -1.14 -0.76 Cerebrospinal fluid biomarker levels; chr7:23154394 chr7:23101228~23105703:- MESO cis rs2882667 0.69 rs288029 ENSG00000253404.1 AC034243.1 8.75 4.55e-12 2.07e-07 1.05 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138881616 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs176382 ENSG00000253404.1 AC034243.1 8.75 4.55e-12 2.07e-07 1.05 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138891078 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs17031 ENSG00000253404.1 AC034243.1 8.75 4.55e-12 2.07e-07 1.05 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138934853 chr5:138744434~138753309:- MESO cis rs916888 0.61 rs199446 ENSG00000262539.1 RP11-259G18.3 -8.75 4.6e-12 2.08e-07 -0.89 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:46259551~46260606:- MESO cis rs916888 0.61 rs199536 ENSG00000262539.1 RP11-259G18.3 -8.75 4.6e-12 2.08e-07 -0.89 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:46259551~46260606:- MESO cis rs916888 0.647 rs199449 ENSG00000262539.1 RP11-259G18.3 8.75 4.6e-12 2.08e-07 0.89 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:46259551~46260606:- MESO cis rs916888 0.61 rs199444 ENSG00000262539.1 RP11-259G18.3 8.75 4.6e-12 2.08e-07 0.89 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:46259551~46260606:- MESO cis rs916888 0.61 rs199442 ENSG00000262539.1 RP11-259G18.3 8.75 4.6e-12 2.08e-07 0.89 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:46259551~46260606:- MESO cis rs9326248 0.954 rs521171 ENSG00000254851.1 RP11-109L13.1 -8.74 4.77e-12 2.09e-07 -1.06 -0.76 Blood protein levels; chr11:117193977 chr11:117135528~117138582:+ MESO cis rs9326248 0.954 rs8521 ENSG00000254851.1 RP11-109L13.1 -8.74 4.77e-12 2.09e-07 -1.06 -0.76 Blood protein levels; chr11:117196983 chr11:117135528~117138582:+ MESO cis rs858239 0.932 rs858272 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23237166 chr7:23101228~23105703:- MESO cis rs858239 1 rs858239 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23246696 chr7:23101228~23105703:- MESO cis rs858239 0.899 rs10262243 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23251368 chr7:23101228~23105703:- MESO cis rs858239 0.899 rs1881203 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23253189 chr7:23101228~23105703:- MESO cis rs858239 1 rs199348 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23253479 chr7:23101228~23105703:- MESO cis rs858239 1 rs199347 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23254127 chr7:23101228~23105703:- MESO cis rs858239 0.932 rs858275 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23254525 chr7:23101228~23105703:- MESO cis rs858239 0.899 rs28458177 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23255253 chr7:23101228~23105703:- MESO cis rs858239 0.899 rs10085838 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23258796 chr7:23101228~23105703:- MESO cis rs858239 1 rs199351 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23260430 chr7:23101228~23105703:- MESO cis rs858239 0.867 rs10250602 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23264082 chr7:23101228~23105703:- MESO cis rs858239 0.965 rs156429 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23266401 chr7:23101228~23105703:- MESO cis rs858239 0.899 rs28635122 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23270562 chr7:23101228~23105703:- MESO cis rs858239 0.899 rs7794684 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23271186 chr7:23101228~23105703:- MESO cis rs858239 1 rs156421 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23272868 chr7:23101228~23105703:- MESO cis rs858239 0.899 rs2268747 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23273843 chr7:23101228~23105703:- MESO cis rs858239 0.899 rs5850 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23274928 chr7:23101228~23105703:- MESO cis rs858239 1 rs156407 ENSG00000230658.1 KLHL7-AS1 8.73 4.9e-12 2.09e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23276020 chr7:23101228~23105703:- MESO cis rs858239 0.932 rs1624451 ENSG00000230658.1 KLHL7-AS1 -8.73 4.9e-12 2.09e-07 -1.14 -0.76 Cerebrospinal fluid biomarker levels; chr7:23222816 chr7:23101228~23105703:- MESO cis rs858239 1 rs199357 ENSG00000230658.1 KLHL7-AS1 -8.73 4.9e-12 2.09e-07 -1.14 -0.76 Cerebrospinal fluid biomarker levels; chr7:23248690 chr7:23101228~23105703:- MESO cis rs858239 0.932 rs1728320 ENSG00000230658.1 KLHL7-AS1 8.73 4.94e-12 2.1e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23280170 chr7:23101228~23105703:- MESO cis rs916888 0.602 rs199508 ENSG00000214401.4 KANSL1-AS1 -8.73 4.97e-12 2.11e-07 -0.96 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781472 chr17:46193576~46196723:+ MESO cis rs2882667 0.69 rs7714455 ENSG00000253404.1 AC034243.1 -8.68 5.85e-12 2.46e-07 -1.04 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138818281 chr5:138744434~138753309:- MESO cis rs2882667 0.659 rs12719515 ENSG00000253404.1 AC034243.1 8.68 5.95e-12 2.49e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138905629 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs17207772 ENSG00000253404.1 AC034243.1 8.68 5.95e-12 2.49e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138906131 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs13172507 ENSG00000253404.1 AC034243.1 8.68 5.95e-12 2.49e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138907409 chr5:138744434~138753309:- MESO cis rs2882667 0.554 rs1368425 ENSG00000253404.1 AC034243.1 8.68 6e-12 2.5e-07 1.04 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138944528 chr5:138744434~138753309:- MESO cis rs858239 1 rs166663 ENSG00000230658.1 KLHL7-AS1 8.68 6.04e-12 2.51e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23277123 chr7:23101228~23105703:- MESO cis rs858239 0.899 rs2268745 ENSG00000230658.1 KLHL7-AS1 8.68 6.04e-12 2.51e-07 1.14 0.76 Cerebrospinal fluid biomarker levels; chr7:23277981 chr7:23101228~23105703:- MESO cis rs2882667 0.621 rs55901834 ENSG00000253404.1 AC034243.1 -8.65 6.68e-12 2.77e-07 -1.04 -0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138844094 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs160405 ENSG00000253404.1 AC034243.1 8.65 6.77e-12 2.8e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138748387 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs288028 ENSG00000253404.1 AC034243.1 8.65 6.77e-12 2.8e-07 1.07 0.76 Age-related hearing impairment (SNP x SNP interaction); chr5:138886300 chr5:138744434~138753309:- MESO cis rs5850 0.602 rs1005786 ENSG00000230658.1 KLHL7-AS1 8.64 6.89e-12 2.84e-07 1.02 0.76 Blood protein levels; chr7:23106218 chr7:23101228~23105703:- MESO cis rs1799949 1 rs35668327 ENSG00000198496.9 NBR2 -8.63 7.17e-12 2.94e-07 -0.96 -0.76 Menopause (age at onset); chr17:43121078 chr17:43125610~43153671:+ MESO cis rs916888 0.686 rs199501 ENSG00000262539.1 RP11-259G18.3 -8.63 7.25e-12 2.97e-07 -0.89 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46785247 chr17:46259551~46260606:- MESO cis rs1799949 0.965 rs4793237 ENSG00000198496.9 NBR2 -8.63 7.3e-12 2.99e-07 -0.95 -0.76 Menopause (age at onset); chr17:43359227 chr17:43125610~43153671:+ MESO cis rs9326248 0.798 rs10892079 ENSG00000254851.1 RP11-109L13.1 -8.61 7.77e-12 3.17e-07 -1.1 -0.75 Blood protein levels; chr11:117146108 chr11:117135528~117138582:+ MESO cis rs2882667 0.658 rs172664 ENSG00000253404.1 AC034243.1 8.59 8.23e-12 3.35e-07 1.01 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138720617 chr5:138744434~138753309:- MESO cis rs858239 0.539 rs870476 ENSG00000230658.1 KLHL7-AS1 8.59 8.38e-12 3.39e-07 1.13 0.75 Cerebrospinal fluid biomarker levels; chr7:23153652 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs2103281 ENSG00000230658.1 KLHL7-AS1 8.59 8.38e-12 3.39e-07 1.13 0.75 Cerebrospinal fluid biomarker levels; chr7:23154612 chr7:23101228~23105703:- MESO cis rs916888 0.779 rs199498 ENSG00000262539.1 RP11-259G18.3 8.59 8.44e-12 3.42e-07 0.95 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:46259551~46260606:- MESO cis rs2882667 0.654 rs1703211 ENSG00000253404.1 AC034243.1 -8.56 9.4e-12 3.61e-07 -1.04 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138740587 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1627698 ENSG00000253404.1 AC034243.1 -8.56 9.4e-12 3.61e-07 -1.04 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138741777 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1703212 ENSG00000253404.1 AC034243.1 -8.56 9.4e-12 3.61e-07 -1.04 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138742863 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1651032 ENSG00000253404.1 AC034243.1 -8.56 9.4e-12 3.61e-07 -1.04 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138743151 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs700616 ENSG00000253404.1 AC034243.1 -8.56 9.4e-12 3.61e-07 -1.04 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138752184 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs700617 ENSG00000253404.1 AC034243.1 -8.56 9.4e-12 3.61e-07 -1.04 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138752290 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs700618 ENSG00000253404.1 AC034243.1 -8.56 9.4e-12 3.61e-07 -1.04 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138752429 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs700619 ENSG00000253404.1 AC034243.1 -8.56 9.4e-12 3.61e-07 -1.04 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138753060 chr5:138744434~138753309:- MESO cis rs9322193 0.884 rs2064521 ENSG00000231760.4 RP11-350J20.5 -8.56 9.41e-12 3.61e-07 -0.96 -0.75 Lung cancer; chr6:149625336 chr6:149796151~149826294:- MESO cis rs2882667 0.893 rs10054796 ENSG00000253404.1 AC034243.1 8.54 9.97e-12 3.61e-07 1.07 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138958655 chr5:138744434~138753309:- MESO cis rs2882667 0.893 rs10069961 ENSG00000253404.1 AC034243.1 8.54 9.97e-12 3.61e-07 1.07 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138958879 chr5:138744434~138753309:- MESO cis rs1799949 0.93 rs3765640 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43124230 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176077 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43124331 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11655505 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43126360 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs4793204 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43127281 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs12947782 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43127865 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs33945274 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43128056 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11653069 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43131360 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs33988650 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43135863 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs33961729 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43135907 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11656097 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43138596 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs2292595 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43138657 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11657835 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43139936 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs1135214 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43140306 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11658754 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43140722 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11652332 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43143472 chr17:43125610~43153671:+ MESO cis rs1799949 0.93 rs33968979 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43145975 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs12952790 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43147590 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs12950607 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43147911 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11079056 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43148782 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs12936816 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43149692 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4793212 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43150733 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs34534709 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43150923 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs34059614 ENSG00000198496.9 NBR2 -8.54 1e-11 3.61e-07 -0.95 -0.75 Menopause (age at onset); chr17:43151054 chr17:43125610~43153671:+ MESO cis rs2882667 0.69 rs311602 ENSG00000253404.1 AC034243.1 8.54 1.01e-11 3.61e-07 1.02 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138717370 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs930063 ENSG00000253404.1 AC034243.1 8.54 1.01e-11 3.61e-07 1.02 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138717929 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs930062 ENSG00000253404.1 AC034243.1 8.54 1.01e-11 3.61e-07 1.02 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138717934 chr5:138744434~138753309:- MESO cis rs1799949 0.93 rs8176194 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43079204 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs1060915 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43082453 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs3950989 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43085936 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs8176161 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43089373 chr17:43125610~43153671:+ MESO cis rs1799949 0.894 rs8176160 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43089486 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs2070834 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43090268 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs16942 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43091983 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs16941 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43092418 chr17:43125610~43153671:+ MESO cis rs1799949 0.93 rs66499067 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43096467 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176145 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43097077 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs8176140 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43099629 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs67060599 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43103085 chr17:43125610~43153671:+ MESO cis rs1799949 0.896 rs35908185 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43103094 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176133 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43105441 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs8176130 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43106026 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176120 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43109216 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176109 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43113759 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176103 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43115033 chr17:43125610~43153671:+ MESO cis rs1799949 0.896 rs8176098 ENSG00000198496.9 NBR2 -8.54 1.01e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43116189 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176273 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43059636 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs35330014 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43060530 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176269 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43061609 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176265 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43061979 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs3092994 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43063808 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176242 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43065857 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4793194 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43066316 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176234 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43067763 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176233 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43067787 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176220 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43070445 chr17:43125610~43153671:+ MESO cis rs1799949 0.93 rs3092987 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43070706 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs1799966 ENSG00000198496.9 NBR2 -8.54 1.02e-11 3.61e-07 -0.94 -0.75 Menopause (age at onset); chr17:43071077 chr17:43125610~43153671:+ MESO cis rs4853012 0.838 rs2177707 ENSG00000217702.2 RP11-287D1.4 8.53 1.05e-11 3.64e-07 1.49 0.75 Gestational age at birth (maternal effect); chr2:74129723 chr2:74130583~74135395:+ MESO cis rs1799949 0.965 rs33925201 ENSG00000198496.9 NBR2 -8.53 1.05e-11 3.64e-07 -0.95 -0.75 Menopause (age at onset); chr17:43128665 chr17:43125610~43153671:+ MESO cis rs9326248 1 rs7946257 ENSG00000254851.1 RP11-109L13.1 -8.53 1.05e-11 3.64e-07 -1.11 -0.75 Blood protein levels; chr11:117182449 chr11:117135528~117138582:+ MESO cis rs1799949 1 rs8176083 ENSG00000198496.9 NBR2 -8.52 1.1e-11 3.64e-07 -0.95 -0.75 Menopause (age at onset); chr17:43123134 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs8176087 ENSG00000198496.9 NBR2 -8.51 1.12e-11 3.64e-07 -0.94 -0.75 Menopause (age at onset); chr17:43118649 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs34942571 ENSG00000198496.9 NBR2 -8.51 1.12e-11 3.64e-07 -0.94 -0.75 Menopause (age at onset); chr17:43121362 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs33926631 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43152446 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs1960605 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43153380 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs2037076 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43153866 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs33920795 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43176993 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs33918839 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43177155 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs11651623 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43177830 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs11657883 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43178007 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs11656945 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43178248 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs12944430 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43178803 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11653460 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43179289 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11653231 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43179443 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs11650913 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43179580 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs12936831 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43179799 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs1399323 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43180313 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs35954893 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43181769 chr17:43125610~43153671:+ MESO cis rs1799949 0.93 rs35292991 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43181999 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs11658499 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43182732 chr17:43125610~43153671:+ MESO cis rs1799949 0.93 rs4445938 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43185883 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8074136 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43190296 chr17:43125610~43153671:+ MESO cis rs1799949 0.501 rs2343819 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43332285 chr17:43125610~43153671:+ MESO cis rs1799949 0.55 rs2343818 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43332406 chr17:43125610~43153671:+ MESO cis rs1799949 0.501 rs35399157 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43334234 chr17:43125610~43153671:+ MESO cis rs1799949 0.602 rs4600503 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43336956 chr17:43125610~43153671:+ MESO cis rs1799949 0.526 rs4352088 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43337311 chr17:43125610~43153671:+ MESO cis rs1799949 0.501 rs9675035 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43337648 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs34633610 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43342017 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs11654051 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43342288 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11649954 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43342667 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs1824889 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43344508 chr17:43125610~43153671:+ MESO cis rs1799949 0.93 rs56729776 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43344763 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs35956818 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43345617 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs9646417 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43346885 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs1545764 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43347197 chr17:43125610~43153671:+ MESO cis rs1799949 0.93 rs4584865 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43347551 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs9646412 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43348525 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4793231 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43350101 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11651341 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43350693 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs34572725 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43351298 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4534897 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.64e-07 -0.93 -0.75 Menopause (age at onset); chr17:43354440 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176126 ENSG00000198496.9 NBR2 8.49 1.22e-11 3.64e-07 0.93 0.75 Menopause (age at onset); chr17:43107032 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4793229 ENSG00000198496.9 NBR2 8.49 1.22e-11 3.64e-07 0.93 0.75 Menopause (age at onset); chr17:43340966 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs33994002 ENSG00000198496.9 NBR2 -8.49 1.22e-11 3.65e-07 -0.93 -0.75 Menopause (age at onset); chr17:43176801 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs8176323 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43043694 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs8176322 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43043756 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs12516 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43044391 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176318 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43045257 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4793190 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43048092 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs3092988 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43049685 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176297 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43051308 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176296 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43051574 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4793191 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43052360 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4793192 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43052373 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs8176289 ENSG00000198496.9 NBR2 -8.48 1.27e-11 3.74e-07 -0.94 -0.75 Menopause (age at onset); chr17:43054039 chr17:43125610~43153671:+ MESO cis rs858239 0.539 rs6461695 ENSG00000230658.1 KLHL7-AS1 8.47 1.3e-11 3.8e-07 1.12 0.75 Cerebrospinal fluid biomarker levels; chr7:23158165 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs10254544 ENSG00000230658.1 KLHL7-AS1 8.47 1.3e-11 3.8e-07 1.12 0.75 Cerebrospinal fluid biomarker levels; chr7:23180616 chr7:23101228~23105703:- MESO cis rs858239 0.508 rs10242104 ENSG00000230658.1 KLHL7-AS1 8.47 1.3e-11 3.8e-07 1.12 0.75 Cerebrospinal fluid biomarker levels; chr7:23180831 chr7:23101228~23105703:- MESO cis rs858239 0.537 rs2286272 ENSG00000230658.1 KLHL7-AS1 8.47 1.3e-11 3.8e-07 1.12 0.75 Cerebrospinal fluid biomarker levels; chr7:23184748 chr7:23101228~23105703:- MESO cis rs858239 0.537 rs6955115 ENSG00000230658.1 KLHL7-AS1 8.47 1.3e-11 3.8e-07 1.12 0.75 Cerebrospinal fluid biomarker levels; chr7:23187525 chr7:23101228~23105703:- MESO cis rs858239 0.537 rs10279691 ENSG00000230658.1 KLHL7-AS1 8.47 1.3e-11 3.8e-07 1.12 0.75 Cerebrospinal fluid biomarker levels; chr7:23188768 chr7:23101228~23105703:- MESO cis rs858239 0.537 rs6942981 ENSG00000230658.1 KLHL7-AS1 8.47 1.3e-11 3.8e-07 1.12 0.75 Cerebrospinal fluid biomarker levels; chr7:23191929 chr7:23101228~23105703:- MESO cis rs9322193 0.923 rs9766004 ENSG00000231760.4 RP11-350J20.5 8.47 1.32e-11 3.86e-07 0.96 0.75 Lung cancer; chr6:149754363 chr6:149796151~149826294:- MESO cis rs2882667 0.69 rs160402 ENSG00000253404.1 AC034243.1 8.46 1.37e-11 3.99e-07 1.03 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138723599 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs825672 ENSG00000253404.1 AC034243.1 -8.46 1.37e-11 3.99e-07 -1.03 -0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138759954 chr5:138744434~138753309:- MESO cis rs1799949 0.929 rs799905 ENSG00000198496.9 NBR2 -8.44 1.44e-11 4.14e-07 -0.95 -0.75 Menopause (age at onset); chr17:43125170 chr17:43125610~43153671:+ MESO cis rs1799949 0.929 rs799906 ENSG00000198496.9 NBR2 -8.44 1.44e-11 4.14e-07 -0.95 -0.75 Menopause (age at onset); chr17:43126099 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs799908 ENSG00000198496.9 NBR2 -8.44 1.44e-11 4.14e-07 -0.95 -0.75 Menopause (age at onset); chr17:43126899 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs799910 ENSG00000198496.9 NBR2 -8.44 1.44e-11 4.14e-07 -0.95 -0.75 Menopause (age at onset); chr17:43127544 chr17:43125610~43153671:+ MESO cis rs1799949 0.93 rs1554063 ENSG00000198496.9 NBR2 -8.44 1.44e-11 4.14e-07 -0.95 -0.75 Menopause (age at onset); chr17:43135128 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs799912 ENSG00000198496.9 NBR2 -8.44 1.47e-11 4.2e-07 -0.94 -0.75 Menopause (age at onset); chr17:43105117 chr17:43125610~43153671:+ MESO cis rs1799949 0.683 rs55737636 ENSG00000198496.9 NBR2 -8.44 1.47e-11 4.2e-07 -0.94 -0.75 Menopause (age at onset); chr17:43112722 chr17:43125610~43153671:+ MESO cis rs2882667 0.628 rs13173618 ENSG00000253404.1 AC034243.1 8.44 1.47e-11 4.2e-07 1.02 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138804091 chr5:138744434~138753309:- MESO cis rs2882667 0.628 rs13154573 ENSG00000253404.1 AC034243.1 8.44 1.47e-11 4.2e-07 1.02 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138812375 chr5:138744434~138753309:- MESO cis rs858239 0.539 rs4295546 ENSG00000230658.1 KLHL7-AS1 8.41 1.62e-11 4.57e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23151402 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs10279194 ENSG00000230658.1 KLHL7-AS1 8.41 1.62e-11 4.57e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23151464 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs3950345 ENSG00000230658.1 KLHL7-AS1 8.41 1.62e-11 4.57e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23151495 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs2390757 ENSG00000230658.1 KLHL7-AS1 8.41 1.62e-11 4.57e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23151873 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs2178140 ENSG00000230658.1 KLHL7-AS1 8.41 1.62e-11 4.57e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23152006 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs2178139 ENSG00000230658.1 KLHL7-AS1 8.41 1.62e-11 4.57e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23152017 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs2141306 ENSG00000230658.1 KLHL7-AS1 8.41 1.62e-11 4.57e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23152045 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs2141305 ENSG00000230658.1 KLHL7-AS1 8.41 1.62e-11 4.57e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23152280 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs6945510 ENSG00000230658.1 KLHL7-AS1 8.41 1.62e-11 4.57e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23152621 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs6965833 ENSG00000230658.1 KLHL7-AS1 8.41 1.62e-11 4.57e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23152747 chr7:23101228~23105703:- MESO cis rs858239 0.67 rs6967526 ENSG00000230658.1 KLHL7-AS1 8.41 1.66e-11 4.66e-07 1.13 0.75 Cerebrospinal fluid biomarker levels; chr7:23119622 chr7:23101228~23105703:- MESO cis rs858239 0.636 rs28706766 ENSG00000230658.1 KLHL7-AS1 8.41 1.66e-11 4.66e-07 1.13 0.75 Cerebrospinal fluid biomarker levels; chr7:23130215 chr7:23101228~23105703:- MESO cis rs858239 0.931 rs9690941 ENSG00000230658.1 KLHL7-AS1 8.39 1.78e-11 4.97e-07 1.13 0.75 Cerebrospinal fluid biomarker levels; chr7:23242134 chr7:23101228~23105703:- MESO cis rs2882667 0.69 rs311597 ENSG00000253404.1 AC034243.1 8.38 1.85e-11 5.1e-07 0.99 0.75 Age-related hearing impairment (SNP x SNP interaction); chr5:138720212 chr5:138744434~138753309:- MESO cis rs858239 0.539 rs57864591 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23144805 chr7:23101228~23105703:- MESO cis rs858239 0.509 rs57611130 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23144933 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs4559148 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23146348 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs4377861 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23146350 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs4294098 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23146376 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs4504540 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23146579 chr7:23101228~23105703:- MESO cis rs858239 0.509 rs6975524 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23146833 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs6955726 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23147072 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs6955969 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23147080 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs10247268 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23147560 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs6976957 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23147714 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs6956828 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23147728 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs6461694 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23148160 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs1358442 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23150120 chr7:23101228~23105703:- MESO cis rs858239 0.508 rs7805071 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23150593 chr7:23101228~23105703:- MESO cis rs858239 0.508 rs7805085 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23150624 chr7:23101228~23105703:- MESO cis rs858239 0.508 rs2390754 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23150875 chr7:23101228~23105703:- MESO cis rs858239 0.571 rs2390755 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23151097 chr7:23101228~23105703:- MESO cis rs858239 0.539 rs4365988 ENSG00000230658.1 KLHL7-AS1 8.38 1.86e-11 5.1e-07 1.1 0.75 Cerebrospinal fluid biomarker levels; chr7:23151252 chr7:23101228~23105703:- MESO cis rs1799949 1 rs8077486 ENSG00000198496.9 NBR2 -8.35 2.07e-11 5.65e-07 -0.94 -0.74 Menopause (age at onset); chr17:43060788 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs799917 ENSG00000198496.9 NBR2 -8.35 2.08e-11 5.66e-07 -0.94 -0.74 Menopause (age at onset); chr17:43092919 chr17:43125610~43153671:+ MESO cis rs9322193 0.923 rs12526675 ENSG00000231760.4 RP11-350J20.5 -8.34 2.11e-11 5.75e-07 -0.97 -0.74 Lung cancer; chr6:149729540 chr6:149796151~149826294:- MESO cis rs1799949 1 rs11659028 ENSG00000198496.9 NBR2 -8.34 2.15e-11 5.84e-07 -0.93 -0.74 Menopause (age at onset); chr17:43043008 chr17:43125610~43153671:+ MESO cis rs2882667 0.69 rs825669 ENSG00000253404.1 AC034243.1 -8.33 2.21e-11 5.98e-07 -1.04 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138731258 chr5:138744434~138753309:- MESO cis rs1799949 1 rs2037075 ENSG00000198496.9 NBR2 -8.32 2.3e-11 6.19e-07 -0.91 -0.74 Menopause (age at onset); chr17:43153809 chr17:43125610~43153671:+ MESO cis rs2882667 0.69 rs311601 ENSG00000253404.1 AC034243.1 8.31 2.4e-11 6.44e-07 1 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138717697 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs311599 ENSG00000253404.1 AC034243.1 8.31 2.4e-11 6.44e-07 1 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138718994 chr5:138744434~138753309:- MESO cis rs1799949 0.86 rs8176279 ENSG00000198496.9 NBR2 -8.31 2.43e-11 6.51e-07 -0.94 -0.74 Menopause (age at onset); chr17:43058379 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs8176310 ENSG00000198496.9 NBR2 -8.3 2.47e-11 6.6e-07 -0.94 -0.74 Menopause (age at onset); chr17:43047896 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs8070179 ENSG00000198496.9 NBR2 -8.3 2.47e-11 6.6e-07 -0.94 -0.74 Menopause (age at onset); chr17:43050671 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs7212284 ENSG00000198496.9 NBR2 -8.3 2.47e-11 6.6e-07 -0.94 -0.74 Menopause (age at onset); chr17:43053924 chr17:43125610~43153671:+ MESO cis rs1799949 0.894 rs36062488 ENSG00000198496.9 NBR2 8.3 2.5e-11 6.61e-07 0.93 0.74 Menopause (age at onset); chr17:43185455 chr17:43125610~43153671:+ MESO cis rs1799949 0.894 rs71367985 ENSG00000198496.9 NBR2 -8.3 2.5e-11 6.61e-07 -0.93 -0.74 Menopause (age at onset); chr17:43222443 chr17:43125610~43153671:+ MESO cis rs1799949 0.536 rs4793227 ENSG00000198496.9 NBR2 -8.3 2.5e-11 6.61e-07 -0.93 -0.74 Menopause (age at onset); chr17:43334882 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs9646418 ENSG00000198496.9 NBR2 -8.3 2.5e-11 6.61e-07 -0.93 -0.74 Menopause (age at onset); chr17:43348533 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs4793230 ENSG00000198496.9 NBR2 -8.3 2.5e-11 6.61e-07 -0.93 -0.74 Menopause (age at onset); chr17:43350035 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs9897425 ENSG00000198496.9 NBR2 -8.3 2.5e-11 6.61e-07 -0.93 -0.74 Menopause (age at onset); chr17:43352811 chr17:43125610~43153671:+ MESO cis rs916888 0.558 rs199521 ENSG00000214401.4 KANSL1-AS1 -8.28 2.68e-11 7.04e-07 -0.89 -0.74 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776090 chr17:46193576~46196723:+ MESO cis rs9322193 0.923 rs1080670 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149620161 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10782310 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149622458 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10782311 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149622592 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs10782312 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149622669 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10747275 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149622782 chr6:149796151~149826294:- MESO cis rs9322193 0.886 rs9322198 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149623772 chr6:149796151~149826294:- MESO cis rs9322193 0.847 rs12234128 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149627553 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs57012784 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149627691 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9322200 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149630078 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9689599 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149631973 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs9688794 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149632121 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9800580 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149632845 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs11155669 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149633501 chr6:149796151~149826294:- MESO cis rs9322193 0.887 rs9505824 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149633663 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9505826 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149633912 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9800686 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149634464 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs55849538 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149635330 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9322204 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149636047 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9766886 ENSG00000231760.4 RP11-350J20.5 8.27 2.78e-11 7.14e-07 0.91 0.74 Lung cancer; chr6:149637048 chr6:149796151~149826294:- MESO cis rs2882667 0.69 rs9327827 ENSG00000253404.1 AC034243.1 8.27 2.79e-11 7.15e-07 1.01 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138846639 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs160404 ENSG00000253404.1 AC034243.1 8.26 2.86e-11 7.34e-07 0.99 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138748580 chr5:138744434~138753309:- MESO cis rs1799949 0.931 rs34410138 ENSG00000198496.9 NBR2 -8.25 3.01e-11 7.69e-07 -0.94 -0.74 Menopause (age at onset); chr17:43127753 chr17:43125610~43153671:+ MESO cis rs9322193 0.923 rs9377230 ENSG00000231760.4 RP11-350J20.5 8.24 3.07e-11 7.75e-07 0.92 0.74 Lung cancer; chr6:149613607 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9404048 ENSG00000231760.4 RP11-350J20.5 8.24 3.07e-11 7.75e-07 0.92 0.74 Lung cancer; chr6:149616188 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9767554 ENSG00000231760.4 RP11-350J20.5 8.24 3.07e-11 7.75e-07 0.92 0.74 Lung cancer; chr6:149616860 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9505982 ENSG00000231760.4 RP11-350J20.5 8.24 3.07e-11 7.75e-07 0.92 0.74 Lung cancer; chr6:149618465 chr6:149796151~149826294:- MESO cis rs9322193 0.886 rs9485408 ENSG00000231760.4 RP11-350J20.5 8.24 3.07e-11 7.75e-07 0.92 0.74 Lung cancer; chr6:149618888 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9322196 ENSG00000231760.4 RP11-350J20.5 8.24 3.07e-11 7.75e-07 0.92 0.74 Lung cancer; chr6:149619645 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs55993747 ENSG00000231760.4 RP11-350J20.5 8.24 3.07e-11 7.75e-07 0.92 0.74 Lung cancer; chr6:149622016 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9505823 ENSG00000231760.4 RP11-350J20.5 8.24 3.07e-11 7.75e-07 0.92 0.74 Lung cancer; chr6:149628899 chr6:149796151~149826294:- MESO cis rs9322193 0.847 rs12191643 ENSG00000231760.4 RP11-350J20.5 8.24 3.07e-11 7.75e-07 0.92 0.74 Lung cancer; chr6:149628912 chr6:149796151~149826294:- MESO cis rs9322193 0.847 rs62439808 ENSG00000231760.4 RP11-350J20.5 8.24 3.07e-11 7.75e-07 0.92 0.74 Lung cancer; chr6:149629690 chr6:149796151~149826294:- MESO cis rs858239 1 rs156425 ENSG00000230658.1 KLHL7-AS1 -8.24 3.08e-11 7.78e-07 -1.11 -0.74 Cerebrospinal fluid biomarker levels; chr7:23269500 chr7:23101228~23105703:- MESO cis rs9322193 0.923 rs1934534 ENSG00000231760.4 RP11-350J20.5 8.23 3.24e-11 8.15e-07 0.92 0.74 Lung cancer; chr6:149711896 chr6:149796151~149826294:- MESO cis rs916888 0.558 rs199521 ENSG00000262539.1 RP11-259G18.3 -8.23 3.24e-11 8.15e-07 -0.9 -0.74 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776090 chr17:46259551~46260606:- MESO cis rs2882667 0.69 rs9942422 ENSG00000253404.1 AC034243.1 8.23 3.24e-11 8.15e-07 1.01 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138936847 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1828187 ENSG00000253404.1 AC034243.1 8.21 3.48e-11 8.72e-07 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138836531 chr5:138744434~138753309:- MESO cis rs9322193 0.923 rs12660304 ENSG00000231760.4 RP11-350J20.5 8.21 3.48e-11 8.72e-07 0.98 0.74 Lung cancer; chr6:149739647 chr6:149796151~149826294:- MESO cis rs1799949 0.931 rs9891977 ENSG00000198496.9 NBR2 -8.19 3.78e-11 9.43e-07 -0.93 -0.74 Menopause (age at onset); chr17:43360030 chr17:43125610~43153671:+ MESO cis rs9322193 0.886 rs4039600 ENSG00000231760.4 RP11-350J20.5 8.19 3.79e-11 9.43e-07 0.93 0.74 Lung cancer; chr6:149576319 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9322197 ENSG00000231760.4 RP11-350J20.5 8.18 3.91e-11 9.69e-07 0.91 0.74 Lung cancer; chr6:149622577 chr6:149796151~149826294:- MESO cis rs2882667 0.69 rs160403 ENSG00000253404.1 AC034243.1 8.18 3.97e-11 9.84e-07 0.99 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138722793 chr5:138744434~138753309:- MESO cis rs1799949 1 rs4793197 ENSG00000198496.9 NBR2 -8.17 4.07e-11 1.01e-06 -0.95 -0.74 Menopause (age at onset); chr17:43079885 chr17:43125610~43153671:+ MESO cis rs858239 0.738 rs13225593 ENSG00000230658.1 KLHL7-AS1 8.17 4.11e-11 1.01e-06 1.13 0.74 Cerebrospinal fluid biomarker levels; chr7:23220688 chr7:23101228~23105703:- MESO cis rs858239 0.738 rs7807879 ENSG00000230658.1 KLHL7-AS1 8.17 4.11e-11 1.01e-06 1.13 0.74 Cerebrospinal fluid biomarker levels; chr7:23220969 chr7:23101228~23105703:- MESO cis rs916888 0.61 rs142167 ENSG00000214401.4 KANSL1-AS1 -8.17 4.11e-11 1.02e-06 -0.87 -0.74 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:46193576~46196723:+ MESO cis rs1799949 1 rs2175957 ENSG00000198496.9 NBR2 -8.16 4.21e-11 1.04e-06 -0.96 -0.74 Menopause (age at onset); chr17:43134805 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs7223952 ENSG00000198496.9 NBR2 -8.16 4.23e-11 1.04e-06 -0.93 -0.74 Menopause (age at onset); chr17:43042868 chr17:43125610~43153671:+ MESO cis rs2882667 0.69 rs1059110 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138930857 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10068280 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138931394 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs13178601 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138931688 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10045605 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138936458 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs9327830 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138936560 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs9327831 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138936597 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs10071381 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138937159 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs6862845 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138937456 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs7709789 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138938762 chr5:138744434~138753309:- MESO cis rs2882667 0.654 rs10044432 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138939207 chr5:138744434~138753309:- MESO cis rs2882667 0.728 rs10068786 ENSG00000253404.1 AC034243.1 8.15 4.34e-11 1.06e-06 1.02 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138941255 chr5:138744434~138753309:- MESO cis rs2882667 0.964 rs67296915 ENSG00000253404.1 AC034243.1 8.15 4.38e-11 1.07e-06 1.06 0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138965910 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs1651358 ENSG00000253404.1 AC034243.1 -8.11 5.05e-11 1.23e-06 -1.05 -0.74 Age-related hearing impairment (SNP x SNP interaction); chr5:138745318 chr5:138744434~138753309:- MESO cis rs1799949 0.965 rs9646413 ENSG00000198496.9 NBR2 -8.11 5.05e-11 1.23e-06 -0.94 -0.74 Menopause (age at onset); chr17:43348789 chr17:43125610~43153671:+ MESO cis rs9322193 0.923 rs9322209 ENSG00000231760.4 RP11-350J20.5 8.11 5.18e-11 1.25e-06 0.98 0.73 Lung cancer; chr6:149691226 chr6:149796151~149826294:- MESO cis rs9326248 0.813 rs7115562 ENSG00000254851.1 RP11-109L13.1 -8.1 5.33e-11 1.29e-06 -1.06 -0.73 Blood protein levels; chr11:117149754 chr11:117135528~117138582:+ MESO cis rs2882667 0.628 rs311606 ENSG00000253404.1 AC034243.1 8.09 5.42e-11 1.31e-06 1 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138709551 chr5:138744434~138753309:- MESO cis rs9326248 0.581 rs7120963 ENSG00000254851.1 RP11-109L13.1 8.08 5.65e-11 1.36e-06 0.94 0.73 Blood protein levels; chr11:116959545 chr11:117135528~117138582:+ MESO cis rs858239 0.806 rs10268610 ENSG00000230658.1 KLHL7-AS1 8.06 6.27e-11 1.5e-06 1.07 0.73 Cerebrospinal fluid biomarker levels; chr7:23235145 chr7:23101228~23105703:- MESO cis rs9322193 0.923 rs9689084 ENSG00000231760.4 RP11-350J20.5 8.05 6.46e-11 1.54e-06 0.9 0.73 Lung cancer; chr6:149639648 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs7740278 ENSG00000231760.4 RP11-350J20.5 8.05 6.46e-11 1.54e-06 0.9 0.73 Lung cancer; chr6:149640116 chr6:149796151~149826294:- MESO cis rs9322193 0.81 rs62439811 ENSG00000231760.4 RP11-350J20.5 8.05 6.46e-11 1.54e-06 0.9 0.73 Lung cancer; chr6:149640416 chr6:149796151~149826294:- MESO cis rs916888 0.531 rs183211 ENSG00000214401.4 KANSL1-AS1 8.03 6.87e-11 1.62e-06 0.88 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:46193576~46196723:+ MESO cis rs916888 0.61 rs199438 ENSG00000214401.4 KANSL1-AS1 8.03 6.87e-11 1.62e-06 0.88 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:46193576~46196723:+ MESO cis rs916888 0.61 rs199453 ENSG00000214401.4 KANSL1-AS1 8.03 6.87e-11 1.62e-06 0.88 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:46193576~46196723:+ MESO cis rs916888 0.61 rs199436 ENSG00000214401.4 KANSL1-AS1 -8.03 6.87e-11 1.62e-06 -0.88 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:46193576~46196723:+ MESO cis rs916888 0.61 rs199454 ENSG00000214401.4 KANSL1-AS1 -8.03 6.87e-11 1.62e-06 -0.88 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:46193576~46196723:+ MESO cis rs9322193 0.923 rs9800736 ENSG00000231760.4 RP11-350J20.5 8.02 7.2e-11 1.69e-06 0.97 0.73 Lung cancer; chr6:149661281 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs3924871 ENSG00000231760.4 RP11-350J20.5 8.02 7.2e-11 1.69e-06 0.97 0.73 Lung cancer; chr6:149662080 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs35961297 ENSG00000231760.4 RP11-350J20.5 8.02 7.2e-11 1.69e-06 0.97 0.73 Lung cancer; chr6:149667929 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs35830138 ENSG00000231760.4 RP11-350J20.5 8.02 7.2e-11 1.69e-06 0.97 0.73 Lung cancer; chr6:149668635 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs62439837 ENSG00000231760.4 RP11-350J20.5 8.02 7.2e-11 1.69e-06 0.97 0.73 Lung cancer; chr6:149670380 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs66516768 ENSG00000231760.4 RP11-350J20.5 8.02 7.2e-11 1.69e-06 0.97 0.73 Lung cancer; chr6:149671999 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs62439840 ENSG00000231760.4 RP11-350J20.5 8.02 7.2e-11 1.69e-06 0.97 0.73 Lung cancer; chr6:149674639 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs35967444 ENSG00000231760.4 RP11-350J20.5 8.02 7.2e-11 1.69e-06 0.97 0.73 Lung cancer; chr6:149675588 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs62439842 ENSG00000231760.4 RP11-350J20.5 8.02 7.2e-11 1.69e-06 0.97 0.73 Lung cancer; chr6:149675847 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9393175 ENSG00000231760.4 RP11-350J20.5 8.02 7.2e-11 1.69e-06 0.97 0.73 Lung cancer; chr6:149677587 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9688861 ENSG00000231760.4 RP11-350J20.5 8.01 7.32e-11 1.71e-06 0.91 0.73 Lung cancer; chr6:149637924 chr6:149796151~149826294:- MESO cis rs916888 0.61 rs199446 ENSG00000214401.4 KANSL1-AS1 -8.01 7.48e-11 1.74e-06 -0.84 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:46193576~46196723:+ MESO cis rs916888 0.61 rs199536 ENSG00000214401.4 KANSL1-AS1 -8.01 7.48e-11 1.74e-06 -0.84 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:46193576~46196723:+ MESO cis rs916888 0.647 rs199449 ENSG00000214401.4 KANSL1-AS1 8.01 7.48e-11 1.74e-06 0.84 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:46193576~46196723:+ MESO cis rs916888 0.61 rs199444 ENSG00000214401.4 KANSL1-AS1 8.01 7.48e-11 1.74e-06 0.84 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:46193576~46196723:+ MESO cis rs916888 0.61 rs199442 ENSG00000214401.4 KANSL1-AS1 8.01 7.48e-11 1.74e-06 0.84 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:46193576~46196723:+ MESO cis rs1799949 1 rs8070085 ENSG00000198496.9 NBR2 7.99 7.97e-11 1.86e-06 0.98 0.73 Menopause (age at onset); chr17:43189967 chr17:43125610~43153671:+ MESO cis rs858239 0.67 rs3807452 ENSG00000230658.1 KLHL7-AS1 -7.99 7.99e-11 1.86e-06 -1.01 -0.73 Cerebrospinal fluid biomarker levels; chr7:23122462 chr7:23101228~23105703:- MESO cis rs9326248 0.861 rs4938343 ENSG00000254851.1 RP11-109L13.1 -7.98 8.42e-11 1.95e-06 -1.09 -0.73 Blood protein levels; chr11:117132812 chr11:117135528~117138582:+ MESO cis rs9322193 0.923 rs9767123 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149660323 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs62439836 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149669173 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs4869812 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149669447 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs4870267 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149671572 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs4380763 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149678086 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs7767622 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149681766 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs4421206 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149682891 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs3798761 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149683643 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs9322210 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149695440 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs4354168 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149696642 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs4455682 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149700161 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs7450246 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149702517 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs11155674 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149711111 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9383812 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149712355 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs2185352 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149714640 chr6:149796151~149826294:- MESO cis rs9322193 0.847 rs9383844 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149716268 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs4870529 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149716436 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9767309 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149716807 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs12174349 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149718012 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs2297932 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149718225 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs2297930 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149718360 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs2297928 ENSG00000231760.4 RP11-350J20.5 7.97 8.57e-11 1.95e-06 0.94 0.73 Lung cancer; chr6:149718584 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs9688858 ENSG00000231760.4 RP11-350J20.5 7.97 8.67e-11 1.97e-06 0.9 0.73 Lung cancer; chr6:149637911 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs17745062 ENSG00000231760.4 RP11-350J20.5 7.97 8.75e-11 1.99e-06 0.94 0.73 Lung cancer; chr6:149721079 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs62441279 ENSG00000231760.4 RP11-350J20.5 7.97 8.75e-11 1.99e-06 0.94 0.73 Lung cancer; chr6:149721194 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9479094 ENSG00000231760.4 RP11-350J20.5 7.97 8.75e-11 1.99e-06 0.94 0.73 Lung cancer; chr6:149725083 chr6:149796151~149826294:- MESO cis rs2882667 0.69 rs311608 ENSG00000253404.1 AC034243.1 7.97 8.82e-11 2e-06 1 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138708000 chr5:138744434~138753309:- MESO cis rs2882667 0.69 rs160401 ENSG00000253404.1 AC034243.1 -7.95 9.32e-11 2.11e-06 -0.97 -0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138725652 chr5:138744434~138753309:- MESO cis rs1799949 0.965 rs799916 ENSG00000198496.9 NBR2 7.95 9.46e-11 2.14e-06 0.92 0.73 Menopause (age at onset); chr17:43091173 chr17:43125610~43153671:+ MESO cis rs2882667 0.69 rs11954103 ENSG00000253404.1 AC034243.1 7.94 9.82e-11 2.22e-06 1.01 0.73 Age-related hearing impairment (SNP x SNP interaction); chr5:138933459 chr5:138744434~138753309:- MESO cis rs9322193 0.923 rs9766037 ENSG00000231760.4 RP11-350J20.5 7.94 9.88e-11 2.24e-06 0.91 0.73 Lung cancer; chr6:149616921 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs6913486 ENSG00000231760.4 RP11-350J20.5 -7.93 9.92e-11 2.24e-06 -0.95 -0.73 Lung cancer; chr6:149705060 chr6:149796151~149826294:- MESO cis rs858239 0.669 rs1990365 ENSG00000230658.1 KLHL7-AS1 7.93 1e-10 2.26e-06 1.07 0.73 Cerebrospinal fluid biomarker levels; chr7:23076347 chr7:23101228~23105703:- MESO cis rs858239 0.669 rs6461687 ENSG00000230658.1 KLHL7-AS1 7.93 1e-10 2.26e-06 1.07 0.73 Cerebrospinal fluid biomarker levels; chr7:23076961 chr7:23101228~23105703:- MESO cis rs858239 0.669 rs6461688 ENSG00000230658.1 KLHL7-AS1 7.93 1e-10 2.26e-06 1.07 0.73 Cerebrospinal fluid biomarker levels; chr7:23076996 chr7:23101228~23105703:- MESO cis rs1799949 0.965 rs12950779 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43154506 chr17:43125610~43153671:+ MESO cis rs1799949 0.929 rs12937015 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43155456 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4340367 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43155755 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4792981 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43156257 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs1973646 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43158478 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs35521261 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43161595 chr17:43125610~43153671:+ MESO cis rs1799949 0.896 rs33933393 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43165415 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4793215 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43166915 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs33946455 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43169829 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs11650132 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43174070 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11654731 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43174923 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs2271574 ENSG00000198496.9 NBR2 -7.93 1.02e-10 2.26e-06 -0.91 -0.73 Menopause (age at onset); chr17:43175631 chr17:43125610~43153671:+ MESO cis rs9322193 0.923 rs12175504 ENSG00000231760.4 RP11-350J20.5 7.92 1.06e-10 2.33e-06 0.95 0.73 Lung cancer; chr6:149664079 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs62439843 ENSG00000231760.4 RP11-350J20.5 7.92 1.06e-10 2.33e-06 0.95 0.73 Lung cancer; chr6:149676521 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs35031906 ENSG00000231760.4 RP11-350J20.5 7.92 1.06e-10 2.33e-06 0.95 0.73 Lung cancer; chr6:149677438 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs7753812 ENSG00000231760.4 RP11-350J20.5 7.92 1.06e-10 2.33e-06 0.95 0.73 Lung cancer; chr6:149690150 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs12195866 ENSG00000231760.4 RP11-350J20.5 7.92 1.06e-10 2.33e-06 0.95 0.73 Lung cancer; chr6:149693334 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9285524 ENSG00000231760.4 RP11-350J20.5 7.92 1.06e-10 2.33e-06 0.95 0.73 Lung cancer; chr6:149694122 chr6:149796151~149826294:- MESO cis rs858239 0.669 rs56400441 ENSG00000230658.1 KLHL7-AS1 7.89 1.15e-10 2.51e-06 1.08 0.73 Cerebrospinal fluid biomarker levels; chr7:23103945 chr7:23101228~23105703:- MESO cis rs916888 0.61 rs199452 ENSG00000214401.4 KANSL1-AS1 7.88 1.23e-10 2.68e-06 0.9 0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:46193576~46196723:+ MESO cis rs916888 0.61 rs199530 ENSG00000214401.4 KANSL1-AS1 -7.88 1.23e-10 2.68e-06 -0.9 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:46193576~46196723:+ MESO cis rs1799949 0.931 rs9912203 ENSG00000198496.9 NBR2 7.87 1.29e-10 2.79e-06 0.91 0.72 Menopause (age at onset); chr17:43367777 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs6503727 ENSG00000198496.9 NBR2 -7.87 1.29e-10 2.79e-06 -0.91 -0.72 Menopause (age at onset); chr17:43160842 chr17:43125610~43153671:+ MESO cis rs858239 0.72 rs10227559 ENSG00000230658.1 KLHL7-AS1 7.86 1.3e-10 2.82e-06 1.11 0.72 Cerebrospinal fluid biomarker levels; chr7:23232525 chr7:23101228~23105703:- MESO cis rs9326248 0.581 rs10892061 ENSG00000254851.1 RP11-109L13.1 -7.86 1.31e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117015398 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs7120706 ENSG00000254851.1 RP11-109L13.1 7.86 1.33e-10 2.83e-06 0.89 0.72 Blood protein levels; chr11:116959371 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs6589582 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:116958484 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs10502222 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:116963014 chr11:117135528~117138582:+ MESO cis rs9326248 0.559 rs10892052 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:116963597 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs10892053 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:116986287 chr11:117135528~117138582:+ MESO cis rs9326248 0.559 rs12808524 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117020277 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs10892063 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117025439 chr11:117135528~117138582:+ MESO cis rs9326248 0.559 rs10892064 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117025837 chr11:117135528~117138582:+ MESO cis rs9326248 0.539 rs10892065 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117026308 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs11216242 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117030833 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs12804122 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117031900 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs4938331 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117059966 chr11:117135528~117138582:+ MESO cis rs9326248 0.51 rs4938332 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117060082 chr11:117135528~117138582:+ MESO cis rs9326248 0.559 rs4938334 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117060326 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs6589590 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117065365 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs11216267 ENSG00000254851.1 RP11-109L13.1 -7.86 1.33e-10 2.83e-06 -0.89 -0.72 Blood protein levels; chr11:117081676 chr11:117135528~117138582:+ MESO cis rs1799949 0.965 rs1842147 ENSG00000198496.9 NBR2 -7.85 1.38e-10 2.92e-06 -0.91 -0.72 Menopause (age at onset); chr17:43357824 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs4793233 ENSG00000198496.9 NBR2 -7.85 1.38e-10 2.92e-06 -0.91 -0.72 Menopause (age at onset); chr17:43358069 chr17:43125610~43153671:+ MESO cis rs1799949 0.864 rs60309406 ENSG00000198496.9 NBR2 -7.85 1.38e-10 2.92e-06 -0.91 -0.72 Menopause (age at onset); chr17:43358297 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs4793234 ENSG00000198496.9 NBR2 -7.85 1.38e-10 2.92e-06 -0.91 -0.72 Menopause (age at onset); chr17:43358815 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs4793236 ENSG00000198496.9 NBR2 -7.85 1.38e-10 2.92e-06 -0.91 -0.72 Menopause (age at onset); chr17:43359072 chr17:43125610~43153671:+ MESO cis rs2486288 0.656 rs9921025 ENSG00000259520.4 CTD-2651B20.3 7.84 1.42e-10 2.98e-06 0.94 0.72 Glomerular filtration rate; chr15:45254404 chr15:45251580~45279251:- MESO cis rs9322193 0.923 rs12529698 ENSG00000231760.4 RP11-350J20.5 7.83 1.45e-10 3.04e-06 0.94 0.72 Lung cancer; chr6:149650951 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs11155671 ENSG00000231760.4 RP11-350J20.5 7.83 1.45e-10 3.04e-06 0.94 0.72 Lung cancer; chr6:149650996 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9689716 ENSG00000231760.4 RP11-350J20.5 7.83 1.45e-10 3.04e-06 0.94 0.72 Lung cancer; chr6:149655662 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9689723 ENSG00000231760.4 RP11-350J20.5 7.83 1.45e-10 3.04e-06 0.94 0.72 Lung cancer; chr6:149655935 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9322207 ENSG00000231760.4 RP11-350J20.5 7.83 1.45e-10 3.04e-06 0.94 0.72 Lung cancer; chr6:149657185 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9968911 ENSG00000231760.4 RP11-350J20.5 7.83 1.45e-10 3.04e-06 0.94 0.72 Lung cancer; chr6:149657419 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9322208 ENSG00000231760.4 RP11-350J20.5 7.83 1.45e-10 3.04e-06 0.94 0.72 Lung cancer; chr6:149658547 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs57938011 ENSG00000231760.4 RP11-350J20.5 7.83 1.46e-10 3.04e-06 0.93 0.72 Lung cancer; chr6:149642969 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs12174716 ENSG00000231760.4 RP11-350J20.5 7.83 1.46e-10 3.04e-06 0.93 0.72 Lung cancer; chr6:149644487 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9800871 ENSG00000231760.4 RP11-350J20.5 7.83 1.46e-10 3.04e-06 0.93 0.72 Lung cancer; chr6:149644540 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9800614 ENSG00000231760.4 RP11-350J20.5 7.83 1.46e-10 3.04e-06 0.93 0.72 Lung cancer; chr6:149644604 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs11155670 ENSG00000231760.4 RP11-350J20.5 7.83 1.46e-10 3.04e-06 0.93 0.72 Lung cancer; chr6:149644992 chr6:149796151~149826294:- MESO cis rs8013143 1 rs11846575 ENSG00000279656.1 RP11-298I3.6 -7.83 1.46e-10 3.05e-06 -0.97 -0.72 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23022075 chr14:23023083~23024217:- MESO cis rs916888 0.686 rs199501 ENSG00000214401.4 KANSL1-AS1 -7.83 1.49e-10 3.11e-06 -0.84 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46785247 chr17:46193576~46196723:+ MESO cis rs9326248 0.652 rs7128382 ENSG00000254851.1 RP11-109L13.1 -7.83 1.5e-10 3.11e-06 -0.97 -0.72 Blood protein levels; chr11:117152771 chr11:117135528~117138582:+ MESO cis rs1799949 0.929 rs4792988 ENSG00000198496.9 NBR2 -7.82 1.51e-10 3.13e-06 -0.91 -0.72 Menopause (age at onset); chr17:43360179 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs4792989 ENSG00000198496.9 NBR2 -7.82 1.51e-10 3.13e-06 -0.91 -0.72 Menopause (age at onset); chr17:43360184 chr17:43125610~43153671:+ MESO cis rs1799949 0.794 rs116409325 ENSG00000198496.9 NBR2 -7.81 1.57e-10 3.24e-06 -0.91 -0.72 Menopause (age at onset); chr17:43368092 chr17:43125610~43153671:+ MESO cis rs2882667 0.69 rs825747 ENSG00000253404.1 AC034243.1 -7.8 1.66e-10 3.4e-06 -1.06 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138800896 chr5:138744434~138753309:- MESO cis rs9322193 0.962 rs9688750 ENSG00000231760.4 RP11-350J20.5 7.79 1.71e-10 3.5e-06 0.95 0.72 Lung cancer; chr6:149657633 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9322206 ENSG00000231760.4 RP11-350J20.5 7.78 1.8e-10 3.67e-06 0.93 0.72 Lung cancer; chr6:149641481 chr6:149796151~149826294:- MESO cis rs1799949 1 rs35070007 ENSG00000198496.9 NBR2 7.77 1.86e-10 3.79e-06 0.91 0.72 Menopause (age at onset); chr17:43164730 chr17:43125610~43153671:+ MESO cis rs1799949 0.773 rs2137990 ENSG00000198496.9 NBR2 7.77 1.86e-10 3.79e-06 0.91 0.72 Menopause (age at onset); chr17:43165879 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs4239149 ENSG00000198496.9 NBR2 7.77 1.86e-10 3.79e-06 0.91 0.72 Menopause (age at onset); chr17:43176078 chr17:43125610~43153671:+ MESO cis rs9326248 0.861 rs11216172 ENSG00000254851.1 RP11-109L13.1 -7.75 1.99e-10 4.05e-06 -1.13 -0.72 Blood protein levels; chr11:116879162 chr11:117135528~117138582:+ MESO cis rs2486288 0.656 rs8041702 ENSG00000259520.4 CTD-2651B20.3 7.74 2.06e-10 4.17e-06 0.92 0.72 Glomerular filtration rate; chr15:45254895 chr15:45251580~45279251:- MESO cis rs9322193 0.923 rs4870509 ENSG00000231760.4 RP11-350J20.5 7.74 2.1e-10 4.21e-06 0.97 0.72 Lung cancer; chr6:149702212 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9322214 ENSG00000231760.4 RP11-350J20.5 7.74 2.1e-10 4.21e-06 0.97 0.72 Lung cancer; chr6:149703986 chr6:149796151~149826294:- MESO cis rs9322193 0.887 rs9767113 ENSG00000231760.4 RP11-350J20.5 7.74 2.1e-10 4.21e-06 0.97 0.72 Lung cancer; chr6:149718157 chr6:149796151~149826294:- MESO cis rs1799949 0.859 rs11657004 ENSG00000198496.9 NBR2 -7.73 2.12e-10 4.25e-06 -0.9 -0.72 Menopause (age at onset); chr17:43365383 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs11080034 ENSG00000198496.9 NBR2 -7.73 2.12e-10 4.25e-06 -0.9 -0.72 Menopause (age at onset); chr17:43365646 chr17:43125610~43153671:+ MESO cis rs1799949 0.931 rs34474989 ENSG00000198496.9 NBR2 -7.73 2.12e-10 4.25e-06 -0.9 -0.72 Menopause (age at onset); chr17:43368042 chr17:43125610~43153671:+ MESO cis rs2486288 0.656 rs8037583 ENSG00000259520.4 CTD-2651B20.3 7.72 2.23e-10 4.46e-06 0.95 0.72 Glomerular filtration rate; chr15:45254180 chr15:45251580~45279251:- MESO cis rs9326248 0.581 rs10892072 ENSG00000254851.1 RP11-109L13.1 -7.72 2.28e-10 4.56e-06 -0.88 -0.72 Blood protein levels; chr11:117089597 chr11:117135528~117138582:+ MESO cis rs9326248 0.603 rs7396061 ENSG00000254851.1 RP11-109L13.1 -7.71 2.28e-10 4.56e-06 -0.89 -0.72 Blood protein levels; chr11:116880158 chr11:117135528~117138582:+ MESO cis rs2882667 0.628 rs13171173 ENSG00000253404.1 AC034243.1 -7.69 2.48e-10 4.94e-06 -0.98 -0.72 Age-related hearing impairment (SNP x SNP interaction); chr5:138706775 chr5:138744434~138753309:- MESO cis rs9322193 0.962 rs35443312 ENSG00000231760.4 RP11-350J20.5 7.69 2.52e-10 5.02e-06 0.92 0.72 Lung cancer; chr6:149670625 chr6:149796151~149826294:- MESO cis rs9326248 0.581 rs10892076 ENSG00000254851.1 RP11-109L13.1 -7.69 2.53e-10 5.03e-06 -0.87 -0.72 Blood protein levels; chr11:117118220 chr11:117135528~117138582:+ MESO cis rs9322193 0.886 rs2065663 ENSG00000231760.4 RP11-350J20.5 7.68 2.56e-10 5.07e-06 0.96 0.72 Lung cancer; chr6:149760331 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs12205092 ENSG00000231760.4 RP11-350J20.5 7.68 2.56e-10 5.07e-06 0.96 0.72 Lung cancer; chr6:149761375 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10872651 ENSG00000231760.4 RP11-350J20.5 7.68 2.56e-10 5.07e-06 0.96 0.72 Lung cancer; chr6:149768273 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs3805749 ENSG00000231760.4 RP11-350J20.5 7.68 2.56e-10 5.07e-06 0.96 0.72 Lung cancer; chr6:149772546 chr6:149796151~149826294:- MESO cis rs9322193 0.847 rs9505972 ENSG00000231760.4 RP11-350J20.5 7.68 2.56e-10 5.07e-06 0.96 0.72 Lung cancer; chr6:149775255 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs3805752 ENSG00000231760.4 RP11-350J20.5 7.68 2.56e-10 5.07e-06 0.96 0.72 Lung cancer; chr6:149795490 chr6:149796151~149826294:- MESO cis rs2486288 0.656 rs11639420 ENSG00000259520.4 CTD-2651B20.3 7.68 2.62e-10 5.18e-06 0.95 0.72 Glomerular filtration rate; chr15:45267070 chr15:45251580~45279251:- MESO cis rs9326248 0.581 rs7120515 ENSG00000254851.1 RP11-109L13.1 -7.68 2.62e-10 5.18e-06 -0.87 -0.72 Blood protein levels; chr11:117121210 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs7106437 ENSG00000254851.1 RP11-109L13.1 -7.68 2.62e-10 5.18e-06 -0.87 -0.72 Blood protein levels; chr11:117121360 chr11:117135528~117138582:+ MESO cis rs916888 0.779 rs199498 ENSG00000214401.4 KANSL1-AS1 7.66 2.82e-10 5.58e-06 0.89 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:46193576~46196723:+ MESO cis rs2486288 0.656 rs2413771 ENSG00000259520.4 CTD-2651B20.3 7.65 2.87e-10 5.67e-06 0.91 0.72 Glomerular filtration rate; chr15:45260942 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11632419 ENSG00000259520.4 CTD-2651B20.3 7.65 2.88e-10 5.68e-06 0.94 0.72 Glomerular filtration rate; chr15:45265258 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs2271438 ENSG00000259520.4 CTD-2651B20.3 7.65 2.88e-10 5.68e-06 0.94 0.72 Glomerular filtration rate; chr15:45265270 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11854365 ENSG00000259520.4 CTD-2651B20.3 7.65 2.88e-10 5.68e-06 0.94 0.72 Glomerular filtration rate; chr15:45265885 chr15:45251580~45279251:- MESO cis rs2882667 0.69 rs11750163 ENSG00000253404.1 AC034243.1 7.65 2.93e-10 5.77e-06 0.98 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138705920 chr5:138744434~138753309:- MESO cis rs9322193 0.962 rs2065664 ENSG00000231760.4 RP11-350J20.5 7.65 2.94e-10 5.78e-06 0.97 0.71 Lung cancer; chr6:149762485 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9688350 ENSG00000231760.4 RP11-350J20.5 7.64 3.01e-10 5.9e-06 0.96 0.71 Lung cancer; chr6:149730977 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs9688699 ENSG00000231760.4 RP11-350J20.5 7.64 3.01e-10 5.9e-06 0.96 0.71 Lung cancer; chr6:149733680 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9767652 ENSG00000231760.4 RP11-350J20.5 7.64 3.01e-10 5.9e-06 0.96 0.71 Lung cancer; chr6:149734502 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10782314 ENSG00000231760.4 RP11-350J20.5 7.64 3.01e-10 5.9e-06 0.96 0.71 Lung cancer; chr6:149735527 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10782318 ENSG00000231760.4 RP11-350J20.5 7.64 3.04e-10 5.95e-06 0.93 0.71 Lung cancer; chr6:149754137 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9688517 ENSG00000231760.4 RP11-350J20.5 7.63 3.19e-10 6.23e-06 0.93 0.71 Lung cancer; chr6:149740655 chr6:149796151~149826294:- MESO cis rs9326248 0.539 rs10892058 ENSG00000254851.1 RP11-109L13.1 -7.62 3.26e-10 6.36e-06 -0.91 -0.71 Blood protein levels; chr11:117005905 chr11:117135528~117138582:+ MESO cis rs9326248 0.52 rs7127881 ENSG00000254851.1 RP11-109L13.1 -7.62 3.26e-10 6.36e-06 -0.91 -0.71 Blood protein levels; chr11:117010082 chr11:117135528~117138582:+ MESO cis rs9322193 0.962 rs7818 ENSG00000231760.4 RP11-350J20.5 7.62 3.33e-10 6.49e-06 0.98 0.71 Lung cancer; chr6:149810956 chr6:149796151~149826294:- MESO cis rs9322193 1 rs9377228 ENSG00000231760.4 RP11-350J20.5 7.61 3.38e-10 6.56e-06 0.88 0.71 Lung cancer; chr6:149600862 chr6:149796151~149826294:- MESO cis rs9322193 0.924 rs9498382 ENSG00000231760.4 RP11-350J20.5 7.61 3.38e-10 6.56e-06 0.88 0.71 Lung cancer; chr6:149610982 chr6:149796151~149826294:- MESO cis rs9322193 1 rs9399693 ENSG00000231760.4 RP11-350J20.5 7.61 3.38e-10 6.56e-06 0.88 0.71 Lung cancer; chr6:149612718 chr6:149796151~149826294:- MESO cis rs2486288 0.656 rs9921035 ENSG00000259520.4 CTD-2651B20.3 7.61 3.46e-10 6.69e-06 0.92 0.71 Glomerular filtration rate; chr15:45254462 chr15:45251580~45279251:- MESO cis rs9322193 0.923 rs12176034 ENSG00000231760.4 RP11-350J20.5 7.58 3.75e-10 7.17e-06 0.99 0.71 Lung cancer; chr6:149800557 chr6:149796151~149826294:- MESO cis rs2486288 0.656 rs11629807 ENSG00000259520.4 CTD-2651B20.3 7.58 3.75e-10 7.17e-06 0.93 0.71 Glomerular filtration rate; chr15:45254839 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11629858 ENSG00000259520.4 CTD-2651B20.3 7.58 3.75e-10 7.17e-06 0.93 0.71 Glomerular filtration rate; chr15:45254916 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11629859 ENSG00000259520.4 CTD-2651B20.3 7.58 3.75e-10 7.17e-06 0.93 0.71 Glomerular filtration rate; chr15:45254923 chr15:45251580~45279251:- MESO cis rs2486288 0.587 rs12899942 ENSG00000259520.4 CTD-2651B20.3 7.58 3.75e-10 7.17e-06 0.93 0.71 Glomerular filtration rate; chr15:45255082 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs12899058 ENSG00000259520.4 CTD-2651B20.3 7.58 3.75e-10 7.17e-06 0.93 0.71 Glomerular filtration rate; chr15:45255126 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs12904150 ENSG00000259520.4 CTD-2651B20.3 7.58 3.75e-10 7.17e-06 0.93 0.71 Glomerular filtration rate; chr15:45255407 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs9920290 ENSG00000259520.4 CTD-2651B20.3 7.58 3.75e-10 7.17e-06 0.93 0.71 Glomerular filtration rate; chr15:45255837 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11854325 ENSG00000259520.4 CTD-2651B20.3 7.58 3.75e-10 7.17e-06 0.93 0.71 Glomerular filtration rate; chr15:45256761 chr15:45251580~45279251:- MESO cis rs9322193 0.923 rs9479494 ENSG00000231760.4 RP11-350J20.5 7.58 3.76e-10 7.17e-06 0.93 0.71 Lung cancer; chr6:149739108 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs56397000 ENSG00000231760.4 RP11-350J20.5 7.58 3.76e-10 7.17e-06 0.93 0.71 Lung cancer; chr6:149739347 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9800806 ENSG00000231760.4 RP11-350J20.5 7.58 3.76e-10 7.17e-06 0.93 0.71 Lung cancer; chr6:149740350 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs9689702 ENSG00000231760.4 RP11-350J20.5 7.58 3.76e-10 7.17e-06 0.93 0.71 Lung cancer; chr6:149740720 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10872644 ENSG00000231760.4 RP11-350J20.5 7.58 3.76e-10 7.17e-06 0.93 0.71 Lung cancer; chr6:149741819 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10782315 ENSG00000231760.4 RP11-350J20.5 7.58 3.76e-10 7.17e-06 0.93 0.71 Lung cancer; chr6:149743093 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs1572229 ENSG00000231760.4 RP11-350J20.5 7.58 3.76e-10 7.17e-06 0.93 0.71 Lung cancer; chr6:149743841 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs10872646 ENSG00000231760.4 RP11-350J20.5 7.58 3.76e-10 7.17e-06 0.93 0.71 Lung cancer; chr6:149746539 chr6:149796151~149826294:- MESO cis rs1799949 1 rs8176202 ENSG00000198496.9 NBR2 -7.58 3.77e-10 7.17e-06 -0.91 -0.71 Menopause (age at onset); chr17:43078211 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs8176193 ENSG00000198496.9 NBR2 -7.58 3.77e-10 7.17e-06 -0.91 -0.71 Menopause (age at onset); chr17:43079499 chr17:43125610~43153671:+ MESO cis rs2486288 0.656 rs8039352 ENSG00000259520.4 CTD-2651B20.3 7.58 3.82e-10 7.25e-06 0.9 0.71 Glomerular filtration rate; chr15:45259592 chr15:45251580~45279251:- MESO cis rs9322193 0.961 rs9767713 ENSG00000231760.4 RP11-350J20.5 7.58 3.82e-10 7.25e-06 0.88 0.71 Lung cancer; chr6:149588241 chr6:149796151~149826294:- MESO cis rs9322193 0.924 rs9322189 ENSG00000231760.4 RP11-350J20.5 7.58 3.82e-10 7.25e-06 0.88 0.71 Lung cancer; chr6:149588797 chr6:149796151~149826294:- MESO cis rs858239 0.932 rs199355 ENSG00000230658.1 KLHL7-AS1 7.56 4.07e-10 7.62e-06 1.08 0.71 Cerebrospinal fluid biomarker levels; chr7:23256914 chr7:23101228~23105703:- MESO cis rs2486288 0.656 rs2413774 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45257225 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs2413773 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45257244 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs2413772 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45257664 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11632724 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45258593 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11632651 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45258640 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11637920 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45258707 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11632777 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45258847 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11632778 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45258858 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs11632752 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45258942 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs12911186 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45259225 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs12915314 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45259293 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs8039138 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45259394 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs8039540 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45259644 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs8040185 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45259883 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs1060896 ENSG00000259520.4 CTD-2651B20.3 7.56 4.07e-10 7.62e-06 0.92 0.71 Glomerular filtration rate; chr15:45262069 chr15:45251580~45279251:- MESO cis rs9322193 0.961 rs9027 ENSG00000231760.4 RP11-350J20.5 7.55 4.33e-10 8.1e-06 0.88 0.71 Lung cancer; chr6:149594921 chr6:149796151~149826294:- MESO cis rs9322193 1 rs9322193 ENSG00000231760.4 RP11-350J20.5 7.55 4.33e-10 8.1e-06 0.88 0.71 Lung cancer; chr6:149598007 chr6:149796151~149826294:- MESO cis rs2882667 0.728 rs13181830 ENSG00000253404.1 AC034243.1 -7.54 4.47e-10 8.33e-06 -1 -0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138944727 chr5:138744434~138753309:- MESO cis rs9322193 0.887 rs4870139 ENSG00000231760.4 RP11-350J20.5 7.53 4.67e-10 8.68e-06 0.87 0.71 Lung cancer; chr6:149575182 chr6:149796151~149826294:- MESO cis rs9322193 0.961 rs4870144 ENSG00000231760.4 RP11-350J20.5 7.53 4.67e-10 8.68e-06 0.87 0.71 Lung cancer; chr6:149575540 chr6:149796151~149826294:- MESO cis rs9326248 0.861 rs4938348 ENSG00000254851.1 RP11-109L13.1 -7.52 4.69e-10 8.71e-06 -1.01 -0.71 Blood protein levels; chr11:117151161 chr11:117135528~117138582:+ MESO cis rs9326248 0.813 rs4938350 ENSG00000254851.1 RP11-109L13.1 -7.52 4.69e-10 8.71e-06 -1.01 -0.71 Blood protein levels; chr11:117151560 chr11:117135528~117138582:+ MESO cis rs9326248 0.768 rs4936366 ENSG00000254851.1 RP11-109L13.1 -7.52 4.69e-10 8.71e-06 -1.01 -0.71 Blood protein levels; chr11:117156169 chr11:117135528~117138582:+ MESO cis rs9326248 0.861 rs4938352 ENSG00000254851.1 RP11-109L13.1 -7.52 4.69e-10 8.71e-06 -1.01 -0.71 Blood protein levels; chr11:117156765 chr11:117135528~117138582:+ MESO cis rs9322193 0.886 rs9718079 ENSG00000231760.4 RP11-350J20.5 7.52 4.78e-10 8.85e-06 0.93 0.71 Lung cancer; chr6:149645947 chr6:149796151~149826294:- MESO cis rs2882667 0.964 rs11739351 ENSG00000253404.1 AC034243.1 7.51 5.03e-10 9.24e-06 0.93 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138976053 chr5:138744434~138753309:- MESO cis rs9322193 0.884 rs12528279 ENSG00000231760.4 RP11-350J20.5 7.5 5.12e-10 9.29e-06 0.92 0.71 Lung cancer; chr6:149750892 chr6:149796151~149826294:- MESO cis rs9322193 0.809 rs9479808 ENSG00000231760.4 RP11-350J20.5 7.5 5.12e-10 9.29e-06 0.92 0.71 Lung cancer; chr6:149751328 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs62441284 ENSG00000231760.4 RP11-350J20.5 7.5 5.12e-10 9.29e-06 0.92 0.71 Lung cancer; chr6:149751542 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10782316 ENSG00000231760.4 RP11-350J20.5 7.5 5.12e-10 9.29e-06 0.92 0.71 Lung cancer; chr6:149752755 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs11155677 ENSG00000231760.4 RP11-350J20.5 7.5 5.12e-10 9.29e-06 0.92 0.71 Lung cancer; chr6:149756953 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs9480009 ENSG00000231760.4 RP11-350J20.5 7.5 5.12e-10 9.29e-06 0.92 0.71 Lung cancer; chr6:149758502 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10747276 ENSG00000231760.4 RP11-350J20.5 7.5 5.12e-10 9.29e-06 0.92 0.71 Lung cancer; chr6:149758739 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9480031 ENSG00000231760.4 RP11-350J20.5 7.5 5.12e-10 9.29e-06 0.92 0.71 Lung cancer; chr6:149758875 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10872649 ENSG00000231760.4 RP11-350J20.5 7.5 5.12e-10 9.29e-06 0.92 0.71 Lung cancer; chr6:149759454 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10872650 ENSG00000231760.4 RP11-350J20.5 7.5 5.12e-10 9.29e-06 0.92 0.71 Lung cancer; chr6:149760959 chr6:149796151~149826294:- MESO cis rs9322193 0.886 rs9767555 ENSG00000231760.4 RP11-350J20.5 7.5 5.24e-10 9.49e-06 0.95 0.71 Lung cancer; chr6:149647022 chr6:149796151~149826294:- MESO cis rs9322193 1 rs9377229 ENSG00000231760.4 RP11-350J20.5 7.5 5.25e-10 9.5e-06 0.88 0.71 Lung cancer; chr6:149607655 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs10872645 ENSG00000231760.4 RP11-350J20.5 7.49 5.33e-10 9.64e-06 0.93 0.71 Lung cancer; chr6:149742840 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs12211511 ENSG00000231760.4 RP11-350J20.5 7.49 5.33e-10 9.64e-06 0.93 0.71 Lung cancer; chr6:149745206 chr6:149796151~149826294:- MESO cis rs977987 0.735 rs11149831 ENSG00000261783.1 RP11-252K23.2 -7.49 5.36e-10 9.69e-06 -0.93 -0.71 Dupuytren's disease; chr16:75417563 chr16:75379818~75381260:- MESO cis rs9322193 0.923 rs9478291 ENSG00000231760.4 RP11-350J20.5 7.48 5.63e-10 1.02e-05 0.92 0.71 Lung cancer; chr6:149729434 chr6:149796151~149826294:- MESO cis rs9322193 1 rs58189451 ENSG00000231760.4 RP11-350J20.5 7.47 5.88e-10 1.06e-05 0.91 0.71 Lung cancer; chr6:149600252 chr6:149796151~149826294:- MESO cis rs2882667 1 rs10515505 ENSG00000253404.1 AC034243.1 7.47 5.89e-10 1.06e-05 0.94 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138977457 chr5:138744434~138753309:- MESO cis rs2882667 0.628 rs311607 ENSG00000253404.1 AC034243.1 7.46 6.04e-10 1.08e-05 0.93 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138709231 chr5:138744434~138753309:- MESO cis rs2882667 0.628 rs311605 ENSG00000253404.1 AC034243.1 7.46 6.04e-10 1.08e-05 0.93 0.71 Age-related hearing impairment (SNP x SNP interaction); chr5:138710150 chr5:138744434~138753309:- MESO cis rs2739330 0.828 rs5760107 ENSG00000218537.1 MIF-AS1 7.44 6.4e-10 1.14e-05 0.87 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23894426~23898930:- MESO cis rs2739330 0.828 rs5760108 ENSG00000218537.1 MIF-AS1 7.44 6.4e-10 1.14e-05 0.87 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23894426~23898930:- MESO cis rs2739330 0.789 rs5760109 ENSG00000218537.1 MIF-AS1 7.44 6.4e-10 1.14e-05 0.87 0.71 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23894426~23898930:- MESO cis rs9326248 0.861 rs7120309 ENSG00000254851.1 RP11-109L13.1 -7.44 6.46e-10 1.15e-05 -0.96 -0.71 Blood protein levels; chr11:117172100 chr11:117135528~117138582:+ MESO cis rs9326248 0.861 rs7120449 ENSG00000254851.1 RP11-109L13.1 -7.44 6.46e-10 1.15e-05 -0.96 -0.71 Blood protein levels; chr11:117172183 chr11:117135528~117138582:+ MESO cis rs2739330 0.828 rs2186366 ENSG00000218537.1 MIF-AS1 -7.44 6.55e-10 1.17e-05 -0.82 -0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23894426~23898930:- MESO cis rs9322193 0.962 rs9688412 ENSG00000231760.4 RP11-350J20.5 -7.43 6.64e-10 1.18e-05 -0.95 -0.7 Lung cancer; chr6:149803147 chr6:149796151~149826294:- MESO cis rs8013143 0.961 rs7147308 ENSG00000279656.1 RP11-298I3.6 -7.43 6.79e-10 1.21e-05 -0.94 -0.7 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23028420 chr14:23023083~23024217:- MESO cis rs113525195 1 rs113525195 ENSG00000279656.1 RP11-298I3.6 -7.43 6.79e-10 1.21e-05 -0.94 -0.7 High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Mean corpuscular hemoglobin; chr14:23030112 chr14:23023083~23024217:- MESO cis rs1799949 1 rs12944458 ENSG00000198496.9 NBR2 -7.42 6.9e-10 1.22e-05 -0.9 -0.7 Menopause (age at onset); chr17:43028755 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs36036395 ENSG00000198496.9 NBR2 -7.42 6.9e-10 1.22e-05 -0.9 -0.7 Menopause (age at onset); chr17:43029280 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs72829113 ENSG00000198496.9 NBR2 -7.42 6.9e-10 1.22e-05 -0.9 -0.7 Menopause (age at onset); chr17:43029818 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11653253 ENSG00000198496.9 NBR2 -7.42 6.9e-10 1.22e-05 -0.9 -0.7 Menopause (age at onset); chr17:43030645 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs12951869 ENSG00000198496.9 NBR2 -7.42 6.9e-10 1.22e-05 -0.9 -0.7 Menopause (age at onset); chr17:43035550 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs12944597 ENSG00000198496.9 NBR2 -7.42 6.9e-10 1.22e-05 -0.9 -0.7 Menopause (age at onset); chr17:43035667 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs12942277 ENSG00000198496.9 NBR2 -7.42 6.9e-10 1.22e-05 -0.9 -0.7 Menopause (age at onset); chr17:43035957 chr17:43125610~43153671:+ MESO cis rs1799949 0.965 rs34616041 ENSG00000198496.9 NBR2 -7.42 6.9e-10 1.22e-05 -0.9 -0.7 Menopause (age at onset); chr17:43036769 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11654452 ENSG00000198496.9 NBR2 -7.42 6.9e-10 1.22e-05 -0.9 -0.7 Menopause (age at onset); chr17:43037366 chr17:43125610~43153671:+ MESO cis rs9326248 0.727 rs4938347 ENSG00000254851.1 RP11-109L13.1 -7.42 7.11e-10 1.24e-05 -1 -0.7 Blood protein levels; chr11:117151043 chr11:117135528~117138582:+ MESO cis rs8013143 1 rs8013143 ENSG00000279656.1 RP11-298I3.6 -7.42 7.12e-10 1.24e-05 -0.94 -0.7 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23025068 chr14:23023083~23024217:- MESO cis rs8013143 1 rs941718 ENSG00000279656.1 RP11-298I3.6 -7.42 7.12e-10 1.24e-05 -0.94 -0.7 Reticulocyte fraction of red cells;Reticulocyte count;Red cell distribution width; chr14:23025839 chr14:23023083~23024217:- MESO cis rs1799949 1 rs2298862 ENSG00000198496.9 NBR2 -7.41 7.26e-10 1.24e-05 -0.91 -0.7 Menopause (age at onset); chr17:43024671 chr17:43125610~43153671:+ MESO cis rs1799949 0.93 rs2298861 ENSG00000198496.9 NBR2 -7.41 7.26e-10 1.24e-05 -0.91 -0.7 Menopause (age at onset); chr17:43024814 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs915945 ENSG00000198496.9 NBR2 -7.41 7.26e-10 1.24e-05 -0.91 -0.7 Menopause (age at onset); chr17:43027847 chr17:43125610~43153671:+ MESO cis rs9322193 0.923 rs9479810 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149751359 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs12175575 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149763351 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs4869966 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149763714 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs1112730 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149766383 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs1112729 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149766491 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs10452626 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149767481 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs62441303 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149767547 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9765929 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149769680 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs3805748 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149772542 chr6:149796151~149826294:- MESO cis rs9322193 0.736 rs10457851 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149775216 chr6:149796151~149826294:- MESO cis rs9322193 0.886 rs10872652 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149775303 chr6:149796151~149826294:- MESO cis rs9322193 0.886 rs12525871 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149775882 chr6:149796151~149826294:- MESO cis rs9322193 0.886 rs17672976 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149776207 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs2184369 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149776681 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs2342861 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149777561 chr6:149796151~149826294:- MESO cis rs9322193 0.926 rs2342860 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149777641 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs10872653 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149778907 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9505974 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149779294 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs11155683 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149779341 chr6:149796151~149826294:- MESO cis rs9322193 0.926 rs9689036 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149780563 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9372044 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149780867 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs11155685 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149781649 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9322218 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149782183 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9322219 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149782263 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9322220 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149782897 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs10214845 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149783124 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9767122 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149783553 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs1413654 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149783956 chr6:149796151~149826294:- MESO cis rs9322193 0.683 rs113281309 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149787289 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9688809 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149787920 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9689242 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149787970 chr6:149796151~149826294:- MESO cis rs9322193 1 rs9767077 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149788479 chr6:149796151~149826294:- MESO cis rs9322193 0.926 rs9766562 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149788709 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9688938 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149788941 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9688940 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149788977 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9689447 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149789350 chr6:149796151~149826294:- MESO cis rs9322193 0.632 rs3828700 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149791033 chr6:149796151~149826294:- MESO cis rs9322193 0.736 rs3828701 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149791063 chr6:149796151~149826294:- MESO cis rs9322193 0.736 rs3805750 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149791065 chr6:149796151~149826294:- MESO cis rs9322193 0.926 rs3805751 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149791193 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9689269 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149791861 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs62441335 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149792658 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs13215691 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149792666 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs4816 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149793609 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs3805753 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149795662 chr6:149796151~149826294:- MESO cis rs9322193 0.926 rs952166 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149798774 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs952165 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149798900 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs10872656 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149799444 chr6:149796151~149826294:- MESO cis rs9322193 0.926 rs9285525 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149801253 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9322223 ENSG00000231760.4 RP11-350J20.5 7.41 7.28e-10 1.24e-05 0.92 0.7 Lung cancer; chr6:149801509 chr6:149796151~149826294:- MESO cis rs9326248 0.861 rs4938353 ENSG00000254851.1 RP11-109L13.1 -7.41 7.35e-10 1.25e-05 -1.03 -0.7 Blood protein levels; chr11:117175481 chr11:117135528~117138582:+ MESO cis rs2882667 0.964 rs12055237 ENSG00000253404.1 AC034243.1 7.4 7.69e-10 1.3e-05 0.99 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138971617 chr5:138744434~138753309:- MESO cis rs9322193 0.923 rs9767105 ENSG00000231760.4 RP11-350J20.5 7.39 7.79e-10 1.32e-05 0.9 0.7 Lung cancer; chr6:149659591 chr6:149796151~149826294:- MESO cis rs2739330 0.828 rs2877178 ENSG00000218537.1 MIF-AS1 7.37 8.49e-10 1.43e-05 0.86 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23894426~23898930:- MESO cis rs2739330 0.828 rs2154593 ENSG00000218537.1 MIF-AS1 7.37 8.49e-10 1.43e-05 0.86 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23894426~23898930:- MESO cis rs9322193 0.923 rs10782317 ENSG00000231760.4 RP11-350J20.5 -7.37 8.51e-10 1.43e-05 -0.94 -0.7 Lung cancer; chr6:149753911 chr6:149796151~149826294:- MESO cis rs2739330 0.828 rs5751770 ENSG00000218537.1 MIF-AS1 7.35 8.99e-10 1.51e-05 0.88 0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23894426~23898930:- MESO cis rs1799949 0.965 rs2236762 ENSG00000198496.9 NBR2 -7.34 9.38e-10 1.58e-05 -0.9 -0.7 Menopause (age at onset); chr17:43074658 chr17:43125610~43153671:+ MESO cis rs9322193 0.961 rs2064520 ENSG00000231760.4 RP11-350J20.5 7.34 9.58e-10 1.61e-05 0.89 0.7 Lung cancer; chr6:149603650 chr6:149796151~149826294:- MESO cis rs2739330 0.828 rs2186366 ENSG00000273295.1 AP000350.5 -7.34 9.58e-10 1.61e-05 -0.74 -0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23901432~23907068:- MESO cis rs2739330 0.796 rs2154594 ENSG00000218537.1 MIF-AS1 -7.33 9.71e-10 1.63e-05 -0.9 -0.7 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23894426~23898930:- MESO cis rs2882667 0.628 rs13162420 ENSG00000253404.1 AC034243.1 7.33 9.72e-10 1.63e-05 0.94 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138839070 chr5:138744434~138753309:- MESO cis rs2882667 0.628 rs13167462 ENSG00000253404.1 AC034243.1 7.33 9.72e-10 1.63e-05 0.94 0.7 Age-related hearing impairment (SNP x SNP interaction); chr5:138841572 chr5:138744434~138753309:- MESO cis rs1799949 0.965 rs8071278 ENSG00000198496.9 NBR2 -7.31 1.07e-09 1.79e-05 -0.9 -0.7 Menopause (age at onset); chr17:43041893 chr17:43125610~43153671:+ MESO cis rs9322193 0.923 rs12174035 ENSG00000231760.4 RP11-350J20.5 7.3 1.09e-09 1.81e-05 0.91 0.7 Lung cancer; chr6:149763311 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs2342858 ENSG00000231760.4 RP11-350J20.5 7.3 1.1e-09 1.83e-05 0.91 0.7 Lung cancer; chr6:149805967 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs6914319 ENSG00000231760.4 RP11-350J20.5 7.3 1.1e-09 1.83e-05 0.91 0.7 Lung cancer; chr6:149806304 chr6:149796151~149826294:- MESO cis rs1799949 1 rs4793189 ENSG00000198496.9 NBR2 -7.3 1.12e-09 1.87e-05 -0.89 -0.7 Menopause (age at onset); chr17:43038698 chr17:43125610~43153671:+ MESO cis rs1799949 1 rs11657053 ENSG00000198496.9 NBR2 -7.3 1.12e-09 1.87e-05 -0.89 -0.7 Menopause (age at onset); chr17:43039112 chr17:43125610~43153671:+ MESO cis rs9326248 0.559 rs482371 ENSG00000254851.1 RP11-109L13.1 -7.29 1.14e-09 1.9e-05 -0.85 -0.7 Blood protein levels; chr11:116881447 chr11:117135528~117138582:+ MESO cis rs9326248 0.559 rs1269329 ENSG00000254851.1 RP11-109L13.1 -7.29 1.14e-09 1.9e-05 -0.85 -0.7 Blood protein levels; chr11:116884325 chr11:117135528~117138582:+ MESO cis rs2486288 0.656 rs2413768 ENSG00000259520.4 CTD-2651B20.3 7.29 1.16e-09 1.92e-05 0.95 0.7 Glomerular filtration rate; chr15:45269786 chr15:45251580~45279251:- MESO cis rs9326248 0.539 rs660443 ENSG00000254851.1 RP11-109L13.1 -7.28 1.17e-09 1.95e-05 -0.85 -0.7 Blood protein levels; chr11:116889977 chr11:117135528~117138582:+ MESO cis rs9326248 0.559 rs484646 ENSG00000254851.1 RP11-109L13.1 -7.28 1.19e-09 1.97e-05 -0.88 -0.7 Blood protein levels; chr11:116862140 chr11:117135528~117138582:+ MESO cis rs9326248 0.509 rs533556 ENSG00000254851.1 RP11-109L13.1 -7.28 1.19e-09 1.97e-05 -0.88 -0.7 Blood protein levels; chr11:116870856 chr11:117135528~117138582:+ MESO cis rs9326248 0.559 rs476399 ENSG00000254851.1 RP11-109L13.1 -7.27 1.23e-09 2.03e-05 -0.87 -0.7 Blood protein levels; chr11:116863012 chr11:117135528~117138582:+ MESO cis rs858239 0.614 rs2014816 ENSG00000230658.1 KLHL7-AS1 7.27 1.25e-09 2.06e-05 1.04 0.7 Cerebrospinal fluid biomarker levels; chr7:23083417 chr7:23101228~23105703:- MESO cis rs950027 0.549 rs1719250 ENSG00000259520.4 CTD-2651B20.3 -7.24 1.4e-09 2.3e-05 -0.9 -0.7 Response to fenofibrate (adiponectin levels); chr15:45317575 chr15:45251580~45279251:- MESO cis rs9326248 0.559 rs609177 ENSG00000254851.1 RP11-109L13.1 -7.24 1.41e-09 2.32e-05 -0.86 -0.7 Blood protein levels; chr11:116899801 chr11:117135528~117138582:+ MESO cis rs2486288 0.656 rs11631021 ENSG00000259520.4 CTD-2651B20.3 7.24 1.41e-09 2.33e-05 0.9 0.7 Glomerular filtration rate; chr15:45264631 chr15:45251580~45279251:- MESO cis rs2882667 0.964 rs12108892 ENSG00000253404.1 AC034243.1 7.23 1.43e-09 2.36e-05 0.99 0.69 Age-related hearing impairment (SNP x SNP interaction); chr5:138963941 chr5:138744434~138753309:- MESO cis rs2739330 0.828 rs5751770 ENSG00000273295.1 AP000350.5 7.22 1.48e-09 2.43e-05 0.8 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23901432~23907068:- MESO cis rs1153858 0.621 rs12913645 ENSG00000259520.4 CTD-2651B20.3 7.21 1.54e-09 2.52e-05 0.94 0.69 Homoarginine levels; chr15:45262868 chr15:45251580~45279251:- MESO cis rs801193 0.66 rs1962050 ENSG00000226824.5 RP4-756H11.3 7.2 1.63e-09 2.67e-05 0.85 0.69 Aortic root size; chr7:66775021 chr7:66654538~66669855:+ MESO cis rs9326248 0.539 rs518181 ENSG00000254851.1 RP11-109L13.1 -7.19 1.65e-09 2.69e-05 -0.86 -0.69 Blood protein levels; chr11:116902071 chr11:117135528~117138582:+ MESO cis rs2739330 0.796 rs1006771 ENSG00000218537.1 MIF-AS1 7.18 1.73e-09 2.82e-05 0.81 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23894426~23898930:- MESO cis rs2486288 0.656 rs11632920 ENSG00000259520.4 CTD-2651B20.3 7.17 1.84e-09 2.99e-05 0.92 0.69 Glomerular filtration rate; chr15:45259066 chr15:45251580~45279251:- MESO cis rs977987 0.735 rs166013 ENSG00000261783.1 RP11-252K23.2 7.16 1.86e-09 3.02e-05 0.88 0.69 Dupuytren's disease; chr16:75400248 chr16:75379818~75381260:- MESO cis rs9326248 0.861 rs1871757 ENSG00000254851.1 RP11-109L13.1 -7.16 1.89e-09 3.06e-05 -0.92 -0.69 Blood protein levels; chr11:117159865 chr11:117135528~117138582:+ MESO cis rs5760092 0.618 rs5996631 ENSG00000273295.1 AP000350.5 -7.14 2.01e-09 3.23e-05 -0.82 -0.69 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23901432~23907068:- MESO cis rs2739330 0.828 rs5760107 ENSG00000273295.1 AP000350.5 7.13 2.07e-09 3.33e-05 0.78 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23901432~23907068:- MESO cis rs2739330 0.828 rs5760108 ENSG00000273295.1 AP000350.5 7.13 2.07e-09 3.33e-05 0.78 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23901432~23907068:- MESO cis rs2739330 0.789 rs5760109 ENSG00000273295.1 AP000350.5 7.13 2.07e-09 3.33e-05 0.78 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23901432~23907068:- MESO cis rs2739330 0.796 rs1006771 ENSG00000273295.1 AP000350.5 7.09 2.5e-09 3.99e-05 0.73 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23901432~23907068:- MESO cis rs2739330 0.753 rs4822452 ENSG00000218537.1 MIF-AS1 7.08 2.54e-09 4.04e-05 0.84 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23894426~23898930:- MESO cis rs2739330 0.828 rs4822454 ENSG00000218537.1 MIF-AS1 7.08 2.54e-09 4.04e-05 0.84 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23894426~23898930:- MESO cis rs9326248 0.813 rs588534 ENSG00000254851.1 RP11-109L13.1 -7.06 2.72e-09 4.31e-05 -0.97 -0.69 Blood protein levels; chr11:117197788 chr11:117135528~117138582:+ MESO cis rs9326248 0.813 rs474488 ENSG00000254851.1 RP11-109L13.1 -7.06 2.72e-09 4.31e-05 -0.97 -0.69 Blood protein levels; chr11:117198261 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs7121898 ENSG00000254851.1 RP11-109L13.1 -7.06 2.8e-09 4.41e-05 -0.86 -0.69 Blood protein levels; chr11:116926130 chr11:117135528~117138582:+ MESO cis rs9326248 0.52 rs1446105 ENSG00000254851.1 RP11-109L13.1 -7.06 2.8e-09 4.41e-05 -0.86 -0.69 Blood protein levels; chr11:116927828 chr11:117135528~117138582:+ MESO cis rs9326248 0.581 rs10790167 ENSG00000254851.1 RP11-109L13.1 -7.06 2.8e-09 4.41e-05 -0.86 -0.69 Blood protein levels; chr11:116930227 chr11:117135528~117138582:+ MESO cis rs7847628 0.587 rs4837796 ENSG00000226752.6 PSMD5-AS1 7.05 2.85e-09 4.48e-05 0.81 0.69 Birth weight; chr9:120848010 chr9:120824828~120854385:+ MESO cis rs2739330 0.753 rs4822452 ENSG00000273295.1 AP000350.5 7.05 2.86e-09 4.51e-05 0.77 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23901432~23907068:- MESO cis rs2739330 0.828 rs4822454 ENSG00000273295.1 AP000350.5 7.05 2.86e-09 4.51e-05 0.77 0.69 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23901432~23907068:- MESO cis rs6452524 0.618 rs10462394 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83058735 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs1871203 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83059567 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs7722924 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83060223 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs10051445 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83060280 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs6867727 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83061333 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs7723639 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83062610 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs2306336 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83064964 chr5:83012285~83013109:- MESO cis rs6452524 0.589 rs6882386 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83065555 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs6860752 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83065587 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs3899556 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83067862 chr5:83012285~83013109:- MESO cis rs6452524 0.56 rs6895174 ENSG00000249664.1 CTD-2227C6.2 7.04 2.95e-09 4.61e-05 0.88 0.69 Hypertension (SNP x SNP interaction); chr5:83071606 chr5:83012285~83013109:- MESO cis rs2486288 0.656 rs7167146 ENSG00000259520.4 CTD-2651B20.3 -7.04 2.95e-09 4.62e-05 -1.02 -0.69 Glomerular filtration rate; chr15:45279188 chr15:45251580~45279251:- MESO cis rs9326248 0.861 rs7931335 ENSG00000254851.1 RP11-109L13.1 -7.04 3.03e-09 4.7e-05 -0.92 -0.68 Blood protein levels; chr11:117166089 chr11:117135528~117138582:+ MESO cis rs2486288 0.656 rs8039354 ENSG00000259520.4 CTD-2651B20.3 -7.03 3.07e-09 4.75e-05 -0.91 -0.68 Glomerular filtration rate; chr15:45259558 chr15:45251580~45279251:- MESO cis rs9326248 1 rs664971 ENSG00000254851.1 RP11-109L13.1 7.02 3.18e-09 4.91e-05 1.02 0.68 Blood protein levels; chr11:117200141 chr11:117135528~117138582:+ MESO cis rs6452524 0.648 rs27364 ENSG00000249664.1 CTD-2227C6.2 7.02 3.21e-09 4.94e-05 0.88 0.68 Hypertension (SNP x SNP interaction); chr5:83052137 chr5:83012285~83013109:- MESO cis rs9326248 0.581 rs12225187 ENSG00000254851.1 RP11-109L13.1 -7.01 3.32e-09 5.09e-05 -0.86 -0.68 Blood protein levels; chr11:116922515 chr11:117135528~117138582:+ MESO cis rs801193 0.66 rs974239 ENSG00000226824.5 RP4-756H11.3 -7.01 3.32e-09 5.09e-05 -0.85 -0.68 Aortic root size; chr7:66748504 chr7:66654538~66669855:+ MESO cis rs801193 0.66 rs1016265 ENSG00000226824.5 RP4-756H11.3 -7.01 3.32e-09 5.09e-05 -0.85 -0.68 Aortic root size; chr7:66749580 chr7:66654538~66669855:+ MESO cis rs801193 0.66 rs4610622 ENSG00000226824.5 RP4-756H11.3 -7.01 3.32e-09 5.09e-05 -0.85 -0.68 Aortic root size; chr7:66759510 chr7:66654538~66669855:+ MESO cis rs801193 0.66 rs10950049 ENSG00000226824.5 RP4-756H11.3 -7.01 3.32e-09 5.09e-05 -0.85 -0.68 Aortic root size; chr7:66765873 chr7:66654538~66669855:+ MESO cis rs2739330 0.828 rs2877178 ENSG00000273295.1 AP000350.5 6.99 3.59e-09 5.41e-05 0.77 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23901432~23907068:- MESO cis rs2739330 0.828 rs2154593 ENSG00000273295.1 AP000350.5 6.99 3.59e-09 5.41e-05 0.77 0.68 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23901432~23907068:- MESO cis rs875971 0.965 rs7794930 ENSG00000226824.5 RP4-756H11.3 6.98 3.68e-09 5.51e-05 0.87 0.68 Aortic root size; chr7:66313559 chr7:66654538~66669855:+ MESO cis rs875971 1 rs937495 ENSG00000226824.5 RP4-756H11.3 6.98 3.68e-09 5.51e-05 0.87 0.68 Aortic root size; chr7:66314811 chr7:66654538~66669855:+ MESO cis rs875971 0.965 rs9969301 ENSG00000226824.5 RP4-756H11.3 6.98 3.68e-09 5.51e-05 0.87 0.68 Aortic root size; chr7:66316668 chr7:66654538~66669855:+ MESO cis rs875971 0.867 rs1002053 ENSG00000226824.5 RP4-756H11.3 6.98 3.68e-09 5.51e-05 0.87 0.68 Aortic root size; chr7:66333558 chr7:66654538~66669855:+ MESO cis rs875971 1 rs2036264 ENSG00000226824.5 RP4-756H11.3 6.98 3.68e-09 5.51e-05 0.87 0.68 Aortic root size; chr7:66334917 chr7:66654538~66669855:+ MESO cis rs875971 1 rs7783613 ENSG00000226824.5 RP4-756H11.3 6.98 3.68e-09 5.51e-05 0.87 0.68 Aortic root size; chr7:66340274 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6956179 ENSG00000226824.5 RP4-756H11.3 6.98 3.68e-09 5.51e-05 0.87 0.68 Aortic root size; chr7:66341672 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6460292 ENSG00000226824.5 RP4-756H11.3 6.98 3.68e-09 5.51e-05 0.87 0.68 Aortic root size; chr7:66345088 chr7:66654538~66669855:+ MESO cis rs875971 1 rs7792762 ENSG00000226824.5 RP4-756H11.3 -6.98 3.68e-09 5.51e-05 -0.87 -0.68 Aortic root size; chr7:66539151 chr7:66654538~66669855:+ MESO cis rs1799949 1 rs2271573 ENSG00000198496.9 NBR2 -6.98 3.75e-09 5.61e-05 -0.91 -0.68 Menopause (age at onset); chr17:43175604 chr17:43125610~43153671:+ MESO cis rs62445005 1 rs62445005 ENSG00000211697.3 TRGV5 6.97 3.86e-09 5.76e-05 0.96 0.68 Shingles; chr7:38346957 chr7:38343894~38350022:- MESO cis rs875971 0.66 rs10272357 ENSG00000226824.5 RP4-756H11.3 6.97 3.86e-09 5.76e-05 0.96 0.68 Aortic root size; chr7:66598087 chr7:66654538~66669855:+ MESO cis rs2882667 0.931 rs11955952 ENSG00000253404.1 AC034243.1 6.97 3.95e-09 5.87e-05 0.89 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138993430 chr5:138744434~138753309:- MESO cis rs1153858 0.621 rs2413769 ENSG00000259520.4 CTD-2651B20.3 -6.95 4.13e-09 6.09e-05 -0.93 -0.68 Homoarginine levels; chr15:45269670 chr15:45251580~45279251:- MESO cis rs801193 0.613 rs2659900 ENSG00000226824.5 RP4-756H11.3 -6.95 4.14e-09 6.1e-05 -0.87 -0.68 Aortic root size; chr7:66719456 chr7:66654538~66669855:+ MESO cis rs2486288 0.656 rs11637838 ENSG00000259520.4 CTD-2651B20.3 6.94 4.27e-09 6.24e-05 0.9 0.68 Glomerular filtration rate; chr15:45258459 chr15:45251580~45279251:- MESO cis rs801193 0.66 rs2659914 ENSG00000226824.5 RP4-756H11.3 -6.94 4.28e-09 6.24e-05 -0.87 -0.68 Aortic root size; chr7:66691927 chr7:66654538~66669855:+ MESO cis rs2882667 0.964 rs2288824 ENSG00000253404.1 AC034243.1 6.94 4.3e-09 6.27e-05 0.94 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138962707 chr5:138744434~138753309:- MESO cis rs2486288 0.656 rs11637364 ENSG00000259520.4 CTD-2651B20.3 6.93 4.43e-09 6.44e-05 0.93 0.68 Glomerular filtration rate; chr15:45287040 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs8039153 ENSG00000259520.4 CTD-2651B20.3 6.93 4.43e-09 6.44e-05 0.93 0.68 Glomerular filtration rate; chr15:45287615 chr15:45251580~45279251:- MESO cis rs801193 0.967 rs2707853 ENSG00000226824.5 RP4-756H11.3 -6.93 4.54e-09 6.57e-05 -0.92 -0.68 Aortic root size; chr7:66749023 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2659889 ENSG00000226824.5 RP4-756H11.3 -6.93 4.54e-09 6.57e-05 -0.92 -0.68 Aortic root size; chr7:66752125 chr7:66654538~66669855:+ MESO cis rs801193 1 rs3800812 ENSG00000226824.5 RP4-756H11.3 -6.93 4.54e-09 6.57e-05 -0.92 -0.68 Aortic root size; chr7:66758474 chr7:66654538~66669855:+ MESO cis rs801193 1 rs4279493 ENSG00000226824.5 RP4-756H11.3 -6.93 4.54e-09 6.57e-05 -0.92 -0.68 Aortic root size; chr7:66761633 chr7:66654538~66669855:+ MESO cis rs801193 0.967 rs34356500 ENSG00000226824.5 RP4-756H11.3 -6.93 4.54e-09 6.57e-05 -0.92 -0.68 Aortic root size; chr7:66771620 chr7:66654538~66669855:+ MESO cis rs801193 1 rs4717319 ENSG00000226824.5 RP4-756H11.3 -6.93 4.54e-09 6.57e-05 -0.92 -0.68 Aortic root size; chr7:66777606 chr7:66654538~66669855:+ MESO cis rs801193 0.904 rs4718403 ENSG00000226824.5 RP4-756H11.3 -6.93 4.54e-09 6.57e-05 -0.92 -0.68 Aortic root size; chr7:66777742 chr7:66654538~66669855:+ MESO cis rs801193 0.904 rs4718405 ENSG00000226824.5 RP4-756H11.3 -6.93 4.54e-09 6.57e-05 -0.92 -0.68 Aortic root size; chr7:66789659 chr7:66654538~66669855:+ MESO cis rs2486288 0.554 rs1719235 ENSG00000259520.4 CTD-2651B20.3 6.93 4.58e-09 6.61e-05 0.94 0.68 Glomerular filtration rate; chr15:45283910 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs1706770 ENSG00000259520.4 CTD-2651B20.3 6.93 4.6e-09 6.63e-05 0.94 0.68 Glomerular filtration rate; chr15:45282864 chr15:45251580~45279251:- MESO cis rs2882667 0.652 rs874115 ENSG00000253404.1 AC034243.1 6.92 4.61e-09 6.64e-05 0.94 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138944367 chr5:138744434~138753309:- MESO cis rs1799949 0.965 rs8067269 ENSG00000198496.9 NBR2 -6.92 4.63e-09 6.66e-05 -0.84 -0.68 Menopause (age at onset); chr17:43083782 chr17:43125610~43153671:+ MESO cis rs801193 1 rs2707850 ENSG00000226824.5 RP4-756H11.3 -6.92 4.68e-09 6.71e-05 -0.92 -0.68 Aortic root size; chr7:66738883 chr7:66654538~66669855:+ MESO cis rs801193 0.967 rs1110414 ENSG00000226824.5 RP4-756H11.3 -6.92 4.68e-09 6.71e-05 -0.92 -0.68 Aortic root size; chr7:66740595 chr7:66654538~66669855:+ MESO cis rs801193 1 rs7783924 ENSG00000226824.5 RP4-756H11.3 -6.92 4.68e-09 6.71e-05 -0.92 -0.68 Aortic root size; chr7:66744070 chr7:66654538~66669855:+ MESO cis rs801193 1 rs7789184 ENSG00000226824.5 RP4-756H11.3 -6.92 4.68e-09 6.71e-05 -0.92 -0.68 Aortic root size; chr7:66745208 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2707856 ENSG00000226824.5 RP4-756H11.3 -6.92 4.68e-09 6.71e-05 -0.92 -0.68 Aortic root size; chr7:66746023 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2707854 ENSG00000226824.5 RP4-756H11.3 -6.92 4.68e-09 6.71e-05 -0.92 -0.68 Aortic root size; chr7:66747610 chr7:66654538~66669855:+ MESO cis rs801193 1 rs3778909 ENSG00000226824.5 RP4-756H11.3 -6.92 4.68e-09 6.71e-05 -0.92 -0.68 Aortic root size; chr7:66790659 chr7:66654538~66669855:+ MESO cis rs2486288 0.656 rs1706768 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45277245 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs62026703 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45277731 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs7171312 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45278027 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs2461705 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45278043 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs7165039 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45278215 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs6493143 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45278583 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs7166580 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45279011 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs12908818 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45279470 chr15:45251580~45279251:- MESO cis rs2486288 0.586 rs12909625 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45279855 chr15:45251580~45279251:- MESO cis rs2486288 0.586 rs12909883 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45279856 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs1719232 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45279874 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs12910009 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45280210 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs6493145 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45281664 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs8024620 ENSG00000259520.4 CTD-2651B20.3 6.91 4.9e-09 6.84e-05 0.94 0.68 Glomerular filtration rate; chr15:45282131 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs6493144 ENSG00000259520.4 CTD-2651B20.3 -6.91 4.9e-09 6.84e-05 -0.94 -0.68 Glomerular filtration rate; chr15:45281291 chr15:45251580~45279251:- MESO cis rs875971 1 rs6945843 ENSG00000226824.5 RP4-756H11.3 6.9 5.14e-09 7.13e-05 0.89 0.68 Aortic root size; chr7:66269796 chr7:66654538~66669855:+ MESO cis rs9322193 0.961 rs9285521 ENSG00000231760.4 RP11-350J20.5 6.89 5.17e-09 7.15e-05 0.85 0.68 Lung cancer; chr6:149585576 chr6:149796151~149826294:- MESO cis rs9322193 0.851 rs9322194 ENSG00000231760.4 RP11-350J20.5 6.89 5.27e-09 7.29e-05 0.89 0.68 Lung cancer; chr6:149599113 chr6:149796151~149826294:- MESO cis rs2882667 0.929 rs17207828 ENSG00000253404.1 AC034243.1 6.89 5.28e-09 7.3e-05 0.95 0.68 Age-related hearing impairment (SNP x SNP interaction); chr5:138964146 chr5:138744434~138753309:- MESO cis rs950027 0.549 rs11636114 ENSG00000259520.4 CTD-2651B20.3 -6.89 5.34e-09 7.37e-05 -0.91 -0.68 Response to fenofibrate (adiponectin levels); chr15:45309214 chr15:45251580~45279251:- MESO cis rs977987 0.832 rs37597 ENSG00000261783.1 RP11-252K23.2 6.87 5.59e-09 7.7e-05 0.89 0.68 Dupuytren's disease; chr16:75466377 chr16:75379818~75381260:- MESO cis rs9322193 0.884 rs11155675 ENSG00000231760.4 RP11-350J20.5 6.85 6.03e-09 8.3e-05 0.92 0.68 Lung cancer; chr6:149742883 chr6:149796151~149826294:- MESO cis rs2882667 1 rs2060222 ENSG00000253404.1 AC034243.1 6.84 6.34e-09 8.72e-05 0.94 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138972777 chr5:138744434~138753309:- MESO cis rs2882667 1 rs10064130 ENSG00000253404.1 AC034243.1 6.84 6.34e-09 8.72e-05 0.94 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138973618 chr5:138744434~138753309:- MESO cis rs2882667 1 rs10064201 ENSG00000253404.1 AC034243.1 6.84 6.34e-09 8.72e-05 0.94 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138973716 chr5:138744434~138753309:- MESO cis rs875971 1 rs6963646 ENSG00000226824.5 RP4-756H11.3 6.83 6.53e-09 8.89e-05 0.88 0.67 Aortic root size; chr7:66220780 chr7:66654538~66669855:+ MESO cis rs875971 0.965 rs28682868 ENSG00000226824.5 RP4-756H11.3 6.83 6.53e-09 8.89e-05 0.88 0.67 Aortic root size; chr7:66224822 chr7:66654538~66669855:+ MESO cis rs875971 0.898 rs6977501 ENSG00000226824.5 RP4-756H11.3 6.83 6.53e-09 8.89e-05 0.88 0.67 Aortic root size; chr7:66228355 chr7:66654538~66669855:+ MESO cis rs875971 1 rs9986696 ENSG00000226824.5 RP4-756H11.3 6.83 6.53e-09 8.89e-05 0.88 0.67 Aortic root size; chr7:66239589 chr7:66654538~66669855:+ MESO cis rs875971 0.965 rs6971509 ENSG00000226824.5 RP4-756H11.3 6.83 6.53e-09 8.89e-05 0.88 0.67 Aortic root size; chr7:66249983 chr7:66654538~66669855:+ MESO cis rs875971 0.965 rs10267430 ENSG00000226824.5 RP4-756H11.3 6.83 6.53e-09 8.89e-05 0.88 0.67 Aortic root size; chr7:66278036 chr7:66654538~66669855:+ MESO cis rs875971 1 rs10257427 ENSG00000226824.5 RP4-756H11.3 6.83 6.53e-09 8.89e-05 0.88 0.67 Aortic root size; chr7:66278221 chr7:66654538~66669855:+ MESO cis rs875971 1 rs10215948 ENSG00000226824.5 RP4-756H11.3 6.83 6.53e-09 8.89e-05 0.88 0.67 Aortic root size; chr7:66282799 chr7:66654538~66669855:+ MESO cis rs875971 0.838 rs2173570 ENSG00000226824.5 RP4-756H11.3 6.83 6.53e-09 8.89e-05 0.88 0.67 Aortic root size; chr7:66297976 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs55748098 ENSG00000226824.5 RP4-756H11.3 6.83 6.53e-09 8.89e-05 0.88 0.67 Aortic root size; chr7:66298631 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs778735 ENSG00000226824.5 RP4-756H11.3 -6.83 6.53e-09 8.89e-05 -0.88 -0.67 Aortic root size; chr7:66349822 chr7:66654538~66669855:+ MESO cis rs875971 1 rs709595 ENSG00000226824.5 RP4-756H11.3 -6.83 6.53e-09 8.89e-05 -0.88 -0.67 Aortic root size; chr7:66352346 chr7:66654538~66669855:+ MESO cis rs875971 1 rs811880 ENSG00000226824.5 RP4-756H11.3 -6.83 6.53e-09 8.89e-05 -0.88 -0.67 Aortic root size; chr7:66353659 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs4718358 ENSG00000226824.5 RP4-756H11.3 -6.83 6.53e-09 8.89e-05 -0.88 -0.67 Aortic root size; chr7:66508681 chr7:66654538~66669855:+ MESO cis rs875971 0.929 rs10950041 ENSG00000226824.5 RP4-756H11.3 -6.83 6.53e-09 8.89e-05 -0.88 -0.67 Aortic root size; chr7:66508888 chr7:66654538~66669855:+ MESO cis rs875971 0.929 rs6970860 ENSG00000226824.5 RP4-756H11.3 -6.83 6.53e-09 8.89e-05 -0.88 -0.67 Aortic root size; chr7:66511647 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6957199 ENSG00000226824.5 RP4-756H11.3 -6.83 6.53e-09 8.89e-05 -0.88 -0.67 Aortic root size; chr7:66513532 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6958271 ENSG00000226824.5 RP4-756H11.3 -6.83 6.53e-09 8.89e-05 -0.88 -0.67 Aortic root size; chr7:66514344 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6958277 ENSG00000226824.5 RP4-756H11.3 -6.83 6.53e-09 8.89e-05 -0.88 -0.67 Aortic root size; chr7:66514362 chr7:66654538~66669855:+ MESO cis rs9326248 0.53 rs11216171 ENSG00000254851.1 RP11-109L13.1 -6.82 6.75e-09 9.11e-05 -1.02 -0.67 Blood protein levels; chr11:116878397 chr11:117135528~117138582:+ MESO cis rs801193 0.591 rs2707839 ENSG00000226824.5 RP4-756H11.3 -6.81 7.03e-09 9.47e-05 -0.85 -0.67 Aortic root size; chr7:66728097 chr7:66654538~66669855:+ MESO cis rs801193 0.636 rs2659895 ENSG00000226824.5 RP4-756H11.3 -6.81 7.03e-09 9.47e-05 -0.85 -0.67 Aortic root size; chr7:66731484 chr7:66654538~66669855:+ MESO cis rs875971 0.929 rs4122249 ENSG00000226824.5 RP4-756H11.3 -6.8 7.29e-09 9.8e-05 -0.88 -0.67 Aortic root size; chr7:66455949 chr7:66654538~66669855:+ MESO cis rs6452524 0.618 rs6452502 ENSG00000249664.1 CTD-2227C6.2 6.8 7.38e-09 9.89e-05 0.88 0.67 Hypertension (SNP x SNP interaction); chr5:83074578 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs6452503 ENSG00000249664.1 CTD-2227C6.2 6.8 7.38e-09 9.89e-05 0.88 0.67 Hypertension (SNP x SNP interaction); chr5:83074596 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs6452504 ENSG00000249664.1 CTD-2227C6.2 6.8 7.38e-09 9.89e-05 0.88 0.67 Hypertension (SNP x SNP interaction); chr5:83074625 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs6452506 ENSG00000249664.1 CTD-2227C6.2 6.8 7.38e-09 9.89e-05 0.88 0.67 Hypertension (SNP x SNP interaction); chr5:83075844 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs1993948 ENSG00000249664.1 CTD-2227C6.2 6.8 7.38e-09 9.89e-05 0.88 0.67 Hypertension (SNP x SNP interaction); chr5:83076461 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs2075685 ENSG00000249664.1 CTD-2227C6.2 6.8 7.38e-09 9.89e-05 0.88 0.67 Hypertension (SNP x SNP interaction); chr5:83076846 chr5:83012285~83013109:- MESO cis rs977987 0.654 rs8054194 ENSG00000261783.1 RP11-252K23.2 -6.79 7.67e-09 0.000102 -0.86 -0.67 Dupuytren's disease; chr16:75463262 chr16:75379818~75381260:- MESO cis rs977987 0.581 rs8056141 ENSG00000261783.1 RP11-252K23.2 -6.79 7.67e-09 0.000102 -0.86 -0.67 Dupuytren's disease; chr16:75463264 chr16:75379818~75381260:- MESO cis rs9326248 0.769 rs499910 ENSG00000254851.1 RP11-109L13.1 -6.79 7.71e-09 0.000103 -1.02 -0.67 Blood protein levels; chr11:116892318 chr11:117135528~117138582:+ MESO cis rs9322193 0.884 rs10872647 ENSG00000231760.4 RP11-350J20.5 6.79 7.74e-09 0.000103 0.92 0.67 Lung cancer; chr6:149758687 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs10872648 ENSG00000231760.4 RP11-350J20.5 6.79 7.74e-09 0.000103 0.92 0.67 Lung cancer; chr6:149758699 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs11155679 ENSG00000231760.4 RP11-350J20.5 6.79 7.74e-09 0.000103 0.92 0.67 Lung cancer; chr6:149758881 chr6:149796151~149826294:- MESO cis rs6452524 0.618 rs255561 ENSG00000249664.1 CTD-2227C6.2 6.79 7.76e-09 0.000103 0.86 0.67 Hypertension (SNP x SNP interaction); chr5:83054991 chr5:83012285~83013109:- MESO cis rs2882667 0.931 rs10044736 ENSG00000253404.1 AC034243.1 -6.78 8.13e-09 0.000103 -0.89 -0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138985120 chr5:138744434~138753309:- MESO cis rs875971 1 rs778726 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66363744 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs778723 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66364510 chr7:66654538~66669855:+ MESO cis rs875971 0.767 rs1695815 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66366357 chr7:66654538~66669855:+ MESO cis rs875971 1 rs778685 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66371189 chr7:66654538~66669855:+ MESO cis rs875971 0.929 rs778682 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66372947 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs11765965 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66377234 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs1643388 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66379575 chr7:66654538~66669855:+ MESO cis rs875971 1 rs778722 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66379841 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs778721 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66380410 chr7:66654538~66669855:+ MESO cis rs875971 0.929 rs778712 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66384991 chr7:66654538~66669855:+ MESO cis rs875971 1 rs778710 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66389847 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs778708 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66391332 chr7:66654538~66669855:+ MESO cis rs875971 1 rs778706 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66395437 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs778700 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66401463 chr7:66654538~66669855:+ MESO cis rs875971 1 rs778699 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66403303 chr7:66654538~66669855:+ MESO cis rs875971 1 rs778696 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66405826 chr7:66654538~66669855:+ MESO cis rs875971 1 rs778694 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66406571 chr7:66654538~66669855:+ MESO cis rs875971 0.929 rs778692 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66407462 chr7:66654538~66669855:+ MESO cis rs875971 1 rs4718343 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66409301 chr7:66654538~66669855:+ MESO cis rs875971 1 rs4718344 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66409394 chr7:66654538~66669855:+ MESO cis rs875971 1 rs1968225 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66409786 chr7:66654538~66669855:+ MESO cis rs875971 0.737 rs7803424 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66415618 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs7799834 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66415707 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6460295 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66417741 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs6978721 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66418217 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6979382 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66421388 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6961990 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66423583 chr7:66654538~66669855:+ MESO cis rs875971 1 rs2077593 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66427543 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6460296 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66430152 chr7:66654538~66669855:+ MESO cis rs875971 1 rs4717292 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66430611 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs4718349 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66444024 chr7:66654538~66669855:+ MESO cis rs875971 1 rs2420591 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66447394 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs10755833 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66448930 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs12668936 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66449417 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs7788984 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66450629 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs12698520 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66453720 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs1833495 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66456608 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs6945032 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66457499 chr7:66654538~66669855:+ MESO cis rs875971 0.929 rs12673810 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66458866 chr7:66654538~66669855:+ MESO cis rs875971 1 rs35149210 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66464938 chr7:66654538~66669855:+ MESO cis rs875971 0.929 rs34406470 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66464969 chr7:66654538~66669855:+ MESO cis rs875971 1 rs2042133 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66466935 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs2161065 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66467918 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6961155 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66468308 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs3857684 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66473171 chr7:66654538~66669855:+ MESO cis rs875971 1 rs7789768 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66473993 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs12698521 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66474502 chr7:66654538~66669855:+ MESO cis rs875971 1 rs1363055 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66478288 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs9691480 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66479319 chr7:66654538~66669855:+ MESO cis rs875971 1 rs7789554 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66481051 chr7:66654538~66669855:+ MESO cis rs875971 1 rs4717300 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66482393 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs1974769 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66485627 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs6460300 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66487937 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs7803416 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66489212 chr7:66654538~66669855:+ MESO cis rs875971 1 rs1981798 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66489916 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1981799 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66490572 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs2277911 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66493638 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs6978429 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66494889 chr7:66654538~66669855:+ MESO cis rs875971 1 rs4718357 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66495891 chr7:66654538~66669855:+ MESO cis rs875971 0.929 rs12535036 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66499076 chr7:66654538~66669855:+ MESO cis rs875971 1 rs12533997 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66500390 chr7:66654538~66669855:+ MESO cis rs875971 1 rs12698523 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66503126 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6970030 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66503692 chr7:66654538~66669855:+ MESO cis rs875971 0.928 rs6970357 ENSG00000226824.5 RP4-756H11.3 -6.78 8.13e-09 0.000103 -0.87 -0.67 Aortic root size; chr7:66503891 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6961717 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66122550 chr7:66654538~66669855:+ MESO cis rs875971 1 rs2087647 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66128201 chr7:66654538~66669855:+ MESO cis rs875971 1 rs6958484 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66134459 chr7:66654538~66669855:+ MESO cis rs875971 1 rs4718307 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66146001 chr7:66654538~66669855:+ MESO cis rs875971 1 rs7801282 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66148700 chr7:66654538~66669855:+ MESO cis rs875971 1 rs55962648 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66160764 chr7:66654538~66669855:+ MESO cis rs875971 1 rs11971949 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66161027 chr7:66654538~66669855:+ MESO cis rs875971 1 rs2420168 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66165644 chr7:66654538~66669855:+ MESO cis rs875971 1 rs11974219 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66182423 chr7:66654538~66669855:+ MESO cis rs875971 1 rs11974264 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66182595 chr7:66654538~66669855:+ MESO cis rs875971 1 rs1540651 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66185134 chr7:66654538~66669855:+ MESO cis rs875971 1 rs1565531 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66198126 chr7:66654538~66669855:+ MESO cis rs875971 1 rs709597 ENSG00000226824.5 RP4-756H11.3 6.78 8.13e-09 0.000103 0.87 0.67 Aortic root size; chr7:66360996 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs6945019 ENSG00000226824.5 RP4-756H11.3 -6.77 8.28e-09 0.000105 -0.88 -0.67 Aortic root size; chr7:66457471 chr7:66654538~66669855:+ MESO cis rs2486288 0.656 rs12440356 ENSG00000259520.4 CTD-2651B20.3 -6.76 8.71e-09 0.000109 -0.93 -0.67 Glomerular filtration rate; chr15:45275331 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs12911861 ENSG00000259520.4 CTD-2651B20.3 6.76 8.71e-09 0.000109 0.93 0.67 Glomerular filtration rate; chr15:45274520 chr15:45251580~45279251:- MESO cis rs875971 1 rs875971 ENSG00000226824.5 RP4-756H11.3 6.75 8.83e-09 0.000111 0.85 0.67 Aortic root size; chr7:66152608 chr7:66654538~66669855:+ MESO cis rs9326248 0.731 rs90192 ENSG00000254851.1 RP11-109L13.1 -6.75 9.08e-09 0.000114 -1.04 -0.67 Blood protein levels; chr11:117188631 chr11:117135528~117138582:+ MESO cis rs2486288 0.656 rs11639349 ENSG00000259520.4 CTD-2651B20.3 6.74 9.12e-09 0.000114 0.93 0.67 Glomerular filtration rate; chr15:45276062 chr15:45251580~45279251:- MESO cis rs2486288 0.656 rs1719236 ENSG00000259520.4 CTD-2651B20.3 6.74 9.2e-09 0.000115 0.88 0.67 Glomerular filtration rate; chr15:45285585 chr15:45251580~45279251:- MESO cis rs6700559 1 rs6700559 ENSG00000260088.1 RP11-92G12.3 6.74 9.39e-09 0.000116 0.77 0.67 Coronary artery disease; chr1:200676945 chr1:200669507~200694250:+ MESO cis rs6700559 0.804 rs11588318 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200669534 chr1:200669507~200694250:+ MESO cis rs6700559 0.903 rs6661240 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200669719 chr1:200669507~200694250:+ MESO cis rs6700559 0.967 rs6688581 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200670028 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs3806358 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200670555 chr1:200669507~200694250:+ MESO cis rs6700559 0.683 rs4915450 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200672461 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs10494821 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200673357 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs4311922 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200674257 chr1:200669507~200694250:+ MESO cis rs6700559 0.967 rs4447009 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200674278 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs4265457 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200674326 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs6667172 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200674710 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs7527499 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200676217 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs6427838 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200676519 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs12061346 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200677648 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs7533971 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200678243 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs10919998 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200679182 chr1:200669507~200694250:+ MESO cis rs6700559 0.967 rs4072552 ENSG00000260088.1 RP11-92G12.3 -6.74 9.39e-09 0.000116 -0.77 -0.67 Coronary artery disease; chr1:200680003 chr1:200669507~200694250:+ MESO cis rs9326248 0.581 rs10892048 ENSG00000254851.1 RP11-109L13.1 -6.73 9.52e-09 0.000118 -0.85 -0.67 Blood protein levels; chr11:116943880 chr11:117135528~117138582:+ MESO cis rs9322193 0.884 rs1125 ENSG00000231760.4 RP11-350J20.5 6.73 9.6e-09 0.000119 0.86 0.67 Lung cancer; chr6:149658280 chr6:149796151~149826294:- MESO cis rs977987 0.868 rs10871313 ENSG00000261783.1 RP11-252K23.2 -6.72 9.86e-09 0.000122 -0.88 -0.67 Dupuytren's disease; chr16:75473196 chr16:75379818~75381260:- MESO cis rs1799949 0.965 rs8176198 ENSG00000198496.9 NBR2 -6.72 1e-08 0.000124 -0.87 -0.67 Menopause (age at onset); chr17:43078520 chr17:43125610~43153671:+ MESO cis rs875971 1 rs10244498 ENSG00000226824.5 RP4-756H11.3 -6.71 1.03e-08 0.000127 -0.84 -0.67 Aortic root size; chr7:66651069 chr7:66654538~66669855:+ MESO cis rs801193 0.66 rs2659897 ENSG00000226824.5 RP4-756H11.3 6.71 1.03e-08 0.000127 0.84 0.67 Aortic root size; chr7:66722728 chr7:66654538~66669855:+ MESO cis rs977987 0.864 rs40446 ENSG00000261783.1 RP11-252K23.2 6.71 1.05e-08 0.000129 0.85 0.67 Dupuytren's disease; chr16:75462760 chr16:75379818~75381260:- MESO cis rs977987 0.864 rs37592 ENSG00000261783.1 RP11-252K23.2 6.71 1.05e-08 0.000129 0.85 0.67 Dupuytren's disease; chr16:75462893 chr16:75379818~75381260:- MESO cis rs977987 0.864 rs37593 ENSG00000261783.1 RP11-252K23.2 6.71 1.05e-08 0.000129 0.85 0.67 Dupuytren's disease; chr16:75463009 chr16:75379818~75381260:- MESO cis rs977987 0.864 rs37594 ENSG00000261783.1 RP11-252K23.2 6.71 1.05e-08 0.000129 0.85 0.67 Dupuytren's disease; chr16:75463045 chr16:75379818~75381260:- MESO cis rs977987 0.864 rs37595 ENSG00000261783.1 RP11-252K23.2 6.71 1.05e-08 0.000129 0.85 0.67 Dupuytren's disease; chr16:75463065 chr16:75379818~75381260:- MESO cis rs801193 1 rs10234018 ENSG00000226824.5 RP4-756H11.3 6.71 1.05e-08 0.000129 0.91 0.67 Aortic root size; chr7:66681297 chr7:66654538~66669855:+ MESO cis rs6700559 1 rs6656619 ENSG00000260088.1 RP11-92G12.3 6.7 1.06e-08 0.000131 0.77 0.67 Coronary artery disease; chr1:200671664 chr1:200669507~200694250:+ MESO cis rs2882667 0.931 rs10070021 ENSG00000253404.1 AC034243.1 6.7 1.07e-08 0.000131 0.89 0.67 Age-related hearing impairment (SNP x SNP interaction); chr5:138989017 chr5:138744434~138753309:- MESO cis rs9322193 0.887 rs11155662 ENSG00000231760.4 RP11-350J20.5 6.69 1.11e-08 0.000135 0.91 0.67 Lung cancer; chr6:149592731 chr6:149796151~149826294:- MESO cis rs9322193 0.887 rs3734295 ENSG00000231760.4 RP11-350J20.5 6.69 1.11e-08 0.000135 0.91 0.67 Lung cancer; chr6:149593917 chr6:149796151~149826294:- MESO cis rs9322193 0.887 rs3777949 ENSG00000231760.4 RP11-350J20.5 6.69 1.11e-08 0.000135 0.91 0.67 Lung cancer; chr6:149596021 chr6:149796151~149826294:- MESO cis rs801193 0.636 rs10233806 ENSG00000226824.5 RP4-756H11.3 6.67 1.2e-08 0.000147 0.86 0.67 Aortic root size; chr7:66653261 chr7:66654538~66669855:+ MESO cis rs2739330 0.734 rs2000467 ENSG00000218537.1 MIF-AS1 -6.66 1.28e-08 0.000153 -0.84 -0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23894426~23898930:- MESO cis rs801193 0.761 rs2659888 ENSG00000226824.5 RP4-756H11.3 -6.65 1.32e-08 0.000157 -0.88 -0.66 Aortic root size; chr7:66765184 chr7:66654538~66669855:+ MESO cis rs2486288 0.656 rs10519018 ENSG00000259520.4 CTD-2651B20.3 6.64 1.34e-08 0.000159 0.92 0.66 Glomerular filtration rate; chr15:45257067 chr15:45251580~45279251:- MESO cis rs858239 0.676 rs274032 ENSG00000230658.1 KLHL7-AS1 6.64 1.36e-08 0.00016 0.95 0.66 Cerebrospinal fluid biomarker levels; chr7:23334940 chr7:23101228~23105703:- MESO cis rs801193 0.935 rs2659916 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66686365 chr7:66654538~66669855:+ MESO cis rs801193 1 rs6958520 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66686466 chr7:66654538~66669855:+ MESO cis rs801193 0.967 rs2707849 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66687725 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2659915 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66688114 chr7:66654538~66669855:+ MESO cis rs801193 0.967 rs2707841 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66692033 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2659912 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66693012 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2659909 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66695292 chr7:66654538~66669855:+ MESO cis rs801193 1 rs4717310 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66696020 chr7:66654538~66669855:+ MESO cis rs801193 0.844 rs7779971 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66696803 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2659906 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66700323 chr7:66654538~66669855:+ MESO cis rs801193 0.935 rs11772264 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66711400 chr7:66654538~66669855:+ MESO cis rs801193 1 rs7782320 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66712111 chr7:66654538~66669855:+ MESO cis rs801193 0.935 rs2659899 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.00016 -0.92 -0.66 Aortic root size; chr7:66721734 chr7:66654538~66669855:+ MESO cis rs875971 0.638 rs7793569 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66651646 chr7:66654538~66669855:+ MESO cis rs801193 1 rs6975195 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66659787 chr7:66654538~66669855:+ MESO cis rs801193 1 rs3857688 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66662819 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2286684 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66664843 chr7:66654538~66669855:+ MESO cis rs801193 0.935 rs2286683 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66664856 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2420824 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66666129 chr7:66654538~66669855:+ MESO cis rs801193 1 rs10274773 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66668591 chr7:66654538~66669855:+ MESO cis rs801193 1 rs7785213 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66673991 chr7:66654538~66669855:+ MESO cis rs801193 1 rs11773829 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66676087 chr7:66654538~66669855:+ MESO cis rs801193 0.935 rs3800820 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66682191 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2003301 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66682669 chr7:66654538~66669855:+ MESO cis rs801193 1 rs7788576 ENSG00000226824.5 RP4-756H11.3 6.64 1.38e-08 0.00016 0.92 0.66 Aortic root size; chr7:66683315 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs60193905 ENSG00000226824.5 RP4-756H11.3 -6.64 1.38e-08 0.000161 -0.87 -0.66 Aortic root size; chr7:66506273 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs79009421 ENSG00000226824.5 RP4-756H11.3 6.63 1.4e-08 0.000162 0.91 0.66 Aortic root size; chr7:66603522 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs6460308 ENSG00000226824.5 RP4-756H11.3 6.63 1.4e-08 0.000162 0.91 0.66 Aortic root size; chr7:66619753 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs7807930 ENSG00000226824.5 RP4-756H11.3 6.63 1.4e-08 0.000162 0.91 0.66 Aortic root size; chr7:66622178 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs7807944 ENSG00000226824.5 RP4-756H11.3 6.63 1.4e-08 0.000162 0.91 0.66 Aortic root size; chr7:66622208 chr7:66654538~66669855:+ MESO cis rs1799949 0.965 rs9911630 ENSG00000198496.9 NBR2 -6.62 1.44e-08 0.000167 -0.84 -0.66 Menopause (age at onset); chr17:43036325 chr17:43125610~43153671:+ MESO cis rs2739330 0.796 rs2154594 ENSG00000273295.1 AP000350.5 -6.62 1.48e-08 0.000171 -0.78 -0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23901432~23907068:- MESO cis rs57502260 0.68 rs7104806 ENSG00000212093.1 AP000807.1 6.6 1.58e-08 0.000179 0.84 0.66 Total body bone mineral density (age 45-60); chr11:68454720 chr11:68506083~68506166:- MESO cis rs57502260 0.764 rs3867143 ENSG00000212093.1 AP000807.1 6.6 1.58e-08 0.000179 0.84 0.66 Total body bone mineral density (age 45-60); chr11:68455606 chr11:68506083~68506166:- MESO cis rs138341189 1 rs138341189 ENSG00000212093.1 AP000807.1 6.6 1.58e-08 0.000179 0.84 0.66 Monobrow; chr11:68456954 chr11:68506083~68506166:- MESO cis rs57502260 0.749 rs67446678 ENSG00000212093.1 AP000807.1 6.6 1.58e-08 0.000179 0.84 0.66 Total body bone mineral density (age 45-60); chr11:68459998 chr11:68506083~68506166:- MESO cis rs875971 0.638 rs801205 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66557157 chr7:66654538~66669855:+ MESO cis rs875971 0.617 rs810400 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66557902 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs801193 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66565625 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs801192 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66566965 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs801190 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66568046 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs2013222 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66570949 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs3857686 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66571204 chr7:66654538~66669855:+ MESO cis rs875971 0.638 rs3898855 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66571411 chr7:66654538~66669855:+ MESO cis rs875971 0.638 rs10278816 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66572000 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs10281080 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66577454 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs10950044 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66577989 chr7:66654538~66669855:+ MESO cis rs6952407 1 rs6952407 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Cotinine glucuronidation; chr7:66580525 chr7:66654538~66669855:+ MESO cis rs875971 0.638 rs10249404 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66581737 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs10215132 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66589419 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs1968127 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66591816 chr7:66654538~66669855:+ MESO cis rs875971 0.638 rs6460305 ENSG00000226824.5 RP4-756H11.3 6.6 1.58e-08 0.000179 0.91 0.66 Aortic root size; chr7:66595421 chr7:66654538~66669855:+ MESO cis rs858239 0.863 rs274054 ENSG00000230658.1 KLHL7-AS1 6.6 1.61e-08 0.000181 0.95 0.66 Cerebrospinal fluid biomarker levels; chr7:23350848 chr7:23101228~23105703:- MESO cis rs2739330 0.828 rs2330635 ENSG00000273295.1 AP000350.5 6.59 1.65e-08 0.000184 0.76 0.66 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23901432~23907068:- MESO cis rs858239 0.712 rs199650 ENSG00000230658.1 KLHL7-AS1 -6.59 1.67e-08 0.000184 -0.96 -0.66 Cerebrospinal fluid biomarker levels; chr7:23327570 chr7:23101228~23105703:- MESO cis rs2882667 0.964 rs12719517 ENSG00000253404.1 AC034243.1 6.58 1.7e-08 0.000187 0.9 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138969813 chr5:138744434~138753309:- MESO cis rs801193 1 rs62466793 ENSG00000226824.5 RP4-756H11.3 -6.58 1.71e-08 0.000188 -0.91 -0.66 Aortic root size; chr7:66726530 chr7:66654538~66669855:+ MESO cis rs801193 1 rs62466794 ENSG00000226824.5 RP4-756H11.3 -6.58 1.71e-08 0.000188 -0.91 -0.66 Aortic root size; chr7:66726592 chr7:66654538~66669855:+ MESO cis rs801193 1 rs1553609 ENSG00000226824.5 RP4-756H11.3 -6.58 1.71e-08 0.000188 -0.91 -0.66 Aortic root size; chr7:66732152 chr7:66654538~66669855:+ MESO cis rs801193 1 rs1553610 ENSG00000226824.5 RP4-756H11.3 -6.58 1.71e-08 0.000188 -0.91 -0.66 Aortic root size; chr7:66732246 chr7:66654538~66669855:+ MESO cis rs801193 1 rs2707845 ENSG00000226824.5 RP4-756H11.3 -6.58 1.71e-08 0.000188 -0.91 -0.66 Aortic root size; chr7:66733811 chr7:66654538~66669855:+ MESO cis rs875971 1 rs3735148 ENSG00000226824.5 RP4-756H11.3 -6.58 1.72e-08 0.000189 -0.87 -0.66 Aortic root size; chr7:66506022 chr7:66654538~66669855:+ MESO cis rs875971 0.965 rs697968 ENSG00000226824.5 RP4-756H11.3 6.58 1.74e-08 0.00019 0.85 0.66 Aortic root size; chr7:66070046 chr7:66654538~66669855:+ MESO cis rs875971 1 rs1183245 ENSG00000226824.5 RP4-756H11.3 6.58 1.74e-08 0.00019 0.85 0.66 Aortic root size; chr7:66076198 chr7:66654538~66669855:+ MESO cis rs875971 1 rs1144895 ENSG00000226824.5 RP4-756H11.3 6.58 1.74e-08 0.00019 0.85 0.66 Aortic root size; chr7:66076320 chr7:66654538~66669855:+ MESO cis rs875971 1 rs1144894 ENSG00000226824.5 RP4-756H11.3 6.58 1.74e-08 0.00019 0.85 0.66 Aortic root size; chr7:66077907 chr7:66654538~66669855:+ MESO cis rs875971 1 rs2220626 ENSG00000226824.5 RP4-756H11.3 6.58 1.74e-08 0.00019 0.85 0.66 Aortic root size; chr7:66081075 chr7:66654538~66669855:+ MESO cis rs2486288 0.656 rs7162022 ENSG00000259520.4 CTD-2651B20.3 6.57 1.79e-08 0.000194 0.92 0.66 Glomerular filtration rate; chr15:45273055 chr15:45251580~45279251:- MESO cis rs875971 0.66 rs28698552 ENSG00000226824.5 RP4-756H11.3 -6.57 1.8e-08 0.000194 -0.9 -0.66 Aortic root size; chr7:66540031 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs62465434 ENSG00000226824.5 RP4-756H11.3 -6.57 1.8e-08 0.000194 -0.9 -0.66 Aortic root size; chr7:66540165 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs801211 ENSG00000226824.5 RP4-756H11.3 6.57 1.8e-08 0.000194 0.9 0.66 Aortic root size; chr7:66550702 chr7:66654538~66669855:+ MESO cis rs875971 0.619 rs2302918 ENSG00000226824.5 RP4-756H11.3 -6.56 1.82e-08 0.000197 -0.9 -0.66 Aortic root size; chr7:66535945 chr7:66654538~66669855:+ MESO cis rs875971 0.619 rs12533585 ENSG00000226824.5 RP4-756H11.3 -6.56 1.84e-08 0.000198 -0.9 -0.66 Aortic root size; chr7:66519618 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs12698534 ENSG00000226824.5 RP4-756H11.3 -6.56 1.84e-08 0.000198 -0.9 -0.66 Aortic root size; chr7:66521858 chr7:66654538~66669855:+ MESO cis rs875971 0.619 rs10278371 ENSG00000226824.5 RP4-756H11.3 6.55 1.89e-08 0.000204 0.9 0.66 Aortic root size; chr7:66586553 chr7:66654538~66669855:+ MESO cis rs875971 0.964 rs697969 ENSG00000226824.5 RP4-756H11.3 6.54 1.98e-08 0.000212 0.85 0.66 Aortic root size; chr7:66093491 chr7:66654538~66669855:+ MESO cis rs875971 1 rs697970 ENSG00000226824.5 RP4-756H11.3 6.54 1.98e-08 0.000212 0.85 0.66 Aortic root size; chr7:66095065 chr7:66654538~66669855:+ MESO cis rs875971 1 rs1182882 ENSG00000226824.5 RP4-756H11.3 6.54 1.98e-08 0.000212 0.85 0.66 Aortic root size; chr7:66097076 chr7:66654538~66669855:+ MESO cis rs875971 1 rs1167612 ENSG00000226824.5 RP4-756H11.3 6.54 1.98e-08 0.000212 0.85 0.66 Aortic root size; chr7:66102989 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs801217 ENSG00000226824.5 RP4-756H11.3 6.54 2.02e-08 0.000216 0.92 0.66 Aortic root size; chr7:66545590 chr7:66654538~66669855:+ MESO cis rs875971 0.638 rs801216 ENSG00000226824.5 RP4-756H11.3 6.54 2.02e-08 0.000216 0.92 0.66 Aortic root size; chr7:66546680 chr7:66654538~66669855:+ MESO cis rs875971 0.66 rs13224319 ENSG00000226824.5 RP4-756H11.3 -6.54 2.02e-08 0.000216 -0.92 -0.66 Aortic root size; chr7:66542376 chr7:66654538~66669855:+ MESO cis rs57502260 0.704 rs55975204 ENSG00000212093.1 AP000807.1 6.53 2.07e-08 0.000221 0.83 0.66 Total body bone mineral density (age 45-60); chr11:68481656 chr11:68506083~68506166:- MESO cis rs57502260 0.704 rs2186937 ENSG00000212093.1 AP000807.1 6.53 2.07e-08 0.000221 0.83 0.66 Total body bone mineral density (age 45-60); chr11:68489379 chr11:68506083~68506166:- MESO cis rs57502260 0.704 rs12286536 ENSG00000212093.1 AP000807.1 6.53 2.07e-08 0.000221 0.83 0.66 Total body bone mineral density (age 45-60); chr11:68522766 chr11:68506083~68506166:- MESO cis rs2882667 1 rs2882667 ENSG00000253404.1 AC034243.1 6.52 2.18e-08 0.000232 0.84 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138978417 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs10074461 ENSG00000253404.1 AC034243.1 6.51 2.19e-08 0.000233 0.88 0.66 Age-related hearing impairment (SNP x SNP interaction); chr5:138984126 chr5:138744434~138753309:- MESO cis rs858239 0.712 rs200717 ENSG00000230658.1 KLHL7-AS1 6.5 2.27e-08 0.000241 0.94 0.66 Cerebrospinal fluid biomarker levels; chr7:23352652 chr7:23101228~23105703:- MESO cis rs875971 1 rs3981131 ENSG00000226824.5 RP4-756H11.3 -6.49 2.41e-08 0.000254 -0.86 -0.66 Aortic root size; chr7:66486690 chr7:66654538~66669855:+ MESO cis rs2739330 0.796 rs5760106 ENSG00000273295.1 AP000350.5 -6.48 2.45e-08 0.000258 -0.71 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23901432~23907068:- MESO cis rs950027 0.549 rs12909409 ENSG00000259520.4 CTD-2651B20.3 6.48 2.46e-08 0.000259 0.88 0.65 Response to fenofibrate (adiponectin levels); chr15:45316384 chr15:45251580~45279251:- MESO cis rs858239 0.698 rs4265084 ENSG00000230658.1 KLHL7-AS1 6.47 2.6e-08 0.000271 0.91 0.65 Cerebrospinal fluid biomarker levels; chr7:23367621 chr7:23101228~23105703:- MESO cis rs858239 0.73 rs10255155 ENSG00000230658.1 KLHL7-AS1 -6.47 2.6e-08 0.000271 -0.91 -0.65 Cerebrospinal fluid biomarker levels; chr7:23362528 chr7:23101228~23105703:- MESO cis rs6452524 0.618 rs6452501 ENSG00000249664.1 CTD-2227C6.2 6.46 2.66e-08 0.000277 0.83 0.65 Hypertension (SNP x SNP interaction); chr5:83068681 chr5:83012285~83013109:- MESO cis rs2117029 1 rs11168827 ENSG00000258017.1 RP11-386G11.10 6.46 2.69e-08 0.00028 0.79 0.65 Intelligence (multi-trait analysis); chr12:49025894 chr12:49127782~49147869:+ MESO cis rs2739330 0.685 rs4822453 ENSG00000250470.1 AP000351.3 6.43 2.97e-08 0.000308 0.82 0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23976904~23977585:- MESO cis rs2019137 0.539 rs4849181 ENSG00000189223.12 PAX8-AS1 -6.43 3e-08 0.00031 -0.83 -0.65 Lymphocyte counts; chr2:113234393 chr2:113211522~113276581:+ MESO cis rs875971 1 rs7781698 ENSG00000226824.5 RP4-756H11.3 -6.43 3.03e-08 0.000313 -0.86 -0.65 Aortic root size; chr7:66431325 chr7:66654538~66669855:+ MESO cis rs950027 0.572 rs12910764 ENSG00000259520.4 CTD-2651B20.3 6.43 3.04e-08 0.000314 0.86 0.65 Response to fenofibrate (adiponectin levels); chr15:45317162 chr15:45251580~45279251:- MESO cis rs57502260 0.704 rs60538784 ENSG00000212093.1 AP000807.1 6.43 3.04e-08 0.000314 0.83 0.65 Total body bone mineral density (age 45-60); chr11:68619267 chr11:68506083~68506166:- MESO cis rs6597981 0.592 rs10902218 ENSG00000279672.1 CMB9-55F22.1 -6.41 3.24e-08 0.000331 -0.65 -0.65 Breast cancer; chr11:743813 chr11:779617~780755:+ MESO cis rs6597981 0.592 rs28625355 ENSG00000279672.1 CMB9-55F22.1 6.41 3.28e-08 0.000336 0.65 0.65 Breast cancer; chr11:736334 chr11:779617~780755:+ MESO cis rs875971 1 rs12532998 ENSG00000226824.5 RP4-756H11.3 -6.4 3.37e-08 0.000345 -0.86 -0.65 Aortic root size; chr7:66502472 chr7:66654538~66669855:+ MESO cis rs2882667 0.964 rs11958050 ENSG00000253404.1 AC034243.1 6.4 3.4e-08 0.000347 0.9 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:138966139 chr5:138744434~138753309:- MESO cis rs2019137 0.56 rs11123172 ENSG00000189223.12 PAX8-AS1 6.39 3.44e-08 0.00035 0.82 0.65 Lymphocyte counts; chr2:113226726 chr2:113211522~113276581:+ MESO cis rs2019137 0.539 rs6755040 ENSG00000189223.12 PAX8-AS1 -6.39 3.44e-08 0.00035 -0.82 -0.65 Lymphocyte counts; chr2:113223560 chr2:113211522~113276581:+ MESO cis rs2019137 0.539 rs4849177 ENSG00000189223.12 PAX8-AS1 -6.39 3.44e-08 0.00035 -0.82 -0.65 Lymphocyte counts; chr2:113225007 chr2:113211522~113276581:+ MESO cis rs2019137 0.56 rs4849179 ENSG00000189223.12 PAX8-AS1 -6.39 3.44e-08 0.00035 -0.82 -0.65 Lymphocyte counts; chr2:113227593 chr2:113211522~113276581:+ MESO cis rs2019137 0.56 rs10175462 ENSG00000189223.12 PAX8-AS1 -6.39 3.44e-08 0.00035 -0.82 -0.65 Lymphocyte counts; chr2:113230915 chr2:113211522~113276581:+ MESO cis rs875971 1 rs1167411 ENSG00000226824.5 RP4-756H11.3 6.39 3.47e-08 0.000353 0.84 0.65 Aortic root size; chr7:66074277 chr7:66654538~66669855:+ MESO cis rs433852 0.718 rs550455 ENSG00000232871.7 SEC1P -6.39 3.5e-08 0.000356 -0.91 -0.65 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48633258 chr19:48638071~48682245:+ MESO cis rs433852 0.718 rs386551 ENSG00000232871.7 SEC1P -6.39 3.5e-08 0.000356 -0.91 -0.65 Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease; chr19:48635029 chr19:48638071~48682245:+ MESO cis rs950027 0.549 rs11070452 ENSG00000259520.4 CTD-2651B20.3 6.38 3.62e-08 0.000368 0.9 0.65 Response to fenofibrate (adiponectin levels); chr15:45302638 chr15:45251580~45279251:- MESO cis rs950027 0.549 rs9920634 ENSG00000259520.4 CTD-2651B20.3 6.38 3.62e-08 0.000368 0.9 0.65 Response to fenofibrate (adiponectin levels); chr15:45304348 chr15:45251580~45279251:- MESO cis rs2117029 1 rs10875913 ENSG00000258017.1 RP11-386G11.10 -6.38 3.63e-08 0.000368 -0.78 -0.65 Intelligence (multi-trait analysis); chr12:49025525 chr12:49127782~49147869:+ MESO cis rs2739330 0.76 rs1002286 ENSG00000273295.1 AP000350.5 -6.37 3.71e-08 0.000376 -0.73 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23901432~23907068:- MESO cis rs2882667 0.858 rs7724108 ENSG00000253404.1 AC034243.1 -6.37 3.78e-08 0.000383 -0.79 -0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:139075233 chr5:138744434~138753309:- MESO cis rs1153858 0.621 rs1719237 ENSG00000259520.4 CTD-2651B20.3 -6.37 3.83e-08 0.000386 -0.97 -0.65 Homoarginine levels; chr15:45287624 chr15:45251580~45279251:- MESO cis rs1153858 0.621 rs1706824 ENSG00000259520.4 CTD-2651B20.3 -6.37 3.83e-08 0.000386 -0.97 -0.65 Homoarginine levels; chr15:45287750 chr15:45251580~45279251:- MESO cis rs2739330 0.76 rs1002286 ENSG00000250470.1 AP000351.3 -6.37 3.84e-08 0.000387 -0.83 -0.65 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23976904~23977585:- MESO cis rs801193 1 rs2707836 ENSG00000226824.5 RP4-756H11.3 -6.36 3.91e-08 0.000394 -0.91 -0.65 Aortic root size; chr7:66695448 chr7:66654538~66669855:+ MESO cis rs2882667 0.931 rs10077796 ENSG00000253404.1 AC034243.1 -6.34 4.21e-08 0.000422 -0.84 -0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:139021086 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs10077896 ENSG00000253404.1 AC034243.1 6.34 4.21e-08 0.000422 0.84 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:139021067 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs10058347 ENSG00000253404.1 AC034243.1 6.34 4.21e-08 0.000422 0.84 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:139025669 chr5:138744434~138753309:- MESO cis rs11673344 0.615 rs2921561 ENSG00000226686.6 LINC01535 6.34 4.27e-08 0.000427 0.7 0.65 Obesity-related traits; chr19:37348969 chr19:37251912~37265535:+ MESO cis rs2882667 0.898 rs6862393 ENSG00000253404.1 AC034243.1 6.33 4.32e-08 0.000432 0.84 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:139029009 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs6890272 ENSG00000253404.1 AC034243.1 6.33 4.32e-08 0.000432 0.84 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:139035427 chr5:138744434~138753309:- MESO cis rs6452524 0.618 rs4266384 ENSG00000249664.1 CTD-2227C6.2 6.33 4.48e-08 0.000447 0.84 0.65 Hypertension (SNP x SNP interaction); chr5:83080872 chr5:83012285~83013109:- MESO cis rs6452524 0.618 rs1478487 ENSG00000249664.1 CTD-2227C6.2 6.33 4.48e-08 0.000447 0.84 0.65 Hypertension (SNP x SNP interaction); chr5:83080900 chr5:83012285~83013109:- MESO cis rs2882667 0.858 rs11957633 ENSG00000253404.1 AC034243.1 6.32 4.49e-08 0.000448 0.83 0.65 Age-related hearing impairment (SNP x SNP interaction); chr5:139028705 chr5:138744434~138753309:- MESO cis rs9326248 0.52 rs74830 ENSG00000254851.1 RP11-109L13.1 6.31 4.66e-08 0.000463 0.83 0.64 Blood protein levels; chr11:117219842 chr11:117135528~117138582:+ MESO cis rs2117029 1 rs3782357 ENSG00000258017.1 RP11-386G11.10 -6.31 4.68e-08 0.000465 -0.78 -0.64 Intelligence (multi-trait analysis); chr12:49033869 chr12:49127782~49147869:+ MESO cis rs2117029 0.862 rs10875915 ENSG00000258017.1 RP11-386G11.10 -6.31 4.68e-08 0.000465 -0.78 -0.64 Intelligence (multi-trait analysis); chr12:49036311 chr12:49127782~49147869:+ MESO cis rs858239 0.676 rs3807459 ENSG00000230658.1 KLHL7-AS1 6.31 4.75e-08 0.000471 0.92 0.64 Cerebrospinal fluid biomarker levels; chr7:23350132 chr7:23101228~23105703:- MESO cis rs9326248 0.689 rs236916 ENSG00000254851.1 RP11-109L13.1 6.31 4.77e-08 0.000472 1.06 0.64 Blood protein levels; chr11:117218912 chr11:117135528~117138582:+ MESO cis rs858239 0.863 rs274058 ENSG00000230658.1 KLHL7-AS1 6.3 4.9e-08 0.000484 0.9 0.64 Cerebrospinal fluid biomarker levels; chr7:23351890 chr7:23101228~23105703:- MESO cis rs9326248 0.52 rs2735183 ENSG00000254851.1 RP11-109L13.1 -6.29 5.07e-08 0.000499 -0.85 -0.64 Blood protein levels; chr11:117144479 chr11:117135528~117138582:+ MESO cis rs2019137 0.56 rs7578633 ENSG00000189223.12 PAX8-AS1 -6.28 5.26e-08 0.000517 -0.84 -0.64 Lymphocyte counts; chr2:113221073 chr2:113211522~113276581:+ MESO cis rs2019137 0.539 rs11123170 ENSG00000189223.12 PAX8-AS1 -6.28 5.26e-08 0.000517 -0.84 -0.64 Lymphocyte counts; chr2:113221363 chr2:113211522~113276581:+ MESO cis rs2019137 0.56 rs6707386 ENSG00000189223.12 PAX8-AS1 -6.28 5.36e-08 0.000523 -0.84 -0.64 Lymphocyte counts; chr2:113223445 chr2:113211522~113276581:+ MESO cis rs2117029 1 rs10783299 ENSG00000258017.1 RP11-386G11.10 -6.28 5.37e-08 0.000523 -0.77 -0.64 Intelligence (multi-trait analysis); chr12:48996894 chr12:49127782~49147869:+ MESO cis rs2117029 0.965 rs1138908 ENSG00000258017.1 RP11-386G11.10 -6.28 5.37e-08 0.000523 -0.77 -0.64 Intelligence (multi-trait analysis); chr12:49008516 chr12:49127782~49147869:+ MESO cis rs2117029 1 rs2117029 ENSG00000258017.1 RP11-386G11.10 -6.28 5.37e-08 0.000523 -0.77 -0.64 Intelligence (multi-trait analysis); chr12:49014657 chr12:49127782~49147869:+ MESO cis rs801193 1 rs2055682 ENSG00000226824.5 RP4-756H11.3 -6.27 5.51e-08 0.000536 -0.86 -0.64 Aortic root size; chr7:66795302 chr7:66654538~66669855:+ MESO cis rs858239 0.539 rs10270695 ENSG00000230658.1 KLHL7-AS1 -6.27 5.51e-08 0.000536 -0.96 -0.64 Cerebrospinal fluid biomarker levels; chr7:23149369 chr7:23101228~23105703:- MESO cis rs6452524 0.534 rs17284134 ENSG00000249664.1 CTD-2227C6.2 -6.27 5.59e-08 0.00054 -0.85 -0.64 Hypertension (SNP x SNP interaction); chr5:83068325 chr5:83012285~83013109:- MESO cis rs6452524 0.537 rs1583 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83052403 chr5:83012285~83013109:- MESO cis rs6452524 0.506 rs7891 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83053558 chr5:83012285~83013109:- MESO cis rs6452524 0.534 rs7724935 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83057264 chr5:83012285~83013109:- MESO cis rs6452524 0.506 rs7707143 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83057268 chr5:83012285~83013109:- MESO cis rs6452524 0.563 rs10473863 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83057500 chr5:83012285~83013109:- MESO cis rs6452524 0.534 rs72765386 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83061502 chr5:83012285~83013109:- MESO cis rs6452524 0.534 rs10061690 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83063226 chr5:83012285~83013109:- MESO cis rs6452524 0.534 rs9293328 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83066855 chr5:83012285~83013109:- MESO cis rs6452524 0.534 rs11746747 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83067666 chr5:83012285~83013109:- MESO cis rs6452524 0.561 rs4331874 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83068253 chr5:83012285~83013109:- MESO cis rs6452524 0.534 rs10037377 ENSG00000249664.1 CTD-2227C6.2 6.27 5.59e-08 0.00054 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83071150 chr5:83012285~83013109:- MESO cis rs5760092 0.618 rs5996631 ENSG00000218537.1 MIF-AS1 -6.26 5.62e-08 0.000542 -0.83 -0.64 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23894426~23898930:- MESO cis rs2882667 0.931 rs10038799 ENSG00000253404.1 AC034243.1 6.26 5.66e-08 0.000545 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139026594 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs2351465 ENSG00000253404.1 AC034243.1 6.26 5.66e-08 0.000545 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139028162 chr5:138744434~138753309:- MESO cis rs2739330 0.828 rs2330635 ENSG00000218537.1 MIF-AS1 6.26 5.75e-08 0.000553 0.8 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23894426~23898930:- MESO cis rs950027 0.62 rs1719246 ENSG00000259520.4 CTD-2651B20.3 -6.25 5.83e-08 0.000559 -0.81 -0.64 Response to fenofibrate (adiponectin levels); chr15:45333281 chr15:45251580~45279251:- MESO cis rs2882667 0.861 rs10037106 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139029801 chr5:138744434~138753309:- MESO cis rs2882667 0.861 rs7703288 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139030850 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs3925110 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139035676 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs4643949 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139036656 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs6867343 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139038739 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs12719519 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139039998 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs13163536 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139041530 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs2882792 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139044791 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs6882330 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139046493 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs6882526 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139046679 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs6882583 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139050107 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs13182437 ENSG00000253404.1 AC034243.1 6.25 5.85e-08 0.000559 0.84 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139051460 chr5:138744434~138753309:- MESO cis rs71335811 1 rs71335811 ENSG00000232871.7 SEC1P -6.25 5.92e-08 0.000565 -0.91 -0.64 Myeloid white cell count; chr19:48626814 chr19:48638071~48682245:+ MESO cis rs2739330 0.828 rs4820572 ENSG00000273295.1 AP000350.5 6.24 6.09e-08 0.000581 0.7 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23901432~23907068:- MESO cis rs801193 1 rs13239306 ENSG00000226824.5 RP4-756H11.3 6.24 6.18e-08 0.000588 0.92 0.64 Aortic root size; chr7:66671030 chr7:66654538~66669855:+ MESO cis rs2019137 0.56 rs7421852 ENSG00000189223.12 PAX8-AS1 -6.24 6.19e-08 0.000589 -0.84 -0.64 Lymphocyte counts; chr2:113232684 chr2:113211522~113276581:+ MESO cis rs2019137 0.56 rs10206269 ENSG00000189223.12 PAX8-AS1 -6.24 6.19e-08 0.000589 -0.84 -0.64 Lymphocyte counts; chr2:113232816 chr2:113211522~113276581:+ MESO cis rs2882667 0.929 rs34846849 ENSG00000253404.1 AC034243.1 6.24 6.22e-08 0.000592 0.82 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139024889 chr5:138744434~138753309:- MESO cis rs2486288 0.656 rs1706767 ENSG00000259520.4 CTD-2651B20.3 6.24 6.25e-08 0.000594 0.92 0.64 Glomerular filtration rate; chr15:45276901 chr15:45251580~45279251:- MESO cis rs7847628 0.55 rs12343516 ENSG00000226752.6 PSMD5-AS1 -6.24 6.26e-08 0.000595 -0.73 -0.64 Birth weight; chr9:120841191 chr9:120824828~120854385:+ MESO cis rs6452524 0.532 rs26263 ENSG00000249664.1 CTD-2227C6.2 6.23 6.37e-08 0.000605 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83044465 chr5:83012285~83013109:- MESO cis rs2739330 0.828 rs4820572 ENSG00000218537.1 MIF-AS1 6.23 6.52e-08 0.000617 0.76 0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23894426~23898930:- MESO cis rs2882667 0.858 rs11951899 ENSG00000253404.1 AC034243.1 6.22 6.54e-08 0.000617 0.82 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139038621 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs35812969 ENSG00000253404.1 AC034243.1 6.22 6.54e-08 0.000617 0.82 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139041861 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs11242442 ENSG00000253404.1 AC034243.1 6.22 6.54e-08 0.000617 0.82 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139044800 chr5:138744434~138753309:- MESO cis rs6700559 0.81 rs2808248 ENSG00000260088.1 RP11-92G12.3 6.22 6.7e-08 0.000627 0.71 0.64 Coronary artery disease; chr1:200623147 chr1:200669507~200694250:+ MESO cis rs6700559 0.81 rs2809344 ENSG00000260088.1 RP11-92G12.3 6.22 6.7e-08 0.000627 0.71 0.64 Coronary artery disease; chr1:200627478 chr1:200669507~200694250:+ MESO cis rs6700559 0.81 rs7521550 ENSG00000260088.1 RP11-92G12.3 -6.22 6.7e-08 0.000627 -0.71 -0.64 Coronary artery disease; chr1:200623235 chr1:200669507~200694250:+ MESO cis rs6700559 0.81 rs2808250 ENSG00000260088.1 RP11-92G12.3 -6.22 6.7e-08 0.000627 -0.71 -0.64 Coronary artery disease; chr1:200623419 chr1:200669507~200694250:+ MESO cis rs6700559 0.81 rs10919990 ENSG00000260088.1 RP11-92G12.3 -6.22 6.7e-08 0.000627 -0.71 -0.64 Coronary artery disease; chr1:200627076 chr1:200669507~200694250:+ MESO cis rs801193 0.901 rs4273746 ENSG00000226824.5 RP4-756H11.3 6.21 6.84e-08 0.000638 0.86 0.64 Aortic root size; chr7:66836124 chr7:66654538~66669855:+ MESO cis rs858239 0.831 rs7796541 ENSG00000230658.1 KLHL7-AS1 6.21 6.86e-08 0.00064 0.93 0.64 Cerebrospinal fluid biomarker levels; chr7:23349454 chr7:23101228~23105703:- MESO cis rs977987 0.798 rs8053852 ENSG00000261783.1 RP11-252K23.2 -6.21 6.88e-08 0.000641 -0.79 -0.64 Dupuytren's disease; chr16:75463051 chr16:75379818~75381260:- MESO cis rs2117029 1 rs2293445 ENSG00000258017.1 RP11-386G11.10 -6.21 6.96e-08 0.000648 -0.77 -0.64 Intelligence (multi-trait analysis); chr12:49005079 chr12:49127782~49147869:+ MESO cis rs2117029 0.965 rs2293446 ENSG00000258017.1 RP11-386G11.10 -6.21 6.96e-08 0.000648 -0.77 -0.64 Intelligence (multi-trait analysis); chr12:49018926 chr12:49127782~49147869:+ MESO cis rs858239 0.796 rs433395 ENSG00000230658.1 KLHL7-AS1 6.21 6.96e-08 0.000648 0.89 0.64 Cerebrospinal fluid biomarker levels; chr7:23362336 chr7:23101228~23105703:- MESO cis rs9326248 0.773 rs1060211 ENSG00000254851.1 RP11-109L13.1 -6.21 7e-08 0.000652 -0.92 -0.64 Blood protein levels; chr11:117169081 chr11:117135528~117138582:+ MESO cis rs2882667 0.861 rs13176902 ENSG00000253404.1 AC034243.1 6.2 7.14e-08 0.000661 0.83 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139057640 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs2116789 ENSG00000253404.1 AC034243.1 6.2 7.14e-08 0.000661 0.83 0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139058573 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs11956089 ENSG00000253404.1 AC034243.1 -6.2 7.14e-08 0.000661 -0.83 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139058915 chr5:138744434~138753309:- MESO cis rs7104764 1 rs6598060 ENSG00000277290.1 RP11-326C3.16 -6.18 7.64e-08 0.000703 -0.77 -0.64 Menarche (age at onset); chr11:243987 chr11:243099~243483:- MESO cis rs6452524 0.532 rs27363 ENSG00000249664.1 CTD-2227C6.2 6.18 7.82e-08 0.000719 0.85 0.64 Hypertension (SNP x SNP interaction); chr5:83040943 chr5:83012285~83013109:- MESO cis rs7847628 0.551 rs10818476 ENSG00000226752.6 PSMD5-AS1 -6.17 7.91e-08 0.000727 -0.73 -0.64 Birth weight; chr9:120809760 chr9:120824828~120854385:+ MESO cis rs7847628 0.587 rs3793638 ENSG00000226752.6 PSMD5-AS1 -6.17 7.91e-08 0.000727 -0.73 -0.64 Birth weight; chr9:120820419 chr9:120824828~120854385:+ MESO cis rs7847628 0.587 rs1060817 ENSG00000226752.6 PSMD5-AS1 -6.17 7.91e-08 0.000727 -0.73 -0.64 Birth weight; chr9:120820914 chr9:120824828~120854385:+ MESO cis rs7847628 0.587 rs10760117 ENSG00000226752.6 PSMD5-AS1 -6.17 7.91e-08 0.000727 -0.73 -0.64 Birth weight; chr9:120824459 chr9:120824828~120854385:+ MESO cis rs7847628 0.587 rs12684934 ENSG00000226752.6 PSMD5-AS1 -6.17 7.91e-08 0.000727 -0.73 -0.64 Birth weight; chr9:120830881 chr9:120824828~120854385:+ MESO cis rs2882667 0.858 rs6882112 ENSG00000253404.1 AC034243.1 -6.17 8.09e-08 0.000741 -0.82 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139078046 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs10900856 ENSG00000253404.1 AC034243.1 -6.16 8.29e-08 0.000758 -0.81 -0.64 Age-related hearing impairment (SNP x SNP interaction); chr5:139082057 chr5:138744434~138753309:- MESO cis rs2739330 0.761 rs5760176 ENSG00000250470.1 AP000351.3 -6.15 8.59e-08 0.000785 -0.83 -0.64 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23976904~23977585:- MESO cis rs875971 0.628 rs6974355 ENSG00000226824.5 RP4-756H11.3 -6.14 9.08e-08 0.000827 -0.91 -0.63 Aortic root size; chr7:66376994 chr7:66654538~66669855:+ MESO cis rs2739330 0.731 rs5751792 ENSG00000250470.1 AP000351.3 6.13 9.2e-08 0.000837 0.83 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23976904~23977585:- MESO cis rs2882667 0.861 rs10043676 ENSG00000253404.1 AC034243.1 6.12 9.79e-08 0.000887 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139053872 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs10038121 ENSG00000253404.1 AC034243.1 6.12 9.79e-08 0.000887 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139053913 chr5:138744434~138753309:- MESO cis rs2882667 0.861 rs10075541 ENSG00000253404.1 AC034243.1 6.12 9.79e-08 0.000887 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139054629 chr5:138744434~138753309:- MESO cis rs4835473 0.932 rs4835455 ENSG00000251600.4 RP11-673E1.1 6.11 9.89e-08 0.000896 0.71 0.63 Immature fraction of reticulocytes; chr4:143962290 chr4:143912331~143982454:+ MESO cis rs2882667 0.931 rs3749665 ENSG00000253404.1 AC034243.1 6.11 9.94e-08 9e-04 0.84 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139021522 chr5:138744434~138753309:- MESO cis rs1930961 1 rs6004669 ENSG00000100058.11 CRYBB2P1 6.11 1.02e-07 0.000923 1.43 0.63 Bipolar disorder with mood-incongruent psychosis; chr22:25479836 chr22:25448105~25520854:+ MESO cis rs1930961 1 rs5996946 ENSG00000100058.11 CRYBB2P1 6.11 1.02e-07 0.000923 1.43 0.63 Bipolar disorder with mood-incongruent psychosis; chr22:25480021 chr22:25448105~25520854:+ MESO cis rs1930961 1 rs997873 ENSG00000100058.11 CRYBB2P1 6.11 1.02e-07 0.000923 1.43 0.63 Bipolar disorder with mood-incongruent psychosis; chr22:25482315 chr22:25448105~25520854:+ MESO cis rs1930961 1 rs997872 ENSG00000100058.11 CRYBB2P1 6.11 1.02e-07 0.000923 1.43 0.63 Bipolar disorder with mood-incongruent psychosis; chr22:25482647 chr22:25448105~25520854:+ MESO cis rs1930961 1 rs6004671 ENSG00000100058.11 CRYBB2P1 6.11 1.02e-07 0.000923 1.43 0.63 Bipolar disorder with mood-incongruent psychosis; chr22:25483507 chr22:25448105~25520854:+ MESO cis rs1930961 1 rs6004672 ENSG00000100058.11 CRYBB2P1 6.11 1.02e-07 0.000923 1.43 0.63 Bipolar disorder with mood-incongruent psychosis; chr22:25485046 chr22:25448105~25520854:+ MESO cis rs11673344 0.563 rs256744 ENSG00000226686.6 LINC01535 -6.11 1.02e-07 0.000923 -0.7 -0.63 Obesity-related traits; chr19:37364586 chr19:37251912~37265535:+ MESO cis rs11673344 0.562 rs256740 ENSG00000226686.6 LINC01535 -6.1 1.04e-07 0.000936 -0.69 -0.63 Obesity-related traits; chr19:37365451 chr19:37251912~37265535:+ MESO cis rs9326248 0.52 rs6589602 ENSG00000254851.1 RP11-109L13.1 -6.1 1.05e-07 0.000941 -0.78 -0.63 Blood protein levels; chr11:117166349 chr11:117135528~117138582:+ MESO cis rs9326248 0.539 rs7120565 ENSG00000254851.1 RP11-109L13.1 -6.1 1.05e-07 0.000941 -0.78 -0.63 Blood protein levels; chr11:117172233 chr11:117135528~117138582:+ MESO cis rs2882667 0.858 rs17207870 ENSG00000253404.1 AC034243.1 6.1 1.05e-07 0.000943 0.81 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139052048 chr5:138744434~138753309:- MESO cis rs6700559 0.81 rs10399615 ENSG00000260088.1 RP11-92G12.3 6.09 1.1e-07 0.000982 0.69 0.63 Coronary artery disease; chr1:200626145 chr1:200669507~200694250:+ MESO cis rs2739330 0.731 rs2000468 ENSG00000273295.1 AP000350.5 6.08 1.11e-07 0.000992 0.7 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23901432~23907068:- MESO cis rs57502260 0.915 rs7106320 ENSG00000212093.1 AP000807.1 6.08 1.15e-07 0.00102 0.82 0.63 Total body bone mineral density (age 45-60); chr11:68442650 chr11:68506083~68506166:- MESO cis rs57502260 0.915 rs75202638 ENSG00000212093.1 AP000807.1 6.08 1.15e-07 0.00102 0.82 0.63 Total body bone mineral density (age 45-60); chr11:68442953 chr11:68506083~68506166:- MESO cis rs2882667 0.861 rs11242445 ENSG00000253404.1 AC034243.1 6.07 1.15e-07 0.00102 0.83 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139081365 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs6596457 ENSG00000253404.1 AC034243.1 6.07 1.15e-07 0.00102 0.83 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138987690 chr5:138744434~138753309:- MESO cis rs6700559 0.742 rs10399790 ENSG00000260088.1 RP11-92G12.3 -6.07 1.17e-07 0.00103 -0.7 -0.63 Coronary artery disease; chr1:200626241 chr1:200669507~200694250:+ MESO cis rs6700559 0.81 rs10919991 ENSG00000260088.1 RP11-92G12.3 -6.07 1.17e-07 0.00103 -0.7 -0.63 Coronary artery disease; chr1:200627217 chr1:200669507~200694250:+ MESO cis rs2739330 0.731 rs2000468 ENSG00000250470.1 AP000351.3 6.07 1.17e-07 0.00104 0.8 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23976904~23977585:- MESO cis rs2882667 0.894 rs1433008 ENSG00000253404.1 AC034243.1 6.06 1.22e-07 0.00107 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138997975 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs1433009 ENSG00000253404.1 AC034243.1 6.06 1.22e-07 0.00107 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138998095 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs7720150 ENSG00000253404.1 AC034243.1 6.06 1.22e-07 0.00107 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:138998380 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs7706391 ENSG00000253404.1 AC034243.1 6.06 1.22e-07 0.00107 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139013475 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs10075951 ENSG00000253404.1 AC034243.1 6.06 1.22e-07 0.00107 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139020274 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs11749944 ENSG00000253404.1 AC034243.1 6.06 1.22e-07 0.00107 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139077090 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs10079634 ENSG00000253404.1 AC034243.1 6.06 1.22e-07 0.00107 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139077364 chr5:138744434~138753309:- MESO cis rs6452524 0.534 rs10514246 ENSG00000249664.1 CTD-2227C6.2 6.05 1.26e-07 0.0011 0.83 0.63 Hypertension (SNP x SNP interaction); chr5:83069979 chr5:83012285~83013109:- MESO cis rs2882667 0.858 rs11956159 ENSG00000253404.1 AC034243.1 6.05 1.26e-07 0.0011 0.81 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139072879 chr5:138744434~138753309:- MESO cis rs57502260 0.68 rs55654976 ENSG00000212093.1 AP000807.1 6.05 1.28e-07 0.00111 0.79 0.63 Total body bone mineral density (age 45-60); chr11:68626073 chr11:68506083~68506166:- MESO cis rs7208859 0.623 rs9914242 ENSG00000263531.1 RP13-753N3.1 6.04 1.31e-07 0.00114 1.2 0.63 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889227 chr17:30863921~30864940:- MESO cis rs11673344 0.642 rs55926714 ENSG00000226686.6 LINC01535 6.03 1.35e-07 0.00117 0.7 0.63 Obesity-related traits; chr19:37307974 chr19:37251912~37265535:+ MESO cis rs11673344 0.642 rs12462487 ENSG00000226686.6 LINC01535 6.03 1.35e-07 0.00117 0.7 0.63 Obesity-related traits; chr19:37311211 chr19:37251912~37265535:+ MESO cis rs11673344 0.642 rs11083420 ENSG00000226686.6 LINC01535 6.03 1.35e-07 0.00117 0.7 0.63 Obesity-related traits; chr19:37317901 chr19:37251912~37265535:+ MESO cis rs11673344 0.642 rs73025481 ENSG00000226686.6 LINC01535 6.03 1.35e-07 0.00117 0.7 0.63 Obesity-related traits; chr19:37346437 chr19:37251912~37265535:+ MESO cis rs11673344 0.642 rs55755939 ENSG00000226686.6 LINC01535 6.03 1.35e-07 0.00117 0.7 0.63 Obesity-related traits; chr19:37353723 chr19:37251912~37265535:+ MESO cis rs11673344 0.642 rs12462708 ENSG00000226686.6 LINC01535 -6.03 1.35e-07 0.00117 -0.7 -0.63 Obesity-related traits; chr19:37306676 chr19:37251912~37265535:+ MESO cis rs11673344 0.555 rs502546 ENSG00000226686.6 LINC01535 -6.03 1.35e-07 0.00117 -0.7 -0.63 Obesity-related traits; chr19:37361788 chr19:37251912~37265535:+ MESO cis rs950027 0.62 rs1617984 ENSG00000259520.4 CTD-2651B20.3 -6.03 1.37e-07 0.00118 -0.78 -0.63 Response to fenofibrate (adiponectin levels); chr15:45330464 chr15:45251580~45279251:- MESO cis rs950027 0.62 rs1719245 ENSG00000259520.4 CTD-2651B20.3 -6.03 1.37e-07 0.00118 -0.78 -0.63 Response to fenofibrate (adiponectin levels); chr15:45331584 chr15:45251580~45279251:- MESO cis rs2739330 0.734 rs2000467 ENSG00000273295.1 AP000350.5 -6.02 1.39e-07 0.00119 -0.73 -0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899346 chr22:23901432~23907068:- MESO cis rs875971 1 rs6946143 ENSG00000226824.5 RP4-756H11.3 -6.02 1.41e-07 0.00121 -0.81 -0.63 Aortic root size; chr7:66114735 chr7:66654538~66669855:+ MESO cis rs9326248 0.861 rs494356 ENSG00000254851.1 RP11-109L13.1 -6.01 1.45e-07 0.00124 -1.01 -0.63 Blood protein levels; chr11:117201254 chr11:117135528~117138582:+ MESO cis rs801193 0.967 rs2420827 ENSG00000226824.5 RP4-756H11.3 6.01 1.47e-07 0.00126 0.86 0.63 Aortic root size; chr7:66682114 chr7:66654538~66669855:+ MESO cis rs1930961 1 rs59226697 ENSG00000100058.11 CRYBB2P1 6 1.49e-07 0.00128 1.57 0.63 Bipolar disorder with mood-incongruent psychosis; chr22:25474070 chr22:25448105~25520854:+ MESO cis rs2882667 0.898 rs3828600 ENSG00000253404.1 AC034243.1 6 1.5e-07 0.00128 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139051170 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs4380651 ENSG00000253404.1 AC034243.1 6 1.5e-07 0.00128 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139055383 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs11952020 ENSG00000253404.1 AC034243.1 6 1.5e-07 0.00128 0.82 0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139059467 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs10075893 ENSG00000253404.1 AC034243.1 -6 1.5e-07 0.00128 -0.82 -0.63 Age-related hearing impairment (SNP x SNP interaction); chr5:139020182 chr5:138744434~138753309:- MESO cis rs3091242 0.934 rs666686 ENSG00000224183.1 SDHDP6 -6 1.52e-07 0.00129 -0.83 -0.63 Erythrocyte sedimentation rate; chr1:25393020 chr1:25294164~25294643:- MESO cis rs2739330 0.76 rs5751760 ENSG00000250470.1 AP000351.3 6 1.52e-07 0.0013 0.84 0.63 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23976904~23977585:- MESO cis rs57502260 1 rs57502260 ENSG00000212093.1 AP000807.1 6 1.53e-07 0.0013 0.79 0.63 Total body bone mineral density (age 45-60); chr11:68453437 chr11:68506083~68506166:- MESO cis rs57502260 0.764 rs7105218 ENSG00000212093.1 AP000807.1 6 1.53e-07 0.0013 0.79 0.63 Total body bone mineral density (age 45-60); chr11:68454993 chr11:68506083~68506166:- MESO cis rs801193 0.967 rs3800823 ENSG00000226824.5 RP4-756H11.3 6 1.54e-07 0.00131 0.86 0.63 Aortic root size; chr7:66682123 chr7:66654538~66669855:+ MESO cis rs875971 0.666 rs13242072 ENSG00000226824.5 RP4-756H11.3 5.99 1.59e-07 0.00135 0.85 0.62 Aortic root size; chr7:66301001 chr7:66654538~66669855:+ MESO cis rs2882667 0.898 rs2043272 ENSG00000253404.1 AC034243.1 5.99 1.59e-07 0.00135 0.82 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139054942 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs10075039 ENSG00000253404.1 AC034243.1 5.98 1.62e-07 0.00137 0.82 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139002165 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs10068237 ENSG00000253404.1 AC034243.1 5.98 1.62e-07 0.00137 0.82 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139002271 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs12719518 ENSG00000253404.1 AC034243.1 5.98 1.62e-07 0.00137 0.82 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139005287 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs13153618 ENSG00000253404.1 AC034243.1 5.98 1.62e-07 0.00137 0.82 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139017087 chr5:138744434~138753309:- MESO cis rs2882667 0.931 rs10069528 ENSG00000253404.1 AC034243.1 5.98 1.62e-07 0.00137 0.82 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139018338 chr5:138744434~138753309:- MESO cis rs2882667 0.894 rs10054478 ENSG00000253404.1 AC034243.1 5.98 1.62e-07 0.00137 0.82 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139018386 chr5:138744434~138753309:- MESO cis rs6452524 0.507 rs28592576 ENSG00000249664.1 CTD-2227C6.2 5.98 1.65e-07 0.00139 0.84 0.62 Hypertension (SNP x SNP interaction); chr5:83074772 chr5:83012285~83013109:- MESO cis rs6452524 0.534 rs7727691 ENSG00000249664.1 CTD-2227C6.2 5.98 1.65e-07 0.00139 0.84 0.62 Hypertension (SNP x SNP interaction); chr5:83075876 chr5:83012285~83013109:- MESO cis rs6452524 0.562 rs10474080 ENSG00000249664.1 CTD-2227C6.2 5.98 1.65e-07 0.00139 0.84 0.62 Hypertension (SNP x SNP interaction); chr5:83078300 chr5:83012285~83013109:- MESO cis rs4835473 0.715 rs1849124 ENSG00000251600.4 RP11-673E1.1 5.97 1.71e-07 0.00144 0.73 0.62 Immature fraction of reticulocytes; chr4:143978494 chr4:143912331~143982454:+ MESO cis rs4835473 0.689 rs1849123 ENSG00000251600.4 RP11-673E1.1 5.97 1.71e-07 0.00144 0.73 0.62 Immature fraction of reticulocytes; chr4:143978495 chr4:143912331~143982454:+ MESO cis rs977987 0.645 rs34904236 ENSG00000261783.1 RP11-252K23.2 -5.97 1.72e-07 0.00145 -0.8 -0.62 Dupuytren's disease; chr16:75464355 chr16:75379818~75381260:- MESO cis rs977987 0.966 rs11643207 ENSG00000261783.1 RP11-252K23.2 -5.97 1.72e-07 0.00145 -0.8 -0.62 Dupuytren's disease; chr16:75464895 chr16:75379818~75381260:- MESO cis rs977987 0.933 rs4888431 ENSG00000261783.1 RP11-252K23.2 -5.97 1.72e-07 0.00145 -0.8 -0.62 Dupuytren's disease; chr16:75466801 chr16:75379818~75381260:- MESO cis rs977987 0.933 rs1834014 ENSG00000261783.1 RP11-252K23.2 -5.97 1.72e-07 0.00145 -0.8 -0.62 Dupuytren's disease; chr16:75467376 chr16:75379818~75381260:- MESO cis rs977987 1 rs62060550 ENSG00000261783.1 RP11-252K23.2 -5.97 1.72e-07 0.00145 -0.8 -0.62 Dupuytren's disease; chr16:75468354 chr16:75379818~75381260:- MESO cis rs977987 0.966 rs62060551 ENSG00000261783.1 RP11-252K23.2 -5.97 1.72e-07 0.00145 -0.8 -0.62 Dupuytren's disease; chr16:75468414 chr16:75379818~75381260:- MESO cis rs7104764 1 rs2293167 ENSG00000277290.1 RP11-326C3.16 5.95 1.81e-07 0.0015 0.83 0.62 Menarche (age at onset); chr11:211644 chr11:243099~243483:- MESO cis rs7104764 1 rs76552490 ENSG00000277290.1 RP11-326C3.16 5.95 1.81e-07 0.0015 0.83 0.62 Menarche (age at onset); chr11:212015 chr11:243099~243483:- MESO cis rs7104764 1 rs1533825 ENSG00000277290.1 RP11-326C3.16 5.95 1.81e-07 0.0015 0.83 0.62 Menarche (age at onset); chr11:214163 chr11:243099~243483:- MESO cis rs7104764 0.879 rs6598072 ENSG00000277290.1 RP11-326C3.16 -5.95 1.81e-07 0.0015 -0.83 -0.62 Menarche (age at onset); chr11:219793 chr11:243099~243483:- MESO cis rs7104764 0.957 rs6598071 ENSG00000277290.1 RP11-326C3.16 -5.95 1.81e-07 0.0015 -0.83 -0.62 Menarche (age at onset); chr11:219800 chr11:243099~243483:- MESO cis rs7104764 0.957 rs10794301 ENSG00000277290.1 RP11-326C3.16 -5.95 1.81e-07 0.0015 -0.83 -0.62 Menarche (age at onset); chr11:220401 chr11:243099~243483:- MESO cis rs7104764 0.879 rs6421986 ENSG00000277290.1 RP11-326C3.16 -5.95 1.81e-07 0.0015 -0.83 -0.62 Menarche (age at onset); chr11:221659 chr11:243099~243483:- MESO cis rs977987 0.966 rs6564261 ENSG00000261783.1 RP11-252K23.2 -5.95 1.81e-07 0.0015 -0.78 -0.62 Dupuytren's disease; chr16:75458344 chr16:75379818~75381260:- MESO cis rs977987 0.902 rs34539062 ENSG00000261783.1 RP11-252K23.2 -5.95 1.81e-07 0.0015 -0.78 -0.62 Dupuytren's disease; chr16:75459381 chr16:75379818~75381260:- MESO cis rs977987 0.866 rs17696831 ENSG00000261783.1 RP11-252K23.2 -5.95 1.81e-07 0.0015 -0.78 -0.62 Dupuytren's disease; chr16:75459400 chr16:75379818~75381260:- MESO cis rs977987 0.898 rs12918797 ENSG00000261783.1 RP11-252K23.2 -5.95 1.81e-07 0.0015 -0.78 -0.62 Dupuytren's disease; chr16:75459912 chr16:75379818~75381260:- MESO cis rs977987 0.898 rs12918974 ENSG00000261783.1 RP11-252K23.2 -5.95 1.81e-07 0.0015 -0.78 -0.62 Dupuytren's disease; chr16:75460045 chr16:75379818~75381260:- MESO cis rs977987 0.866 rs12932606 ENSG00000261783.1 RP11-252K23.2 -5.95 1.81e-07 0.0015 -0.78 -0.62 Dupuytren's disease; chr16:75460046 chr16:75379818~75381260:- MESO cis rs977987 0.931 rs11641430 ENSG00000261783.1 RP11-252K23.2 -5.95 1.81e-07 0.0015 -0.78 -0.62 Dupuytren's disease; chr16:75461378 chr16:75379818~75381260:- MESO cis rs977987 0.931 rs7195161 ENSG00000261783.1 RP11-252K23.2 -5.95 1.81e-07 0.0015 -0.78 -0.62 Dupuytren's disease; chr16:75461674 chr16:75379818~75381260:- MESO cis rs977987 0.931 rs1424013 ENSG00000261783.1 RP11-252K23.2 -5.95 1.81e-07 0.0015 -0.78 -0.62 Dupuytren's disease; chr16:75462088 chr16:75379818~75381260:- MESO cis rs62388641 0.547 rs9391923 ENSG00000272279.1 RP11-157J24.2 -5.95 1.82e-07 0.0015 -0.7 -0.62 Daytime sleep phenotypes; chr6:1554089 chr6:1528364~1528911:- MESO cis rs2882667 0.867 rs11749045 ENSG00000253404.1 AC034243.1 5.95 1.84e-07 0.00151 0.82 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139085271 chr5:138744434~138753309:- MESO cis rs801193 1 rs17566701 ENSG00000226824.5 RP4-756H11.3 -5.95 1.87e-07 0.00153 -0.85 -0.62 Aortic root size; chr7:66728196 chr7:66654538~66669855:+ MESO cis rs5760092 0.618 rs5996631 ENSG00000225282.1 AP000350.6 -5.94 1.9e-07 0.00156 -0.75 -0.62 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23926900~23929574:+ MESO cis rs7104764 0.957 rs1045454 ENSG00000277290.1 RP11-326C3.16 5.94 1.9e-07 0.00156 0.83 0.62 Menarche (age at onset); chr11:204228 chr11:243099~243483:- MESO cis rs7104764 0.957 rs56357554 ENSG00000277290.1 RP11-326C3.16 5.94 1.9e-07 0.00156 0.83 0.62 Menarche (age at onset); chr11:204715 chr11:243099~243483:- MESO cis rs875971 0.558 rs4433015 ENSG00000226824.5 RP4-756H11.3 5.94 1.93e-07 0.00158 0.85 0.62 Aortic root size; chr7:66174736 chr7:66654538~66669855:+ MESO cis rs950027 0.62 rs1153860 ENSG00000259520.4 CTD-2651B20.3 5.93 1.95e-07 0.00159 0.77 0.62 Response to fenofibrate (adiponectin levels); chr15:45344386 chr15:45251580~45279251:- MESO cis rs950027 0.62 rs35861938 ENSG00000259520.4 CTD-2651B20.3 -5.93 1.95e-07 0.00159 -0.77 -0.62 Response to fenofibrate (adiponectin levels); chr15:45345145 chr15:45251580~45279251:- MESO cis rs950027 0.596 rs2467865 ENSG00000259520.4 CTD-2651B20.3 -5.93 1.95e-07 0.00159 -0.77 -0.62 Response to fenofibrate (adiponectin levels); chr15:45346109 chr15:45251580~45279251:- MESO cis rs950027 0.62 rs2461700 ENSG00000259520.4 CTD-2651B20.3 -5.93 1.95e-07 0.00159 -0.77 -0.62 Response to fenofibrate (adiponectin levels); chr15:45348429 chr15:45251580~45279251:- MESO cis rs950027 0.62 rs2453533 ENSG00000259520.4 CTD-2651B20.3 -5.93 1.95e-07 0.00159 -0.77 -0.62 Response to fenofibrate (adiponectin levels); chr15:45349027 chr15:45251580~45279251:- MESO cis rs2882667 0.858 rs11949916 ENSG00000253404.1 AC034243.1 5.93 1.95e-07 0.0016 0.8 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139060588 chr5:138744434~138753309:- MESO cis rs950027 0.549 rs2899375 ENSG00000259520.4 CTD-2651B20.3 5.93 1.97e-07 0.00161 0.84 0.62 Response to fenofibrate (adiponectin levels); chr15:45306137 chr15:45251580~45279251:- MESO cis rs950027 0.62 rs1153862 ENSG00000259520.4 CTD-2651B20.3 -5.93 1.98e-07 0.00161 -0.77 -0.62 Response to fenofibrate (adiponectin levels); chr15:45339670 chr15:45251580~45279251:- MESO cis rs2882667 0.822 rs11738376 ENSG00000253404.1 AC034243.1 5.93 2e-07 0.00163 0.79 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139062483 chr5:138744434~138753309:- MESO cis rs2882667 0.822 rs13187096 ENSG00000253404.1 AC034243.1 5.93 2e-07 0.00163 0.79 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139068399 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs11957527 ENSG00000253404.1 AC034243.1 5.93 2e-07 0.00163 0.79 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139069206 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs11242444 ENSG00000253404.1 AC034243.1 5.93 2e-07 0.00163 0.79 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139070690 chr5:138744434~138753309:- MESO cis rs9326248 0.501 rs4938351 ENSG00000254851.1 RP11-109L13.1 -5.92 2.02e-07 0.00164 -0.8 -0.62 Blood protein levels; chr11:117151636 chr11:117135528~117138582:+ MESO cis rs7104764 0.957 rs3782120 ENSG00000277290.1 RP11-326C3.16 5.92 2.02e-07 0.00164 0.82 0.62 Menarche (age at onset); chr11:206089 chr11:243099~243483:- MESO cis rs7104764 0.957 rs6598075 ENSG00000277290.1 RP11-326C3.16 5.92 2.02e-07 0.00164 0.82 0.62 Menarche (age at onset); chr11:207275 chr11:243099~243483:- MESO cis rs7104764 0.957 rs58692051 ENSG00000277290.1 RP11-326C3.16 5.92 2.02e-07 0.00164 0.82 0.62 Menarche (age at onset); chr11:207410 chr11:243099~243483:- MESO cis rs3931020 0.72 rs927904 ENSG00000272864.1 RP11-17E13.2 -5.92 2.08e-07 0.00169 -0.89 -0.62 Resistin levels; chr1:74794644 chr1:74698769~74699333:- MESO cis rs1153858 0.723 rs1719238 ENSG00000259520.4 CTD-2651B20.3 5.91 2.1e-07 0.0017 0.94 0.62 Homoarginine levels; chr15:45302568 chr15:45251580~45279251:- MESO cis rs1153858 0.723 rs4580098 ENSG00000259520.4 CTD-2651B20.3 -5.91 2.1e-07 0.0017 -0.94 -0.62 Homoarginine levels; chr15:45304711 chr15:45251580~45279251:- MESO cis rs1153858 0.668 rs63603561 ENSG00000259520.4 CTD-2651B20.3 5.91 2.13e-07 0.00172 0.94 0.62 Homoarginine levels; chr15:45301125 chr15:45251580~45279251:- MESO cis rs2882667 0.838 rs11958529 ENSG00000253404.1 AC034243.1 5.91 2.13e-07 0.00172 0.81 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139059379 chr5:138744434~138753309:- MESO cis rs2882667 0.861 rs11959727 ENSG00000253404.1 AC034243.1 5.91 2.13e-07 0.00172 0.81 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139061276 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs11950819 ENSG00000253404.1 AC034243.1 5.91 2.13e-07 0.00172 0.81 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139061411 chr5:138744434~138753309:- MESO cis rs2882667 0.898 rs10045761 ENSG00000253404.1 AC034243.1 5.91 2.13e-07 0.00172 0.81 0.62 Age-related hearing impairment (SNP x SNP interaction); chr5:139061600 chr5:138744434~138753309:- MESO cis rs1153858 1 rs12439274 ENSG00000259520.4 CTD-2651B20.3 -5.9 2.19e-07 0.00177 -0.85 -0.62 Homoarginine levels; chr15:45344469 chr15:45251580~45279251:- MESO cis rs977987 0.902 rs4888430 ENSG00000261783.1 RP11-252K23.2 -5.9 2.22e-07 0.00179 -0.77 -0.62 Dupuytren's disease; chr16:75460526 chr16:75379818~75381260:- MESO cis rs977987 0.931 rs1834013 ENSG00000261783.1 RP11-252K23.2 -5.9 2.22e-07 0.00179 -0.77 -0.62 Dupuytren's disease; chr16:75462265 chr16:75379818~75381260:- MESO cis rs977987 0.966 rs8055490 ENSG00000261783.1 RP11-252K23.2 -5.9 2.22e-07 0.00179 -0.77 -0.62 Dupuytren's disease; chr16:75463237 chr16:75379818~75381260:- MESO cis rs1153858 0.621 rs2687512 ENSG00000259520.4 CTD-2651B20.3 5.9 2.25e-07 0.00181 0.94 0.62 Homoarginine levels; chr15:45289297 chr15:45251580~45279251:- MESO cis rs9322193 0.962 rs3763162 ENSG00000231760.4 RP11-350J20.5 -5.88 2.4e-07 0.00191 -0.86 -0.62 Lung cancer; chr6:149819674 chr6:149796151~149826294:- MESO cis rs7847628 0.765 rs7026635 ENSG00000226752.6 PSMD5-AS1 5.88 2.41e-07 0.00191 0.79 0.62 Birth weight; chr9:120787749 chr9:120824828~120854385:+ MESO cis rs864745 0.967 rs849133 ENSG00000253187.2 HOXA10-AS 5.86 2.55e-07 0.002 0.69 0.62 Crohn's disease;Type 2 diabetes; chr7:28152661 chr7:27168619~27171915:+ MESO cis rs864745 0.967 rs860262 ENSG00000253187.2 HOXA10-AS 5.86 2.55e-07 0.002 0.69 0.62 Crohn's disease;Type 2 diabetes; chr7:28154778 chr7:27168619~27171915:+ MESO cis rs864745 0.967 rs849135 ENSG00000253187.2 HOXA10-AS 5.86 2.55e-07 0.002 0.69 0.62 Crohn's disease;Type 2 diabetes; chr7:28156794 chr7:27168619~27171915:+ MESO cis rs7208859 0.673 rs3816780 ENSG00000263531.1 RP13-753N3.1 5.85 2.64e-07 0.00206 1.07 0.62 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834340 chr17:30863921~30864940:- MESO cis rs8177876 0.749 rs11537 ENSG00000261838.4 RP11-303E16.6 5.84 2.79e-07 0.00216 1.32 0.62 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81046894 chr16:81069854~81076598:+ MESO cis rs3931020 0.772 rs1475396 ENSG00000272864.1 RP11-17E13.2 -5.83 2.83e-07 0.00218 -0.79 -0.61 Resistin levels; chr1:74776712 chr1:74698769~74699333:- MESO cis rs7104764 1 rs10400248 ENSG00000277290.1 RP11-326C3.16 -5.83 2.83e-07 0.00219 -0.79 -0.61 Menarche (age at onset); chr11:247029 chr11:243099~243483:- MESO cis rs9326248 0.52 rs236919 ENSG00000254851.1 RP11-109L13.1 -5.83 2.86e-07 0.00221 -0.81 -0.61 Blood protein levels; chr11:117224645 chr11:117135528~117138582:+ MESO cis rs3931020 0.772 rs11485555 ENSG00000272864.1 RP11-17E13.2 -5.83 2.86e-07 0.00221 -0.81 -0.61 Resistin levels; chr1:74720825 chr1:74698769~74699333:- MESO cis rs11428934 1 rs11428934 ENSG00000232871.7 SEC1P 5.82 2.98e-07 0.00229 0.94 0.61 Granulocyte count;Neutrophil count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts; chr19:48640988 chr19:48638071~48682245:+ MESO cis rs2117029 0.898 rs10875914 ENSG00000258017.1 RP11-386G11.10 -5.82 3e-07 0.0023 -0.76 -0.61 Intelligence (multi-trait analysis); chr12:49028311 chr12:49127782~49147869:+ MESO cis rs6700559 0.967 rs10919992 ENSG00000260088.1 RP11-92G12.3 -5.82 3.01e-07 0.00231 -0.67 -0.61 Coronary artery disease; chr1:200638338 chr1:200669507~200694250:+ MESO cis rs4835473 0.864 rs2323418 ENSG00000251600.4 RP11-673E1.1 5.8 3.16e-07 0.00241 0.69 0.61 Immature fraction of reticulocytes; chr4:143969141 chr4:143912331~143982454:+ MESO cis rs1930961 1 rs6004662 ENSG00000100058.11 CRYBB2P1 5.8 3.16e-07 0.00241 1.67 0.61 Bipolar disorder with mood-incongruent psychosis; chr22:25466157 chr22:25448105~25520854:+ MESO cis rs2882667 0.858 rs6596460 ENSG00000253404.1 AC034243.1 5.8 3.19e-07 0.00242 0.79 0.61 Age-related hearing impairment (SNP x SNP interaction); chr5:139078491 chr5:138744434~138753309:- MESO cis rs864745 0.967 rs849134 ENSG00000253187.2 HOXA10-AS 5.8 3.19e-07 0.00243 0.68 0.61 Crohn's disease;Type 2 diabetes; chr7:28156603 chr7:27168619~27171915:+ MESO cis rs9322193 0.884 rs2095375 ENSG00000231760.4 RP11-350J20.5 5.8 3.2e-07 0.00243 0.84 0.61 Lung cancer; chr6:149807037 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs4869730 ENSG00000231760.4 RP11-350J20.5 5.8 3.2e-07 0.00243 0.84 0.61 Lung cancer; chr6:149808187 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs11155689 ENSG00000231760.4 RP11-350J20.5 5.8 3.2e-07 0.00243 0.84 0.61 Lung cancer; chr6:149808470 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs2151913 ENSG00000231760.4 RP11-350J20.5 5.8 3.2e-07 0.00243 0.84 0.61 Lung cancer; chr6:149809506 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs933055 ENSG00000231760.4 RP11-350J20.5 5.8 3.2e-07 0.00243 0.84 0.61 Lung cancer; chr6:149809701 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs4869731 ENSG00000231760.4 RP11-350J20.5 5.8 3.2e-07 0.00243 0.84 0.61 Lung cancer; chr6:149810072 chr6:149796151~149826294:- MESO cis rs9322193 0.847 rs12210605 ENSG00000231760.4 RP11-350J20.5 5.8 3.25e-07 0.00247 0.86 0.61 Lung cancer; chr6:149817267 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs9371199 ENSG00000231760.4 RP11-350J20.5 5.8 3.25e-07 0.00247 0.86 0.61 Lung cancer; chr6:149817526 chr6:149796151~149826294:- MESO cis rs977987 1 rs977985 ENSG00000261783.1 RP11-252K23.2 -5.8 3.26e-07 0.00247 -0.79 -0.61 Dupuytren's disease; chr16:75473049 chr16:75379818~75381260:- MESO cis rs6700559 0.81 rs7529962 ENSG00000260088.1 RP11-92G12.3 -5.79 3.29e-07 0.00249 -0.66 -0.61 Coronary artery disease; chr1:200627849 chr1:200669507~200694250:+ MESO cis rs2739330 0.796 rs5760106 ENSG00000218537.1 MIF-AS1 -5.79 3.29e-07 0.00249 -0.73 -0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23894426~23898930:- MESO cis rs4835473 0.9 rs10027246 ENSG00000251600.4 RP11-673E1.1 -5.79 3.34e-07 0.00252 -0.7 -0.61 Immature fraction of reticulocytes; chr4:143935069 chr4:143912331~143982454:+ MESO cis rs7104764 1 rs6598074 ENSG00000277290.1 RP11-326C3.16 -5.79 3.37e-07 0.00254 -0.83 -0.61 Menarche (age at onset); chr11:219398 chr11:243099~243483:- MESO cis rs1799949 0.602 rs8176235 ENSG00000198496.9 NBR2 -5.79 3.38e-07 0.00255 -0.84 -0.61 Menopause (age at onset); chr17:43067543 chr17:43125610~43153671:+ MESO cis rs755249 0.753 rs72663529 ENSG00000237624.1 OXCT2P1 5.78 3.42e-07 0.00258 0.74 0.61 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39557684 chr1:39514956~39516490:+ MESO cis rs9322193 0.923 rs2342857 ENSG00000231760.4 RP11-350J20.5 5.78 3.44e-07 0.00259 0.84 0.61 Lung cancer; chr6:149809537 chr6:149796151~149826294:- MESO cis rs2739330 0.796 rs2154594 ENSG00000225282.1 AP000350.6 -5.78 3.51e-07 0.00264 -0.73 -0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911868 chr22:23926900~23929574:+ MESO cis rs9322193 0.962 rs4552 ENSG00000231760.4 RP11-350J20.5 5.76 3.68e-07 0.00276 0.83 0.61 Lung cancer; chr6:149811183 chr6:149796151~149826294:- MESO cis rs6700559 0.967 rs12041320 ENSG00000260088.1 RP11-92G12.3 -5.76 3.71e-07 0.00277 -0.67 -0.61 Coronary artery disease; chr1:200652107 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs12076877 ENSG00000260088.1 RP11-92G12.3 -5.76 3.71e-07 0.00277 -0.67 -0.61 Coronary artery disease; chr1:200674277 chr1:200669507~200694250:+ MESO cis rs6700559 1 rs10800720 ENSG00000260088.1 RP11-92G12.3 -5.76 3.71e-07 0.00277 -0.67 -0.61 Coronary artery disease; chr1:200679441 chr1:200669507~200694250:+ MESO cis rs6700559 0.935 rs4072553 ENSG00000260088.1 RP11-92G12.3 -5.76 3.71e-07 0.00277 -0.67 -0.61 Coronary artery disease; chr1:200680036 chr1:200669507~200694250:+ MESO cis rs755249 0.701 rs1180342 ENSG00000237624.1 OXCT2P1 -5.76 3.78e-07 0.00281 -0.74 -0.61 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39527206 chr1:39514956~39516490:+ MESO cis rs1799949 0.602 rs8176257 ENSG00000198496.9 NBR2 -5.75 3.85e-07 0.00285 -0.84 -0.61 Menopause (age at onset); chr17:43064188 chr17:43125610~43153671:+ MESO cis rs6700559 0.935 rs10920001 ENSG00000260088.1 RP11-92G12.3 -5.75 3.88e-07 0.00286 -0.67 -0.61 Coronary artery disease; chr1:200682420 chr1:200669507~200694250:+ MESO cis rs4835473 0.838 rs10024263 ENSG00000251600.4 RP11-673E1.1 5.75 3.89e-07 0.00287 0.74 0.61 Immature fraction of reticulocytes; chr4:144038174 chr4:143912331~143982454:+ MESO cis rs3018712 0.532 rs57813595 ENSG00000212093.1 AP000807.1 5.74 3.95e-07 0.0029 0.78 0.61 Total body bone mineral density; chr11:68635138 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs55761963 ENSG00000212093.1 AP000807.1 5.74 3.95e-07 0.0029 0.78 0.61 Total body bone mineral density; chr11:68635161 chr11:68506083~68506166:- MESO cis rs3736228 0.522 rs111564249 ENSG00000212093.1 AP000807.1 5.74 3.95e-07 0.0029 0.78 0.61 Bone mineral density; chr11:68636752 chr11:68506083~68506166:- MESO cis rs3736228 0.604 rs3018716 ENSG00000212093.1 AP000807.1 5.74 3.95e-07 0.0029 0.78 0.61 Bone mineral density; chr11:68636754 chr11:68506083~68506166:- MESO cis rs57502260 0.679 rs72936524 ENSG00000212093.1 AP000807.1 5.74 4.01e-07 0.00293 0.79 0.61 Total body bone mineral density (age 45-60); chr11:68508430 chr11:68506083~68506166:- MESO cis rs57502260 0.704 rs72936599 ENSG00000212093.1 AP000807.1 5.74 4.01e-07 0.00293 0.79 0.61 Total body bone mineral density (age 45-60); chr11:68552937 chr11:68506083~68506166:- MESO cis rs57502260 0.704 rs17149179 ENSG00000212093.1 AP000807.1 5.74 4.01e-07 0.00293 0.79 0.61 Total body bone mineral density (age 45-60); chr11:68584254 chr11:68506083~68506166:- MESO cis rs7208859 0.725 rs9891656 ENSG00000263531.1 RP13-753N3.1 5.74 4.08e-07 0.00296 1.04 0.61 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916337 chr17:30863921~30864940:- MESO cis rs950027 0.787 rs1547487 ENSG00000259520.4 CTD-2651B20.3 -5.73 4.11e-07 0.00296 -0.82 -0.61 Response to fenofibrate (adiponectin levels); chr15:45431785 chr15:45251580~45279251:- MESO cis rs7899628 1 rs7899628 ENSG00000226864.1 ATE1-AS1 -5.73 4.11e-07 0.00296 -0.74 -0.61 Breast cancer; chr10:121904429 chr10:121928312~121951965:+ MESO cis rs2739330 0.731 rs4822450 ENSG00000250470.1 AP000351.3 5.73 4.13e-07 0.00296 0.81 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23976904~23977585:- MESO cis rs3018712 0.532 rs28551086 ENSG00000212093.1 AP000807.1 5.73 4.16e-07 0.00297 0.78 0.61 Total body bone mineral density; chr11:68633271 chr11:68506083~68506166:- MESO cis rs2739330 0.76 rs1007888 ENSG00000250470.1 AP000351.3 5.73 4.2e-07 0.003 0.81 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23976904~23977585:- MESO cis rs2882667 0.898 rs6863347 ENSG00000253404.1 AC034243.1 5.72 4.24e-07 0.00303 0.79 0.61 Age-related hearing impairment (SNP x SNP interaction); chr5:139025446 chr5:138744434~138753309:- MESO cis rs1930961 1 rs6004668 ENSG00000100058.11 CRYBB2P1 -5.72 4.31e-07 0.00307 -1.28 -0.61 Bipolar disorder with mood-incongruent psychosis; chr22:25478535 chr22:25448105~25520854:+ MESO cis rs1930961 1 rs760554 ENSG00000100058.11 CRYBB2P1 5.72 4.31e-07 0.00307 1.28 0.61 Bipolar disorder with mood-incongruent psychosis; chr22:25476625 chr22:25448105~25520854:+ MESO cis rs1930961 1 rs760555 ENSG00000100058.11 CRYBB2P1 5.72 4.31e-07 0.00307 1.28 0.61 Bipolar disorder with mood-incongruent psychosis; chr22:25476870 chr22:25448105~25520854:+ MESO cis rs1930961 1 rs7285549 ENSG00000100058.11 CRYBB2P1 5.72 4.31e-07 0.00307 1.28 0.61 Bipolar disorder with mood-incongruent psychosis; chr22:25478613 chr22:25448105~25520854:+ MESO cis rs4835473 0.8 rs1849134 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143958260 chr4:143912331~143982454:+ MESO cis rs4835473 0.8 rs1849133 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143958262 chr4:143912331~143982454:+ MESO cis rs4835473 0.864 rs1849132 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143958309 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs13123407 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143958713 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs61611095 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143958802 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs4835449 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143958830 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs4835095 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143960431 chr4:143912331~143982454:+ MESO cis rs4835473 0.831 rs2667353 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143960462 chr4:143912331~143982454:+ MESO cis rs4835473 0.77 rs4835096 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143960685 chr4:143912331~143982454:+ MESO cis rs4835473 0.771 rs4835097 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143960687 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1838516 ENSG00000251600.4 RP11-673E1.1 5.71 4.48e-07 0.00311 0.71 0.61 Immature fraction of reticulocytes; chr4:143962082 chr4:143912331~143982454:+ MESO cis rs4964805 0.594 rs4981036 ENSG00000257681.1 RP11-341G23.4 5.7 4.59e-07 0.00318 0.87 0.61 Attention deficit hyperactivity disorder; chr12:103770566 chr12:103746315~103768858:- MESO cis rs4964805 0.594 rs10861095 ENSG00000257681.1 RP11-341G23.4 5.7 4.59e-07 0.00318 0.87 0.61 Attention deficit hyperactivity disorder; chr12:103771609 chr12:103746315~103768858:- MESO cis rs4964805 0.505 rs4981032 ENSG00000257681.1 RP11-341G23.4 5.7 4.59e-07 0.00318 0.87 0.61 Attention deficit hyperactivity disorder; chr12:103772086 chr12:103746315~103768858:- MESO cis rs4964805 0.594 rs9132 ENSG00000257681.1 RP11-341G23.4 5.7 4.59e-07 0.00318 0.87 0.61 Attention deficit hyperactivity disorder; chr12:103772465 chr12:103746315~103768858:- MESO cis rs2117029 0.782 rs10459232 ENSG00000258017.1 RP11-386G11.10 -5.7 4.59e-07 0.00318 -0.73 -0.61 Intelligence (multi-trait analysis); chr12:49073293 chr12:49127782~49147869:+ MESO cis rs9322193 0.847 rs56103941 ENSG00000231760.4 RP11-350J20.5 5.7 4.69e-07 0.00325 0.83 0.61 Lung cancer; chr6:149816095 chr6:149796151~149826294:- MESO cis rs2739330 0.731 rs4822450 ENSG00000273295.1 AP000350.5 5.69 4.84e-07 0.00332 0.71 0.61 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23901432~23907068:- MESO cis rs4835473 0.742 rs7654409 ENSG00000251600.4 RP11-673E1.1 5.69 4.85e-07 0.00333 0.71 0.61 Immature fraction of reticulocytes; chr4:143956842 chr4:143912331~143982454:+ MESO cis rs7396835 0.5 rs5092 ENSG00000254851.1 RP11-109L13.1 -5.69 4.88e-07 0.00334 -0.9 -0.61 Quantitative traits; chr11:116822748 chr11:117135528~117138582:+ MESO cis rs2739330 0.76 rs1007888 ENSG00000273295.1 AP000350.5 5.69 4.92e-07 0.00335 0.71 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23901432~23907068:- MESO cis rs2117029 0.782 rs7969091 ENSG00000258017.1 RP11-386G11.10 -5.68 4.94e-07 0.00336 -0.73 -0.6 Intelligence (multi-trait analysis); chr12:49070666 chr12:49127782~49147869:+ MESO cis rs10459221 1 rs10459221 ENSG00000258017.1 RP11-386G11.10 -5.68 4.94e-07 0.00336 -0.73 -0.6 Bipolar disorder; chr12:49073211 chr12:49127782~49147869:+ MESO cis rs875971 0.706 rs1643374 ENSG00000226824.5 RP4-756H11.3 -5.68 5.01e-07 0.0034 -0.84 -0.6 Aortic root size; chr7:66407695 chr7:66654538~66669855:+ MESO cis rs9326248 0.817 rs6589598 ENSG00000254851.1 RP11-109L13.1 -5.68 5.03e-07 0.00342 -1.01 -0.6 Blood protein levels; chr11:117131687 chr11:117135528~117138582:+ MESO cis rs977987 0.931 rs8057084 ENSG00000261783.1 RP11-252K23.2 5.68 5.05e-07 0.00343 0.77 0.6 Dupuytren's disease; chr16:75458808 chr16:75379818~75381260:- MESO cis rs62388641 0.547 rs4513844 ENSG00000272279.1 RP11-157J24.2 -5.67 5.13e-07 0.00346 -0.69 -0.6 Daytime sleep phenotypes; chr6:1551747 chr6:1528364~1528911:- MESO cis rs4964805 0.594 rs10861096 ENSG00000257681.1 RP11-341G23.4 5.67 5.21e-07 0.00352 0.87 0.6 Attention deficit hyperactivity disorder; chr12:103775578 chr12:103746315~103768858:- MESO cis rs4964805 0.58 rs10861097 ENSG00000257681.1 RP11-341G23.4 5.67 5.21e-07 0.00352 0.87 0.6 Attention deficit hyperactivity disorder; chr12:103776696 chr12:103746315~103768858:- MESO cis rs57502260 0.704 rs72936570 ENSG00000212093.1 AP000807.1 5.67 5.25e-07 0.00354 0.79 0.6 Total body bone mineral density (age 45-60); chr11:68539671 chr11:68506083~68506166:- MESO cis rs4835473 0.868 rs1822841 ENSG00000251600.4 RP11-673E1.1 5.66 5.32e-07 0.00358 0.73 0.6 Immature fraction of reticulocytes; chr4:143921485 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs10857413 ENSG00000251600.4 RP11-673E1.1 5.66 5.34e-07 0.00359 0.73 0.6 Immature fraction of reticulocytes; chr4:143827752 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs6828935 ENSG00000251600.4 RP11-673E1.1 5.66 5.34e-07 0.00359 0.73 0.6 Immature fraction of reticulocytes; chr4:143829113 chr4:143912331~143982454:+ MESO cis rs4835473 0.778 rs6856553 ENSG00000251600.4 RP11-673E1.1 -5.66 5.34e-07 0.00359 -0.73 -0.6 Immature fraction of reticulocytes; chr4:143825973 chr4:143912331~143982454:+ MESO cis rs4835473 0.868 rs11737787 ENSG00000251600.4 RP11-673E1.1 -5.66 5.34e-07 0.00359 -0.73 -0.6 Immature fraction of reticulocytes; chr4:143826498 chr4:143912331~143982454:+ MESO cis rs62388641 0.547 rs2745610 ENSG00000272279.1 RP11-157J24.2 -5.66 5.34e-07 0.00359 -0.73 -0.6 Daytime sleep phenotypes; chr6:1553741 chr6:1528364~1528911:- MESO cis rs11673344 0.58 rs320881 ENSG00000226686.6 LINC01535 5.66 5.35e-07 0.00359 0.68 0.6 Obesity-related traits; chr19:37246948 chr19:37251912~37265535:+ MESO cis rs864745 0.967 rs1708302 ENSG00000253187.2 HOXA10-AS 5.66 5.35e-07 0.00359 0.69 0.6 Crohn's disease;Type 2 diabetes; chr7:28159058 chr7:27168619~27171915:+ MESO cis rs7617773 0.817 rs6787500 ENSG00000229759.1 MRPS18AP1 5.66 5.38e-07 0.00361 0.71 0.6 Coronary artery disease; chr3:48257949 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs11130163 ENSG00000229759.1 MRPS18AP1 5.66 5.38e-07 0.00361 0.71 0.6 Coronary artery disease; chr3:48271168 chr3:48256350~48256938:- MESO cis rs2739330 0.76 rs1002286 ENSG00000218537.1 MIF-AS1 -5.66 5.42e-07 0.00363 -0.74 -0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23894426~23898930:- MESO cis rs7927592 0.913 rs7106339 ENSG00000212093.1 AP000807.1 5.66 5.43e-07 0.00363 0.59 0.6 Total body bone mineral density; chr11:68472773 chr11:68506083~68506166:- MESO cis rs4835473 0.932 rs13134808 ENSG00000251600.4 RP11-673E1.1 -5.66 5.45e-07 0.00363 -0.74 -0.6 Immature fraction of reticulocytes; chr4:143798339 chr4:143912331~143982454:+ MESO cis rs1930961 1 rs6004675 ENSG00000100058.11 CRYBB2P1 5.65 5.51e-07 0.00367 1.47 0.6 Bipolar disorder with mood-incongruent psychosis; chr22:25493418 chr22:25448105~25520854:+ MESO cis rs4835473 0.808 rs1984810 ENSG00000251600.4 RP11-673E1.1 5.65 5.52e-07 0.00368 0.73 0.6 Immature fraction of reticulocytes; chr4:143824970 chr4:143912331~143982454:+ MESO cis rs4835473 0.831 rs1984809 ENSG00000251600.4 RP11-673E1.1 5.65 5.52e-07 0.00368 0.73 0.6 Immature fraction of reticulocytes; chr4:143825018 chr4:143912331~143982454:+ MESO cis rs4835473 0.868 rs62337303 ENSG00000251600.4 RP11-673E1.1 -5.65 5.54e-07 0.00369 -0.71 -0.6 Immature fraction of reticulocytes; chr4:143824967 chr4:143912331~143982454:+ MESO cis rs4835473 0.838 rs6838981 ENSG00000251600.4 RP11-673E1.1 -5.65 5.54e-07 0.00369 -0.71 -0.6 Immature fraction of reticulocytes; chr4:143826484 chr4:143912331~143982454:+ MESO cis rs62388641 0.547 rs2317966 ENSG00000272279.1 RP11-157J24.2 -5.65 5.59e-07 0.00372 -0.68 -0.6 Daytime sleep phenotypes; chr6:1550651 chr6:1528364~1528911:- MESO cis rs875971 0.964 rs160635 ENSG00000226824.5 RP4-756H11.3 -5.65 5.62e-07 0.00373 -0.77 -0.6 Aortic root size; chr7:66063931 chr7:66654538~66669855:+ MESO cis rs4835473 0.897 rs7662736 ENSG00000251600.4 RP11-673E1.1 5.65 5.66e-07 0.00375 0.71 0.6 Immature fraction of reticulocytes; chr4:143958036 chr4:143912331~143982454:+ MESO cis rs7104764 1 rs7104764 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:229977 chr11:243099~243483:- MESO cis rs7104764 0.957 rs3829998 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:230751 chr11:243099~243483:- MESO cis rs7104764 1 rs7483951 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:231758 chr11:243099~243483:- MESO cis rs7104764 1 rs10794302 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:234102 chr11:243099~243483:- MESO cis rs7104764 1 rs9795476 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:235894 chr11:243099~243483:- MESO cis rs7104764 0.957 rs519592 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:236811 chr11:243099~243483:- MESO cis rs7104764 1 rs2272563 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:236871 chr11:243099~243483:- MESO cis rs7104764 0.917 rs1045288 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:237087 chr11:243099~243483:- MESO cis rs7104764 0.957 rs3817629 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:237312 chr11:243099~243483:- MESO cis rs7104764 1 rs10902110 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:237648 chr11:243099~243483:- MESO cis rs7104764 1 rs7481993 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:237875 chr11:243099~243483:- MESO cis rs7104764 1 rs6598069 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:240664 chr11:243099~243483:- MESO cis rs7104764 1 rs7395328 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:242624 chr11:243099~243483:- MESO cis rs7104764 0.917 rs6598068 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:243092 chr11:243099~243483:- MESO cis rs7104764 0.917 rs6598067 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:243093 chr11:243099~243483:- MESO cis rs7104764 1 rs6598065 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:243211 chr11:243099~243483:- MESO cis rs7104764 0.957 rs6598064 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:243557 chr11:243099~243483:- MESO cis rs7104764 1 rs6598063 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:243672 chr11:243099~243483:- MESO cis rs7104764 1 rs6598062 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:243712 chr11:243099~243483:- MESO cis rs7104764 1 rs6598061 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:243853 chr11:243099~243483:- MESO cis rs7104764 1 rs10902112 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:244106 chr11:243099~243483:- MESO cis rs7104764 0.917 rs7107362 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:244108 chr11:243099~243483:- MESO cis rs7104764 1 rs7128044 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:244115 chr11:243099~243483:- MESO cis rs7104764 0.957 rs7116130 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:244129 chr11:243099~243483:- MESO cis rs7104764 1 rs7128029 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:244141 chr11:243099~243483:- MESO cis rs7104764 1 rs1128320 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:244167 chr11:243099~243483:- MESO cis rs7104764 0.957 rs1128321 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:244171 chr11:243099~243483:- MESO cis rs7104764 1 rs2272565 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:244414 chr11:243099~243483:- MESO cis rs7104764 1 rs10902113 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:245523 chr11:243099~243483:- MESO cis rs7104764 1 rs7482591 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:245861 chr11:243099~243483:- MESO cis rs7104764 1 rs10902114 ENSG00000277290.1 RP11-326C3.16 -5.64 5.73e-07 0.00377 -0.77 -0.6 Menarche (age at onset); chr11:246234 chr11:243099~243483:- MESO cis rs4835473 0.808 rs11725413 ENSG00000251600.4 RP11-673E1.1 -5.64 5.74e-07 0.00377 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143943366 chr4:143912331~143982454:+ MESO cis rs1799949 0.628 rs4474733 ENSG00000198496.9 NBR2 -5.64 5.83e-07 0.00382 -0.83 -0.6 Menopause (age at onset); chr17:43356292 chr17:43125610~43153671:+ MESO cis rs4835473 0.932 rs6849896 ENSG00000251600.4 RP11-673E1.1 -5.63 6.01e-07 0.00392 -0.74 -0.6 Immature fraction of reticulocytes; chr4:143794927 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs6826665 ENSG00000251600.4 RP11-673E1.1 -5.63 6.01e-07 0.00392 -0.74 -0.6 Immature fraction of reticulocytes; chr4:143795140 chr4:143912331~143982454:+ MESO cis rs4835473 0.838 rs35998817 ENSG00000251600.4 RP11-673E1.1 -5.63 6.01e-07 0.00392 -0.74 -0.6 Immature fraction of reticulocytes; chr4:143795355 chr4:143912331~143982454:+ MESO cis rs9322193 0.962 rs7740784 ENSG00000231760.4 RP11-350J20.5 5.63 6.04e-07 0.00393 0.84 0.6 Lung cancer; chr6:149833364 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs2342764 ENSG00000231760.4 RP11-350J20.5 5.63 6.04e-07 0.00393 0.84 0.6 Lung cancer; chr6:149835068 chr6:149796151~149826294:- MESO cis rs4835473 0.669 rs56112476 ENSG00000251600.4 RP11-673E1.1 -5.63 6.08e-07 0.00395 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143948716 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs13103072 ENSG00000251600.4 RP11-673E1.1 -5.63 6.08e-07 0.00395 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143952116 chr4:143912331~143982454:+ MESO cis rs4835473 0.864 rs28609839 ENSG00000251600.4 RP11-673E1.1 -5.63 6.08e-07 0.00395 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143954160 chr4:143912331~143982454:+ MESO cis rs4835473 0.708 rs7655939 ENSG00000251600.4 RP11-673E1.1 5.63 6.08e-07 0.00395 0.7 0.6 Immature fraction of reticulocytes; chr4:143956889 chr4:143912331~143982454:+ MESO cis rs875971 0.54 rs35510581 ENSG00000226824.5 RP4-756H11.3 5.63 6.08e-07 0.00395 0.84 0.6 Aortic root size; chr7:66113790 chr7:66654538~66669855:+ MESO cis rs4835473 0.932 rs17018500 ENSG00000251600.4 RP11-673E1.1 -5.62 6.18e-07 0.00399 -0.73 -0.6 Immature fraction of reticulocytes; chr4:143824849 chr4:143912331~143982454:+ MESO cis rs1930961 0.85 rs5996945 ENSG00000100058.11 CRYBB2P1 -5.62 6.2e-07 0.00401 -1.6 -0.6 Bipolar disorder with mood-incongruent psychosis; chr22:25479606 chr22:25448105~25520854:+ MESO cis rs2882667 0.788 rs11959691 ENSG00000253404.1 AC034243.1 5.62 6.27e-07 0.00404 0.8 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:139145399 chr5:138744434~138753309:- MESO cis rs6700559 0.873 rs7542210 ENSG00000260088.1 RP11-92G12.3 -5.62 6.29e-07 0.00405 -0.65 -0.6 Coronary artery disease; chr1:200693087 chr1:200669507~200694250:+ MESO cis rs4835473 0.8 rs2089839 ENSG00000251600.4 RP11-673E1.1 5.62 6.29e-07 0.00405 0.7 0.6 Immature fraction of reticulocytes; chr4:143980955 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs36018946 ENSG00000251600.4 RP11-673E1.1 -5.62 6.29e-07 0.00405 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143980942 chr4:143912331~143982454:+ MESO cis rs9322193 0.962 rs9397022 ENSG00000231760.4 RP11-350J20.5 5.62 6.34e-07 0.00408 0.82 0.6 Lung cancer; chr6:149812052 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs9397357 ENSG00000231760.4 RP11-350J20.5 5.62 6.34e-07 0.00408 0.82 0.6 Lung cancer; chr6:149812465 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs17673294 ENSG00000231760.4 RP11-350J20.5 5.62 6.34e-07 0.00408 0.82 0.6 Lung cancer; chr6:149813857 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs6899661 ENSG00000231760.4 RP11-350J20.5 5.62 6.34e-07 0.00408 0.82 0.6 Lung cancer; chr6:149818093 chr6:149796151~149826294:- MESO cis rs4835473 0.932 rs4835305 ENSG00000251600.4 RP11-673E1.1 -5.62 6.34e-07 0.00408 -0.72 -0.6 Immature fraction of reticulocytes; chr4:143823646 chr4:143912331~143982454:+ MESO cis rs875971 0.577 rs34888281 ENSG00000226824.5 RP4-756H11.3 5.62 6.36e-07 0.00409 0.84 0.6 Aortic root size; chr7:66120784 chr7:66654538~66669855:+ MESO cis rs4835473 0.932 rs6826862 ENSG00000251600.4 RP11-673E1.1 5.61 6.41e-07 0.00411 0.7 0.6 Immature fraction of reticulocytes; chr4:143978180 chr4:143912331~143982454:+ MESO cis rs4835473 0.8 rs1849122 ENSG00000251600.4 RP11-673E1.1 5.61 6.41e-07 0.00411 0.7 0.6 Immature fraction of reticulocytes; chr4:143978699 chr4:143912331~143982454:+ MESO cis rs4835473 0.663 rs4835115 ENSG00000251600.4 RP11-673E1.1 5.61 6.41e-07 0.00411 0.7 0.6 Immature fraction of reticulocytes; chr4:143979308 chr4:143912331~143982454:+ MESO cis rs4835473 0.771 rs4443231 ENSG00000251600.4 RP11-673E1.1 5.61 6.41e-07 0.00411 0.7 0.6 Immature fraction of reticulocytes; chr4:143979501 chr4:143912331~143982454:+ MESO cis rs4835473 0.771 rs4261935 ENSG00000251600.4 RP11-673E1.1 5.61 6.41e-07 0.00411 0.7 0.6 Immature fraction of reticulocytes; chr4:143979751 chr4:143912331~143982454:+ MESO cis rs4835473 0.524 rs4404495 ENSG00000251600.4 RP11-673E1.1 5.61 6.41e-07 0.00411 0.7 0.6 Immature fraction of reticulocytes; chr4:143979791 chr4:143912331~143982454:+ MESO cis rs4835473 0.864 rs4257604 ENSG00000251600.4 RP11-673E1.1 5.61 6.41e-07 0.00411 0.7 0.6 Immature fraction of reticulocytes; chr4:143980261 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs35599924 ENSG00000251600.4 RP11-673E1.1 5.61 6.41e-07 0.00411 0.7 0.6 Immature fraction of reticulocytes; chr4:143980602 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4516663 ENSG00000251600.4 RP11-673E1.1 5.61 6.41e-07 0.00411 0.7 0.6 Immature fraction of reticulocytes; chr4:143980791 chr4:143912331~143982454:+ MESO cis rs7617773 0.817 rs13068265 ENSG00000229759.1 MRPS18AP1 5.61 6.45e-07 0.00414 0.76 0.6 Coronary artery disease; chr3:48260124 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs11709691 ENSG00000229759.1 MRPS18AP1 5.61 6.45e-07 0.00414 0.76 0.6 Coronary artery disease; chr3:48262179 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs34225441 ENSG00000229759.1 MRPS18AP1 5.61 6.45e-07 0.00414 0.76 0.6 Coronary artery disease; chr3:48267401 chr3:48256350~48256938:- MESO cis rs2882667 0.858 rs11959851 ENSG00000253404.1 AC034243.1 5.61 6.54e-07 0.00418 0.78 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:139085716 chr5:138744434~138753309:- MESO cis rs4835473 0.932 rs11734290 ENSG00000251600.4 RP11-673E1.1 -5.61 6.55e-07 0.00419 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143823636 chr4:143912331~143982454:+ MESO cis rs2019137 0.776 rs4849183 ENSG00000189223.12 PAX8-AS1 -5.61 6.56e-07 0.00419 -0.76 -0.6 Lymphocyte counts; chr2:113234797 chr2:113211522~113276581:+ MESO cis rs11123694 1 rs11123694 ENSG00000214184.3 AC012487.2 -5.61 6.59e-07 0.00421 -0.72 -0.6 Mean platelet volume; chr2:108448107 chr2:108507515~108534196:- MESO cis rs864745 0.967 rs1513272 ENSG00000253187.2 HOXA10-AS 5.6 6.66e-07 0.00425 0.68 0.6 Crohn's disease;Type 2 diabetes; chr7:28160478 chr7:27168619~27171915:+ MESO cis rs9322193 0.962 rs4870048 ENSG00000231760.4 RP11-350J20.5 5.6 6.69e-07 0.00426 0.82 0.6 Lung cancer; chr6:149834324 chr6:149796151~149826294:- MESO cis rs858239 0.614 rs10229956 ENSG00000230658.1 KLHL7-AS1 -5.6 6.76e-07 0.00427 -0.78 -0.6 Cerebrospinal fluid biomarker levels; chr7:23363317 chr7:23101228~23105703:- MESO cis rs4835473 0.897 rs3874 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143968795 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs2323417 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143969108 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs11931330 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143970808 chr4:143912331~143982454:+ MESO cis rs4835473 0.549 rs11940719 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143970855 chr4:143912331~143982454:+ MESO cis rs4835473 0.83 rs7692672 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143971048 chr4:143912331~143982454:+ MESO cis rs4835473 0.766 rs6537222 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143971459 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs6537223 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143971541 chr4:143912331~143982454:+ MESO cis rs4835473 0.615 rs6857432 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143971912 chr4:143912331~143982454:+ MESO cis rs4835473 0.742 rs1838519 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143972242 chr4:143912331~143982454:+ MESO cis rs4835473 0.831 rs4452380 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143972856 chr4:143912331~143982454:+ MESO cis rs4835473 0.831 rs7689328 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143973768 chr4:143912331~143982454:+ MESO cis rs4835473 0.831 rs7694353 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143973787 chr4:143912331~143982454:+ MESO cis rs4835473 0.798 rs34353812 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143973949 chr4:143912331~143982454:+ MESO cis rs4835473 0.831 rs10428468 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143974104 chr4:143912331~143982454:+ MESO cis rs4835473 0.75 rs57610804 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143974341 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs13148097 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143976238 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs28377887 ENSG00000251600.4 RP11-673E1.1 5.6 6.78e-07 0.00427 0.7 0.6 Immature fraction of reticulocytes; chr4:143977075 chr4:143912331~143982454:+ MESO cis rs4835473 0.868 rs35809032 ENSG00000251600.4 RP11-673E1.1 -5.6 6.8e-07 0.00428 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143824797 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs17763107 ENSG00000251600.4 RP11-673E1.1 -5.6 6.8e-07 0.00428 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143828512 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs17695782 ENSG00000251600.4 RP11-673E1.1 -5.6 6.8e-07 0.00428 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143830311 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs34917094 ENSG00000251600.4 RP11-673E1.1 -5.6 6.8e-07 0.00428 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143832003 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs11736609 ENSG00000251600.4 RP11-673E1.1 -5.6 6.8e-07 0.00428 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143832876 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs11730929 ENSG00000251600.4 RP11-673E1.1 -5.6 6.8e-07 0.00428 -0.7 -0.6 Immature fraction of reticulocytes; chr4:143834795 chr4:143912331~143982454:+ MESO cis rs2882667 0.867 rs6868085 ENSG00000253404.1 AC034243.1 5.59 6.89e-07 0.00432 0.79 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:139096757 chr5:138744434~138753309:- MESO cis rs875971 0.577 rs35072105 ENSG00000226824.5 RP4-756H11.3 5.59 6.9e-07 0.00433 0.84 0.6 Aortic root size; chr7:66144830 chr7:66654538~66669855:+ MESO cis rs4835473 0.932 rs4585249 ENSG00000251600.4 RP11-673E1.1 -5.59 6.99e-07 0.00437 -0.69 -0.6 Immature fraction of reticulocytes; chr4:143981173 chr4:143912331~143982454:+ MESO cis rs950027 0.787 rs1153845 ENSG00000259520.4 CTD-2651B20.3 5.59 7.06e-07 0.00442 0.83 0.6 Response to fenofibrate (adiponectin levels); chr15:45432531 chr15:45251580~45279251:- MESO cis rs4964805 0.641 rs11111755 ENSG00000257681.1 RP11-341G23.4 5.59 7.09e-07 0.00442 0.86 0.6 Attention deficit hyperactivity disorder; chr12:103765889 chr12:103746315~103768858:- MESO cis rs4964805 0.641 rs10861094 ENSG00000257681.1 RP11-341G23.4 5.59 7.09e-07 0.00442 0.86 0.6 Attention deficit hyperactivity disorder; chr12:103765938 chr12:103746315~103768858:- MESO cis rs4964805 0.594 rs11111759 ENSG00000257681.1 RP11-341G23.4 5.59 7.09e-07 0.00442 0.86 0.6 Attention deficit hyperactivity disorder; chr12:103769405 chr12:103746315~103768858:- MESO cis rs9322193 0.962 rs9478848 ENSG00000231760.4 RP11-350J20.5 5.59 7.11e-07 0.00442 0.84 0.6 Lung cancer; chr6:149825080 chr6:149796151~149826294:- MESO cis rs4835473 0.838 rs6832094 ENSG00000251600.4 RP11-673E1.1 -5.58 7.2e-07 0.00443 -0.75 -0.6 Immature fraction of reticulocytes; chr4:143795388 chr4:143912331~143982454:+ MESO cis rs7208859 0.673 rs999798 ENSG00000263531.1 RP13-753N3.1 5.58 7.21e-07 0.00443 1.07 0.6 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831822 chr17:30863921~30864940:- MESO cis rs4835473 0.897 rs4054616 ENSG00000251600.4 RP11-673E1.1 5.58 7.25e-07 0.00445 0.7 0.6 Immature fraction of reticulocytes; chr4:143837472 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs2323325 ENSG00000251600.4 RP11-673E1.1 5.58 7.25e-07 0.00445 0.7 0.6 Immature fraction of reticulocytes; chr4:143837561 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs7682204 ENSG00000251600.4 RP11-673E1.1 5.57 7.39e-07 0.0045 0.71 0.6 Immature fraction of reticulocytes; chr4:143966306 chr4:143912331~143982454:+ MESO cis rs4835473 0.639 rs28674022 ENSG00000251600.4 RP11-673E1.1 5.57 7.39e-07 0.0045 0.71 0.6 Immature fraction of reticulocytes; chr4:143966409 chr4:143912331~143982454:+ MESO cis rs4835473 0.864 rs28423022 ENSG00000251600.4 RP11-673E1.1 5.57 7.39e-07 0.0045 0.71 0.6 Immature fraction of reticulocytes; chr4:143966416 chr4:143912331~143982454:+ MESO cis rs4835473 0.864 rs35888177 ENSG00000251600.4 RP11-673E1.1 5.57 7.39e-07 0.0045 0.71 0.6 Immature fraction of reticulocytes; chr4:143966863 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs10033382 ENSG00000251600.4 RP11-673E1.1 5.57 7.39e-07 0.0045 0.71 0.6 Immature fraction of reticulocytes; chr4:143967103 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs7667092 ENSG00000251600.4 RP11-673E1.1 5.57 7.39e-07 0.0045 0.71 0.6 Immature fraction of reticulocytes; chr4:143968604 chr4:143912331~143982454:+ MESO cis rs2117029 1 rs10783301 ENSG00000258017.1 RP11-386G11.10 -5.57 7.44e-07 0.00453 -0.7 -0.6 Intelligence (multi-trait analysis); chr12:49045593 chr12:49127782~49147869:+ MESO cis rs62388641 0.539 rs56304710 ENSG00000272279.1 RP11-157J24.2 5.57 7.47e-07 0.00455 0.7 0.6 Daytime sleep phenotypes; chr6:1542341 chr6:1528364~1528911:- MESO cis rs2882667 0.858 rs11948429 ENSG00000253404.1 AC034243.1 5.57 7.59e-07 0.00462 0.78 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:139122895 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs2043271 ENSG00000253404.1 AC034243.1 5.57 7.59e-07 0.00462 0.78 0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:139123419 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs11750382 ENSG00000253404.1 AC034243.1 -5.57 7.59e-07 0.00462 -0.78 -0.6 Age-related hearing impairment (SNP x SNP interaction); chr5:139121305 chr5:138744434~138753309:- MESO cis rs2739330 0.892 rs4822455 ENSG00000225282.1 AP000350.6 5.57 7.63e-07 0.00464 0.69 0.6 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913109 chr22:23926900~23929574:+ MESO cis rs875971 0.862 rs11773628 ENSG00000226824.5 RP4-756H11.3 5.56 7.78e-07 0.00473 0.82 0.6 Aortic root size; chr7:66517644 chr7:66654538~66669855:+ MESO cis rs755249 0.727 rs2242500 ENSG00000237624.1 OXCT2P1 5.56 7.78e-07 0.00473 0.71 0.6 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572230 chr1:39514956~39516490:+ MESO cis rs755249 0.727 rs16826349 ENSG00000237624.1 OXCT2P1 5.56 7.78e-07 0.00473 0.71 0.6 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39573264 chr1:39514956~39516490:+ MESO cis rs4835473 0.897 rs35140014 ENSG00000251600.4 RP11-673E1.1 5.56 7.85e-07 0.00476 0.72 0.6 Immature fraction of reticulocytes; chr4:143964292 chr4:143912331~143982454:+ MESO cis rs7617773 0.817 rs6796490 ENSG00000229759.1 MRPS18AP1 5.56 7.93e-07 0.00481 0.71 0.6 Coronary artery disease; chr3:48195614 chr3:48256350~48256938:- MESO cis rs4835473 0.932 rs11721700 ENSG00000251600.4 RP11-673E1.1 -5.55 8.03e-07 0.00486 -0.72 -0.6 Immature fraction of reticulocytes; chr4:143824264 chr4:143912331~143982454:+ MESO cis rs5760092 0.618 rs5996631 ENSG00000250470.1 AP000351.3 -5.55 8.05e-07 0.00486 -0.81 -0.6 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23914707 chr22:23976904~23977585:- MESO cis rs73086581 0.741 rs17212649 ENSG00000229539.1 RP11-119B16.2 5.55 8.09e-07 0.00488 0.8 0.6 Response to antidepressants in depression; chr20:3872446 chr20:3888239~3888868:- MESO cis rs4835473 0.932 rs11734383 ENSG00000251600.4 RP11-673E1.1 -5.55 8.09e-07 0.00488 -0.71 -0.6 Immature fraction of reticulocytes; chr4:143824093 chr4:143912331~143982454:+ MESO cis rs4835473 0.868 rs11735295 ENSG00000251600.4 RP11-673E1.1 -5.55 8.09e-07 0.00488 -0.71 -0.6 Immature fraction of reticulocytes; chr4:143824150 chr4:143912331~143982454:+ MESO cis rs4964805 0.594 rs3751204 ENSG00000257681.1 RP11-341G23.4 5.55 8.14e-07 0.00489 0.86 0.6 Attention deficit hyperactivity disorder; chr12:103777677 chr12:103746315~103768858:- MESO cis rs4835473 0.932 rs11100824 ENSG00000251600.4 RP11-673E1.1 5.55 8.14e-07 0.00489 0.71 0.6 Immature fraction of reticulocytes; chr4:143964845 chr4:143912331~143982454:+ MESO cis rs4835473 0.592 rs11100825 ENSG00000251600.4 RP11-673E1.1 5.55 8.14e-07 0.00489 0.71 0.6 Immature fraction of reticulocytes; chr4:143964903 chr4:143912331~143982454:+ MESO cis rs4835473 0.864 rs2089837 ENSG00000251600.4 RP11-673E1.1 5.55 8.14e-07 0.00489 0.71 0.6 Immature fraction of reticulocytes; chr4:143965038 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs2089835 ENSG00000251600.4 RP11-673E1.1 5.55 8.14e-07 0.00489 0.71 0.6 Immature fraction of reticulocytes; chr4:143965127 chr4:143912331~143982454:+ MESO cis rs7617773 0.784 rs9850672 ENSG00000229759.1 MRPS18AP1 5.55 8.14e-07 0.00489 0.75 0.6 Coronary artery disease; chr3:48259682 chr3:48256350~48256938:- MESO cis rs7617773 0.779 rs11718329 ENSG00000229759.1 MRPS18AP1 5.55 8.14e-07 0.00489 0.75 0.6 Coronary artery disease; chr3:48268338 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs6442111 ENSG00000229759.1 MRPS18AP1 5.55 8.14e-07 0.00489 0.75 0.6 Coronary artery disease; chr3:48270570 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs3937 ENSG00000229759.1 MRPS18AP1 5.55 8.14e-07 0.00489 0.75 0.6 Coronary artery disease; chr3:48270912 chr3:48256350~48256938:- MESO cis rs7617773 0.851 rs6775179 ENSG00000229759.1 MRPS18AP1 5.55 8.14e-07 0.00489 0.75 0.6 Coronary artery disease; chr3:48271928 chr3:48256350~48256938:- MESO cis rs950027 0.787 rs2433616 ENSG00000259520.4 CTD-2651B20.3 -5.55 8.17e-07 0.00491 -0.77 -0.6 Response to fenofibrate (adiponectin levels); chr15:45436401 chr15:45251580~45279251:- MESO cis rs3931020 0.772 rs1409785 ENSG00000272864.1 RP11-17E13.2 -5.54 8.27e-07 0.00496 -0.78 -0.6 Resistin levels; chr1:74782438 chr1:74698769~74699333:- MESO cis rs755249 0.727 rs12028034 ENSG00000237624.1 OXCT2P1 -5.54 8.27e-07 0.00496 -0.73 -0.6 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39574035 chr1:39514956~39516490:+ MESO cis rs858239 0.862 rs1728292 ENSG00000230658.1 KLHL7-AS1 5.54 8.3e-07 0.00498 0.82 0.6 Cerebrospinal fluid biomarker levels; chr7:23223855 chr7:23101228~23105703:- MESO cis rs4835473 0.831 rs4125544 ENSG00000251600.4 RP11-673E1.1 5.54 8.35e-07 0.005 0.74 0.6 Immature fraction of reticulocytes; chr4:143962542 chr4:143912331~143982454:+ MESO cis rs1799949 0.602 rs8176199 ENSG00000198496.9 NBR2 -5.54 8.36e-07 0.005 -0.85 -0.6 Menopause (age at onset); chr17:43078507 chr17:43125610~43153671:+ MESO cis rs9322193 0.962 rs7745915 ENSG00000231760.4 RP11-350J20.5 5.54 8.43e-07 0.00504 0.8 0.59 Lung cancer; chr6:149834111 chr6:149796151~149826294:- MESO cis rs4835473 0.932 rs4835118 ENSG00000251600.4 RP11-673E1.1 5.54 8.46e-07 0.00505 0.72 0.59 Immature fraction of reticulocytes; chr4:143981994 chr4:143912331~143982454:+ MESO cis rs8091660 1 rs8091660 ENSG00000278983.1 RP11-426J5.3 5.54 8.47e-07 0.00505 0.68 0.59 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48561565 chr18:48564795~48568342:+ MESO cis rs73086581 0.787 rs67633417 ENSG00000229539.1 RP11-119B16.2 5.54 8.48e-07 0.00506 0.79 0.59 Response to antidepressants in depression; chr20:3887610 chr20:3888239~3888868:- MESO cis rs73086581 0.787 rs68127408 ENSG00000229539.1 RP11-119B16.2 5.54 8.48e-07 0.00506 0.79 0.59 Response to antidepressants in depression; chr20:3887800 chr20:3888239~3888868:- MESO cis rs73086581 0.787 rs67724338 ENSG00000229539.1 RP11-119B16.2 5.54 8.48e-07 0.00506 0.79 0.59 Response to antidepressants in depression; chr20:3888410 chr20:3888239~3888868:- MESO cis rs73086581 0.787 rs67202952 ENSG00000229539.1 RP11-119B16.2 5.54 8.48e-07 0.00506 0.79 0.59 Response to antidepressants in depression; chr20:3888452 chr20:3888239~3888868:- MESO cis rs1150668 0.745 rs213238 ENSG00000216901.1 AL022393.7 5.54 8.54e-07 0.00509 0.82 0.59 Pubertal anthropometrics; chr6:28354216 chr6:28176188~28176674:+ MESO cis rs801193 0.548 rs7805152 ENSG00000226824.5 RP4-756H11.3 -5.53 8.56e-07 0.00509 -0.78 -0.59 Aortic root size; chr7:66744266 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs11772819 ENSG00000226824.5 RP4-756H11.3 -5.53 8.56e-07 0.00509 -0.78 -0.59 Aortic root size; chr7:66752983 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs11761542 ENSG00000226824.5 RP4-756H11.3 -5.53 8.56e-07 0.00509 -0.78 -0.59 Aortic root size; chr7:66753209 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs7800620 ENSG00000226824.5 RP4-756H11.3 -5.53 8.56e-07 0.00509 -0.78 -0.59 Aortic root size; chr7:66758701 chr7:66654538~66669855:+ MESO cis rs801193 0.548 rs6975044 ENSG00000226824.5 RP4-756H11.3 -5.53 8.56e-07 0.00509 -0.78 -0.59 Aortic root size; chr7:66762495 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs13226966 ENSG00000226824.5 RP4-756H11.3 -5.53 8.56e-07 0.00509 -0.78 -0.59 Aortic root size; chr7:66768636 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs35070132 ENSG00000226824.5 RP4-756H11.3 -5.53 8.56e-07 0.00509 -0.78 -0.59 Aortic root size; chr7:66773096 chr7:66654538~66669855:+ MESO cis rs3091242 1 rs3091242 ENSG00000224183.1 SDHDP6 -5.53 8.64e-07 0.00513 -0.81 -0.59 Erythrocyte sedimentation rate; chr1:25348294 chr1:25294164~25294643:- MESO cis rs3091242 0.967 rs3091240 ENSG00000224183.1 SDHDP6 -5.53 8.64e-07 0.00513 -0.81 -0.59 Erythrocyte sedimentation rate; chr1:25350444 chr1:25294164~25294643:- MESO cis rs3091242 0.935 rs3093632 ENSG00000224183.1 SDHDP6 -5.53 8.64e-07 0.00513 -0.81 -0.59 Erythrocyte sedimentation rate; chr1:25357521 chr1:25294164~25294643:- MESO cis rs7927592 0.913 rs10047412 ENSG00000212093.1 AP000807.1 5.53 8.73e-07 0.00517 0.59 0.59 Total body bone mineral density; chr11:68465444 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs12363722 ENSG00000212093.1 AP000807.1 5.53 8.73e-07 0.00517 0.59 0.59 Total body bone mineral density; chr11:68468823 chr11:68506083~68506166:- MESO cis rs7927592 0.871 rs12360903 ENSG00000212093.1 AP000807.1 5.53 8.73e-07 0.00517 0.59 0.59 Total body bone mineral density; chr11:68468846 chr11:68506083~68506166:- MESO cis rs11673344 0.583 rs10421436 ENSG00000226686.6 LINC01535 -5.53 8.79e-07 0.0052 -0.64 -0.59 Obesity-related traits; chr19:37394601 chr19:37251912~37265535:+ MESO cis rs4835473 0.932 rs1849112 ENSG00000251600.4 RP11-673E1.1 5.52 9.15e-07 0.00539 0.74 0.59 Immature fraction of reticulocytes; chr4:143962502 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1849113 ENSG00000251600.4 RP11-673E1.1 -5.52 9.15e-07 0.00539 -0.74 -0.59 Immature fraction of reticulocytes; chr4:143962512 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs28701142 ENSG00000251600.4 RP11-673E1.1 5.52 9.19e-07 0.0054 0.69 0.59 Immature fraction of reticulocytes; chr4:143945730 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs3872 ENSG00000251600.4 RP11-673E1.1 5.51 9.24e-07 0.00543 0.69 0.59 Immature fraction of reticulocytes; chr4:143968788 chr4:143912331~143982454:+ MESO cis rs11673344 0.583 rs10425719 ENSG00000226686.6 LINC01535 -5.51 9.51e-07 0.00556 -0.63 -0.59 Obesity-related traits; chr19:37459896 chr19:37251912~37265535:+ MESO cis rs7927592 0.913 rs10896329 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68482561 chr11:68506083~68506166:- MESO cis rs12364620 1 rs12364620 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density (age 0-15); chr11:68484655 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs12272917 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68495902 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs59056571 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68505505 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs66752716 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68506158 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs11228262 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68507439 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs55883802 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68511361 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs11228268 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68519979 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs4084149 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68521099 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7925275 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68522965 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs6591340 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68530168 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs10896338 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68531892 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7115374 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68532608 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs67605986 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68533487 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs12285993 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68535070 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs11228276 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68540057 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs67005337 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68540290 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs948316 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68542202 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs10896341 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68545712 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs67947146 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68547512 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7104345 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68549304 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs12284933 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68552021 chr11:68506083~68506166:- MESO cis rs7927592 0.871 rs11228284 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68555299 chr11:68506083~68506166:- MESO cis rs7927592 0.871 rs55953412 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68560815 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7102898 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68561402 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7109294 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68564625 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs2282563 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68565732 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs3740631 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68574254 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs3824850 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68574405 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs3740629 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68576125 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs11228287 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68582286 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs10896346 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68585203 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs10896347 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68585659 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7118897 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68593212 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs6591344 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68593405 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7123564 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68594696 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7127948 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68595594 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7106010 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68597744 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs3758643 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68599725 chr11:68506083~68506166:- MESO cis rs7927592 0.871 rs17603185 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68608773 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs2236708 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68610577 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs11228292 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68612304 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs4988291 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68614139 chr11:68506083~68506166:- MESO cis rs7927592 0.871 rs12941 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68614725 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs11228293 ENSG00000212093.1 AP000807.1 5.5 9.78e-07 0.00564 0.58 0.59 Total body bone mineral density; chr11:68617178 chr11:68506083~68506166:- MESO cis rs2117029 0.782 rs6580698 ENSG00000258017.1 RP11-386G11.10 -5.5 9.79e-07 0.00564 -0.71 -0.59 Intelligence (multi-trait analysis); chr12:49084875 chr12:49127782~49147869:+ MESO cis rs9322193 0.962 rs3763163 ENSG00000231760.4 RP11-350J20.5 5.5 9.79e-07 0.00564 0.81 0.59 Lung cancer; chr6:149819770 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs14314 ENSG00000231760.4 RP11-350J20.5 5.5 9.79e-07 0.00564 0.81 0.59 Lung cancer; chr6:149820395 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs1413655 ENSG00000231760.4 RP11-350J20.5 5.5 9.79e-07 0.00564 0.81 0.59 Lung cancer; chr6:149821815 chr6:149796151~149826294:- MESO cis rs9322193 0.926 rs9383546 ENSG00000231760.4 RP11-350J20.5 5.5 9.79e-07 0.00564 0.81 0.59 Lung cancer; chr6:149822743 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs1889473 ENSG00000231760.4 RP11-350J20.5 5.5 9.79e-07 0.00564 0.81 0.59 Lung cancer; chr6:149825485 chr6:149796151~149826294:- MESO cis rs55794721 0.509 rs873308 ENSG00000224183.1 SDHDP6 5.49 1.01e-06 0.00578 0.76 0.59 Mean corpuscular volume;Plateletcrit; chr1:25432164 chr1:25294164~25294643:- MESO cis rs7617773 0.851 rs7647817 ENSG00000229759.1 MRPS18AP1 5.49 1.01e-06 0.0058 0.79 0.59 Coronary artery disease; chr3:48195017 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs11707606 ENSG00000229759.1 MRPS18AP1 5.49 1.01e-06 0.0058 0.79 0.59 Coronary artery disease; chr3:48195597 chr3:48256350~48256938:- MESO cis rs7617773 0.71 rs36064160 ENSG00000229759.1 MRPS18AP1 5.49 1.01e-06 0.0058 0.79 0.59 Coronary artery disease; chr3:48201611 chr3:48256350~48256938:- MESO cis rs4835473 0.808 rs6831401 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143801038 chr4:143912331~143982454:+ MESO cis rs4835473 0.778 rs6853798 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143801153 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs12502940 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143812117 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs12503900 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143812459 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs12503074 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143812560 chr4:143912331~143982454:+ MESO cis rs4835473 0.778 rs2622380 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143814571 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs35792820 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143814806 chr4:143912331~143982454:+ MESO cis rs4835473 0.864 rs62337300 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143815897 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs7697498 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143816854 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs7656455 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143817005 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs13133239 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143818894 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs13106488 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143818969 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs13105102 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143819046 chr4:143912331~143982454:+ MESO cis rs4835473 0.868 rs13105118 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143819077 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs35271123 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143819629 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1383443 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143819940 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs7669198 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143821229 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs6834494 ENSG00000251600.4 RP11-673E1.1 -5.49 1.02e-06 0.0058 -0.72 -0.59 Immature fraction of reticulocytes; chr4:143822257 chr4:143912331~143982454:+ MESO cis rs2739330 0.76 rs5751760 ENSG00000273295.1 AP000350.5 5.49 1.02e-06 0.00581 0.69 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23901432~23907068:- MESO cis rs7927592 0.871 rs113020558 ENSG00000212093.1 AP000807.1 5.49 1.03e-06 0.00583 0.58 0.59 Total body bone mineral density; chr11:68529364 chr11:68506083~68506166:- MESO cis rs2019137 0.868 rs6755639 ENSG00000189223.12 PAX8-AS1 -5.49 1.03e-06 0.00585 -0.74 -0.59 Lymphocyte counts; chr2:113224233 chr2:113211522~113276581:+ MESO cis rs2739330 0.753 rs4822452 ENSG00000225282.1 AP000350.6 5.48 1.05e-06 0.00594 0.67 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912176 chr22:23926900~23929574:+ MESO cis rs2739330 0.828 rs4822454 ENSG00000225282.1 AP000350.6 5.48 1.05e-06 0.00594 0.67 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23913021 chr22:23926900~23929574:+ MESO cis rs73086581 1 rs73088421 ENSG00000229539.1 RP11-119B16.2 5.48 1.06e-06 0.00598 0.8 0.59 Response to antidepressants in depression; chr20:4017224 chr20:3888239~3888868:- MESO cis rs7104764 0.879 rs6598070 ENSG00000277290.1 RP11-326C3.16 -5.48 1.06e-06 0.00599 -0.76 -0.59 Menarche (age at onset); chr11:225466 chr11:243099~243483:- MESO cis rs7104764 1 rs6598066 ENSG00000277290.1 RP11-326C3.16 -5.48 1.06e-06 0.00599 -0.76 -0.59 Menarche (age at onset); chr11:243185 chr11:243099~243483:- MESO cis rs57502260 0.79 rs7128942 ENSG00000212093.1 AP000807.1 5.47 1.07e-06 0.00603 0.73 0.59 Total body bone mineral density (age 45-60); chr11:68620516 chr11:68506083~68506166:- MESO cis rs57502260 0.79 rs7129320 ENSG00000212093.1 AP000807.1 5.47 1.07e-06 0.00603 0.73 0.59 Total body bone mineral density (age 45-60); chr11:68620752 chr11:68506083~68506166:- MESO cis rs4835473 0.868 rs62337291 ENSG00000251600.4 RP11-673E1.1 -5.47 1.08e-06 0.00606 -0.73 -0.59 Immature fraction of reticulocytes; chr4:143807903 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs13121861 ENSG00000251600.4 RP11-673E1.1 -5.47 1.08e-06 0.00606 -0.73 -0.59 Immature fraction of reticulocytes; chr4:143814007 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs4835303 ENSG00000251600.4 RP11-673E1.1 -5.47 1.08e-06 0.00606 -0.73 -0.59 Immature fraction of reticulocytes; chr4:143821533 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4835034 ENSG00000251600.4 RP11-673E1.1 -5.47 1.08e-06 0.00606 -0.73 -0.59 Immature fraction of reticulocytes; chr4:143821538 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs6827971 ENSG00000251600.4 RP11-673E1.1 -5.47 1.08e-06 0.00606 -0.73 -0.59 Immature fraction of reticulocytes; chr4:143822126 chr4:143912331~143982454:+ MESO cis rs2882667 0.858 rs66839813 ENSG00000253404.1 AC034243.1 5.47 1.09e-06 0.00611 0.77 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139106633 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs11242448 ENSG00000253404.1 AC034243.1 5.47 1.09e-06 0.00611 0.77 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139107465 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs13174479 ENSG00000253404.1 AC034243.1 5.47 1.09e-06 0.00611 0.77 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139108481 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs13176497 ENSG00000253404.1 AC034243.1 5.47 1.09e-06 0.00611 0.77 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139110385 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs11959803 ENSG00000253404.1 AC034243.1 5.47 1.09e-06 0.00611 0.77 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139115626 chr5:138744434~138753309:- MESO cis rs9322193 0.962 rs6903998 ENSG00000231760.4 RP11-350J20.5 5.47 1.1e-06 0.00616 0.81 0.59 Lung cancer; chr6:149831357 chr6:149796151~149826294:- MESO cis rs9322193 0.923 rs1984111 ENSG00000231760.4 RP11-350J20.5 5.47 1.1e-06 0.00616 0.81 0.59 Lung cancer; chr6:149831720 chr6:149796151~149826294:- MESO cis rs9322193 0.962 rs2151912 ENSG00000231760.4 RP11-350J20.5 5.47 1.1e-06 0.00616 0.81 0.59 Lung cancer; chr6:149831772 chr6:149796151~149826294:- MESO cis rs4835473 0.932 rs10025527 ENSG00000251600.4 RP11-673E1.1 5.47 1.1e-06 0.00616 0.7 0.59 Immature fraction of reticulocytes; chr4:143968391 chr4:143912331~143982454:+ MESO cis rs7208859 0.614 rs73265646 ENSG00000263531.1 RP13-753N3.1 5.47 1.11e-06 0.00618 1.04 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917005 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs58908911 ENSG00000263531.1 RP13-753N3.1 5.47 1.11e-06 0.00618 1.04 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30917540 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs28588622 ENSG00000263531.1 RP13-753N3.1 5.47 1.11e-06 0.00618 1.04 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30918681 chr17:30863921~30864940:- MESO cis rs1577917 0.655 rs9450311 ENSG00000203875.9 SNHG5 5.47 1.11e-06 0.00618 0.79 0.59 Response to antipsychotic treatment; chr6:85666868 chr6:85660950~85678736:- MESO cis rs4835473 0.864 rs12507633 ENSG00000251600.4 RP11-673E1.1 5.46 1.11e-06 0.00619 0.74 0.59 Immature fraction of reticulocytes; chr4:143962730 chr4:143912331~143982454:+ MESO cis rs875971 0.862 rs801195 ENSG00000226824.5 RP4-756H11.3 5.46 1.12e-06 0.00625 0.8 0.59 Aortic root size; chr7:66561128 chr7:66654538~66669855:+ MESO cis rs864745 0.967 rs1635852 ENSG00000253187.2 HOXA10-AS 5.46 1.13e-06 0.00629 0.66 0.59 Crohn's disease;Type 2 diabetes; chr7:28149792 chr7:27168619~27171915:+ MESO cis rs875971 0.83 rs12673450 ENSG00000226824.5 RP4-756H11.3 -5.46 1.13e-06 0.0063 -0.8 -0.59 Aortic root size; chr7:66544233 chr7:66654538~66669855:+ MESO cis rs977987 0.671 rs9922008 ENSG00000261783.1 RP11-252K23.2 -5.46 1.13e-06 0.0063 -0.79 -0.59 Dupuytren's disease; chr16:75301508 chr16:75379818~75381260:- MESO cis rs2019137 0.539 rs4849181 ENSG00000274877.1 RP11-65I12.1 -5.46 1.13e-06 0.00631 -0.75 -0.59 Lymphocyte counts; chr2:113234393 chr2:113237595~113240825:+ MESO cis rs55794721 0.543 rs1293260 ENSG00000224183.1 SDHDP6 -5.46 1.13e-06 0.00631 -0.79 -0.59 Mean corpuscular volume;Plateletcrit; chr1:25382613 chr1:25294164~25294643:- MESO cis rs3018712 0.532 rs2513294 ENSG00000212093.1 AP000807.1 -5.46 1.14e-06 0.00634 -0.68 -0.59 Total body bone mineral density; chr11:68653726 chr11:68506083~68506166:- MESO cis rs7104764 1 rs1128322 ENSG00000277290.1 RP11-326C3.16 5.46 1.14e-06 0.00636 0.74 0.59 Menarche (age at onset); chr11:244197 chr11:243099~243483:- MESO cis rs2882667 0.627 rs1549203 ENSG00000253404.1 AC034243.1 -5.45 1.16e-06 0.00643 -0.77 -0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139132655 chr5:138744434~138753309:- MESO cis rs7301826 0.651 rs12820597 ENSG00000256250.1 RP11-989F5.1 5.45 1.17e-06 0.00647 0.74 0.59 Plasma plasminogen activator levels; chr12:130795640 chr12:130810606~130812438:+ MESO cis rs4835473 0.932 rs4092718 ENSG00000251600.4 RP11-673E1.1 -5.45 1.18e-06 0.00654 -0.71 -0.59 Immature fraction of reticulocytes; chr4:143799637 chr4:143912331~143982454:+ MESO cis rs1577917 0.654 rs9450284 ENSG00000203875.9 SNHG5 5.45 1.19e-06 0.00654 0.77 0.59 Response to antipsychotic treatment; chr6:85489611 chr6:85660950~85678736:- MESO cis rs1577917 0.629 rs7761762 ENSG00000203875.9 SNHG5 5.45 1.19e-06 0.00654 0.77 0.59 Response to antipsychotic treatment; chr6:85496250 chr6:85660950~85678736:- MESO cis rs975739 0.843 rs9574113 ENSG00000236051.5 MYCBP2-AS1 -5.44 1.21e-06 0.00666 -0.7 -0.59 Hair color; chr13:77843996 chr13:77075514~77129717:+ MESO cis rs62388641 0.813 rs62390562 ENSG00000272279.1 RP11-157J24.2 5.44 1.23e-06 0.00669 0.82 0.59 Daytime sleep phenotypes; chr6:1551467 chr6:1528364~1528911:- MESO cis rs62388641 0.813 rs34114087 ENSG00000272279.1 RP11-157J24.2 5.44 1.23e-06 0.00669 0.82 0.59 Daytime sleep phenotypes; chr6:1553203 chr6:1528364~1528911:- MESO cis rs7208859 0.673 rs9915139 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30831497 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73263776 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30884313 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs11650271 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30886925 chr17:30863921~30864940:- MESO cis rs7208859 0.573 rs11656121 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887025 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs11650973 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887027 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11657270 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887369 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73263785 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30887790 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs78799101 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888142 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs55904046 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30888373 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs73263788 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30889472 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs56085216 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30890216 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9889968 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30893110 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs61348930 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30894745 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs12949860 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896014 chr17:30863921~30864940:- MESO cis rs7208859 0.614 rs28758251 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896294 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9899943 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30896907 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11080138 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30897524 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73265612 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30898965 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs2433 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30899210 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11658435 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30901543 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11650305 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902343 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11654914 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30902406 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73265624 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905048 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9914271 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30905607 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs2269915 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906326 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs2269916 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906745 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11649765 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30906870 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs12103759 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908669 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs59029591 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30908728 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73265633 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30909288 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9913782 ENSG00000263531.1 RP13-753N3.1 5.44 1.23e-06 0.00669 1.08 0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910366 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9911989 ENSG00000263531.1 RP13-753N3.1 -5.44 1.23e-06 0.00669 -1.08 -0.59 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30910684 chr17:30863921~30864940:- MESO cis rs4835473 0.808 rs6836630 ENSG00000251600.4 RP11-673E1.1 -5.43 1.25e-06 0.00674 -0.7 -0.59 Immature fraction of reticulocytes; chr4:143801068 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs13101541 ENSG00000251600.4 RP11-673E1.1 -5.43 1.25e-06 0.00674 -0.7 -0.59 Immature fraction of reticulocytes; chr4:143806590 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs17695238 ENSG00000251600.4 RP11-673E1.1 -5.43 1.25e-06 0.00674 -0.7 -0.59 Immature fraction of reticulocytes; chr4:143820720 chr4:143912331~143982454:+ MESO cis rs2117029 0.5 rs1054442 ENSG00000258017.1 RP11-386G11.10 -5.43 1.26e-06 0.00679 -0.74 -0.59 Intelligence (multi-trait analysis); chr12:48995537 chr12:49127782~49147869:+ MESO cis rs2019137 0.539 rs6755040 ENSG00000274877.1 RP11-65I12.1 -5.43 1.27e-06 0.00683 -0.75 -0.59 Lymphocyte counts; chr2:113223560 chr2:113237595~113240825:+ MESO cis rs2019137 0.539 rs4849177 ENSG00000274877.1 RP11-65I12.1 -5.43 1.27e-06 0.00683 -0.75 -0.59 Lymphocyte counts; chr2:113225007 chr2:113237595~113240825:+ MESO cis rs2019137 0.56 rs11123172 ENSG00000274877.1 RP11-65I12.1 5.43 1.27e-06 0.00683 0.75 0.59 Lymphocyte counts; chr2:113226726 chr2:113237595~113240825:+ MESO cis rs2019137 0.56 rs4849179 ENSG00000274877.1 RP11-65I12.1 -5.43 1.27e-06 0.00683 -0.75 -0.59 Lymphocyte counts; chr2:113227593 chr2:113237595~113240825:+ MESO cis rs2019137 0.56 rs10175462 ENSG00000274877.1 RP11-65I12.1 -5.43 1.27e-06 0.00683 -0.75 -0.59 Lymphocyte counts; chr2:113230915 chr2:113237595~113240825:+ MESO cis rs2882667 0.824 rs1560656 ENSG00000253404.1 AC034243.1 -5.43 1.27e-06 0.00683 -0.78 -0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139135100 chr5:138744434~138753309:- MESO cis rs2882667 0.755 rs55650316 ENSG00000253404.1 AC034243.1 5.43 1.27e-06 0.00683 0.78 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139131603 chr5:138744434~138753309:- MESO cis rs2882667 0.824 rs13189485 ENSG00000253404.1 AC034243.1 5.43 1.27e-06 0.00683 0.78 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139139712 chr5:138744434~138753309:- MESO cis rs2882667 0.756 rs11957953 ENSG00000253404.1 AC034243.1 5.43 1.27e-06 0.00683 0.78 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139143688 chr5:138744434~138753309:- MESO cis rs2882667 0.824 rs11748097 ENSG00000253404.1 AC034243.1 5.43 1.27e-06 0.00683 0.78 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139144198 chr5:138744434~138753309:- MESO cis rs2882667 0.824 rs12173085 ENSG00000253404.1 AC034243.1 5.43 1.27e-06 0.00683 0.78 0.59 Age-related hearing impairment (SNP x SNP interaction); chr5:139144336 chr5:138744434~138753309:- MESO cis rs7617773 0.817 rs13072018 ENSG00000229759.1 MRPS18AP1 5.43 1.27e-06 0.00683 0.75 0.59 Coronary artery disease; chr3:48278842 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs13094727 ENSG00000229759.1 MRPS18AP1 5.43 1.27e-06 0.00683 0.75 0.59 Coronary artery disease; chr3:48281999 chr3:48256350~48256938:- MESO cis rs2739330 0.828 rs5760107 ENSG00000225282.1 AP000350.6 5.42 1.29e-06 0.00694 0.67 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910410 chr22:23926900~23929574:+ MESO cis rs2739330 0.828 rs5760108 ENSG00000225282.1 AP000350.6 5.42 1.29e-06 0.00694 0.67 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910481 chr22:23926900~23929574:+ MESO cis rs2739330 0.789 rs5760109 ENSG00000225282.1 AP000350.6 5.42 1.29e-06 0.00694 0.67 0.59 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910751 chr22:23926900~23929574:+ MESO cis rs1577917 0.655 rs6454472 ENSG00000203875.9 SNHG5 5.42 1.3e-06 0.00696 0.75 0.59 Response to antipsychotic treatment; chr6:85514335 chr6:85660950~85678736:- MESO cis rs6700559 0.654 rs66717951 ENSG00000260088.1 RP11-92G12.3 5.42 1.3e-06 0.00697 0.63 0.59 Coronary artery disease; chr1:200626437 chr1:200669507~200694250:+ MESO cis rs6700559 0.654 rs2809346 ENSG00000260088.1 RP11-92G12.3 5.42 1.3e-06 0.00697 0.63 0.59 Coronary artery disease; chr1:200627089 chr1:200669507~200694250:+ MESO cis rs6700559 0.654 rs2809345 ENSG00000260088.1 RP11-92G12.3 5.42 1.3e-06 0.00697 0.63 0.59 Coronary artery disease; chr1:200627135 chr1:200669507~200694250:+ MESO cis rs1153858 0.723 rs11855527 ENSG00000259520.4 CTD-2651B20.3 5.42 1.31e-06 0.00697 0.88 0.59 Homoarginine levels; chr15:45314487 chr15:45251580~45279251:- MESO cis rs3091242 0.933 rs4649084 ENSG00000224183.1 SDHDP6 -5.42 1.31e-06 0.00697 -0.78 -0.59 Erythrocyte sedimentation rate; chr1:25426126 chr1:25294164~25294643:- MESO cis rs73086581 0.687 rs73082600 ENSG00000229539.1 RP11-119B16.2 5.42 1.31e-06 0.00697 0.76 0.59 Response to antidepressants in depression; chr20:3863718 chr20:3888239~3888868:- MESO cis rs6700559 0.873 rs7526031 ENSG00000260088.1 RP11-92G12.3 -5.42 1.33e-06 0.00706 -0.63 -0.59 Coronary artery disease; chr1:200695174 chr1:200669507~200694250:+ MESO cis rs6964833 0.786 rs35633336 ENSG00000123965.13 PMS2P5 5.42 1.33e-06 0.00706 0.94 0.59 Menarche (age at onset); chr7:74643961 chr7:74894116~74897835:+ MESO cis rs6964833 0.935 rs34630792 ENSG00000123965.13 PMS2P5 5.42 1.33e-06 0.00706 0.94 0.59 Menarche (age at onset); chr7:74646869 chr7:74894116~74897835:+ MESO cis rs6964833 0.935 rs35735900 ENSG00000123965.13 PMS2P5 5.42 1.33e-06 0.00706 0.94 0.59 Menarche (age at onset); chr7:74651887 chr7:74894116~74897835:+ MESO cis rs6964833 0.872 rs4717903 ENSG00000123965.13 PMS2P5 5.42 1.33e-06 0.00706 0.94 0.59 Menarche (age at onset); chr7:74653827 chr7:74894116~74897835:+ MESO cis rs4835473 0.618 rs7685385 ENSG00000251600.4 RP11-673E1.1 -5.41 1.34e-06 0.00709 -0.73 -0.59 Immature fraction of reticulocytes; chr4:144029851 chr4:143912331~143982454:+ MESO cis rs62388641 0.813 rs34779492 ENSG00000272279.1 RP11-157J24.2 5.41 1.35e-06 0.00716 0.82 0.59 Daytime sleep phenotypes; chr6:1547737 chr6:1528364~1528911:- MESO cis rs62388641 0.774 rs13212794 ENSG00000272279.1 RP11-157J24.2 5.41 1.35e-06 0.00716 0.82 0.59 Daytime sleep phenotypes; chr6:1548349 chr6:1528364~1528911:- MESO cis rs62388641 0.813 rs55821127 ENSG00000272279.1 RP11-157J24.2 5.41 1.35e-06 0.00716 0.82 0.59 Daytime sleep phenotypes; chr6:1550635 chr6:1528364~1528911:- MESO cis rs7260538 0.773 rs1552223 ENSG00000267107.5 PCAT19 -5.41 1.38e-06 0.00722 -0.77 -0.59 DDT metabolite (p,p'-DDE levels); chr19:41020047 chr19:41454169~41500649:- MESO cis rs875971 0.862 rs6944374 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66221942 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs2901152 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66300017 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10263690 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66301466 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10250544 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66301574 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs949930 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66301835 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs12531677 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66304099 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs7798630 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66306492 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs11984115 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66308872 chr7:66654538~66669855:+ MESO cis rs875971 0.755 rs10228885 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66315542 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs3893216 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66325720 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6958294 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66329809 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs2088655 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66330724 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs10447522 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66331087 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs7783779 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66331639 chr7:66654538~66669855:+ MESO cis rs875971 0.928 rs2036263 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66335210 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10240949 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66339430 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs7782704 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66340379 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs2088653 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66343621 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6460290 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66344119 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6460293 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66345205 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6959268 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66347979 chr7:66654538~66669855:+ MESO cis rs875971 0.861 rs801215 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66546951 chr7:66654538~66669855:+ MESO cis rs875971 0.756 rs2901210 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66552518 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs13536 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66554203 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs801209 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66554403 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs801206 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66556979 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs801204 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66557934 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs801203 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66558025 chr7:66654538~66669855:+ MESO cis rs875971 0.825 rs801202 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66558942 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs801194 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66563508 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs2024192 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66576460 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6955837 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66578155 chr7:66654538~66669855:+ MESO cis rs875971 0.825 rs10281499 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66583979 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs4718377 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66584691 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10278014 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66586277 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1968126 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66592017 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6460306 ENSG00000226824.5 RP4-756H11.3 5.41 1.38e-06 0.00722 0.79 0.59 Aortic root size; chr7:66595806 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs12537823 ENSG00000226824.5 RP4-756H11.3 -5.41 1.38e-06 0.00722 -0.79 -0.59 Aortic root size; chr7:66255897 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs778736 ENSG00000226824.5 RP4-756H11.3 -5.41 1.38e-06 0.00722 -0.79 -0.59 Aortic root size; chr7:66348861 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs11763189 ENSG00000226824.5 RP4-756H11.3 -5.41 1.38e-06 0.00722 -0.79 -0.59 Aortic root size; chr7:66518542 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs13232191 ENSG00000226824.5 RP4-756H11.3 -5.41 1.38e-06 0.00722 -0.79 -0.59 Aortic root size; chr7:66521661 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs35378740 ENSG00000226824.5 RP4-756H11.3 -5.41 1.38e-06 0.00722 -0.79 -0.59 Aortic root size; chr7:66522725 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10950043 ENSG00000226824.5 RP4-756H11.3 -5.41 1.38e-06 0.00722 -0.79 -0.59 Aortic root size; chr7:66523623 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs17747530 ENSG00000226824.5 RP4-756H11.3 -5.41 1.38e-06 0.00722 -0.79 -0.59 Aortic root size; chr7:66529742 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs13226170 ENSG00000226824.5 RP4-756H11.3 -5.41 1.38e-06 0.00722 -0.79 -0.59 Aortic root size; chr7:66534311 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs2420611 ENSG00000226824.5 RP4-756H11.3 -5.41 1.38e-06 0.00722 -0.79 -0.59 Aortic root size; chr7:66534333 chr7:66654538~66669855:+ MESO cis rs875971 0.767 rs61348003 ENSG00000226824.5 RP4-756H11.3 -5.41 1.38e-06 0.00722 -0.79 -0.59 Aortic root size; chr7:66540947 chr7:66654538~66669855:+ MESO cis rs4835473 0.932 rs7693772 ENSG00000251600.4 RP11-673E1.1 5.4 1.4e-06 0.00727 0.71 0.59 Immature fraction of reticulocytes; chr4:143965614 chr4:143912331~143982454:+ MESO cis rs9322193 0.651 rs9322188 ENSG00000231760.4 RP11-350J20.5 -5.4 1.43e-06 0.00736 -0.79 -0.58 Lung cancer; chr6:149588355 chr6:149796151~149826294:- MESO cis rs2739330 0.828 rs5751770 ENSG00000225282.1 AP000350.6 5.39 1.44e-06 0.00743 0.68 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23910655 chr22:23926900~23929574:+ MESO cis rs7208859 0.673 rs75142521 ENSG00000263531.1 RP13-753N3.1 5.39 1.44e-06 0.00743 1.07 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913519 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9895684 ENSG00000263531.1 RP13-753N3.1 5.39 1.44e-06 0.00743 1.07 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30915582 chr17:30863921~30864940:- MESO cis rs9918079 0.56 rs4698409 ENSG00000273133.1 RP11-799M12.2 -5.39 1.44e-06 0.00744 -0.77 -0.58 Obesity-related traits; chr4:15658143 chr4:15563698~15564253:- MESO cis rs9918079 0.542 rs1789 ENSG00000273133.1 RP11-799M12.2 -5.39 1.44e-06 0.00744 -0.77 -0.58 Obesity-related traits; chr4:15662912 chr4:15563698~15564253:- MESO cis rs4853012 0.539 rs9789534 ENSG00000217702.2 RP11-287D1.4 5.39 1.45e-06 0.00744 0.95 0.58 Gestational age at birth (maternal effect); chr2:74135863 chr2:74130583~74135395:+ MESO cis rs1150668 0.768 rs1150716 ENSG00000216901.1 AL022393.7 5.39 1.45e-06 0.00746 0.75 0.58 Pubertal anthropometrics; chr6:28294921 chr6:28176188~28176674:+ MESO cis rs4323050 0.546 rs13124157 ENSG00000251600.4 RP11-673E1.1 5.39 1.46e-06 0.00748 0.68 0.58 High light scatter reticulocyte percentage of red cells; chr4:143975741 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs13147170 ENSG00000251600.4 RP11-673E1.1 5.39 1.46e-06 0.00748 0.68 0.58 Immature fraction of reticulocytes; chr4:143975848 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs13147184 ENSG00000251600.4 RP11-673E1.1 5.39 1.46e-06 0.00748 0.68 0.58 Immature fraction of reticulocytes; chr4:143975873 chr4:143912331~143982454:+ MESO cis rs4835473 0.8 rs13124170 ENSG00000251600.4 RP11-673E1.1 5.39 1.46e-06 0.00748 0.68 0.58 Immature fraction of reticulocytes; chr4:143975951 chr4:143912331~143982454:+ MESO cis rs7208859 0.725 rs9897673 ENSG00000263531.1 RP13-753N3.1 5.39 1.47e-06 0.00752 1.05 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30916348 chr17:30863921~30864940:- MESO cis rs7301826 0.651 rs34749116 ENSG00000256250.1 RP11-989F5.1 5.38 1.49e-06 0.00761 0.74 0.58 Plasma plasminogen activator levels; chr12:130796207 chr12:130810606~130812438:+ MESO cis rs7301826 0.627 rs7978987 ENSG00000256250.1 RP11-989F5.1 5.38 1.49e-06 0.00761 0.74 0.58 Plasma plasminogen activator levels; chr12:130796949 chr12:130810606~130812438:+ MESO cis rs755249 0.701 rs4660823 ENSG00000237624.1 OXCT2P1 5.38 1.49e-06 0.00762 0.71 0.58 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39532851 chr1:39514956~39516490:+ MESO cis rs10083777 0.551 rs79623059 ENSG00000261838.4 RP11-303E16.6 5.38 1.49e-06 0.00763 1.13 0.58 Metabolite levels (small molecules and protein measures); chr16:80973348 chr16:81069854~81076598:+ MESO cis rs2487048 0.725 rs2246293 ENSG00000226334.1 RP11-217B7.2 5.38 1.5e-06 0.00763 0.81 0.58 Intraocular pressure; chr9:104928557 chr9:104927553~104928892:+ MESO cis rs1799949 0.587 rs1824890 ENSG00000198496.9 NBR2 -5.38 1.5e-06 0.00763 -0.84 -0.58 Menopause (age at onset); chr17:43344536 chr17:43125610~43153671:+ MESO cis rs6964833 1 rs4717906 ENSG00000123965.13 PMS2P5 5.38 1.54e-06 0.00782 0.94 0.58 Menarche (age at onset); chr7:74671923 chr7:74894116~74897835:+ MESO cis rs6964833 1 rs4717907 ENSG00000123965.13 PMS2P5 5.38 1.54e-06 0.00782 0.94 0.58 Menarche (age at onset); chr7:74672169 chr7:74894116~74897835:+ MESO cis rs2882667 0.858 rs11242447 ENSG00000253404.1 AC034243.1 5.37 1.54e-06 0.00782 0.77 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:139090484 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs11744972 ENSG00000253404.1 AC034243.1 5.37 1.54e-06 0.00782 0.77 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:139093100 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs11741150 ENSG00000253404.1 AC034243.1 5.37 1.54e-06 0.00782 0.77 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:139095768 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs13177503 ENSG00000253404.1 AC034243.1 5.37 1.54e-06 0.00782 0.77 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:139097070 chr5:138744434~138753309:- MESO cis rs2882667 0.754 rs11746434 ENSG00000253404.1 AC034243.1 5.37 1.54e-06 0.00782 0.77 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:139099614 chr5:138744434~138753309:- MESO cis rs2882667 0.858 rs13170388 ENSG00000253404.1 AC034243.1 5.37 1.54e-06 0.00782 0.77 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:139101176 chr5:138744434~138753309:- MESO cis rs7617773 0.817 rs11720622 ENSG00000229759.1 MRPS18AP1 5.37 1.57e-06 0.00786 0.68 0.58 Coronary artery disease; chr3:48205189 chr3:48256350~48256938:- MESO cis rs2739330 0.828 rs2877178 ENSG00000225282.1 AP000350.6 5.37 1.57e-06 0.00786 0.66 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909330 chr22:23926900~23929574:+ MESO cis rs2739330 0.828 rs2154593 ENSG00000225282.1 AP000350.6 5.37 1.57e-06 0.00786 0.66 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909898 chr22:23926900~23929574:+ MESO cis rs9322193 0.607 rs9322229 ENSG00000231760.4 RP11-350J20.5 5.37 1.59e-06 0.00786 0.83 0.58 Lung cancer; chr6:149908949 chr6:149796151~149826294:- MESO cis rs4835473 0.643 rs34680080 ENSG00000251600.4 RP11-673E1.1 -5.37 1.59e-06 0.00786 -0.76 -0.58 Immature fraction of reticulocytes; chr4:143797290 chr4:143912331~143982454:+ MESO cis rs9918079 0.56 rs6449153 ENSG00000273133.1 RP11-799M12.2 -5.36 1.62e-06 0.00787 -0.75 -0.58 Obesity-related traits; chr4:15629593 chr4:15563698~15564253:- MESO cis rs9918079 0.56 rs4698406 ENSG00000273133.1 RP11-799M12.2 -5.36 1.62e-06 0.00787 -0.75 -0.58 Obesity-related traits; chr4:15638994 chr4:15563698~15564253:- MESO cis rs9918079 0.542 rs7688984 ENSG00000273133.1 RP11-799M12.2 -5.36 1.62e-06 0.00787 -0.75 -0.58 Obesity-related traits; chr4:15655630 chr4:15563698~15564253:- MESO cis rs73086581 1 rs56141565 ENSG00000229539.1 RP11-119B16.2 5.36 1.63e-06 0.00791 0.75 0.58 Response to antidepressants in depression; chr20:4017956 chr20:3888239~3888868:- MESO cis rs73086581 0.617 rs2300213 ENSG00000229539.1 RP11-119B16.2 -5.36 1.65e-06 0.00797 -0.72 -0.58 Response to antidepressants in depression; chr20:4006076 chr20:3888239~3888868:- MESO cis rs7208859 0.623 rs9906957 ENSG00000263531.1 RP13-753N3.1 5.35 1.67e-06 0.00804 1.08 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30830737 chr17:30863921~30864940:- MESO cis rs1577917 0.655 rs1059307 ENSG00000203875.9 SNHG5 5.35 1.68e-06 0.00805 0.71 0.58 Response to antipsychotic treatment; chr6:85678170 chr6:85660950~85678736:- MESO cis rs801193 0.569 rs2659893 ENSG00000226824.5 RP4-756H11.3 -5.35 1.68e-06 0.00805 -0.78 -0.58 Aortic root size; chr7:66735006 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs2659892 ENSG00000226824.5 RP4-756H11.3 -5.35 1.68e-06 0.00805 -0.78 -0.58 Aortic root size; chr7:66735318 chr7:66654538~66669855:+ MESO cis rs801193 0.548 rs2659891 ENSG00000226824.5 RP4-756H11.3 -5.35 1.68e-06 0.00805 -0.78 -0.58 Aortic root size; chr7:66736127 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs2707847 ENSG00000226824.5 RP4-756H11.3 -5.35 1.68e-06 0.00805 -0.78 -0.58 Aortic root size; chr7:66737884 chr7:66654538~66669855:+ MESO cis rs864745 0.902 rs12531540 ENSG00000253187.2 HOXA10-AS 5.35 1.69e-06 0.0081 0.67 0.58 Crohn's disease;Type 2 diabetes; chr7:28123055 chr7:27168619~27171915:+ MESO cis rs1577917 0.56 rs9450288 ENSG00000203875.9 SNHG5 5.35 1.7e-06 0.00814 0.68 0.58 Response to antipsychotic treatment; chr6:85511868 chr6:85660950~85678736:- MESO cis rs11673344 0.566 rs256733 ENSG00000226686.6 LINC01535 5.35 1.71e-06 0.00817 0.63 0.58 Obesity-related traits; chr19:37384729 chr19:37251912~37265535:+ MESO cis rs11673344 0.566 rs256735 ENSG00000226686.6 LINC01535 -5.35 1.71e-06 0.00817 -0.63 -0.58 Obesity-related traits; chr19:37375141 chr19:37251912~37265535:+ MESO cis rs11673344 0.566 rs185369 ENSG00000226686.6 LINC01535 -5.35 1.71e-06 0.00817 -0.63 -0.58 Obesity-related traits; chr19:37376137 chr19:37251912~37265535:+ MESO cis rs11673344 0.566 rs185368 ENSG00000226686.6 LINC01535 -5.35 1.71e-06 0.00817 -0.63 -0.58 Obesity-related traits; chr19:37381827 chr19:37251912~37265535:+ MESO cis rs4964805 0.505 rs15918 ENSG00000257681.1 RP11-341G23.4 5.34 1.72e-06 0.00822 0.81 0.58 Attention deficit hyperactivity disorder; chr12:103773246 chr12:103746315~103768858:- MESO cis rs4964805 0.594 rs751448 ENSG00000257681.1 RP11-341G23.4 5.34 1.72e-06 0.00822 0.81 0.58 Attention deficit hyperactivity disorder; chr12:103773407 chr12:103746315~103768858:- MESO cis rs73086581 0.687 rs16989002 ENSG00000229539.1 RP11-119B16.2 5.34 1.75e-06 0.00833 0.76 0.58 Response to antidepressants in depression; chr20:3870056 chr20:3888239~3888868:- MESO cis rs950027 0.596 rs2467853 ENSG00000259520.4 CTD-2651B20.3 -5.34 1.75e-06 0.00834 -0.75 -0.58 Response to fenofibrate (adiponectin levels); chr15:45406595 chr15:45251580~45279251:- MESO cis rs950027 0.595 rs2486288 ENSG00000259520.4 CTD-2651B20.3 -5.34 1.75e-06 0.00834 -0.75 -0.58 Response to fenofibrate (adiponectin levels); chr15:45420141 chr15:45251580~45279251:- MESO cis rs2486288 0.539 rs2433601 ENSG00000259520.4 CTD-2651B20.3 -5.34 1.75e-06 0.00834 -0.75 -0.58 Glomerular filtration rate; chr15:45424227 chr15:45251580~45279251:- MESO cis rs5760092 0.572 rs738806 ENSG00000273295.1 AP000350.5 5.34 1.77e-06 0.0084 0.68 0.58 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23901432~23907068:- MESO cis rs1150668 0.799 rs2142730 ENSG00000216901.1 AL022393.7 5.34 1.77e-06 0.0084 0.75 0.58 Pubertal anthropometrics; chr6:28298372 chr6:28176188~28176674:+ MESO cis rs11673344 0.526 rs17244713 ENSG00000226686.6 LINC01535 5.33 1.79e-06 0.00844 0.7 0.58 Obesity-related traits; chr19:37559938 chr19:37251912~37265535:+ MESO cis rs11673344 0.526 rs17244769 ENSG00000226686.6 LINC01535 5.33 1.79e-06 0.00844 0.7 0.58 Obesity-related traits; chr19:37562031 chr19:37251912~37265535:+ MESO cis rs11673344 0.526 rs8111790 ENSG00000226686.6 LINC01535 5.33 1.79e-06 0.00844 0.7 0.58 Obesity-related traits; chr19:37565861 chr19:37251912~37265535:+ MESO cis rs11673344 0.526 rs55909413 ENSG00000226686.6 LINC01535 5.33 1.79e-06 0.00844 0.7 0.58 Obesity-related traits; chr19:37578663 chr19:37251912~37265535:+ MESO cis rs11673344 0.526 rs55865869 ENSG00000226686.6 LINC01535 5.33 1.79e-06 0.00844 0.7 0.58 Obesity-related traits; chr19:37578683 chr19:37251912~37265535:+ MESO cis rs11673344 0.502 rs17304703 ENSG00000226686.6 LINC01535 5.33 1.79e-06 0.00844 0.7 0.58 Obesity-related traits; chr19:37582646 chr19:37251912~37265535:+ MESO cis rs11673344 0.526 rs73033122 ENSG00000226686.6 LINC01535 5.33 1.79e-06 0.00844 0.7 0.58 Obesity-related traits; chr19:37586006 chr19:37251912~37265535:+ MESO cis rs11673344 0.526 rs2306201 ENSG00000226686.6 LINC01535 5.33 1.79e-06 0.00844 0.7 0.58 Obesity-related traits; chr19:37586573 chr19:37251912~37265535:+ MESO cis rs11673344 0.526 rs57654288 ENSG00000226686.6 LINC01535 5.33 1.79e-06 0.00844 0.7 0.58 Obesity-related traits; chr19:37587870 chr19:37251912~37265535:+ MESO cis rs950027 0.62 rs1346267 ENSG00000259520.4 CTD-2651B20.3 -5.33 1.79e-06 0.00844 -0.75 -0.58 Response to fenofibrate (adiponectin levels); chr15:45398791 chr15:45251580~45279251:- MESO cis rs6700559 0.873 rs6427840 ENSG00000260088.1 RP11-92G12.3 -5.33 1.79e-06 0.00845 -0.63 -0.58 Coronary artery disease; chr1:200685659 chr1:200669507~200694250:+ MESO cis rs2487048 0.761 rs2980083 ENSG00000226334.1 RP11-217B7.2 -5.33 1.79e-06 0.00845 -0.82 -0.58 Intraocular pressure; chr9:104929081 chr9:104927553~104928892:+ MESO cis rs11650106 0.529 rs35391268 ENSG00000266992.1 DHX40P1 -5.33 1.8e-06 0.00845 -0.63 -0.58 Lipoprotein-associated phospholipase A2 activity and mass; chr17:59692637 chr17:59976009~60002384:- MESO cis rs6964833 0.873 rs4717905 ENSG00000123965.13 PMS2P5 5.33 1.8e-06 0.00847 0.94 0.58 Menarche (age at onset); chr7:74668903 chr7:74894116~74897835:+ MESO cis rs2019137 0.901 rs4849176 ENSG00000189223.12 PAX8-AS1 5.33 1.81e-06 0.00847 0.71 0.58 Lymphocyte counts; chr2:113220359 chr2:113211522~113276581:+ MESO cis rs9918079 0.56 rs13147590 ENSG00000273133.1 RP11-799M12.2 5.33 1.83e-06 0.00854 0.78 0.58 Obesity-related traits; chr4:15619565 chr4:15563698~15564253:- MESO cis rs73086581 0.838 rs73088426 ENSG00000229539.1 RP11-119B16.2 5.33 1.83e-06 0.00854 0.74 0.58 Response to antidepressants in depression; chr20:4022636 chr20:3888239~3888868:- MESO cis rs2019137 0.868 rs3748916 ENSG00000189223.12 PAX8-AS1 5.33 1.84e-06 0.0086 0.71 0.58 Lymphocyte counts; chr2:113226456 chr2:113211522~113276581:+ MESO cis rs9326248 0.689 rs4516002 ENSG00000254851.1 RP11-109L13.1 -5.32 1.85e-06 0.00864 -0.92 -0.58 Blood protein levels; chr11:117128343 chr11:117135528~117138582:+ MESO cis rs8177876 0.658 rs16954513 ENSG00000261838.4 RP11-303E16.6 5.32 1.88e-06 0.00876 1.22 0.58 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81043599 chr16:81069854~81076598:+ MESO cis rs73086581 0.838 rs11907416 ENSG00000229539.1 RP11-119B16.2 5.32 1.89e-06 0.00881 0.73 0.58 Response to antidepressants in depression; chr20:4024972 chr20:3888239~3888868:- MESO cis rs2739330 0.76 rs5751761 ENSG00000250470.1 AP000351.3 -5.32 1.89e-06 0.00881 -0.84 -0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23976904~23977585:- MESO cis rs4964805 0.594 rs3812805 ENSG00000257681.1 RP11-341G23.4 5.31 1.92e-06 0.00894 0.81 0.58 Attention deficit hyperactivity disorder; chr12:103777094 chr12:103746315~103768858:- MESO cis rs1577917 0.655 rs2842605 ENSG00000203875.9 SNHG5 -5.31 1.94e-06 0.00898 -0.76 -0.58 Response to antipsychotic treatment; chr6:85625432 chr6:85660950~85678736:- MESO cis rs1577917 0.655 rs2758849 ENSG00000203875.9 SNHG5 -5.31 1.94e-06 0.00898 -0.76 -0.58 Response to antipsychotic treatment; chr6:85634578 chr6:85660950~85678736:- MESO cis rs1577917 0.655 rs2758848 ENSG00000203875.9 SNHG5 -5.31 1.94e-06 0.00898 -0.76 -0.58 Response to antipsychotic treatment; chr6:85637887 chr6:85660950~85678736:- MESO cis rs1577917 0.681 rs4348284 ENSG00000203875.9 SNHG5 -5.31 1.94e-06 0.00898 -0.76 -0.58 Response to antipsychotic treatment; chr6:85640676 chr6:85660950~85678736:- MESO cis rs1577917 0.727 rs9344539 ENSG00000203875.9 SNHG5 -5.31 1.94e-06 0.00898 -0.76 -0.58 Response to antipsychotic treatment; chr6:85643903 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs9362232 ENSG00000203875.9 SNHG5 -5.31 1.94e-06 0.00898 -0.76 -0.58 Response to antipsychotic treatment; chr6:85643904 chr6:85660950~85678736:- MESO cis rs73086581 0.838 rs41398349 ENSG00000229539.1 RP11-119B16.2 -5.31 1.95e-06 0.00905 -0.74 -0.58 Response to antidepressants in depression; chr20:4043792 chr20:3888239~3888868:- MESO cis rs2739330 0.731 rs2000468 ENSG00000218537.1 MIF-AS1 5.31 1.96e-06 0.00909 0.7 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23894426~23898930:- MESO cis rs62388641 1 rs62388641 ENSG00000272279.1 RP11-157J24.2 5.31 1.97e-06 0.00909 0.8 0.58 Daytime sleep phenotypes; chr6:1539849 chr6:1528364~1528911:- MESO cis rs9898641 1 rs9898641 ENSG00000266992.1 DHX40P1 5.31 1.97e-06 0.00909 0.59 0.58 Interleukin-1-beta levels; chr17:59493672 chr17:59976009~60002384:- MESO cis rs1577917 0.839 rs6454492 ENSG00000203875.9 SNHG5 -5.31 1.97e-06 0.00909 -0.77 -0.58 Response to antipsychotic treatment; chr6:85773496 chr6:85660950~85678736:- MESO cis rs1577917 0.793 rs9362245 ENSG00000203875.9 SNHG5 -5.31 1.97e-06 0.00909 -0.77 -0.58 Response to antipsychotic treatment; chr6:85786602 chr6:85660950~85678736:- MESO cis rs7396835 0.537 rs10892035 ENSG00000254851.1 RP11-109L13.1 -5.31 1.97e-06 0.0091 -0.87 -0.58 Quantitative traits; chr11:116824222 chr11:117135528~117138582:+ MESO cis rs2117029 0.767 rs10875912 ENSG00000258017.1 RP11-386G11.10 -5.31 1.98e-06 0.00914 -0.74 -0.58 Intelligence (multi-trait analysis); chr12:49023161 chr12:49127782~49147869:+ MESO cis rs73086581 1 rs73084594 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3935733 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086505 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3940924 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086508 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3941068 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086510 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3941484 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086512 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3942125 chr20:3888239~3888868:- MESO cis rs73086581 1 rs17286768 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3943922 chr20:3888239~3888868:- MESO cis rs73086581 1 rs17214621 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3945277 chr20:3888239~3888868:- MESO cis rs73086581 1 rs17214949 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3960305 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086535 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3963503 chr20:3888239~3888868:- MESO cis rs73086581 1 rs17215054 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3964132 chr20:3888239~3888868:- MESO cis rs73086581 1 rs11906274 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3964889 chr20:3888239~3888868:- MESO cis rs73086581 1 rs6052196 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3965177 chr20:3888239~3888868:- MESO cis rs73086581 1 rs17287486 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3965620 chr20:3888239~3888868:- MESO cis rs73086581 1 rs6116130 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3966379 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086540 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3970203 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086544 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3970281 chr20:3888239~3888868:- MESO cis rs73086581 1 rs2326289 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3971653 chr20:3888239~3888868:- MESO cis rs73086581 0.786 rs6037705 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3972183 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086549 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3974015 chr20:3888239~3888868:- MESO cis rs73086581 0.947 rs55794220 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3975755 chr20:3888239~3888868:- MESO cis rs73086581 1 rs6037708 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3980606 chr20:3888239~3888868:- MESO cis rs73086581 1 rs6052209 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3981100 chr20:3888239~3888868:- MESO cis rs73086581 1 rs113812453 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3982546 chr20:3888239~3888868:- MESO cis rs73086581 0.891 rs55871214 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3985059 chr20:3888239~3888868:- MESO cis rs73086581 1 rs56069856 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3985062 chr20:3888239~3888868:- MESO cis rs73086581 0.947 rs17287577 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3985607 chr20:3888239~3888868:- MESO cis rs73086581 1 rs6052217 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3989564 chr20:3888239~3888868:- MESO cis rs73086581 1 rs6052218 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3989565 chr20:3888239~3888868:- MESO cis rs73086581 0.945 rs6052219 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3989660 chr20:3888239~3888868:- MESO cis rs73086581 1 rs6052220 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3989947 chr20:3888239~3888868:- MESO cis rs73086581 0.945 rs6037715 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3991519 chr20:3888239~3888868:- MESO cis rs73086581 1 rs6107386 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3992109 chr20:3888239~3888868:- MESO cis rs73086581 0.945 rs6052222 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3992146 chr20:3888239~3888868:- MESO cis rs73086581 1 rs17215529 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3994755 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086581 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:3996678 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086588 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:4001577 chr20:3888239~3888868:- MESO cis rs73086581 1 rs6107391 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:4002436 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086595 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:4002801 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73086597 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:4002924 chr20:3888239~3888868:- MESO cis rs73086581 1 rs6107393 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:4007091 chr20:3888239~3888868:- MESO cis rs73086581 1 rs34640283 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:4008929 chr20:3888239~3888868:- MESO cis rs73086581 1 rs73088416 ENSG00000229539.1 RP11-119B16.2 5.3 2e-06 0.00915 0.78 0.58 Response to antidepressants in depression; chr20:4014629 chr20:3888239~3888868:- MESO cis rs1150668 0.799 rs7206 ENSG00000216901.1 AL022393.7 5.3 2e-06 0.00915 0.74 0.58 Pubertal anthropometrics; chr6:28233360 chr6:28176188~28176674:+ MESO cis rs2117029 0.782 rs11168850 ENSG00000258017.1 RP11-386G11.10 -5.3 2.01e-06 0.00918 -0.69 -0.58 Intelligence (multi-trait analysis); chr12:49079182 chr12:49127782~49147869:+ MESO cis rs4835473 0.932 rs7670010 ENSG00000251600.4 RP11-673E1.1 5.3 2.04e-06 0.00929 0.68 0.58 Immature fraction of reticulocytes; chr4:143821679 chr4:143912331~143982454:+ MESO cis rs6565180 0.507 rs4471699 ENSG00000183604.13 SMG1P5 -5.3 2.04e-06 0.00929 -0.56 -0.58 Tonsillectomy; chr16:30308986 chr16:30267553~30335374:- MESO cis rs1122900 0.653 rs12651999 ENSG00000250155.1 CTD-2353F22.1 5.3 2.04e-06 0.0093 0.63 0.58 Aggressive periodontitis; chr5:36692331 chr5:36666214~36725195:- MESO cis rs7617773 0.746 rs6796343 ENSG00000229759.1 MRPS18AP1 5.3 2.06e-06 0.00937 0.75 0.58 Coronary artery disease; chr3:48240531 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs13100815 ENSG00000229759.1 MRPS18AP1 5.3 2.06e-06 0.00937 0.75 0.58 Coronary artery disease; chr3:48245959 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs13059037 ENSG00000229759.1 MRPS18AP1 5.3 2.06e-06 0.00937 0.75 0.58 Coronary artery disease; chr3:48246389 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs35414021 ENSG00000229759.1 MRPS18AP1 5.3 2.06e-06 0.00937 0.75 0.58 Coronary artery disease; chr3:48252034 chr3:48256350~48256938:- MESO cis rs7617773 0.744 rs2125482 ENSG00000229759.1 MRPS18AP1 5.29 2.07e-06 0.00939 0.73 0.58 Coronary artery disease; chr3:48281643 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs6800492 ENSG00000229759.1 MRPS18AP1 5.29 2.07e-06 0.00939 0.73 0.58 Coronary artery disease; chr3:48282400 chr3:48256350~48256938:- MESO cis rs864745 1 rs849142 ENSG00000253187.2 HOXA10-AS 5.29 2.07e-06 0.00939 0.64 0.58 Crohn's disease;Type 2 diabetes; chr7:28146272 chr7:27168619~27171915:+ MESO cis rs950027 0.583 rs66893308 ENSG00000259520.4 CTD-2651B20.3 -5.29 2.07e-06 0.00939 -0.73 -0.58 Response to fenofibrate (adiponectin levels); chr15:45324461 chr15:45251580~45279251:- MESO cis rs9918079 0.56 rs7438356 ENSG00000273133.1 RP11-799M12.2 -5.29 2.07e-06 0.00939 -0.77 -0.58 Obesity-related traits; chr4:15623147 chr4:15563698~15564253:- MESO cis rs801193 0.569 rs6978178 ENSG00000226824.5 RP4-756H11.3 5.29 2.07e-06 0.00939 0.78 0.58 Aortic root size; chr7:66658097 chr7:66654538~66669855:+ MESO cis rs73086581 0.838 rs73088424 ENSG00000229539.1 RP11-119B16.2 5.29 2.07e-06 0.00939 0.73 0.58 Response to antidepressants in depression; chr20:4020359 chr20:3888239~3888868:- MESO cis rs1150668 0.799 rs1736891 ENSG00000216901.1 AL022393.7 5.29 2.09e-06 0.00944 0.74 0.58 Pubertal anthropometrics; chr6:28219323 chr6:28176188~28176674:+ MESO cis rs1150668 0.799 rs1150707 ENSG00000216901.1 AL022393.7 5.29 2.09e-06 0.00944 0.74 0.58 Pubertal anthropometrics; chr6:28229827 chr6:28176188~28176674:+ MESO cis rs1150668 0.768 rs1233713 ENSG00000216901.1 AL022393.7 5.29 2.09e-06 0.00944 0.74 0.58 Pubertal anthropometrics; chr6:28230503 chr6:28176188~28176674:+ MESO cis rs7301826 0.651 rs7956851 ENSG00000256250.1 RP11-989F5.1 -5.29 2.1e-06 0.00944 -0.73 -0.58 Plasma plasminogen activator levels; chr12:130834554 chr12:130810606~130812438:+ MESO cis rs7301826 0.627 rs34103763 ENSG00000256250.1 RP11-989F5.1 5.29 2.1e-06 0.00944 0.73 0.58 Plasma plasminogen activator levels; chr12:130805604 chr12:130810606~130812438:+ MESO cis rs7301826 0.61 rs7961690 ENSG00000256250.1 RP11-989F5.1 5.29 2.1e-06 0.00944 0.73 0.58 Plasma plasminogen activator levels; chr12:130812335 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs6486601 ENSG00000256250.1 RP11-989F5.1 5.29 2.1e-06 0.00944 0.73 0.58 Plasma plasminogen activator levels; chr12:130816692 chr12:130810606~130812438:+ MESO cis rs7301826 0.627 rs61937256 ENSG00000256250.1 RP11-989F5.1 5.29 2.1e-06 0.00944 0.73 0.58 Plasma plasminogen activator levels; chr12:130818100 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs7299281 ENSG00000256250.1 RP11-989F5.1 5.29 2.1e-06 0.00944 0.73 0.58 Plasma plasminogen activator levels; chr12:130818587 chr12:130810606~130812438:+ MESO cis rs7301826 0.56 rs12829294 ENSG00000256250.1 RP11-989F5.1 5.29 2.1e-06 0.00944 0.73 0.58 Plasma plasminogen activator levels; chr12:130825427 chr12:130810606~130812438:+ MESO cis rs7301826 0.58 rs61938969 ENSG00000256250.1 RP11-989F5.1 5.29 2.1e-06 0.00944 0.73 0.58 Plasma plasminogen activator levels; chr12:130831525 chr12:130810606~130812438:+ MESO cis rs7208859 0.673 rs11080135 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30849463 chr17:30863921~30864940:- MESO cis rs7208859 0.573 rs73277960 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30850423 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73277964 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30852183 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9894876 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855002 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11652409 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30855689 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73277967 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30857148 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs60020217 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30858036 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9896095 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30860479 chr17:30863921~30864940:- MESO cis rs7208859 0.573 rs73277974 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862851 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73277978 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864431 chr17:30863921~30864940:- MESO cis rs7208859 0.573 rs58920731 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30864728 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs11657391 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30867269 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73277984 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869115 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73277986 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869179 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs58089675 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30869746 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs12103588 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30870442 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73263755 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30871954 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9899349 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30873104 chr17:30863921~30864940:- MESO cis rs7208859 0.614 rs9914534 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30875646 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs4131618 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30877783 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs11652358 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30878462 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11656845 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879146 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11658344 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30880727 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9891179 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881142 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9891413 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881191 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs9900144 ENSG00000263531.1 RP13-753N3.1 5.29 2.11e-06 0.00944 1.06 0.58 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30881371 chr17:30863921~30864940:- MESO cis rs1150668 0.799 rs9301 ENSG00000216901.1 AL022393.7 5.29 2.11e-06 0.00944 0.74 0.58 Pubertal anthropometrics; chr6:28324929 chr6:28176188~28176674:+ MESO cis rs1150668 0.799 rs853684 ENSG00000216901.1 AL022393.7 5.29 2.11e-06 0.00944 0.74 0.58 Pubertal anthropometrics; chr6:28326773 chr6:28176188~28176674:+ MESO cis rs1153858 1 rs2056493 ENSG00000259520.4 CTD-2651B20.3 -5.29 2.11e-06 0.00944 -0.78 -0.58 Homoarginine levels; chr15:45356074 chr15:45251580~45279251:- MESO cis rs2019137 0.967 rs902695 ENSG00000189223.12 PAX8-AS1 5.29 2.12e-06 0.0095 0.7 0.58 Lymphocyte counts; chr2:113197497 chr2:113211522~113276581:+ MESO cis rs2739330 0.761 rs5760176 ENSG00000218537.1 MIF-AS1 -5.28 2.14e-06 0.00959 -0.72 -0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23894426~23898930:- MESO cis rs73086581 0.592 rs6037702 ENSG00000229539.1 RP11-119B16.2 -5.28 2.15e-06 0.0096 -0.69 -0.58 Response to antidepressants in depression; chr20:3955745 chr20:3888239~3888868:- MESO cis rs7301826 0.61 rs7957899 ENSG00000256250.1 RP11-989F5.1 -5.28 2.15e-06 0.00961 -0.73 -0.58 Plasma plasminogen activator levels; chr12:130794531 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs1973834 ENSG00000256250.1 RP11-989F5.1 -5.28 2.15e-06 0.00961 -0.73 -0.58 Plasma plasminogen activator levels; chr12:130795612 chr12:130810606~130812438:+ MESO cis rs7617773 0.817 rs17786132 ENSG00000229759.1 MRPS18AP1 5.28 2.15e-06 0.00961 0.75 0.58 Coronary artery disease; chr3:48207930 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs35456569 ENSG00000229759.1 MRPS18AP1 5.28 2.15e-06 0.00961 0.75 0.58 Coronary artery disease; chr3:48209409 chr3:48256350~48256938:- MESO cis rs7617773 0.784 rs11715799 ENSG00000229759.1 MRPS18AP1 5.28 2.15e-06 0.00961 0.75 0.58 Coronary artery disease; chr3:48213730 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs34728236 ENSG00000229759.1 MRPS18AP1 5.28 2.15e-06 0.00961 0.75 0.58 Coronary artery disease; chr3:48217618 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs79310258 ENSG00000229759.1 MRPS18AP1 5.28 2.15e-06 0.00961 0.75 0.58 Coronary artery disease; chr3:48218177 chr3:48256350~48256938:- MESO cis rs9660180 0.846 rs10907195 ENSG00000268575.1 RP1-283E3.8 5.28 2.16e-06 0.00962 0.67 0.58 Body mass index; chr1:1781909 chr1:1702736~1737688:- MESO cis rs2882667 0.652 rs6596463 ENSG00000253404.1 AC034243.1 5.28 2.16e-06 0.00964 0.73 0.58 Age-related hearing impairment (SNP x SNP interaction); chr5:139109237 chr5:138744434~138753309:- MESO cis rs2739330 0.731 rs5751792 ENSG00000218537.1 MIF-AS1 5.28 2.16e-06 0.00965 0.72 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23894426~23898930:- MESO cis rs2739330 0.587 rs4820571 ENSG00000250470.1 AP000351.3 5.28 2.17e-06 0.00966 0.74 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900786 chr22:23976904~23977585:- MESO cis rs2739330 0.828 rs2186366 ENSG00000225282.1 AP000350.6 -5.28 2.17e-06 0.00967 -0.62 -0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23911926 chr22:23926900~23929574:+ MESO cis rs1150668 0.699 rs2394049 ENSG00000216901.1 AL022393.7 5.28 2.17e-06 0.00967 0.73 0.58 Pubertal anthropometrics; chr6:28271903 chr6:28176188~28176674:+ MESO cis rs1577917 0.681 rs4707211 ENSG00000203875.9 SNHG5 5.28 2.17e-06 0.00968 0.74 0.58 Response to antipsychotic treatment; chr6:85522992 chr6:85660950~85678736:- MESO cis rs875971 0.793 rs460678 ENSG00000226824.5 RP4-756H11.3 -5.28 2.19e-06 0.00977 -0.76 -0.58 Aortic root size; chr7:66062213 chr7:66654538~66669855:+ MESO cis rs9918079 0.56 rs10008975 ENSG00000273133.1 RP11-799M12.2 -5.28 2.22e-06 0.00984 -0.76 -0.58 Obesity-related traits; chr4:15622948 chr4:15563698~15564253:- MESO cis rs9918079 0.542 rs6414765 ENSG00000273133.1 RP11-799M12.2 -5.28 2.22e-06 0.00984 -0.76 -0.58 Obesity-related traits; chr4:15624870 chr4:15563698~15564253:- MESO cis rs9918079 0.56 rs4557256 ENSG00000273133.1 RP11-799M12.2 -5.28 2.22e-06 0.00984 -0.76 -0.58 Obesity-related traits; chr4:15625024 chr4:15563698~15564253:- MESO cis rs9918079 0.56 rs4698402 ENSG00000273133.1 RP11-799M12.2 -5.28 2.22e-06 0.00984 -0.76 -0.58 Obesity-related traits; chr4:15628180 chr4:15563698~15564253:- MESO cis rs9918079 0.56 rs7662032 ENSG00000273133.1 RP11-799M12.2 -5.28 2.22e-06 0.00984 -0.76 -0.58 Obesity-related traits; chr4:15633791 chr4:15563698~15564253:- MESO cis rs9918079 0.56 rs12651550 ENSG00000273133.1 RP11-799M12.2 -5.28 2.22e-06 0.00984 -0.76 -0.58 Obesity-related traits; chr4:15639395 chr4:15563698~15564253:- MESO cis rs9918079 0.506 rs7696127 ENSG00000273133.1 RP11-799M12.2 -5.28 2.22e-06 0.00984 -0.76 -0.58 Obesity-related traits; chr4:15641330 chr4:15563698~15564253:- MESO cis rs1789 0.839 rs9997068 ENSG00000273133.1 RP11-799M12.2 -5.28 2.22e-06 0.00984 -0.76 -0.58 Blood protein levels; chr4:15649367 chr4:15563698~15564253:- MESO cis rs9918079 0.56 rs6414767 ENSG00000273133.1 RP11-799M12.2 -5.28 2.22e-06 0.00984 -0.76 -0.58 Obesity-related traits; chr4:15654098 chr4:15563698~15564253:- MESO cis rs3931020 1 rs3931020 ENSG00000272864.1 RP11-17E13.2 -5.27 2.24e-06 0.00992 -0.84 -0.58 Resistin levels; chr1:74769633 chr1:74698769~74699333:- MESO cis rs3931020 1 rs10874122 ENSG00000272864.1 RP11-17E13.2 -5.27 2.24e-06 0.00992 -0.84 -0.58 Resistin levels; chr1:74770182 chr1:74698769~74699333:- MESO cis rs801193 0.569 rs2659908 ENSG00000226824.5 RP4-756H11.3 -5.27 2.25e-06 0.00993 -0.77 -0.58 Aortic root size; chr7:66695835 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs2659907 ENSG00000226824.5 RP4-756H11.3 -5.27 2.25e-06 0.00993 -0.77 -0.58 Aortic root size; chr7:66699045 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs7782587 ENSG00000226824.5 RP4-756H11.3 -5.27 2.25e-06 0.00993 -0.77 -0.58 Aortic root size; chr7:66701485 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs4717315 ENSG00000226824.5 RP4-756H11.3 -5.27 2.25e-06 0.00993 -0.77 -0.58 Aortic root size; chr7:66713338 chr7:66654538~66669855:+ MESO cis rs801193 0.527 rs2707837 ENSG00000226824.5 RP4-756H11.3 -5.27 2.25e-06 0.00993 -0.77 -0.58 Aortic root size; chr7:66716086 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs2707824 ENSG00000226824.5 RP4-756H11.3 -5.27 2.25e-06 0.00993 -0.77 -0.58 Aortic root size; chr7:66724256 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10274883 ENSG00000226824.5 RP4-756H11.3 5.27 2.25e-06 0.00993 0.77 0.58 Aortic root size; chr7:66651104 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs881285 ENSG00000226824.5 RP4-756H11.3 5.27 2.25e-06 0.00993 0.77 0.58 Aortic root size; chr7:66654433 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs3846973 ENSG00000226824.5 RP4-756H11.3 5.27 2.25e-06 0.00993 0.77 0.58 Aortic root size; chr7:66655048 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs2013908 ENSG00000226824.5 RP4-756H11.3 5.27 2.25e-06 0.00993 0.77 0.58 Aortic root size; chr7:66656082 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs13242290 ENSG00000226824.5 RP4-756H11.3 5.27 2.25e-06 0.00993 0.77 0.58 Aortic root size; chr7:66656898 chr7:66654538~66669855:+ MESO cis rs801193 0.548 rs2109297 ENSG00000226824.5 RP4-756H11.3 5.27 2.25e-06 0.00993 0.77 0.58 Aortic root size; chr7:66657397 chr7:66654538~66669855:+ MESO cis rs801193 0.591 rs721717 ENSG00000226824.5 RP4-756H11.3 5.27 2.25e-06 0.00993 0.77 0.58 Aortic root size; chr7:66665305 chr7:66654538~66669855:+ MESO cis rs801193 0.569 rs6951302 ENSG00000226824.5 RP4-756H11.3 5.27 2.25e-06 0.00993 0.77 0.58 Aortic root size; chr7:66667525 chr7:66654538~66669855:+ MESO cis rs801193 0.591 rs4506088 ENSG00000226824.5 RP4-756H11.3 5.27 2.25e-06 0.00993 0.77 0.58 Aortic root size; chr7:66670470 chr7:66654538~66669855:+ MESO cis rs73086581 0.787 rs73084505 ENSG00000229539.1 RP11-119B16.2 5.27 2.26e-06 0.01 0.76 0.58 Response to antidepressants in depression; chr20:3876227 chr20:3888239~3888868:- MESO cis rs2739330 0.828 rs2330635 ENSG00000225282.1 AP000350.6 5.27 2.29e-06 0.01 0.67 0.58 Liver enzyme levels (gamma-glutamyl transferase); chr22:23909157 chr22:23926900~23929574:+ MESO cis rs7617773 0.817 rs11130162 ENSG00000229759.1 MRPS18AP1 5.26 2.31e-06 0.0101 0.68 0.58 Coronary artery disease; chr3:48256121 chr3:48256350~48256938:- MESO cis rs875971 0.862 rs6971059 ENSG00000226824.5 RP4-756H11.3 5.26 2.31e-06 0.0101 0.79 0.58 Aortic root size; chr7:66602045 chr7:66654538~66669855:+ MESO cis rs875971 0.789 rs7808013 ENSG00000226824.5 RP4-756H11.3 5.26 2.31e-06 0.0101 0.79 0.58 Aortic root size; chr7:66606209 chr7:66654538~66669855:+ MESO cis rs875971 0.825 rs7384021 ENSG00000226824.5 RP4-756H11.3 5.26 2.31e-06 0.0101 0.79 0.58 Aortic root size; chr7:66612917 chr7:66654538~66669855:+ MESO cis rs875971 0.825 rs66981195 ENSG00000226824.5 RP4-756H11.3 5.26 2.31e-06 0.0101 0.79 0.58 Aortic root size; chr7:66614048 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs3926380 ENSG00000226824.5 RP4-756H11.3 5.26 2.31e-06 0.0101 0.79 0.58 Aortic root size; chr7:66615658 chr7:66654538~66669855:+ MESO cis rs875971 0.825 rs1860472 ENSG00000226824.5 RP4-756H11.3 5.26 2.31e-06 0.0101 0.79 0.58 Aortic root size; chr7:66617736 chr7:66654538~66669855:+ MESO cis rs1153858 1 rs4395020 ENSG00000259520.4 CTD-2651B20.3 -5.26 2.32e-06 0.0101 -0.78 -0.58 Homoarginine levels; chr15:45360691 chr15:45251580~45279251:- MESO cis rs9918079 0.56 rs10008376 ENSG00000273133.1 RP11-799M12.2 5.26 2.33e-06 0.0102 0.76 0.58 Obesity-related traits; chr4:15622332 chr4:15563698~15564253:- MESO cis rs3091242 0.933 rs35148262 ENSG00000224183.1 SDHDP6 -5.26 2.33e-06 0.0102 -0.76 -0.58 Erythrocyte sedimentation rate; chr1:25440132 chr1:25294164~25294643:- MESO cis rs3091242 0.904 rs6661533 ENSG00000224183.1 SDHDP6 -5.26 2.33e-06 0.0102 -0.76 -0.58 Erythrocyte sedimentation rate; chr1:25445224 chr1:25294164~25294643:- MESO cis rs55794721 0.509 rs12027110 ENSG00000224183.1 SDHDP6 -5.26 2.33e-06 0.0102 -0.76 -0.58 Mean corpuscular volume;Plateletcrit; chr1:25449191 chr1:25294164~25294643:- MESO cis rs55794721 0.509 rs12027135 ENSG00000224183.1 SDHDP6 -5.26 2.33e-06 0.0102 -0.76 -0.58 Mean corpuscular volume;Plateletcrit; chr1:25449242 chr1:25294164~25294643:- MESO cis rs55794721 0.509 rs6699113 ENSG00000224183.1 SDHDP6 -5.26 2.33e-06 0.0102 -0.76 -0.58 Mean corpuscular volume;Plateletcrit; chr1:25451252 chr1:25294164~25294643:- MESO cis rs55794721 0.509 rs7554255 ENSG00000224183.1 SDHDP6 -5.26 2.33e-06 0.0102 -0.76 -0.58 Mean corpuscular volume;Plateletcrit; chr1:25451615 chr1:25294164~25294643:- MESO cis rs55794721 0.509 rs4649085 ENSG00000224183.1 SDHDP6 -5.26 2.33e-06 0.0102 -0.76 -0.58 Mean corpuscular volume;Plateletcrit; chr1:25452341 chr1:25294164~25294643:- MESO cis rs3091242 0.836 rs34997029 ENSG00000224183.1 SDHDP6 5.26 2.33e-06 0.0102 0.76 0.58 Erythrocyte sedimentation rate; chr1:25457332 chr1:25294164~25294643:- MESO cis rs11673344 0.526 rs17303902 ENSG00000226686.6 LINC01535 5.26 2.34e-06 0.0102 0.7 0.58 Obesity-related traits; chr19:37551912 chr19:37251912~37265535:+ MESO cis rs11673344 0.526 rs55754546 ENSG00000226686.6 LINC01535 5.26 2.34e-06 0.0102 0.7 0.58 Obesity-related traits; chr19:37552860 chr19:37251912~37265535:+ MESO cis rs8177876 0.597 rs1048194 ENSG00000261838.4 RP11-303E16.6 -5.26 2.36e-06 0.0103 -1.1 -0.57 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81031097 chr16:81069854~81076598:+ MESO cis rs2739330 0.731 rs4822450 ENSG00000218537.1 MIF-AS1 5.26 2.36e-06 0.0103 0.74 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23894426~23898930:- MESO cis rs8091660 0.929 rs12456253 ENSG00000278983.1 RP11-426J5.3 -5.26 2.36e-06 0.0103 -0.66 -0.57 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48550603 chr18:48564795~48568342:+ MESO cis rs853679 0.527 rs853693 ENSG00000216901.1 AL022393.7 5.26 2.38e-06 0.0104 0.86 0.57 Depression; chr6:28314871 chr6:28176188~28176674:+ MESO cis rs7927592 0.913 rs4316515 ENSG00000212093.1 AP000807.1 -5.25 2.39e-06 0.0104 -0.57 -0.57 Total body bone mineral density; chr11:68541372 chr11:68506083~68506166:- MESO cis rs2739330 0.76 rs1007888 ENSG00000218537.1 MIF-AS1 5.25 2.4e-06 0.0104 0.73 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23898914 chr22:23894426~23898930:- MESO cis rs494459 0.838 rs555639 ENSG00000278376.1 RP11-158I9.8 5.25 2.41e-06 0.0105 0.57 0.57 Height; chr11:118758322 chr11:118791254~118793137:+ MESO cis rs7208859 0.673 rs999796 ENSG00000263531.1 RP13-753N3.1 5.25 2.46e-06 0.0106 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832386 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11656462 ENSG00000263531.1 RP13-753N3.1 5.25 2.46e-06 0.0106 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30833682 chr17:30863921~30864940:- MESO cis rs7208859 0.725 rs9910051 ENSG00000263531.1 RP13-753N3.1 5.25 2.46e-06 0.0106 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834184 chr17:30863921~30864940:- MESO cis rs2117029 0.727 rs10875910 ENSG00000258017.1 RP11-386G11.10 -5.24 2.48e-06 0.0107 -0.74 -0.57 Intelligence (multi-trait analysis); chr12:49008610 chr12:49127782~49147869:+ MESO cis rs875971 0.825 rs1000464 ENSG00000226824.5 RP4-756H11.3 5.24 2.49e-06 0.0107 0.76 0.57 Aortic root size; chr7:66312922 chr7:66654538~66669855:+ MESO cis rs4835473 0.637 rs1825040 ENSG00000251600.4 RP11-673E1.1 -5.24 2.49e-06 0.0107 -0.75 -0.57 Immature fraction of reticulocytes; chr4:143794417 chr4:143912331~143982454:+ MESO cis rs73086581 1 rs56324992 ENSG00000229539.1 RP11-119B16.2 5.24 2.5e-06 0.0108 0.77 0.57 Response to antidepressants in depression; chr20:3997506 chr20:3888239~3888868:- MESO cis rs801193 1 rs10252765 ENSG00000226824.5 RP4-756H11.3 -5.24 2.5e-06 0.0108 -0.69 -0.57 Aortic root size; chr7:66763745 chr7:66654538~66669855:+ MESO cis rs9918079 0.524 rs4235379 ENSG00000273133.1 RP11-799M12.2 -5.24 2.51e-06 0.0108 -0.74 -0.57 Obesity-related traits; chr4:15657655 chr4:15563698~15564253:- MESO cis rs172166 0.516 rs1225618 ENSG00000216901.1 AL022393.7 5.24 2.52e-06 0.0108 0.73 0.57 Cardiac Troponin-T levels; chr6:28161935 chr6:28176188~28176674:+ MESO cis rs172166 0.516 rs1225710 ENSG00000216901.1 AL022393.7 -5.24 2.55e-06 0.0109 -0.75 -0.57 Cardiac Troponin-T levels; chr6:28132862 chr6:28176188~28176674:+ MESO cis rs1577917 0.559 rs1173418 ENSG00000203875.9 SNHG5 5.24 2.55e-06 0.0109 0.71 0.57 Response to antipsychotic treatment; chr6:85693198 chr6:85660950~85678736:- MESO cis rs73086581 1 rs3746666 ENSG00000229539.1 RP11-119B16.2 5.24 2.55e-06 0.0109 0.77 0.57 Response to antidepressants in depression; chr20:3930214 chr20:3888239~3888868:- MESO cis rs73086581 1 rs14047 ENSG00000229539.1 RP11-119B16.2 5.24 2.55e-06 0.0109 0.77 0.57 Response to antidepressants in depression; chr20:3933568 chr20:3888239~3888868:- MESO cis rs73086581 1 rs17286349 ENSG00000229539.1 RP11-119B16.2 5.24 2.55e-06 0.0109 0.77 0.57 Response to antidepressants in depression; chr20:3933655 chr20:3888239~3888868:- MESO cis rs4964805 0.672 rs11111757 ENSG00000257681.1 RP11-341G23.4 5.24 2.56e-06 0.011 0.8 0.57 Attention deficit hyperactivity disorder; chr12:103766984 chr12:103746315~103768858:- MESO cis rs4964805 0.612 rs11111758 ENSG00000257681.1 RP11-341G23.4 5.24 2.56e-06 0.011 0.8 0.57 Attention deficit hyperactivity disorder; chr12:103767306 chr12:103746315~103768858:- MESO cis rs6964833 0.935 rs34762099 ENSG00000123965.13 PMS2P5 5.24 2.57e-06 0.011 0.9 0.57 Menarche (age at onset); chr7:74636378 chr7:74894116~74897835:+ MESO cis rs875971 0.862 rs778734 ENSG00000226824.5 RP4-756H11.3 -5.23 2.57e-06 0.011 -0.79 -0.57 Aortic root size; chr7:66349862 chr7:66654538~66669855:+ MESO cis rs875971 0.798 rs57739047 ENSG00000226824.5 RP4-756H11.3 -5.23 2.57e-06 0.011 -0.79 -0.57 Aortic root size; chr7:66507579 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs6950137 ENSG00000226824.5 RP4-756H11.3 -5.23 2.57e-06 0.011 -0.79 -0.57 Aortic root size; chr7:66511623 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6952182 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66218330 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6964437 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66221457 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6460282 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66226259 chr7:66654538~66669855:+ MESO cis rs875971 0.756 rs4718328 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66228350 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs4718330 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66250256 chr7:66654538~66669855:+ MESO cis rs875971 0.825 rs6951503 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66253949 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10282433 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66256452 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10276077 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66263424 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1875057 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66266868 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6960446 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66268272 chr7:66654538~66669855:+ MESO cis rs875971 0.789 rs10260426 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66271055 chr7:66654538~66669855:+ MESO cis rs875971 0.825 rs4587224 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66271195 chr7:66654538~66669855:+ MESO cis rs875971 0.792 rs6971752 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66272999 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10950033 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66274686 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs11760844 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66274896 chr7:66654538~66669855:+ MESO cis rs875971 0.79 rs10257911 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66278783 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs4149461 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66279745 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs7796162 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66280771 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs4236208 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66284091 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10261398 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66285177 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs10224872 ENSG00000226824.5 RP4-756H11.3 5.23 2.57e-06 0.011 0.79 0.57 Aortic root size; chr7:66294786 chr7:66654538~66669855:+ MESO cis rs6921919 0.583 rs9461459 ENSG00000216901.1 AL022393.7 5.23 2.59e-06 0.011 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28394139 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs28360638 ENSG00000216901.1 AL022393.7 5.23 2.59e-06 0.011 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28394552 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs16894060 ENSG00000216901.1 AL022393.7 5.23 2.59e-06 0.011 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28394694 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs9468368 ENSG00000216901.1 AL022393.7 5.23 2.59e-06 0.011 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28397172 chr6:28176188~28176674:+ MESO cis rs6921919 0.609 rs1005127 ENSG00000216901.1 AL022393.7 5.23 2.59e-06 0.011 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28399881 chr6:28176188~28176674:+ MESO cis rs853679 0.515 rs4580862 ENSG00000216901.1 AL022393.7 5.23 2.59e-06 0.011 0.86 0.57 Depression; chr6:28399886 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs4357130 ENSG00000216901.1 AL022393.7 5.23 2.59e-06 0.011 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28399906 chr6:28176188~28176674:+ MESO cis rs950027 0.62 rs1145093 ENSG00000259520.4 CTD-2651B20.3 -5.23 2.59e-06 0.011 -0.72 -0.57 Response to fenofibrate (adiponectin levels); chr15:45357615 chr15:45251580~45279251:- MESO cis rs950027 0.62 rs1145089 ENSG00000259520.4 CTD-2651B20.3 -5.23 2.59e-06 0.011 -0.72 -0.57 Response to fenofibrate (adiponectin levels); chr15:45359856 chr15:45251580~45279251:- MESO cis rs950027 0.62 rs1049518 ENSG00000259520.4 CTD-2651B20.3 -5.23 2.59e-06 0.011 -0.72 -0.57 Response to fenofibrate (adiponectin levels); chr15:45361169 chr15:45251580~45279251:- MESO cis rs950027 0.584 rs1145086 ENSG00000259520.4 CTD-2651B20.3 -5.23 2.59e-06 0.011 -0.72 -0.57 Response to fenofibrate (adiponectin levels); chr15:45362129 chr15:45251580~45279251:- MESO cis rs950027 0.62 rs1153857 ENSG00000259520.4 CTD-2651B20.3 -5.23 2.59e-06 0.011 -0.72 -0.57 Response to fenofibrate (adiponectin levels); chr15:45366897 chr15:45251580~45279251:- MESO cis rs950027 0.62 rs1153855 ENSG00000259520.4 CTD-2651B20.3 -5.23 2.59e-06 0.011 -0.72 -0.57 Response to fenofibrate (adiponectin levels); chr15:45368560 chr15:45251580~45279251:- MESO cis rs4964805 0.594 rs954920 ENSG00000257681.1 RP11-341G23.4 5.22 2.66e-06 0.0113 0.86 0.57 Attention deficit hyperactivity disorder; chr12:103779532 chr12:103746315~103768858:- MESO cis rs7927592 0.956 rs12365160 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68482951 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs11228256 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68483992 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7116994 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68487159 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs10896330 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68487530 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs12274114 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68488109 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs12294029 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68489591 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs7126340 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68489825 chr11:68506083~68506166:- MESO cis rs7927592 0.83 rs7120635 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68493825 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs55816191 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68495511 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs10896334 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68514026 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs10896337 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68516768 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs11228269 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68522328 chr11:68506083~68506166:- MESO cis rs7927592 0.83 rs10896339 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68535378 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs60212556 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68538026 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs11228277 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68540856 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs11228278 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68541062 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs948315 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68541672 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs10896343 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68550392 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs2155730 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68562006 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs6591341 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68568010 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs12277225 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68573499 chr11:68506083~68506166:- MESO cis rs7927592 0.871 rs871212 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68581227 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs10896348 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68589900 chr11:68506083~68506166:- MESO cis rs7927592 1 rs7927592 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68602492 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs7113287 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68604718 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs7107622 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68606715 chr11:68506083~68506166:- MESO cis rs7927592 0.912 rs55767696 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68607652 chr11:68506083~68506166:- MESO cis rs7927592 0.913 rs6591346 ENSG00000212093.1 AP000807.1 5.22 2.69e-06 0.0113 0.57 0.57 Total body bone mineral density; chr11:68617150 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs11228258 ENSG00000212093.1 AP000807.1 -5.22 2.69e-06 0.0113 -0.57 -0.57 Total body bone mineral density; chr11:68486860 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs12281742 ENSG00000212093.1 AP000807.1 -5.22 2.69e-06 0.0113 -0.57 -0.57 Total body bone mineral density; chr11:68536161 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs12271290 ENSG00000212093.1 AP000807.1 -5.22 2.69e-06 0.0113 -0.57 -0.57 Total body bone mineral density; chr11:68558768 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs7104877 ENSG00000212093.1 AP000807.1 -5.22 2.69e-06 0.0113 -0.57 -0.57 Total body bone mineral density; chr11:68610134 chr11:68506083~68506166:- MESO cis rs7617773 0.817 rs745116 ENSG00000229759.1 MRPS18AP1 5.22 2.7e-06 0.0114 0.73 0.57 Coronary artery disease; chr3:48231046 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs9847953 ENSG00000229759.1 MRPS18AP1 5.22 2.7e-06 0.0114 0.73 0.57 Coronary artery disease; chr3:48241205 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs11928691 ENSG00000229759.1 MRPS18AP1 5.22 2.7e-06 0.0114 0.73 0.57 Coronary artery disease; chr3:48245275 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs9311421 ENSG00000229759.1 MRPS18AP1 5.22 2.7e-06 0.0114 0.73 0.57 Coronary artery disease; chr3:48251588 chr3:48256350~48256938:- MESO cis rs2487048 0.725 rs2422493 ENSG00000226334.1 RP11-217B7.2 -5.22 2.7e-06 0.0114 -0.81 -0.57 Intraocular pressure; chr9:104928714 chr9:104927553~104928892:+ MESO cis rs2117029 0.554 rs35884657 ENSG00000258017.1 RP11-386G11.10 -5.22 2.71e-06 0.0114 -0.77 -0.57 Intelligence (multi-trait analysis); chr12:49137317 chr12:49127782~49147869:+ MESO cis rs11168854 0.62 rs11168888 ENSG00000258017.1 RP11-386G11.10 -5.22 2.71e-06 0.0114 -0.77 -0.57 Body mass index; chr12:49149614 chr12:49127782~49147869:+ MESO cis rs6921919 0.583 rs11755942 ENSG00000216901.1 AL022393.7 5.22 2.71e-06 0.0114 0.88 0.57 Autism spectrum disorder or schizophrenia; chr6:28401760 chr6:28176188~28176674:+ MESO cis rs57502260 1 rs56312530 ENSG00000212093.1 AP000807.1 5.22 2.72e-06 0.0114 0.73 0.57 Total body bone mineral density (age 45-60); chr11:68451947 chr11:68506083~68506166:- MESO cis rs3091242 0.9 rs669063 ENSG00000224183.1 SDHDP6 -5.22 2.72e-06 0.0114 -0.76 -0.57 Erythrocyte sedimentation rate; chr1:25394663 chr1:25294164~25294643:- MESO cis rs3091242 0.9 rs1883427 ENSG00000224183.1 SDHDP6 -5.22 2.72e-06 0.0114 -0.76 -0.57 Erythrocyte sedimentation rate; chr1:25417977 chr1:25294164~25294643:- MESO cis rs55794721 0.509 rs2375313 ENSG00000224183.1 SDHDP6 -5.22 2.72e-06 0.0114 -0.76 -0.57 Mean corpuscular volume;Plateletcrit; chr1:25421744 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs12402120 ENSG00000224183.1 SDHDP6 -5.22 2.72e-06 0.0114 -0.76 -0.57 Erythrocyte sedimentation rate; chr1:25425141 chr1:25294164~25294643:- MESO cis rs3091242 0.9 rs1811832 ENSG00000224183.1 SDHDP6 -5.22 2.72e-06 0.0114 -0.76 -0.57 Erythrocyte sedimentation rate; chr1:25427074 chr1:25294164~25294643:- MESO cis rs2739330 0.731 rs5751792 ENSG00000273295.1 AP000350.5 5.22 2.72e-06 0.0114 0.65 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005096 chr22:23901432~23907068:- MESO cis rs8177876 0.658 rs12444747 ENSG00000261838.4 RP11-303E16.6 5.22 2.72e-06 0.0114 1.09 0.57 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81041299 chr16:81069854~81076598:+ MESO cis rs8177876 0.658 rs2278022 ENSG00000261838.4 RP11-303E16.6 5.22 2.72e-06 0.0114 1.09 0.57 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81043216 chr16:81069854~81076598:+ MESO cis rs8177876 0.749 rs2278024 ENSG00000261838.4 RP11-303E16.6 5.22 2.72e-06 0.0114 1.09 0.57 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81045628 chr16:81069854~81076598:+ MESO cis rs8177876 0.749 rs78707250 ENSG00000261838.4 RP11-303E16.6 5.22 2.72e-06 0.0114 1.09 0.57 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81046757 chr16:81069854~81076598:+ MESO cis rs4835473 0.722 rs7666296 ENSG00000251600.4 RP11-673E1.1 -5.22 2.73e-06 0.0114 -0.71 -0.57 Immature fraction of reticulocytes; chr4:143999004 chr4:143912331~143982454:+ MESO cis rs2739330 0.761 rs5760176 ENSG00000273295.1 AP000350.5 -5.22 2.73e-06 0.0115 -0.65 -0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:24005875 chr22:23901432~23907068:- MESO cis rs3931020 1 rs12410060 ENSG00000272864.1 RP11-17E13.2 -5.22 2.74e-06 0.0115 -0.83 -0.57 Resistin levels; chr1:74780164 chr1:74698769~74699333:- MESO cis rs7301826 0.557 rs7953184 ENSG00000256250.1 RP11-989F5.1 5.21 2.77e-06 0.0116 0.72 0.57 Plasma plasminogen activator levels; chr12:130800307 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs2277336 ENSG00000256250.1 RP11-989F5.1 5.21 2.77e-06 0.0116 0.72 0.57 Plasma plasminogen activator levels; chr12:130801574 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs10848206 ENSG00000256250.1 RP11-989F5.1 -5.21 2.77e-06 0.0116 -0.72 -0.57 Plasma plasminogen activator levels; chr12:130796926 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs4759517 ENSG00000256250.1 RP11-989F5.1 -5.21 2.77e-06 0.0116 -0.72 -0.57 Plasma plasminogen activator levels; chr12:130799153 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs7132657 ENSG00000256250.1 RP11-989F5.1 -5.21 2.77e-06 0.0116 -0.72 -0.57 Plasma plasminogen activator levels; chr12:130800642 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs7971046 ENSG00000256250.1 RP11-989F5.1 -5.21 2.77e-06 0.0116 -0.72 -0.57 Plasma plasminogen activator levels; chr12:130802262 chr12:130810606~130812438:+ MESO cis rs7927592 0.956 rs7124078 ENSG00000212093.1 AP000807.1 5.21 2.77e-06 0.0116 0.57 0.57 Total body bone mineral density; chr11:68531165 chr11:68506083~68506166:- MESO cis rs9322193 0.884 rs9371201 ENSG00000231760.4 RP11-350J20.5 5.21 2.78e-06 0.0116 0.78 0.57 Lung cancer; chr6:149823865 chr6:149796151~149826294:- MESO cis rs1577917 0.771 rs4419647 ENSG00000203875.9 SNHG5 5.21 2.78e-06 0.0116 0.76 0.57 Response to antipsychotic treatment; chr6:85516021 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs9353318 ENSG00000203875.9 SNHG5 5.21 2.78e-06 0.0116 0.76 0.57 Response to antipsychotic treatment; chr6:85522003 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs9450290 ENSG00000203875.9 SNHG5 5.21 2.78e-06 0.0116 0.76 0.57 Response to antipsychotic treatment; chr6:85523679 chr6:85660950~85678736:- MESO cis rs875971 0.767 rs1643394 ENSG00000226824.5 RP4-756H11.3 -5.21 2.79e-06 0.0117 -0.79 -0.57 Aortic root size; chr7:66371107 chr7:66654538~66669855:+ MESO cis rs62388641 0.539 rs56016631 ENSG00000272279.1 RP11-157J24.2 5.21 2.8e-06 0.0117 0.68 0.57 Daytime sleep phenotypes; chr6:1542340 chr6:1528364~1528911:- MESO cis rs950027 0.62 rs2467862 ENSG00000259520.4 CTD-2651B20.3 -5.21 2.81e-06 0.0117 -0.72 -0.57 Response to fenofibrate (adiponectin levels); chr15:45351645 chr15:45251580~45279251:- MESO cis rs875971 0.522 rs7784623 ENSG00000226824.5 RP4-756H11.3 -5.21 2.81e-06 0.0117 -0.79 -0.57 Aortic root size; chr7:65930047 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs34973832 ENSG00000226824.5 RP4-756H11.3 -5.21 2.81e-06 0.0117 -0.79 -0.57 Aortic root size; chr7:65931217 chr7:66654538~66669855:+ MESO cis rs17711722 0.74 rs7809991 ENSG00000226824.5 RP4-756H11.3 -5.21 2.81e-06 0.0117 -0.79 -0.57 Calcium levels; chr7:65941231 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs6960048 ENSG00000226824.5 RP4-756H11.3 -5.21 2.81e-06 0.0117 -0.79 -0.57 Aortic root size; chr7:65943052 chr7:66654538~66669855:+ MESO cis rs4835473 0.571 rs1992656 ENSG00000251600.4 RP11-673E1.1 5.21 2.82e-06 0.0117 0.71 0.57 Immature fraction of reticulocytes; chr4:143855286 chr4:143912331~143982454:+ MESO cis rs4835473 0.571 rs1992655 ENSG00000251600.4 RP11-673E1.1 5.21 2.82e-06 0.0117 0.71 0.57 Immature fraction of reticulocytes; chr4:143855290 chr4:143912331~143982454:+ MESO cis rs4835473 0.591 rs6822129 ENSG00000251600.4 RP11-673E1.1 -5.21 2.83e-06 0.0118 -0.72 -0.57 Immature fraction of reticulocytes; chr4:144058755 chr4:143912331~143982454:+ MESO cis rs7208859 0.673 rs3764421 ENSG00000263531.1 RP13-753N3.1 5.2 2.86e-06 0.0119 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30840635 chr17:30863921~30864940:- MESO cis rs7208859 0.725 rs7210904 ENSG00000263531.1 RP13-753N3.1 5.2 2.86e-06 0.0119 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843187 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs11651858 ENSG00000263531.1 RP13-753N3.1 5.2 2.86e-06 0.0119 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30843700 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs36056619 ENSG00000263531.1 RP13-753N3.1 5.2 2.86e-06 0.0119 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30845266 chr17:30863921~30864940:- MESO cis rs7208859 0.725 rs9915802 ENSG00000263531.1 RP13-753N3.1 5.2 2.86e-06 0.0119 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846040 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9909497 ENSG00000263531.1 RP13-753N3.1 5.2 2.86e-06 0.0119 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30846210 chr17:30863921~30864940:- MESO cis rs7208859 0.725 rs7342938 ENSG00000263531.1 RP13-753N3.1 5.2 2.86e-06 0.0119 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862812 chr17:30863921~30864940:- MESO cis rs7208859 0.725 rs6505215 ENSG00000263531.1 RP13-753N3.1 5.2 2.86e-06 0.0119 1.06 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30862885 chr17:30863921~30864940:- MESO cis rs7617773 0.779 rs77957078 ENSG00000229759.1 MRPS18AP1 5.2 2.87e-06 0.0119 0.73 0.57 Coronary artery disease; chr3:48289796 chr3:48256350~48256938:- MESO cis rs9309473 0.606 rs6759452 ENSG00000163016.8 ALMS1P 5.2 2.87e-06 0.0119 0.99 0.57 Metabolite levels; chr2:73651225 chr2:73644919~73685576:+ MESO cis rs8177876 0.749 rs12444969 ENSG00000261838.4 RP11-303E16.6 5.2 2.91e-06 0.0121 1.09 0.57 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81050211 chr16:81069854~81076598:+ MESO cis rs1577917 0.839 rs9450333 ENSG00000203875.9 SNHG5 -5.2 2.92e-06 0.0121 -0.73 -0.57 Response to antipsychotic treatment; chr6:85810037 chr6:85660950~85678736:- MESO cis rs1577917 0.839 rs6929514 ENSG00000203875.9 SNHG5 -5.2 2.92e-06 0.0121 -0.73 -0.57 Response to antipsychotic treatment; chr6:85816050 chr6:85660950~85678736:- MESO cis rs4835473 0.618 rs12499429 ENSG00000251600.4 RP11-673E1.1 -5.2 2.92e-06 0.0121 -0.68 -0.57 Immature fraction of reticulocytes; chr4:143889914 chr4:143912331~143982454:+ MESO cis rs4835473 0.801 rs28715976 ENSG00000251600.4 RP11-673E1.1 -5.2 2.92e-06 0.0121 -0.68 -0.57 Immature fraction of reticulocytes; chr4:143891603 chr4:143912331~143982454:+ MESO cis rs4835473 0.838 rs12507468 ENSG00000251600.4 RP11-673E1.1 -5.2 2.92e-06 0.0121 -0.68 -0.57 Immature fraction of reticulocytes; chr4:143908061 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1849135 ENSG00000251600.4 RP11-673E1.1 -5.2 2.92e-06 0.0121 -0.68 -0.57 Immature fraction of reticulocytes; chr4:143912279 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1849136 ENSG00000251600.4 RP11-673E1.1 -5.2 2.92e-06 0.0121 -0.68 -0.57 Immature fraction of reticulocytes; chr4:143912380 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs12508285 ENSG00000251600.4 RP11-673E1.1 -5.19 2.98e-06 0.0123 -0.67 -0.57 Immature fraction of reticulocytes; chr4:143792642 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs7667544 ENSG00000251600.4 RP11-673E1.1 -5.19 2.98e-06 0.0123 -0.67 -0.57 Immature fraction of reticulocytes; chr4:143793802 chr4:143912331~143982454:+ MESO cis rs11673344 0.566 rs2385181 ENSG00000226686.6 LINC01535 -5.19 2.98e-06 0.0123 -0.61 -0.57 Obesity-related traits; chr19:37395428 chr19:37251912~37265535:+ MESO cis rs11673344 0.544 rs6508721 ENSG00000226686.6 LINC01535 -5.19 2.98e-06 0.0123 -0.61 -0.57 Obesity-related traits; chr19:37419119 chr19:37251912~37265535:+ MESO cis rs11673344 0.566 rs7254009 ENSG00000226686.6 LINC01535 -5.19 2.98e-06 0.0123 -0.61 -0.57 Obesity-related traits; chr19:37427707 chr19:37251912~37265535:+ MESO cis rs11673344 0.566 rs2385180 ENSG00000226686.6 LINC01535 -5.19 2.98e-06 0.0123 -0.61 -0.57 Obesity-related traits; chr19:37431454 chr19:37251912~37265535:+ MESO cis rs11673344 0.566 rs1968251 ENSG00000226686.6 LINC01535 -5.19 2.98e-06 0.0123 -0.61 -0.57 Obesity-related traits; chr19:37457005 chr19:37251912~37265535:+ MESO cis rs11673344 0.566 rs10419281 ENSG00000226686.6 LINC01535 -5.19 2.98e-06 0.0123 -0.61 -0.57 Obesity-related traits; chr19:37459351 chr19:37251912~37265535:+ MESO cis rs7927592 0.956 rs7106259 ENSG00000212093.1 AP000807.1 5.19 2.98e-06 0.0123 0.57 0.57 Total body bone mineral density; chr11:68531044 chr11:68506083~68506166:- MESO cis rs10256972 0.552 rs6978842 ENSG00000229043.2 AC091729.9 -5.19 2.99e-06 0.0123 -0.68 -0.57 Endometriosis;Longevity; chr7:1164963 chr7:1160374~1165267:+ MESO cis rs7301826 0.603 rs7975825 ENSG00000256250.1 RP11-989F5.1 -5.19 3.02e-06 0.0124 -0.72 -0.57 Plasma plasminogen activator levels; chr12:130803899 chr12:130810606~130812438:+ MESO cis rs9322193 0.923 rs9371486 ENSG00000231760.4 RP11-350J20.5 5.19 3.05e-06 0.0125 0.78 0.57 Lung cancer; chr6:149832090 chr6:149796151~149826294:- MESO cis rs4835473 0.897 rs2590034 ENSG00000251600.4 RP11-673E1.1 5.19 3.05e-06 0.0125 0.66 0.57 Immature fraction of reticulocytes; chr4:143926778 chr4:143912331~143982454:+ MESO cis rs3091242 0.933 rs61775174 ENSG00000224183.1 SDHDP6 5.19 3.07e-06 0.0126 0.74 0.57 Erythrocyte sedimentation rate; chr1:25460822 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs34933589 ENSG00000224183.1 SDHDP6 5.19 3.07e-06 0.0126 0.74 0.57 Erythrocyte sedimentation rate; chr1:25461707 chr1:25294164~25294643:- MESO cis rs7617773 0.817 rs9819094 ENSG00000229759.1 MRPS18AP1 5.18 3.09e-06 0.0126 0.69 0.57 Coronary artery disease; chr3:48278068 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs11710861 ENSG00000229759.1 MRPS18AP1 5.18 3.1e-06 0.0127 0.73 0.57 Coronary artery disease; chr3:48256070 chr3:48256350~48256938:- MESO cis rs2739330 0.76 rs1002286 ENSG00000231271.1 AP000350.8 -5.18 3.11e-06 0.0127 -0.71 -0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23949918~23954042:+ MESO cis rs7301826 0.651 rs2037789 ENSG00000256250.1 RP11-989F5.1 5.18 3.11e-06 0.0127 0.73 0.57 Plasma plasminogen activator levels; chr12:130803747 chr12:130810606~130812438:+ MESO cis rs3091242 0.933 rs34006994 ENSG00000224183.1 SDHDP6 5.18 3.13e-06 0.0128 0.73 0.57 Erythrocyte sedimentation rate; chr1:25454177 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs61775167 ENSG00000224183.1 SDHDP6 5.18 3.13e-06 0.0128 0.73 0.57 Erythrocyte sedimentation rate; chr1:25454402 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs35497030 ENSG00000224183.1 SDHDP6 5.18 3.13e-06 0.0128 0.73 0.57 Erythrocyte sedimentation rate; chr1:25456575 chr1:25294164~25294643:- MESO cis rs3091242 0.902 rs36003018 ENSG00000224183.1 SDHDP6 5.18 3.13e-06 0.0128 0.73 0.57 Erythrocyte sedimentation rate; chr1:25457827 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs35403885 ENSG00000224183.1 SDHDP6 5.18 3.13e-06 0.0128 0.73 0.57 Erythrocyte sedimentation rate; chr1:25458060 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs35530120 ENSG00000224183.1 SDHDP6 5.18 3.13e-06 0.0128 0.73 0.57 Erythrocyte sedimentation rate; chr1:25458960 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs11249250 ENSG00000224183.1 SDHDP6 -5.18 3.13e-06 0.0128 -0.73 -0.57 Erythrocyte sedimentation rate; chr1:25441118 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs10903130 ENSG00000224183.1 SDHDP6 -5.18 3.13e-06 0.0128 -0.73 -0.57 Erythrocyte sedimentation rate; chr1:25442730 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs11249251 ENSG00000224183.1 SDHDP6 -5.18 3.13e-06 0.0128 -0.73 -0.57 Erythrocyte sedimentation rate; chr1:25443697 chr1:25294164~25294643:- MESO cis rs3091242 0.9 rs4649086 ENSG00000224183.1 SDHDP6 -5.18 3.13e-06 0.0128 -0.73 -0.57 Erythrocyte sedimentation rate; chr1:25452476 chr1:25294164~25294643:- MESO cis rs6700559 0.873 rs7542840 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200686558 chr1:200669507~200694250:+ MESO cis rs6700559 0.815 rs7526365 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200688020 chr1:200669507~200694250:+ MESO cis rs6700559 0.873 rs7526482 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200688310 chr1:200669507~200694250:+ MESO cis rs6700559 0.873 rs7526853 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200688529 chr1:200669507~200694250:+ MESO cis rs6700559 0.844 rs61825137 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200689267 chr1:200669507~200694250:+ MESO cis rs6700559 0.873 rs7545177 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200690727 chr1:200669507~200694250:+ MESO cis rs6700559 0.873 rs7539646 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200692534 chr1:200669507~200694250:+ MESO cis rs6700559 0.873 rs7519383 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200692968 chr1:200669507~200694250:+ MESO cis rs6700559 0.815 rs12141497 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200693389 chr1:200669507~200694250:+ MESO cis rs6700559 0.873 rs12126708 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200693397 chr1:200669507~200694250:+ MESO cis rs6700559 0.873 rs10920008 ENSG00000260088.1 RP11-92G12.3 -5.18 3.14e-06 0.0128 -0.61 -0.57 Coronary artery disease; chr1:200694546 chr1:200669507~200694250:+ MESO cis rs1577917 0.74 rs2842604 ENSG00000203875.9 SNHG5 -5.18 3.14e-06 0.0128 -0.76 -0.57 Response to antipsychotic treatment; chr6:85626582 chr6:85660950~85678736:- MESO cis rs3091242 0.933 rs10903129 ENSG00000224183.1 SDHDP6 -5.18 3.15e-06 0.0128 -0.73 -0.57 Erythrocyte sedimentation rate; chr1:25442446 chr1:25294164~25294643:- MESO cis rs17826219 0.706 rs9905827 ENSG00000263531.1 RP13-753N3.1 5.18 3.18e-06 0.0129 1.08 0.57 Body mass index; chr17:30865150 chr17:30863921~30864940:- MESO cis rs3091242 0.9 rs35345536 ENSG00000224183.1 SDHDP6 -5.17 3.2e-06 0.0129 -0.76 -0.57 Erythrocyte sedimentation rate; chr1:25439997 chr1:25294164~25294643:- MESO cis rs73086581 1 rs73084575 ENSG00000229539.1 RP11-119B16.2 5.17 3.2e-06 0.0129 0.73 0.57 Response to antidepressants in depression; chr20:3926121 chr20:3888239~3888868:- MESO cis rs55794721 0.509 rs11249248 ENSG00000224183.1 SDHDP6 -5.17 3.21e-06 0.0129 -0.75 -0.57 Mean corpuscular volume;Plateletcrit; chr1:25426560 chr1:25294164~25294643:- MESO cis rs172166 0.516 rs1225715 ENSG00000216901.1 AL022393.7 -5.17 3.22e-06 0.0129 -0.8 -0.57 Cardiac Troponin-T levels; chr6:28145595 chr6:28176188~28176674:+ MESO cis rs875971 0.862 rs2909688 ENSG00000226824.5 RP4-756H11.3 -5.17 3.22e-06 0.0129 -0.78 -0.57 Aortic root size; chr7:66376625 chr7:66654538~66669855:+ MESO cis rs1153858 1 rs9783731 ENSG00000259520.4 CTD-2651B20.3 5.17 3.23e-06 0.0129 0.75 0.57 Homoarginine levels; chr15:45350686 chr15:45251580~45279251:- MESO cis rs1153858 1 rs1554521 ENSG00000259520.4 CTD-2651B20.3 5.17 3.23e-06 0.0129 0.75 0.57 Homoarginine levels; chr15:45371991 chr15:45251580~45279251:- MESO cis rs1153858 1 rs16942000 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45340805 chr15:45251580~45279251:- MESO cis rs1153858 1 rs56850226 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45340920 chr15:45251580~45279251:- MESO cis rs1153858 0.945 rs7182300 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45342730 chr15:45251580~45279251:- MESO cis rs1153858 0.887 rs7171163 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45344197 chr15:45251580~45279251:- MESO cis rs1153858 1 rs56669689 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45345531 chr15:45251580~45279251:- MESO cis rs1153858 1 rs56806728 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45345616 chr15:45251580~45279251:- MESO cis rs1153858 1 rs4775906 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45346096 chr15:45251580~45279251:- MESO cis rs1153858 1 rs7179743 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45346133 chr15:45251580~45279251:- MESO cis rs1153858 1 rs4775907 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45346449 chr15:45251580~45279251:- MESO cis rs1153858 1 rs7163720 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45347176 chr15:45251580~45279251:- MESO cis rs1153858 1 rs7167900 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45347273 chr15:45251580~45279251:- MESO cis rs1153858 1 rs12591058 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45347974 chr15:45251580~45279251:- MESO cis rs1153858 1 rs7169587 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45348181 chr15:45251580~45279251:- MESO cis rs1153858 0.943 rs28605551 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45349522 chr15:45251580~45279251:- MESO cis rs1153858 1 rs2467863 ENSG00000259520.4 CTD-2651B20.3 -5.17 3.23e-06 0.0129 -0.75 -0.57 Homoarginine levels; chr15:45349682 chr15:45251580~45279251:- MESO cis rs875971 0.54 rs736270 ENSG00000226824.5 RP4-756H11.3 -5.17 3.26e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65963835 chr7:66654538~66669855:+ MESO cis rs2739330 0.828 rs4820572 ENSG00000225282.1 AP000350.6 5.17 3.28e-06 0.0129 0.63 0.57 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908168 chr22:23926900~23929574:+ MESO cis rs4835473 0.736 rs11724009 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143984291 chr4:143912331~143982454:+ MESO cis rs4323050 0.514 rs28647406 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 High light scatter reticulocyte percentage of red cells; chr4:143984437 chr4:143912331~143982454:+ MESO cis rs4835473 0.604 rs11938387 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143984476 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1511425 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143985122 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1849120 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143985337 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4835476 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143985517 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1828502 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143985797 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs7668698 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143986333 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs6537231 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143986489 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1877234 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143986774 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs6852502 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143987174 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4260486 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143987556 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4287958 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143987719 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4125545 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143988650 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs12649594 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143989307 chr4:143912331~143982454:+ MESO cis rs4835473 0.864 rs13101482 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143989463 chr4:143912331~143982454:+ MESO cis rs4835473 0.864 rs13135472 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143989465 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1849115 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143989687 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1849118 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143989822 chr4:143912331~143982454:+ MESO cis rs4835473 0.663 rs1511423 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143990136 chr4:143912331~143982454:+ MESO cis rs4835473 0.639 rs5029916 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143990684 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1988206 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143991344 chr4:143912331~143982454:+ MESO cis rs4835473 0.831 rs4323050 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143992106 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs4423826 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143992165 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1849128 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143992582 chr4:143912331~143982454:+ MESO cis rs4835473 0.715 rs4538428 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143992751 chr4:143912331~143982454:+ MESO cis rs4835473 0.771 rs2175452 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143992887 chr4:143912331~143982454:+ MESO cis rs4835473 0.8 rs2175451 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143992964 chr4:143912331~143982454:+ MESO cis rs4323050 0.51 rs4254715 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 High light scatter reticulocyte percentage of red cells; chr4:143993140 chr4:143912331~143982454:+ MESO cis rs4323050 0.51 rs4273414 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 High light scatter reticulocyte percentage of red cells; chr4:143993142 chr4:143912331~143982454:+ MESO cis rs4835473 0.831 rs1912743 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143993705 chr4:143912331~143982454:+ MESO cis rs4835473 0.614 rs4487293 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143993880 chr4:143912331~143982454:+ MESO cis rs4835473 0.742 rs6537238 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143996463 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1473055 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143997714 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4835126 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143997740 chr4:143912331~143982454:+ MESO cis rs4835473 0.699 rs4835127 ENSG00000251600.4 RP11-673E1.1 5.17 3.28e-06 0.0129 0.7 0.57 Immature fraction of reticulocytes; chr4:143997972 chr4:143912331~143982454:+ MESO cis rs4835473 0.868 rs1828503 ENSG00000251600.4 RP11-673E1.1 -5.17 3.28e-06 0.0129 -0.7 -0.57 Immature fraction of reticulocytes; chr4:143993354 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs10025455 ENSG00000251600.4 RP11-673E1.1 -5.17 3.28e-06 0.0129 -0.7 -0.57 Immature fraction of reticulocytes; chr4:143998417 chr4:143912331~143982454:+ MESO cis rs875971 0.862 rs6460307 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.78 -0.57 Aortic root size; chr7:66595884 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs4718285 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65827018 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs4718286 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65827777 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs4502988 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65832759 chr7:66654538~66669855:+ MESO cis rs17711722 0.585 rs6942660 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Calcium levels; chr7:65837419 chr7:66654538~66669855:+ MESO cis rs17711722 0.64 rs13237956 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Calcium levels; chr7:65853042 chr7:66654538~66669855:+ MESO cis rs875971 0.516 rs6945322 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65871069 chr7:66654538~66669855:+ MESO cis rs17711722 0.701 rs55773927 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Calcium levels; chr7:65872915 chr7:66654538~66669855:+ MESO cis rs17711722 0.727 rs35850374 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Calcium levels; chr7:65892789 chr7:66654538~66669855:+ MESO cis rs17711722 0.701 rs4467826 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Calcium levels; chr7:65903721 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs10807697 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65951183 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs2008188 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65964026 chr7:66654538~66669855:+ MESO cis rs875971 0.505 rs6955582 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65966699 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs1880556 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65967557 chr7:66654538~66669855:+ MESO cis rs17711722 0.727 rs1880555 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Calcium levels; chr7:65967580 chr7:66654538~66669855:+ MESO cis rs17711722 0.701 rs781143 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Calcium levels; chr7:65974892 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs781144 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65975357 chr7:66654538~66669855:+ MESO cis rs17711722 0.701 rs781145 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Calcium levels; chr7:65975383 chr7:66654538~66669855:+ MESO cis rs17711722 0.727 rs2658585 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Calcium levels; chr7:65996954 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs1617484 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:65998108 chr7:66654538~66669855:+ MESO cis rs875971 0.54 rs1723268 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:66008093 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs1701760 ENSG00000226824.5 RP4-756H11.3 -5.17 3.29e-06 0.0129 -0.79 -0.57 Aortic root size; chr7:66008701 chr7:66654538~66669855:+ MESO cis rs11763147 1 rs11763147 ENSG00000226824.5 RP4-756H11.3 5.17 3.29e-06 0.0129 0.79 0.57 Corneal structure; chr7:65861834 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs1917563 ENSG00000226824.5 RP4-756H11.3 5.17 3.29e-06 0.0129 0.79 0.57 Aortic root size; chr7:65950660 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs2949690 ENSG00000226824.5 RP4-756H11.3 5.17 3.29e-06 0.0129 0.79 0.57 Aortic root size; chr7:66018255 chr7:66654538~66669855:+ MESO cis rs875971 0.522 rs709604 ENSG00000226824.5 RP4-756H11.3 5.17 3.29e-06 0.0129 0.79 0.57 Aortic root size; chr7:66032447 chr7:66654538~66669855:+ MESO cis rs875971 0.505 rs1723275 ENSG00000226824.5 RP4-756H11.3 5.17 3.29e-06 0.0129 0.79 0.57 Aortic root size; chr7:66039646 chr7:66654538~66669855:+ MESO cis rs875971 0.505 rs2462573 ENSG00000226824.5 RP4-756H11.3 5.17 3.29e-06 0.0129 0.79 0.57 Aortic root size; chr7:66042405 chr7:66654538~66669855:+ MESO cis rs875971 0.505 rs1167386 ENSG00000226824.5 RP4-756H11.3 5.17 3.29e-06 0.0129 0.79 0.57 Aortic root size; chr7:66048109 chr7:66654538~66669855:+ MESO cis rs875971 0.505 rs1167385 ENSG00000226824.5 RP4-756H11.3 5.17 3.29e-06 0.0129 0.79 0.57 Aortic root size; chr7:66048321 chr7:66654538~66669855:+ MESO cis rs11168854 0.719 rs11168902 ENSG00000258017.1 RP11-386G11.10 -5.17 3.29e-06 0.0129 -0.76 -0.57 Body mass index; chr12:49174483 chr12:49127782~49147869:+ MESO cis rs2117029 0.553 rs11168903 ENSG00000258017.1 RP11-386G11.10 -5.17 3.29e-06 0.0129 -0.76 -0.57 Intelligence (multi-trait analysis); chr12:49174883 chr12:49127782~49147869:+ MESO cis rs4835473 0.742 rs7695853 ENSG00000251600.4 RP11-673E1.1 5.16 3.31e-06 0.013 0.69 0.57 Immature fraction of reticulocytes; chr4:143883243 chr4:143912331~143982454:+ MESO cis rs10769945 0.538 rs217217 ENSG00000226416.1 MRPL23-AS1 -5.16 3.33e-06 0.0131 -0.72 -0.57 DNA methylation (variation); chr11:1985500 chr11:1983237~1989920:- MESO cis rs4835473 0.932 rs11724752 ENSG00000251600.4 RP11-673E1.1 -5.16 3.33e-06 0.0131 -0.65 -0.57 Immature fraction of reticulocytes; chr4:143769473 chr4:143912331~143982454:+ MESO cis rs2117029 0.767 rs11614738 ENSG00000258017.1 RP11-386G11.10 -5.16 3.33e-06 0.0131 -0.74 -0.57 Intelligence (multi-trait analysis); chr12:49030833 chr12:49127782~49147869:+ MESO cis rs2117029 0.767 rs3741622 ENSG00000258017.1 RP11-386G11.10 -5.16 3.33e-06 0.0131 -0.74 -0.57 Intelligence (multi-trait analysis); chr12:49032195 chr12:49127782~49147869:+ MESO cis rs9890032 0.934 rs7225461 ENSG00000263531.1 RP13-753N3.1 5.16 3.36e-06 0.0132 0.7 0.57 Hip circumference adjusted for BMI; chr17:30932881 chr17:30863921~30864940:- MESO cis rs2487048 0.761 rs1800976 ENSG00000226334.1 RP11-217B7.2 -5.16 3.39e-06 0.0133 -0.8 -0.57 Intraocular pressure; chr9:104928428 chr9:104927553~104928892:+ MESO cis rs73086581 0.838 rs56401022 ENSG00000229539.1 RP11-119B16.2 5.16 3.41e-06 0.0133 0.73 0.57 Response to antidepressants in depression; chr20:4043634 chr20:3888239~3888868:- MESO cis rs1577917 0.655 rs12203963 ENSG00000203875.9 SNHG5 5.16 3.42e-06 0.0133 0.69 0.57 Response to antipsychotic treatment; chr6:85513598 chr6:85660950~85678736:- MESO cis rs1930961 1 rs1930961 ENSG00000100058.11 CRYBB2P1 5.15 3.44e-06 0.0133 1.28 0.57 Bipolar disorder with mood-incongruent psychosis; chr22:25479298 chr22:25448105~25520854:+ MESO cis rs4835473 0.932 rs9308176 ENSG00000251600.4 RP11-673E1.1 -5.15 3.46e-06 0.0133 -0.73 -0.57 Immature fraction of reticulocytes; chr4:144072718 chr4:143912331~143982454:+ MESO cis rs875971 0.862 rs10256544 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66210141 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs709596 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66360926 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs778724 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66364304 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs778686 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66370923 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs778684 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66371416 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs778680 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66375427 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs11769079 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66377141 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1695820 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66379576 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs778715 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66384222 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs809025 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66384832 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs778711 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66386670 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1083554 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66387354 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs778707 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66392040 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs778705 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66396128 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs778702 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66399848 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs778697 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66405439 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1643375 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66407690 chr7:66654538~66669855:+ MESO cis rs875971 0.798 rs7789615 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66413674 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6962717 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66418748 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6978028 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66421313 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6947339 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66423483 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs6976714 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66426474 chr7:66654538~66669855:+ MESO cis rs875971 0.767 rs12668005 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66444034 chr7:66654538~66669855:+ MESO cis rs875971 0.651 rs2420596 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66450996 chr7:66654538~66669855:+ MESO cis rs875971 0.52 rs2420597 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66450999 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs11765791 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66471587 chr7:66654538~66669855:+ MESO cis rs875971 0.798 rs6460304 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66499741 chr7:66654538~66669855:+ MESO cis rs875971 0.798 rs12698522 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66502354 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs28714531 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66503250 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6945775 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66503987 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs12698526 ENSG00000226824.5 RP4-756H11.3 -5.15 3.46e-06 0.0133 -0.78 -0.57 Aortic root size; chr7:66504118 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs2460432 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66089398 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1167408 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66091121 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs1167406 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66091949 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs709609 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66095574 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1167399 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66096890 chr7:66654538~66669855:+ MESO cis rs875971 0.825 rs59466412 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66100371 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs57866200 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66100405 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1612452 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66108909 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1167390 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66110906 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs35034167 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66115179 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs28470208 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66119713 chr7:66654538~66669855:+ MESO cis rs875971 0.893 rs62465470 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66136231 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs4368860 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66143495 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs1983372 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66146364 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs908915 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66149664 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs7809814 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66150410 chr7:66654538~66669855:+ MESO cis rs875971 0.825 rs1129531 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66154117 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs7786892 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66163889 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs2420174 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66180374 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs2420173 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66180412 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs4718319 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66187797 chr7:66654538~66669855:+ MESO cis rs875971 0.723 rs28391294 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66189328 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs6967708 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66192326 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs7782806 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66192910 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs6460278 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66197749 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs6460279 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66197774 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs28491091 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66204077 chr7:66654538~66669855:+ MESO cis rs875971 0.862 rs880166 ENSG00000226824.5 RP4-756H11.3 5.15 3.46e-06 0.0133 0.78 0.57 Aortic root size; chr7:66205775 chr7:66654538~66669855:+ MESO cis rs975739 0.933 rs1759976 ENSG00000236051.5 MYCBP2-AS1 -5.15 3.46e-06 0.0133 -0.71 -0.57 Hair color; chr13:77811040 chr13:77075514~77129717:+ MESO cis rs975739 0.933 rs1668620 ENSG00000236051.5 MYCBP2-AS1 -5.15 3.46e-06 0.0133 -0.71 -0.57 Hair color; chr13:77811048 chr13:77075514~77129717:+ MESO cis rs977987 0.705 rs4888377 ENSG00000261783.1 RP11-252K23.2 -5.15 3.48e-06 0.0134 -0.76 -0.57 Dupuytren's disease; chr16:75291788 chr16:75379818~75381260:- MESO cis rs3091242 1 rs9689 ENSG00000224183.1 SDHDP6 -5.15 3.49e-06 0.0134 -0.75 -0.57 Erythrocyte sedimentation rate; chr1:25361785 chr1:25294164~25294643:- MESO cis rs3091242 0.967 rs665372 ENSG00000224183.1 SDHDP6 -5.15 3.49e-06 0.0134 -0.75 -0.57 Erythrocyte sedimentation rate; chr1:25392744 chr1:25294164~25294643:- MESO cis rs3091242 0.867 rs602052 ENSG00000224183.1 SDHDP6 -5.15 3.49e-06 0.0134 -0.75 -0.57 Erythrocyte sedimentation rate; chr1:25395715 chr1:25294164~25294643:- MESO cis rs3091242 0.804 rs631133 ENSG00000224183.1 SDHDP6 -5.15 3.49e-06 0.0134 -0.75 -0.57 Erythrocyte sedimentation rate; chr1:25397655 chr1:25294164~25294643:- MESO cis rs3091242 0.809 rs660129 ENSG00000224183.1 SDHDP6 -5.15 3.49e-06 0.0134 -0.75 -0.57 Erythrocyte sedimentation rate; chr1:25400947 chr1:25294164~25294643:- MESO cis rs3091242 0.728 rs706845 ENSG00000224183.1 SDHDP6 -5.15 3.49e-06 0.0134 -0.75 -0.57 Erythrocyte sedimentation rate; chr1:25404222 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs28633797 ENSG00000224183.1 SDHDP6 -5.15 3.49e-06 0.0134 -0.75 -0.57 Erythrocyte sedimentation rate; chr1:25415138 chr1:25294164~25294643:- MESO cis rs1153858 0.945 rs16943246 ENSG00000259520.4 CTD-2651B20.3 -5.15 3.51e-06 0.0134 -0.77 -0.57 Homoarginine levels; chr15:45428399 chr15:45251580~45279251:- MESO cis rs2117029 0.521 rs1039225 ENSG00000258017.1 RP11-386G11.10 -5.15 3.52e-06 0.0135 -0.75 -0.57 Intelligence (multi-trait analysis); chr12:49188909 chr12:49127782~49147869:+ MESO cis rs4835473 0.932 rs1877235 ENSG00000251600.4 RP11-673E1.1 -5.15 3.53e-06 0.0135 -0.69 -0.57 Immature fraction of reticulocytes; chr4:143986961 chr4:143912331~143982454:+ MESO cis rs7208859 0.673 rs999797 ENSG00000263531.1 RP13-753N3.1 5.15 3.53e-06 0.0135 1.05 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832311 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11651802 ENSG00000263531.1 RP13-753N3.1 5.15 3.53e-06 0.0135 1.05 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30832642 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs17826219 ENSG00000263531.1 RP13-753N3.1 5.15 3.53e-06 0.0135 1.05 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30834827 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11655623 ENSG00000263531.1 RP13-753N3.1 5.15 3.53e-06 0.0135 1.05 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30835155 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs61223749 ENSG00000263531.1 RP13-753N3.1 5.15 3.53e-06 0.0135 1.05 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30836729 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs3764420 ENSG00000263531.1 RP13-753N3.1 5.15 3.53e-06 0.0135 1.05 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837136 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs11654331 ENSG00000263531.1 RP13-753N3.1 5.15 3.53e-06 0.0135 1.05 0.57 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30837999 chr17:30863921~30864940:- MESO cis rs6921919 0.583 rs7764737 ENSG00000216901.1 AL022393.7 5.14 3.57e-06 0.0136 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28386838 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs9461458 ENSG00000216901.1 AL022393.7 5.14 3.57e-06 0.0136 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28388098 chr6:28176188~28176674:+ MESO cis rs6921919 0.609 rs9468365 ENSG00000216901.1 AL022393.7 5.14 3.57e-06 0.0136 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28390189 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs1361385 ENSG00000216901.1 AL022393.7 5.14 3.57e-06 0.0136 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28390543 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs1416918 ENSG00000216901.1 AL022393.7 5.14 3.57e-06 0.0136 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28390558 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs9468367 ENSG00000216901.1 AL022393.7 5.14 3.57e-06 0.0136 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28392469 chr6:28176188~28176674:+ MESO cis rs975739 1 rs1766347 ENSG00000236051.5 MYCBP2-AS1 5.14 3.58e-06 0.0136 0.7 0.57 Hair color; chr13:77813828 chr13:77075514~77129717:+ MESO cis rs9322193 0.886 rs4870049 ENSG00000231760.4 RP11-350J20.5 5.14 3.59e-06 0.0136 0.81 0.57 Lung cancer; chr6:149837058 chr6:149796151~149826294:- MESO cis rs172166 0.516 rs2791333 ENSG00000216901.1 AL022393.7 5.14 3.59e-06 0.0136 0.73 0.57 Cardiac Troponin-T levels; chr6:28143336 chr6:28176188~28176674:+ MESO cis rs172166 0.516 rs2622322 ENSG00000216901.1 AL022393.7 5.14 3.59e-06 0.0136 0.73 0.57 Cardiac Troponin-T levels; chr6:28149665 chr6:28176188~28176674:+ MESO cis rs172166 0.516 rs1150670 ENSG00000216901.1 AL022393.7 5.14 3.59e-06 0.0136 0.73 0.57 Cardiac Troponin-T levels; chr6:28162781 chr6:28176188~28176674:+ MESO cis rs172166 0.516 rs2021826 ENSG00000216901.1 AL022393.7 5.14 3.59e-06 0.0136 0.73 0.57 Cardiac Troponin-T levels; chr6:28164978 chr6:28176188~28176674:+ MESO cis rs1150668 0.835 rs1233696 ENSG00000216901.1 AL022393.7 5.14 3.59e-06 0.0136 0.73 0.57 Pubertal anthropometrics; chr6:28175232 chr6:28176188~28176674:+ MESO cis rs73086581 0.592 rs2300217 ENSG00000229539.1 RP11-119B16.2 5.14 3.62e-06 0.0137 0.67 0.57 Response to antidepressants in depression; chr20:3957928 chr20:3888239~3888868:- MESO cis rs9918079 0.6 rs61021642 ENSG00000273133.1 RP11-799M12.2 5.14 3.65e-06 0.0138 0.74 0.57 Obesity-related traits; chr4:15575702 chr4:15563698~15564253:- MESO cis rs9918079 0.6 rs12500587 ENSG00000273133.1 RP11-799M12.2 5.14 3.65e-06 0.0138 0.74 0.57 Obesity-related traits; chr4:15579131 chr4:15563698~15564253:- MESO cis rs755249 0.642 rs28788506 ENSG00000237624.1 OXCT2P1 5.14 3.68e-06 0.0139 0.69 0.57 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39611108 chr1:39514956~39516490:+ MESO cis rs755249 0.669 rs4660311 ENSG00000237624.1 OXCT2P1 5.14 3.68e-06 0.0139 0.69 0.57 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39613442 chr1:39514956~39516490:+ MESO cis rs3931020 0.745 rs10874274 ENSG00000272864.1 RP11-17E13.2 -5.13 3.71e-06 0.014 -0.75 -0.57 Resistin levels; chr1:74786450 chr1:74698769~74699333:- MESO cis rs62388641 0.802 rs13202504 ENSG00000272279.1 RP11-157J24.2 5.13 3.75e-06 0.0141 0.79 0.57 Daytime sleep phenotypes; chr6:1537640 chr6:1528364~1528911:- MESO cis rs73086581 0.947 rs11906612 ENSG00000229539.1 RP11-119B16.2 5.13 3.75e-06 0.0141 0.77 0.57 Response to antidepressants in depression; chr20:3922987 chr20:3888239~3888868:- MESO cis rs4835473 0.897 rs11100812 ENSG00000251600.4 RP11-673E1.1 5.13 3.77e-06 0.0142 0.67 0.57 Immature fraction of reticulocytes; chr4:143790400 chr4:143912331~143982454:+ MESO cis rs4835473 0.808 rs62339607 ENSG00000251600.4 RP11-673E1.1 -5.13 3.77e-06 0.0142 -0.67 -0.57 Immature fraction of reticulocytes; chr4:143791474 chr4:143912331~143982454:+ MESO cis rs4835473 0.838 rs56033497 ENSG00000251600.4 RP11-673E1.1 -5.13 3.77e-06 0.0142 -0.67 -0.57 Immature fraction of reticulocytes; chr4:143792341 chr4:143912331~143982454:+ MESO cis rs4835473 0.801 rs35839125 ENSG00000251600.4 RP11-673E1.1 -5.13 3.77e-06 0.0142 -0.67 -0.57 Immature fraction of reticulocytes; chr4:143792351 chr4:143912331~143982454:+ MESO cis rs4835473 0.545 rs10022856 ENSG00000251600.4 RP11-673E1.1 5.13 3.77e-06 0.0142 0.67 0.57 Immature fraction of reticulocytes; chr4:143793157 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1842484 ENSG00000251600.4 RP11-673E1.1 5.13 3.77e-06 0.0142 0.67 0.57 Immature fraction of reticulocytes; chr4:143793829 chr4:143912331~143982454:+ MESO cis rs4835473 0.75 rs12498381 ENSG00000251600.4 RP11-673E1.1 -5.13 3.77e-06 0.0142 -0.67 -0.57 Immature fraction of reticulocytes; chr4:143793928 chr4:143912331~143982454:+ MESO cis rs172166 0.538 rs1150686 ENSG00000216901.1 AL022393.7 5.13 3.77e-06 0.0142 0.73 0.57 Cardiac Troponin-T levels; chr6:28193493 chr6:28176188~28176674:+ MESO cis rs1150688 1 rs1150688 ENSG00000216901.1 AL022393.7 5.13 3.77e-06 0.0142 0.73 0.57 Autism spectrum disorder or schizophrenia; chr6:28195002 chr6:28176188~28176674:+ MESO cis rs4835473 0.932 rs9997931 ENSG00000251600.4 RP11-673E1.1 5.13 3.81e-06 0.0143 0.69 0.57 Immature fraction of reticulocytes; chr4:143904601 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs2036880 ENSG00000251600.4 RP11-673E1.1 5.13 3.81e-06 0.0143 0.69 0.57 Immature fraction of reticulocytes; chr4:143907834 chr4:143912331~143982454:+ MESO cis rs864745 0.967 rs702814 ENSG00000253187.2 HOXA10-AS 5.13 3.81e-06 0.0143 0.67 0.57 Crohn's disease;Type 2 diabetes; chr7:28133113 chr7:27168619~27171915:+ MESO cis rs950027 0.62 rs1426932 ENSG00000259520.4 CTD-2651B20.3 -5.13 3.81e-06 0.0143 -0.73 -0.57 Response to fenofibrate (adiponectin levels); chr15:45395058 chr15:45251580~45279251:- MESO cis rs6921919 0.583 rs7759191 ENSG00000216901.1 AL022393.7 5.13 3.81e-06 0.0143 0.86 0.57 Autism spectrum disorder or schizophrenia; chr6:28385657 chr6:28176188~28176674:+ MESO cis rs4835473 0.868 rs4350958 ENSG00000251600.4 RP11-673E1.1 5.12 3.85e-06 0.0145 0.66 0.56 Immature fraction of reticulocytes; chr4:143744656 chr4:143912331~143982454:+ MESO cis rs7301826 0.651 rs10734979 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130804409 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs4759519 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130804963 chr12:130810606~130812438:+ MESO cis rs7301826 0.61 rs36051740 ENSG00000256250.1 RP11-989F5.1 5.12 3.87e-06 0.0145 0.71 0.56 Plasma plasminogen activator levels; chr12:130808177 chr12:130810606~130812438:+ MESO cis rs7301826 0.585 rs6486600 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130808432 chr12:130810606~130812438:+ MESO cis rs7301826 0.627 rs10773823 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130809956 chr12:130810606~130812438:+ MESO cis rs7301826 0.627 rs73162873 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130811468 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs12228957 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130811521 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs12228959 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130811523 chr12:130810606~130812438:+ MESO cis rs7301826 0.571 rs4759788 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130811769 chr12:130810606~130812438:+ MESO cis rs7301826 0.61 rs4759789 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130811835 chr12:130810606~130812438:+ MESO cis rs7301826 0.61 rs4759791 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130811950 chr12:130810606~130812438:+ MESO cis rs7301826 0.61 rs9668291 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130812363 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs4759521 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130812768 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs4759794 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130812803 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs10734981 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130813350 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs10744483 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130813661 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs10744484 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130813961 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs10744485 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130814005 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs10773824 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130814306 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs10773825 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130814368 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs7295705 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130817340 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs7968675 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130818832 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs10848209 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130826727 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs10848210 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130827475 chr12:130810606~130812438:+ MESO cis rs7301826 0.627 rs4325342 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130827937 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs4514465 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130829124 chr12:130810606~130812438:+ MESO cis rs7301826 0.627 rs4334059 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130829669 chr12:130810606~130812438:+ MESO cis rs7301826 0.627 rs1077317 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130830432 chr12:130810606~130812438:+ MESO cis rs7301826 0.651 rs4759525 ENSG00000256250.1 RP11-989F5.1 -5.12 3.87e-06 0.0145 -0.71 -0.56 Plasma plasminogen activator levels; chr12:130831736 chr12:130810606~130812438:+ MESO cis rs8091660 0.929 rs11082685 ENSG00000278983.1 RP11-426J5.3 5.12 3.89e-06 0.0145 0.64 0.56 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48566806 chr18:48564795~48568342:+ MESO cis rs8091660 0.929 rs4939780 ENSG00000278983.1 RP11-426J5.3 5.12 3.89e-06 0.0145 0.64 0.56 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48568873 chr18:48564795~48568342:+ MESO cis rs17711722 1 rs17711722 ENSG00000226824.5 RP4-756H11.3 5.12 3.89e-06 0.0145 0.78 0.56 Calcium levels; chr7:65806210 chr7:66654538~66669855:+ MESO cis rs17711722 0.675 rs6947132 ENSG00000226824.5 RP4-756H11.3 5.12 3.89e-06 0.0145 0.78 0.56 Calcium levels; chr7:65808508 chr7:66654538~66669855:+ MESO cis rs507080 0.501 rs494459 ENSG00000278376.1 RP11-158I9.8 5.12 3.91e-06 0.0146 0.56 0.56 Serum metabolite levels; chr11:118703966 chr11:118791254~118793137:+ MESO cis rs7927592 0.956 rs7116899 ENSG00000212093.1 AP000807.1 5.12 3.91e-06 0.0146 0.56 0.56 Total body bone mineral density; chr11:68618067 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs7102273 ENSG00000212093.1 AP000807.1 5.12 3.91e-06 0.0146 0.56 0.56 Total body bone mineral density; chr11:68618111 chr11:68506083~68506166:- MESO cis rs2739330 0.731 rs2000468 ENSG00000231271.1 AP000350.8 5.12 3.92e-06 0.0146 0.7 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23899424 chr22:23949918~23954042:+ MESO cis rs7626444 0.584 rs11711813 ENSG00000272359.1 U4 -5.12 3.94e-06 0.0147 -0.65 -0.56 Monocyte count; chr3:196740467 chr3:196747192~196747324:- MESO cis rs864745 0.967 rs34824357 ENSG00000253187.2 HOXA10-AS 5.12 3.95e-06 0.0147 0.67 0.56 Crohn's disease;Type 2 diabetes; chr7:28134645 chr7:27168619~27171915:+ MESO cis rs864745 0.967 rs849138 ENSG00000253187.2 HOXA10-AS 5.12 3.95e-06 0.0147 0.67 0.56 Crohn's disease;Type 2 diabetes; chr7:28137719 chr7:27168619~27171915:+ MESO cis rs1577917 0.629 rs9450285 ENSG00000203875.9 SNHG5 5.11 4.01e-06 0.0149 0.69 0.56 Response to antipsychotic treatment; chr6:85498378 chr6:85660950~85678736:- MESO cis rs875971 0.508 rs10258739 ENSG00000226824.5 RP4-756H11.3 5.11 4.02e-06 0.0149 0.83 0.56 Aortic root size; chr7:66597948 chr7:66654538~66669855:+ MESO cis rs3018712 0.59 rs4930236 ENSG00000212093.1 AP000807.1 -5.11 4.02e-06 0.0149 -0.68 -0.56 Total body bone mineral density; chr11:68646532 chr11:68506083~68506166:- MESO cis rs3091242 0.933 rs9438905 ENSG00000224183.1 SDHDP6 -5.1 4.12e-06 0.0152 -0.74 -0.56 Erythrocyte sedimentation rate; chr1:25437686 chr1:25294164~25294643:- MESO cis rs3091242 0.935 rs4233043 ENSG00000224183.1 SDHDP6 -5.1 4.12e-06 0.0152 -0.74 -0.56 Erythrocyte sedimentation rate; chr1:25438992 chr1:25294164~25294643:- MESO cis rs4964805 0.537 rs11111750 ENSG00000257681.1 RP11-341G23.4 5.1 4.13e-06 0.0152 0.8 0.56 Attention deficit hyperactivity disorder; chr12:103761762 chr12:103746315~103768858:- MESO cis rs4835473 0.8 rs4835330 ENSG00000251600.4 RP11-673E1.1 5.1 4.13e-06 0.0152 0.67 0.56 Immature fraction of reticulocytes; chr4:143846303 chr4:143912331~143982454:+ MESO cis rs4835473 0.736 rs6851661 ENSG00000251600.4 RP11-673E1.1 5.1 4.13e-06 0.0152 0.67 0.56 Immature fraction of reticulocytes; chr4:143850587 chr4:143912331~143982454:+ MESO cis rs4835473 0.864 rs4835343 ENSG00000251600.4 RP11-673E1.1 5.1 4.13e-06 0.0152 0.67 0.56 Immature fraction of reticulocytes; chr4:143866038 chr4:143912331~143982454:+ MESO cis rs4835473 0.831 rs1579816 ENSG00000251600.4 RP11-673E1.1 5.1 4.13e-06 0.0152 0.67 0.56 Immature fraction of reticulocytes; chr4:143866772 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4240334 ENSG00000251600.4 RP11-673E1.1 5.1 4.13e-06 0.0152 0.67 0.56 Immature fraction of reticulocytes; chr4:143871352 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs10857415 ENSG00000251600.4 RP11-673E1.1 5.1 4.13e-06 0.0152 0.67 0.56 Immature fraction of reticulocytes; chr4:143908753 chr4:143912331~143982454:+ MESO cis rs7617773 0.78 rs3197223 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48294367 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs13067450 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48295716 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs4479622 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48296683 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs34946886 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48296997 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs13079728 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48297870 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs34589064 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48298059 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs2541 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48298128 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs13085251 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48298555 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs35297395 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48301392 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs36075665 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48301597 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs34630841 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48301771 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs35190747 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48301800 chr3:48256350~48256938:- MESO cis rs7617773 0.743 rs7621785 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48302218 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs4511915 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48302368 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs13066758 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48302387 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs4392440 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48302430 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs13082859 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48303185 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs36121690 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48304021 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs35778847 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48305495 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs34749846 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48305678 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs7632297 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48306673 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs79089926 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48307074 chr3:48256350~48256938:- MESO cis rs7617773 0.643 rs78159520 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48307533 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs77044321 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48307824 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs4511916 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48308876 chr3:48256350~48256938:- MESO cis rs7617773 0.815 rs7624450 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48308885 chr3:48256350~48256938:- MESO cis rs7617773 0.815 rs6793150 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48310070 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs6793239 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48310128 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs6782166 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48310193 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs4130522 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48310823 chr3:48256350~48256938:- MESO cis rs7617773 0.746 rs4371540 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48312053 chr3:48256350~48256938:- MESO cis rs7617773 0.709 rs4404473 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48312136 chr3:48256350~48256938:- MESO cis rs7617773 0.674 rs13069029 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48313534 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs13081169 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48315307 chr3:48256350~48256938:- MESO cis rs7617773 0.743 rs13081633 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48315791 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs35411187 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48318527 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs11714176 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48319372 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs11718350 ENSG00000229759.1 MRPS18AP1 5.1 4.21e-06 0.0153 0.72 0.56 Coronary artery disease; chr3:48319502 chr3:48256350~48256938:- MESO cis rs875971 0.862 rs6460302 ENSG00000226824.5 RP4-756H11.3 -5.1 4.23e-06 0.0154 -0.76 -0.56 Aortic root size; chr7:66495270 chr7:66654538~66669855:+ MESO cis rs4964805 0.802 rs934847 ENSG00000257681.1 RP11-341G23.4 5.1 4.24e-06 0.0154 0.89 0.56 Attention deficit hyperactivity disorder; chr12:103791915 chr12:103746315~103768858:- MESO cis rs710913 0.717 rs2068473 ENSG00000237624.1 OXCT2P1 -5.1 4.24e-06 0.0154 -0.66 -0.56 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39572925 chr1:39514956~39516490:+ MESO cis rs1577917 0.771 rs2783171 ENSG00000203875.9 SNHG5 5.1 4.25e-06 0.0154 0.75 0.56 Response to antipsychotic treatment; chr6:85673047 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs2842602 ENSG00000203875.9 SNHG5 -5.1 4.25e-06 0.0154 -0.75 -0.56 Response to antipsychotic treatment; chr6:85622169 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs12205013 ENSG00000203875.9 SNHG5 -5.1 4.25e-06 0.0154 -0.75 -0.56 Response to antipsychotic treatment; chr6:85623311 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs2475791 ENSG00000203875.9 SNHG5 -5.1 4.25e-06 0.0154 -0.75 -0.56 Response to antipsychotic treatment; chr6:85658446 chr6:85660950~85678736:- MESO cis rs875971 0.83 rs427575 ENSG00000226824.5 RP4-756H11.3 -5.09 4.27e-06 0.0154 -0.73 -0.56 Aortic root size; chr7:66054232 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs587360 ENSG00000226824.5 RP4-756H11.3 -5.09 4.27e-06 0.0154 -0.73 -0.56 Aortic root size; chr7:66057711 chr7:66654538~66669855:+ MESO cis rs875971 0.83 rs427973 ENSG00000226824.5 RP4-756H11.3 -5.09 4.27e-06 0.0154 -0.73 -0.56 Aortic root size; chr7:66061661 chr7:66654538~66669855:+ MESO cis rs2117029 0.737 rs34436857 ENSG00000258017.1 RP11-386G11.10 -5.09 4.28e-06 0.0154 -0.72 -0.56 Intelligence (multi-trait analysis); chr12:49045738 chr12:49127782~49147869:+ MESO cis rs1150668 0.835 rs203869 ENSG00000216901.1 AL022393.7 5.09 4.31e-06 0.0154 0.7 0.56 Pubertal anthropometrics; chr6:28073041 chr6:28176188~28176674:+ MESO cis rs875971 0.522 rs9530 ENSG00000226824.5 RP4-756H11.3 -5.09 4.31e-06 0.0155 -0.85 -0.56 Aortic root size; chr7:65960907 chr7:66654538~66669855:+ MESO cis rs2117029 0.554 rs12579015 ENSG00000258017.1 RP11-386G11.10 -5.09 4.33e-06 0.0155 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49162648 chr12:49127782~49147869:+ MESO cis rs2117029 0.521 rs58336603 ENSG00000258017.1 RP11-386G11.10 -5.09 4.33e-06 0.0155 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49163105 chr12:49127782~49147869:+ MESO cis rs2117029 0.553 rs1991427 ENSG00000258017.1 RP11-386G11.10 -5.09 4.33e-06 0.0155 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49164175 chr12:49127782~49147869:+ MESO cis rs2117029 0.521 rs2114845 ENSG00000258017.1 RP11-386G11.10 -5.09 4.33e-06 0.0155 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49164750 chr12:49127782~49147869:+ MESO cis rs2117029 0.521 rs6580702 ENSG00000258017.1 RP11-386G11.10 -5.09 4.33e-06 0.0155 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49169483 chr12:49127782~49147869:+ MESO cis rs9660180 0.62 rs3817856 ENSG00000268575.1 RP1-283E3.8 5.09 4.39e-06 0.0157 0.57 0.56 Body mass index; chr1:1732392 chr1:1702736~1737688:- MESO cis rs2117029 0.521 rs11168910 ENSG00000258017.1 RP11-386G11.10 -5.09 4.4e-06 0.0157 -0.75 -0.56 Intelligence (multi-trait analysis); chr12:49192707 chr12:49127782~49147869:+ MESO cis rs950027 0.62 rs2486274 ENSG00000259520.4 CTD-2651B20.3 -5.09 4.4e-06 0.0157 -0.72 -0.56 Response to fenofibrate (adiponectin levels); chr15:45374030 chr15:45251580~45279251:- MESO cis rs950027 0.62 rs1145080 ENSG00000259520.4 CTD-2651B20.3 -5.09 4.4e-06 0.0157 -0.72 -0.56 Response to fenofibrate (adiponectin levels); chr15:45389140 chr15:45251580~45279251:- MESO cis rs710913 0.816 rs1180341 ENSG00000237624.1 OXCT2P1 -5.09 4.4e-06 0.0157 -0.67 -0.56 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39527136 chr1:39514956~39516490:+ MESO cis rs7617773 0.817 rs9837228 ENSG00000229759.1 MRPS18AP1 -5.09 4.41e-06 0.0157 -0.7 -0.56 Coronary artery disease; chr3:48282976 chr3:48256350~48256938:- MESO cis rs7786410 1 rs7786410 ENSG00000226278.1 PSPHP1 5.08 4.44e-06 0.0158 1.32 0.56 Age-related hearing impairment; chr7:55854630 chr7:55764797~55773288:+ MESO cis rs875971 0.8 rs427557 ENSG00000226824.5 RP4-756H11.3 -5.08 4.44e-06 0.0158 -0.72 -0.56 Aortic root size; chr7:66054263 chr7:66654538~66669855:+ MESO cis rs875971 0.54 rs4717275 ENSG00000226824.5 RP4-756H11.3 5.08 4.45e-06 0.0158 0.78 0.56 Aortic root size; chr7:65800193 chr7:66654538~66669855:+ MESO cis rs9918079 0.56 rs7685083 ENSG00000273133.1 RP11-799M12.2 5.08 4.46e-06 0.0159 0.76 0.56 Obesity-related traits; chr4:15609148 chr4:15563698~15564253:- MESO cis rs9918079 0.58 rs13120905 ENSG00000273133.1 RP11-799M12.2 5.08 4.46e-06 0.0159 0.76 0.56 Obesity-related traits; chr4:15610665 chr4:15563698~15564253:- MESO cis rs6700559 0.873 rs7526367 ENSG00000260088.1 RP11-92G12.3 -5.08 4.47e-06 0.0159 -0.61 -0.56 Coronary artery disease; chr1:200688025 chr1:200669507~200694250:+ MESO cis rs1577917 0.629 rs6927475 ENSG00000203875.9 SNHG5 5.08 4.51e-06 0.016 0.69 0.56 Response to antipsychotic treatment; chr6:85497055 chr6:85660950~85678736:- MESO cis rs645901 1 rs645901 ENSG00000254851.1 RP11-109L13.1 -5.08 4.51e-06 0.016 -0.91 -0.56 Plateletcrit; chr11:116831646 chr11:117135528~117138582:+ MESO cis rs10256972 0.577 rs6962809 ENSG00000229043.2 AC091729.9 -5.08 4.53e-06 0.016 -0.67 -0.56 Endometriosis;Longevity; chr7:1169253 chr7:1160374~1165267:+ MESO cis rs10256972 0.567 rs2949185 ENSG00000229043.2 AC091729.9 -5.08 4.53e-06 0.016 -0.67 -0.56 Endometriosis;Longevity; chr7:1169377 chr7:1160374~1165267:+ MESO cis rs10256972 0.552 rs7805591 ENSG00000229043.2 AC091729.9 -5.08 4.53e-06 0.016 -0.67 -0.56 Endometriosis;Longevity; chr7:1171109 chr7:1160374~1165267:+ MESO cis rs513088 0.512 rs520343 ENSG00000241666.2 RP3-455J7.4 -5.08 4.55e-06 0.016 -0.84 -0.56 Schizophrenia; chr1:166740505 chr1:167627385~167630674:- MESO cis rs3091242 0.933 rs932372 ENSG00000224183.1 SDHDP6 -5.08 4.56e-06 0.016 -0.76 -0.56 Erythrocyte sedimentation rate; chr1:25428523 chr1:25294164~25294643:- MESO cis rs3091242 0.866 rs11249249 ENSG00000224183.1 SDHDP6 -5.08 4.56e-06 0.016 -0.76 -0.56 Erythrocyte sedimentation rate; chr1:25431643 chr1:25294164~25294643:- MESO cis rs7847628 0.765 rs10985024 ENSG00000226752.6 PSMD5-AS1 -5.08 4.56e-06 0.016 -0.75 -0.56 Birth weight; chr9:120754534 chr9:120824828~120854385:+ MESO cis rs7847628 0.666 rs2031974 ENSG00000226752.6 PSMD5-AS1 -5.08 4.56e-06 0.016 -0.75 -0.56 Birth weight; chr9:120765243 chr9:120824828~120854385:+ MESO cis rs7617773 0.817 rs9818937 ENSG00000229759.1 MRPS18AP1 5.08 4.57e-06 0.016 0.71 0.56 Coronary artery disease; chr3:48283791 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs6801801 ENSG00000229759.1 MRPS18AP1 5.08 4.57e-06 0.016 0.71 0.56 Coronary artery disease; chr3:48284943 chr3:48256350~48256938:- MESO cis rs7617773 0.779 rs9833309 ENSG00000229759.1 MRPS18AP1 5.08 4.57e-06 0.016 0.71 0.56 Coronary artery disease; chr3:48285960 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs9853804 ENSG00000229759.1 MRPS18AP1 5.08 4.57e-06 0.016 0.71 0.56 Coronary artery disease; chr3:48286239 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs9834095 ENSG00000229759.1 MRPS18AP1 5.08 4.57e-06 0.016 0.71 0.56 Coronary artery disease; chr3:48286261 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs4131361 ENSG00000229759.1 MRPS18AP1 5.08 4.57e-06 0.016 0.71 0.56 Coronary artery disease; chr3:48287322 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs4131362 ENSG00000229759.1 MRPS18AP1 5.08 4.57e-06 0.016 0.71 0.56 Coronary artery disease; chr3:48287546 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs6791930 ENSG00000229759.1 MRPS18AP1 5.08 4.57e-06 0.016 0.71 0.56 Coronary artery disease; chr3:48288410 chr3:48256350~48256938:- MESO cis rs7617773 0.817 rs6794644 ENSG00000229759.1 MRPS18AP1 5.08 4.57e-06 0.016 0.71 0.56 Coronary artery disease; chr3:48288547 chr3:48256350~48256938:- MESO cis rs73086581 0.947 rs56123574 ENSG00000229539.1 RP11-119B16.2 5.08 4.57e-06 0.016 0.74 0.56 Response to antidepressants in depression; chr20:3897434 chr20:3888239~3888868:- MESO cis rs73086581 0.947 rs73084531 ENSG00000229539.1 RP11-119B16.2 5.08 4.57e-06 0.016 0.74 0.56 Response to antidepressants in depression; chr20:3897782 chr20:3888239~3888868:- MESO cis rs73086581 0.891 rs11907503 ENSG00000229539.1 RP11-119B16.2 5.08 4.57e-06 0.016 0.74 0.56 Response to antidepressants in depression; chr20:3906943 chr20:3888239~3888868:- MESO cis rs73086581 0.947 rs67356712 ENSG00000229539.1 RP11-119B16.2 5.08 4.57e-06 0.016 0.74 0.56 Response to antidepressants in depression; chr20:3912239 chr20:3888239~3888868:- MESO cis rs950027 0.62 rs1145076 ENSG00000259520.4 CTD-2651B20.3 -5.07 4.66e-06 0.0163 -0.71 -0.56 Response to fenofibrate (adiponectin levels); chr15:45392310 chr15:45251580~45279251:- MESO cis rs4835473 0.808 rs62334569 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144081617 chr4:143912331~143982454:+ MESO cis rs4835473 0.838 rs62334572 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144082688 chr4:143912331~143982454:+ MESO cis rs4835473 0.838 rs7675833 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144083315 chr4:143912331~143982454:+ MESO cis rs4835473 0.808 rs62334580 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144084916 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs7654746 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144084996 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs12506168 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144085653 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs13131176 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144086655 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs13118488 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144087490 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs34113094 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144087840 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs6537249 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144088897 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs3901418 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144089427 chr4:143912331~143982454:+ MESO cis rs4835473 0.808 rs35793856 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144090587 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs34343851 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144091704 chr4:143912331~143982454:+ MESO cis rs4835473 0.722 rs3901420 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144092039 chr4:143912331~143982454:+ MESO cis rs4835473 0.669 rs4407447 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144092958 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs62334608 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144093427 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs62334609 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144093452 chr4:143912331~143982454:+ MESO cis rs4835473 0.838 rs6836228 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144093788 chr4:143912331~143982454:+ MESO cis rs4835473 0.868 rs6834756 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144093813 chr4:143912331~143982454:+ MESO cis rs4835473 0.778 rs6818017 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144093868 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs28617357 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144096343 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs13112465 ENSG00000251600.4 RP11-673E1.1 -5.07 4.7e-06 0.0163 -0.7 -0.56 Immature fraction of reticulocytes; chr4:144096711 chr4:143912331~143982454:+ MESO cis rs11770797 0.527 rs60576079 ENSG00000127957.15 PMS2P3 -5.07 4.72e-06 0.0164 -0.66 -0.56 Blood protein levels; chr7:76259743 chr7:75502930~75528148:- MESO cis rs3091242 0.933 rs926438 ENSG00000224183.1 SDHDP6 -5.07 4.72e-06 0.0164 -0.75 -0.56 Erythrocyte sedimentation rate; chr1:25427147 chr1:25294164~25294643:- MESO cis rs11673344 0.526 rs2291001 ENSG00000226686.6 LINC01535 5.07 4.74e-06 0.0164 0.68 0.56 Obesity-related traits; chr19:37594431 chr19:37251912~37265535:+ MESO cis rs11673344 0.518 rs73033134 ENSG00000226686.6 LINC01535 5.07 4.74e-06 0.0164 0.68 0.56 Obesity-related traits; chr19:37596046 chr19:37251912~37265535:+ MESO cis rs11673344 0.526 rs17305193 ENSG00000226686.6 LINC01535 5.07 4.74e-06 0.0164 0.68 0.56 Obesity-related traits; chr19:37598764 chr19:37251912~37265535:+ MESO cis rs9918079 0.643 rs35414597 ENSG00000273133.1 RP11-799M12.2 5.06 4.76e-06 0.0165 0.73 0.56 Obesity-related traits; chr4:15564113 chr4:15563698~15564253:- MESO cis rs864745 1 rs864745 ENSG00000253187.2 HOXA10-AS -5.06 4.77e-06 0.0165 -0.61 -0.56 Crohn's disease;Type 2 diabetes; chr7:28140937 chr7:27168619~27171915:+ MESO cis rs7188445 0.592 rs7199794 ENSG00000261390.4 RP11-345M22.2 5.06 4.79e-06 0.0166 0.7 0.56 Urate levels; chr16:79708296 chr16:79715232~79770563:- MESO cis rs1150668 0.83 rs213240 ENSG00000216901.1 AL022393.7 5.06 4.81e-06 0.0167 0.75 0.56 Pubertal anthropometrics; chr6:28348098 chr6:28176188~28176674:+ MESO cis rs7617773 0.817 rs9830016 ENSG00000229759.1 MRPS18AP1 5.06 4.83e-06 0.0167 0.74 0.56 Coronary artery disease; chr3:48241004 chr3:48256350~48256938:- MESO cis rs1153858 1 rs11852800 ENSG00000259520.4 CTD-2651B20.3 5.05 4.94e-06 0.017 0.75 0.56 Homoarginine levels; chr15:45346933 chr15:45251580~45279251:- MESO cis rs17711722 0.522 rs6957759 ENSG00000164669.11 INTS4P1 -5.05 4.94e-06 0.017 -0.68 -0.56 Calcium levels; chr7:65806798 chr7:65141225~65234216:+ MESO cis rs875971 0.564 rs313804 ENSG00000226824.5 RP4-756H11.3 -5.05 4.98e-06 0.0171 -0.72 -0.56 Aortic root size; chr7:66049635 chr7:66654538~66669855:+ MESO cis rs875971 0.662 rs448725 ENSG00000226824.5 RP4-756H11.3 -5.05 4.98e-06 0.0171 -0.72 -0.56 Aortic root size; chr7:66049641 chr7:66654538~66669855:+ MESO cis rs875971 0.658 rs432667 ENSG00000226824.5 RP4-756H11.3 -5.05 4.98e-06 0.0171 -0.72 -0.56 Aortic root size; chr7:66049646 chr7:66654538~66669855:+ MESO cis rs2117029 0.586 rs10875928 ENSG00000258017.1 RP11-386G11.10 -5.05 4.99e-06 0.0172 -0.7 -0.56 Intelligence (multi-trait analysis); chr12:49162520 chr12:49127782~49147869:+ MESO cis rs2117029 0.619 rs2241727 ENSG00000258017.1 RP11-386G11.10 -5.05 5.01e-06 0.0172 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49131225 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs11168874 ENSG00000258017.1 RP11-386G11.10 -5.05 5.01e-06 0.0172 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49133753 chr12:49127782~49147869:+ MESO cis rs2117029 0.523 rs12227296 ENSG00000258017.1 RP11-386G11.10 -5.05 5.01e-06 0.0172 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49136712 chr12:49127782~49147869:+ MESO cis rs2117029 0.521 rs10875925 ENSG00000258017.1 RP11-386G11.10 -5.05 5.01e-06 0.0172 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49142575 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs11168882 ENSG00000258017.1 RP11-386G11.10 -5.05 5.01e-06 0.0172 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49143560 chr12:49127782~49147869:+ MESO cis rs2117029 0.521 rs12227610 ENSG00000258017.1 RP11-386G11.10 -5.05 5.01e-06 0.0172 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49146153 chr12:49127782~49147869:+ MESO cis rs2117029 0.521 rs11168885 ENSG00000258017.1 RP11-386G11.10 -5.05 5.01e-06 0.0172 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49146204 chr12:49127782~49147869:+ MESO cis rs3018712 0.532 rs4930588 ENSG00000212093.1 AP000807.1 5.05 5.04e-06 0.0173 0.68 0.56 Total body bone mineral density; chr11:68647767 chr11:68506083~68506166:- MESO cis rs3018712 0.547 rs4930237 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68646570 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs7932726 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68647259 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs4930587 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68647667 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs4930589 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68647789 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs11228312 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68648049 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs10791988 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68648583 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs2513280 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68649439 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs2513281 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68649626 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs2510396 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68650184 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs2513282 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68650843 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs2510397 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68652091 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs2513289 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68652187 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs948861 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68653154 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs948863 ENSG00000212093.1 AP000807.1 -5.05 5.04e-06 0.0173 -0.68 -0.56 Total body bone mineral density; chr11:68653506 chr11:68506083~68506166:- MESO cis rs7927592 0.956 rs7944870 ENSG00000212093.1 AP000807.1 5.05 5.04e-06 0.0173 0.57 0.56 Total body bone mineral density; chr11:68541640 chr11:68506083~68506166:- MESO cis rs2283792 0.812 rs240066 ENSG00000224086.5 LL22NC03-86G7.1 5.05 5.07e-06 0.0173 0.71 0.56 Multiple sclerosis; chr22:21938623 chr22:21938293~21977632:+ MESO cis rs1930961 1 rs6004667 ENSG00000100058.11 CRYBB2P1 -5.05 5.09e-06 0.0174 -1.39 -0.56 Bipolar disorder with mood-incongruent psychosis; chr22:25478497 chr22:25448105~25520854:+ MESO cis rs6921919 0.583 rs7764722 ENSG00000216901.1 AL022393.7 5.04 5.14e-06 0.0176 0.84 0.56 Autism spectrum disorder or schizophrenia; chr6:28386756 chr6:28176188~28176674:+ MESO cis rs853679 0.567 rs1005126 ENSG00000216901.1 AL022393.7 5.04 5.21e-06 0.0177 0.92 0.56 Depression; chr6:28399846 chr6:28176188~28176674:+ MESO cis rs4835473 0.8 rs1849117 ENSG00000251600.4 RP11-673E1.1 5.04 5.24e-06 0.0178 0.69 0.56 Immature fraction of reticulocytes; chr4:143989791 chr4:143912331~143982454:+ MESO cis rs4835473 0.868 rs7683365 ENSG00000251600.4 RP11-673E1.1 -5.04 5.24e-06 0.0178 -0.69 -0.56 Immature fraction of reticulocytes; chr4:143999443 chr4:143912331~143982454:+ MESO cis rs4835473 0.722 rs7662277 ENSG00000251600.4 RP11-673E1.1 -5.04 5.24e-06 0.0178 -0.69 -0.56 Immature fraction of reticulocytes; chr4:143999485 chr4:143912331~143982454:+ MESO cis rs4835473 0.618 rs12499907 ENSG00000251600.4 RP11-673E1.1 -5.04 5.24e-06 0.0178 -0.69 -0.56 Immature fraction of reticulocytes; chr4:143999748 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4835278 ENSG00000251600.4 RP11-673E1.1 -5.04 5.25e-06 0.0178 -0.67 -0.56 Immature fraction of reticulocytes; chr4:143788433 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4835471 ENSG00000251600.4 RP11-673E1.1 5.04 5.25e-06 0.0178 0.68 0.56 Immature fraction of reticulocytes; chr4:143982153 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs4835119 ENSG00000251600.4 RP11-673E1.1 5.04 5.25e-06 0.0178 0.68 0.56 Immature fraction of reticulocytes; chr4:143982210 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4835120 ENSG00000251600.4 RP11-673E1.1 5.04 5.25e-06 0.0178 0.68 0.56 Immature fraction of reticulocytes; chr4:143982370 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4835472 ENSG00000251600.4 RP11-673E1.1 5.04 5.25e-06 0.0178 0.68 0.56 Immature fraction of reticulocytes; chr4:143982398 chr4:143912331~143982454:+ MESO cis rs4835473 1 rs4835473 ENSG00000251600.4 RP11-673E1.1 5.04 5.25e-06 0.0178 0.68 0.56 Immature fraction of reticulocytes; chr4:143982419 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs4835474 ENSG00000251600.4 RP11-673E1.1 5.04 5.25e-06 0.0178 0.68 0.56 Immature fraction of reticulocytes; chr4:143982444 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs6847869 ENSG00000251600.4 RP11-673E1.1 5.04 5.25e-06 0.0178 0.68 0.56 Immature fraction of reticulocytes; chr4:143982881 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs6846984 ENSG00000251600.4 RP11-673E1.1 5.04 5.25e-06 0.0178 0.68 0.56 Immature fraction of reticulocytes; chr4:143983098 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs34617134 ENSG00000251600.4 RP11-673E1.1 5.04 5.25e-06 0.0178 0.68 0.56 Immature fraction of reticulocytes; chr4:143983606 chr4:143912331~143982454:+ MESO cis rs4835473 0.798 rs11100829 ENSG00000251600.4 RP11-673E1.1 5.04 5.25e-06 0.0178 0.68 0.56 Immature fraction of reticulocytes; chr4:143984761 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs13101531 ENSG00000251600.4 RP11-673E1.1 -5.04 5.25e-06 0.0178 -0.68 -0.56 Immature fraction of reticulocytes; chr4:143982197 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs28668841 ENSG00000251600.4 RP11-673E1.1 -5.04 5.25e-06 0.0178 -0.68 -0.56 Immature fraction of reticulocytes; chr4:143982530 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs13135034 ENSG00000251600.4 RP11-673E1.1 5.03 5.39e-06 0.0182 0.67 0.56 Immature fraction of reticulocytes; chr4:143738247 chr4:143912331~143982454:+ MESO cis rs3091242 0.933 rs9438904 ENSG00000224183.1 SDHDP6 -5.03 5.43e-06 0.0183 -0.74 -0.56 Erythrocyte sedimentation rate; chr1:25430369 chr1:25294164~25294643:- MESO cis rs55794721 0.509 rs909834 ENSG00000224183.1 SDHDP6 -5.03 5.43e-06 0.0183 -0.74 -0.56 Mean corpuscular volume;Plateletcrit; chr1:25431505 chr1:25294164~25294643:- MESO cis rs4835473 0.618 rs7666297 ENSG00000251600.4 RP11-673E1.1 -5.03 5.43e-06 0.0184 -0.7 -0.56 Immature fraction of reticulocytes; chr4:143999005 chr4:143912331~143982454:+ MESO cis rs3091242 0.933 rs909833 ENSG00000224183.1 SDHDP6 -5.03 5.44e-06 0.0184 -0.74 -0.56 Erythrocyte sedimentation rate; chr1:25427649 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs1534954 ENSG00000224183.1 SDHDP6 -5.03 5.45e-06 0.0184 -0.74 -0.56 Erythrocyte sedimentation rate; chr1:25435433 chr1:25294164~25294643:- MESO cis rs55794721 0.509 rs6699896 ENSG00000224183.1 SDHDP6 -5.03 5.45e-06 0.0184 -0.74 -0.56 Mean corpuscular volume;Plateletcrit; chr1:25436411 chr1:25294164~25294643:- MESO cis rs2729354 0.909 rs2729374 ENSG00000265566.2 RN7SL605P -5.03 5.46e-06 0.0184 -0.66 -0.56 Blood protein levels; chr11:57559454 chr11:57528085~57528365:- MESO cis rs2117029 0.767 rs12580349 ENSG00000258017.1 RP11-386G11.10 5.02 5.49e-06 0.0185 0.72 0.56 Intelligence (multi-trait analysis); chr12:49042941 chr12:49127782~49147869:+ MESO cis rs1577917 0.739 rs6922 ENSG00000203875.9 SNHG5 5.02 5.51e-06 0.0186 0.74 0.56 Response to antipsychotic treatment; chr6:85495605 chr6:85660950~85678736:- MESO cis rs1577917 0.666 rs6454471 ENSG00000203875.9 SNHG5 5.02 5.51e-06 0.0186 0.74 0.56 Response to antipsychotic treatment; chr6:85504738 chr6:85660950~85678736:- MESO cis rs1577917 0.665 rs4304137 ENSG00000203875.9 SNHG5 5.02 5.51e-06 0.0186 0.74 0.56 Response to antipsychotic treatment; chr6:85507730 chr6:85660950~85678736:- MESO cis rs7560272 0.538 rs6732812 ENSG00000163016.8 ALMS1P -5.02 5.57e-06 0.0187 -0.88 -0.56 Schizophrenia; chr2:73695348 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs35767294 ENSG00000163016.8 ALMS1P -5.02 5.57e-06 0.0187 -0.88 -0.56 Schizophrenia; chr2:73695707 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs17350056 ENSG00000163016.8 ALMS1P -5.02 5.57e-06 0.0187 -0.88 -0.56 Schizophrenia; chr2:73695750 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs17434634 ENSG00000163016.8 ALMS1P -5.02 5.57e-06 0.0187 -0.88 -0.56 Schizophrenia; chr2:73695799 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs13006448 ENSG00000163016.8 ALMS1P -5.02 5.57e-06 0.0187 -0.88 -0.56 Schizophrenia; chr2:73697297 chr2:73644919~73685576:+ MESO cis rs7560272 0.502 rs13013228 ENSG00000163016.8 ALMS1P -5.02 5.57e-06 0.0187 -0.88 -0.56 Schizophrenia; chr2:73698089 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs7370393 ENSG00000163016.8 ALMS1P -5.02 5.57e-06 0.0187 -0.88 -0.56 Schizophrenia; chr2:73698509 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs4852975 ENSG00000163016.8 ALMS1P -5.02 5.57e-06 0.0187 -0.88 -0.56 Schizophrenia; chr2:73705338 chr2:73644919~73685576:+ MESO cis rs7617773 0.78 rs11706277 ENSG00000229759.1 MRPS18AP1 5.02 5.57e-06 0.0187 0.7 0.56 Coronary artery disease; chr3:48318943 chr3:48256350~48256938:- MESO cis rs13134327 0.513 rs7679687 ENSG00000251600.4 RP11-673E1.1 -5.02 5.58e-06 0.0187 -0.69 -0.56 Glycated hemoglobin levels; chr4:144024031 chr4:143912331~143982454:+ MESO cis rs10256972 0.577 rs2949179 ENSG00000229043.2 AC091729.9 -5.02 5.58e-06 0.0187 -0.66 -0.56 Endometriosis;Longevity; chr7:1170249 chr7:1160374~1165267:+ MESO cis rs10256972 0.504 rs2949178 ENSG00000229043.2 AC091729.9 -5.02 5.58e-06 0.0187 -0.66 -0.56 Endometriosis;Longevity; chr7:1170289 chr7:1160374~1165267:+ MESO cis rs801193 0.844 rs2244022 ENSG00000226824.5 RP4-756H11.3 -5.02 5.58e-06 0.0187 -0.82 -0.56 Aortic root size; chr7:66737443 chr7:66654538~66669855:+ MESO cis rs875971 0.895 rs4145009 ENSG00000226824.5 RP4-756H11.3 5.02 5.6e-06 0.0187 0.77 0.56 Aortic root size; chr7:66261628 chr7:66654538~66669855:+ MESO cis rs2739330 0.685 rs4822453 ENSG00000273295.1 AP000350.5 5.02 5.6e-06 0.0187 0.61 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23901432~23907068:- MESO cis rs2739330 0.685 rs4822453 ENSG00000231271.1 AP000350.8 5.02 5.62e-06 0.0187 0.68 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23912675 chr22:23949918~23954042:+ MESO cis rs2739330 0.76 rs5751760 ENSG00000218537.1 MIF-AS1 5.02 5.63e-06 0.0187 0.71 0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23894426~23898930:- MESO cis rs3814244 0.528 rs7952790 ENSG00000255733.4 IFNG-AS1 5.02 5.65e-06 0.0187 0.78 0.56 Itch intensity from mosquito bite adjusted by bite size; chr12:68012672 chr12:67989445~68234686:+ MESO cis rs710913 0.618 rs11206437 ENSG00000237624.1 OXCT2P1 5.02 5.66e-06 0.0187 0.66 0.56 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39613039 chr1:39514956~39516490:+ MESO cis rs710913 0.557 rs1180320 ENSG00000237624.1 OXCT2P1 5.02 5.66e-06 0.0187 0.66 0.56 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39616330 chr1:39514956~39516490:+ MESO cis rs2019137 0.56 rs7421852 ENSG00000274877.1 RP11-65I12.1 -5.02 5.67e-06 0.0187 -0.73 -0.56 Lymphocyte counts; chr2:113232684 chr2:113237595~113240825:+ MESO cis rs2019137 0.56 rs10206269 ENSG00000274877.1 RP11-65I12.1 -5.02 5.67e-06 0.0187 -0.73 -0.56 Lymphocyte counts; chr2:113232816 chr2:113237595~113240825:+ MESO cis rs1153858 0.887 rs28569043 ENSG00000259520.4 CTD-2651B20.3 -5.01 5.71e-06 0.0188 -0.76 -0.56 Homoarginine levels; chr15:45438728 chr15:45251580~45279251:- MESO cis rs9322193 0.566 rs3922947 ENSG00000231760.4 RP11-350J20.5 -5.01 5.71e-06 0.0188 -0.74 -0.56 Lung cancer; chr6:149924856 chr6:149796151~149826294:- MESO cis rs9322193 0.566 rs5024811 ENSG00000231760.4 RP11-350J20.5 -5.01 5.71e-06 0.0188 -0.74 -0.56 Lung cancer; chr6:149924898 chr6:149796151~149826294:- MESO cis rs3018712 0.508 rs4930581 ENSG00000212093.1 AP000807.1 -5.01 5.71e-06 0.0188 -0.68 -0.56 Total body bone mineral density; chr11:68643625 chr11:68506083~68506166:- MESO cis rs3018712 0.508 rs4930582 ENSG00000212093.1 AP000807.1 -5.01 5.71e-06 0.0188 -0.68 -0.56 Total body bone mineral density; chr11:68643636 chr11:68506083~68506166:- MESO cis rs3018712 0.547 rs4930583 ENSG00000212093.1 AP000807.1 -5.01 5.71e-06 0.0188 -0.68 -0.56 Total body bone mineral density; chr11:68643711 chr11:68506083~68506166:- MESO cis rs3018712 0.59 rs4930584 ENSG00000212093.1 AP000807.1 -5.01 5.71e-06 0.0188 -0.68 -0.56 Total body bone mineral density; chr11:68643828 chr11:68506083~68506166:- MESO cis rs3018712 0.59 rs4930585 ENSG00000212093.1 AP000807.1 -5.01 5.71e-06 0.0188 -0.68 -0.56 Total body bone mineral density; chr11:68643879 chr11:68506083~68506166:- MESO cis rs3018712 0.532 rs7116363 ENSG00000212093.1 AP000807.1 -5.01 5.71e-06 0.0188 -0.68 -0.56 Total body bone mineral density; chr11:68645330 chr11:68506083~68506166:- MESO cis rs2882667 0.515 rs13161286 ENSG00000253404.1 AC034243.1 5.01 5.72e-06 0.0188 0.77 0.56 Age-related hearing impairment (SNP x SNP interaction); chr5:139148416 chr5:138744434~138753309:- MESO cis rs494459 0.838 rs488219 ENSG00000278376.1 RP11-158I9.8 -5.01 5.76e-06 0.0189 -0.58 -0.56 Height; chr11:118749988 chr11:118791254~118793137:+ MESO cis rs7208859 0.673 rs79541516 ENSG00000263531.1 RP13-753N3.1 5.01 5.78e-06 0.019 0.99 0.56 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30913565 chr17:30863921~30864940:- MESO cis rs7044106 0.734 rs12553070 ENSG00000226752.6 PSMD5-AS1 -5.01 5.78e-06 0.019 -0.77 -0.56 Hip circumference adjusted for BMI; chr9:120722988 chr9:120824828~120854385:+ MESO cis rs7044106 0.791 rs12554440 ENSG00000226752.6 PSMD5-AS1 -5.01 5.78e-06 0.019 -0.77 -0.56 Hip circumference adjusted for BMI; chr9:120723055 chr9:120824828~120854385:+ MESO cis rs7044106 0.791 rs747819 ENSG00000226752.6 PSMD5-AS1 -5.01 5.78e-06 0.019 -0.77 -0.56 Hip circumference adjusted for BMI; chr9:120726163 chr9:120824828~120854385:+ MESO cis rs975739 0.931 rs1279393 ENSG00000236051.5 MYCBP2-AS1 -5.01 5.8e-06 0.019 -0.7 -0.56 Hair color; chr13:77803462 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1279396 ENSG00000236051.5 MYCBP2-AS1 -5.01 5.8e-06 0.019 -0.7 -0.56 Hair color; chr13:77804458 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1279397 ENSG00000236051.5 MYCBP2-AS1 -5.01 5.8e-06 0.019 -0.7 -0.56 Hair color; chr13:77804552 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1279399 ENSG00000236051.5 MYCBP2-AS1 -5.01 5.8e-06 0.019 -0.7 -0.56 Hair color; chr13:77805064 chr13:77075514~77129717:+ MESO cis rs975739 0.933 rs1759974 ENSG00000236051.5 MYCBP2-AS1 -5.01 5.8e-06 0.019 -0.7 -0.56 Hair color; chr13:77809863 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1766341 ENSG00000236051.5 MYCBP2-AS1 -5.01 5.8e-06 0.019 -0.7 -0.56 Hair color; chr13:77810129 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1766342 ENSG00000236051.5 MYCBP2-AS1 -5.01 5.8e-06 0.019 -0.7 -0.56 Hair color; chr13:77810161 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1766343 ENSG00000236051.5 MYCBP2-AS1 -5.01 5.8e-06 0.019 -0.7 -0.56 Hair color; chr13:77810836 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1766344 ENSG00000236051.5 MYCBP2-AS1 -5.01 5.8e-06 0.019 -0.7 -0.56 Hair color; chr13:77810933 chr13:77075514~77129717:+ MESO cis rs11168854 0.651 rs12227770 ENSG00000258017.1 RP11-386G11.10 -5.01 5.82e-06 0.0191 -0.73 -0.56 Body mass index; chr12:49183065 chr12:49127782~49147869:+ MESO cis rs2117029 0.521 rs7953169 ENSG00000258017.1 RP11-386G11.10 -5.01 5.82e-06 0.0191 -0.73 -0.56 Intelligence (multi-trait analysis); chr12:49184389 chr12:49127782~49147869:+ MESO cis rs1577917 0.655 rs9342045 ENSG00000203875.9 SNHG5 5.01 5.82e-06 0.0191 0.68 0.56 Response to antipsychotic treatment; chr6:85715430 chr6:85660950~85678736:- MESO cis rs1577917 0.839 rs12055653 ENSG00000203875.9 SNHG5 -5.01 5.83e-06 0.0191 -0.78 -0.56 Response to antipsychotic treatment; chr6:85836945 chr6:85660950~85678736:- MESO cis rs1577917 0.839 rs1596990 ENSG00000203875.9 SNHG5 -5.01 5.83e-06 0.0191 -0.78 -0.56 Response to antipsychotic treatment; chr6:85840974 chr6:85660950~85678736:- MESO cis rs1577917 0.916 rs12661611 ENSG00000203875.9 SNHG5 -5.01 5.83e-06 0.0191 -0.78 -0.56 Response to antipsychotic treatment; chr6:85844117 chr6:85660950~85678736:- MESO cis rs1577917 0.637 rs1838957 ENSG00000203875.9 SNHG5 -5.01 5.83e-06 0.0191 -0.78 -0.56 Response to antipsychotic treatment; chr6:85855338 chr6:85660950~85678736:- MESO cis rs1577917 0.839 rs1838956 ENSG00000203875.9 SNHG5 -5.01 5.83e-06 0.0191 -0.78 -0.56 Response to antipsychotic treatment; chr6:85855545 chr6:85660950~85678736:- MESO cis rs1577917 0.839 rs12216103 ENSG00000203875.9 SNHG5 -5.01 5.83e-06 0.0191 -0.78 -0.56 Response to antipsychotic treatment; chr6:85861410 chr6:85660950~85678736:- MESO cis rs9326248 0.53 rs579890 ENSG00000254851.1 RP11-109L13.1 -5.01 5.83e-06 0.0191 -1.15 -0.56 Blood protein levels; chr11:116928247 chr11:117135528~117138582:+ MESO cis rs9660180 0.875 rs4648727 ENSG00000268575.1 RP1-283E3.8 5.01 5.86e-06 0.0192 0.65 0.56 Body mass index; chr1:1844830 chr1:1702736~1737688:- MESO cis rs200367988 1 rs200367988 ENSG00000271670.1 RP11-95I16.4 -5 5.89e-06 0.0192 -0.61 -0.56 Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels; chr10:120915337 chr10:120879256~120880667:- MESO cis rs7560272 0.588 rs4852959 ENSG00000163016.8 ALMS1P -5 5.89e-06 0.0192 -0.84 -0.56 Schizophrenia; chr2:73653474 chr2:73644919~73685576:+ MESO cis rs172166 0.538 rs149956 ENSG00000216901.1 AL022393.7 5 5.89e-06 0.0192 0.7 0.56 Cardiac Troponin-T levels; chr6:28068473 chr6:28176188~28176674:+ MESO cis rs172166 0.56 rs203878 ENSG00000216901.1 AL022393.7 5 5.89e-06 0.0192 0.7 0.56 Cardiac Troponin-T levels; chr6:28081218 chr6:28176188~28176674:+ MESO cis rs7617773 0.746 rs7619865 ENSG00000229759.1 MRPS18AP1 5 5.89e-06 0.0193 0.64 0.56 Coronary artery disease; chr3:48329090 chr3:48256350~48256938:- MESO cis rs9918079 0.506 rs10214 ENSG00000273133.1 RP11-799M12.2 5 5.9e-06 0.0193 0.75 0.56 Obesity-related traits; chr4:15604808 chr4:15563698~15564253:- MESO cis rs1150668 0.796 rs1005125 ENSG00000216901.1 AL022393.7 5 5.9e-06 0.0193 0.73 0.56 Pubertal anthropometrics; chr6:28399578 chr6:28176188~28176674:+ MESO cis rs1153858 1 rs2467864 ENSG00000259520.4 CTD-2651B20.3 5 5.93e-06 0.0194 0.79 0.56 Homoarginine levels; chr15:45348900 chr15:45251580~45279251:- MESO cis rs2019137 0.56 rs6707386 ENSG00000274877.1 RP11-65I12.1 -5 5.97e-06 0.0195 -0.73 -0.56 Lymphocyte counts; chr2:113223445 chr2:113237595~113240825:+ MESO cis rs2739330 0.796 rs5760106 ENSG00000225282.1 AP000350.6 -5 6e-06 0.0196 -0.61 -0.56 Liver enzyme levels (gamma-glutamyl transferase); chr22:23908458 chr22:23926900~23929574:+ MESO cis rs4835473 0.662 rs4340756 ENSG00000251600.4 RP11-673E1.1 5 6.02e-06 0.0196 0.71 0.56 Immature fraction of reticulocytes; chr4:144017063 chr4:143912331~143982454:+ MESO cis rs73086581 0.645 rs2103659 ENSG00000229539.1 RP11-119B16.2 -5 6.07e-06 0.0198 -0.71 -0.56 Response to antidepressants in depression; chr20:4001925 chr20:3888239~3888868:- MESO cis rs3091242 1 rs646867 ENSG00000224183.1 SDHDP6 -4.99 6.14e-06 0.02 -0.71 -0.56 Erythrocyte sedimentation rate; chr1:25382767 chr1:25294164~25294643:- MESO cis rs4835473 0.932 rs62339580 ENSG00000251600.4 RP11-673E1.1 -4.99 6.17e-06 0.02 -0.66 -0.55 Immature fraction of reticulocytes; chr4:143785090 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs62339581 ENSG00000251600.4 RP11-673E1.1 -4.99 6.17e-06 0.02 -0.66 -0.55 Immature fraction of reticulocytes; chr4:143785172 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs7666368 ENSG00000251600.4 RP11-673E1.1 -4.99 6.17e-06 0.02 -0.66 -0.55 Immature fraction of reticulocytes; chr4:143785372 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs7690428 ENSG00000251600.4 RP11-673E1.1 -4.99 6.17e-06 0.02 -0.66 -0.55 Immature fraction of reticulocytes; chr4:143785400 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs34781605 ENSG00000251600.4 RP11-673E1.1 -4.99 6.17e-06 0.02 -0.66 -0.55 Immature fraction of reticulocytes; chr4:143785486 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs11100810 ENSG00000251600.4 RP11-673E1.1 -4.99 6.17e-06 0.02 -0.66 -0.55 Immature fraction of reticulocytes; chr4:143787518 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs13129702 ENSG00000251600.4 RP11-673E1.1 4.99 6.17e-06 0.02 0.66 0.55 Immature fraction of reticulocytes; chr4:143785132 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4383567 ENSG00000251600.4 RP11-673E1.1 4.99 6.17e-06 0.02 0.66 0.55 Immature fraction of reticulocytes; chr4:143788873 chr4:143912331~143982454:+ MESO cis rs7560272 0.538 rs2012574 ENSG00000163016.8 ALMS1P -4.99 6.18e-06 0.02 -0.88 -0.55 Schizophrenia; chr2:73701239 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs2001436 ENSG00000163016.8 ALMS1P -4.99 6.18e-06 0.02 -0.88 -0.55 Schizophrenia; chr2:73701838 chr2:73644919~73685576:+ MESO cis rs7560272 0.512 rs4530394 ENSG00000163016.8 ALMS1P -4.99 6.18e-06 0.02 -0.88 -0.55 Schizophrenia; chr2:73702523 chr2:73644919~73685576:+ MESO cis rs7560272 0.512 rs12998980 ENSG00000163016.8 ALMS1P -4.99 6.18e-06 0.02 -0.88 -0.55 Schizophrenia; chr2:73703599 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs12233112 ENSG00000163016.8 ALMS1P -4.99 6.18e-06 0.02 -0.88 -0.55 Schizophrenia; chr2:73704637 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs12233115 ENSG00000163016.8 ALMS1P -4.99 6.18e-06 0.02 -0.88 -0.55 Schizophrenia; chr2:73704764 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs11126414 ENSG00000163016.8 ALMS1P -4.99 6.18e-06 0.02 -0.88 -0.55 Schizophrenia; chr2:73704917 chr2:73644919~73685576:+ MESO cis rs1577917 0.796 rs12661231 ENSG00000203875.9 SNHG5 -4.99 6.18e-06 0.02 -0.79 -0.55 Response to antipsychotic treatment; chr6:85834753 chr6:85660950~85678736:- MESO cis rs6921919 0.583 rs1054372 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28368965 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs9468354 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28370024 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs7773051 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28372539 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs12697938 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28373322 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs13437294 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28373758 chr6:28176188~28176674:+ MESO cis rs6921919 0.609 rs9468357 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28374276 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs34513104 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28375566 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs9461456 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28376039 chr6:28176188~28176674:+ MESO cis rs6921919 0.525 rs9468360 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28376661 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs16894021 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28377249 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs11751693 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28377306 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs7749736 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28378254 chr6:28176188~28176674:+ MESO cis rs6921919 0.525 rs9468361 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28378541 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs7775132 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28379236 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs3734563 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28381948 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs1591913 ENSG00000216901.1 AL022393.7 4.99 6.19e-06 0.02 0.82 0.55 Autism spectrum disorder or schizophrenia; chr6:28383951 chr6:28176188~28176674:+ MESO cis rs7617773 0.78 rs7645425 ENSG00000229759.1 MRPS18AP1 4.99 6.19e-06 0.02 0.7 0.55 Coronary artery disease; chr3:48320879 chr3:48256350~48256938:- MESO cis rs7617773 0.743 rs11716371 ENSG00000229759.1 MRPS18AP1 4.99 6.19e-06 0.02 0.7 0.55 Coronary artery disease; chr3:48321260 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs6793223 ENSG00000229759.1 MRPS18AP1 4.99 6.19e-06 0.02 0.7 0.55 Coronary artery disease; chr3:48322611 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs4541431 ENSG00000229759.1 MRPS18AP1 4.99 6.19e-06 0.02 0.7 0.55 Coronary artery disease; chr3:48323728 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs11714944 ENSG00000229759.1 MRPS18AP1 4.99 6.19e-06 0.02 0.7 0.55 Coronary artery disease; chr3:48325481 chr3:48256350~48256938:- MESO cis rs7617773 0.743 rs13071960 ENSG00000229759.1 MRPS18AP1 4.99 6.19e-06 0.02 0.7 0.55 Coronary artery disease; chr3:48326047 chr3:48256350~48256938:- MESO cis rs7617773 0.743 rs4632568 ENSG00000229759.1 MRPS18AP1 4.99 6.19e-06 0.02 0.7 0.55 Coronary artery disease; chr3:48326329 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs11130164 ENSG00000229759.1 MRPS18AP1 4.99 6.19e-06 0.02 0.7 0.55 Coronary artery disease; chr3:48327544 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs7653336 ENSG00000229759.1 MRPS18AP1 4.99 6.19e-06 0.02 0.7 0.55 Coronary artery disease; chr3:48327974 chr3:48256350~48256938:- MESO cis rs7617773 0.747 rs34076262 ENSG00000229759.1 MRPS18AP1 4.99 6.19e-06 0.02 0.7 0.55 Coronary artery disease; chr3:48328926 chr3:48256350~48256938:- MESO cis rs3091242 0.933 rs9645452 ENSG00000224183.1 SDHDP6 4.99 6.2e-06 0.02 0.71 0.55 Erythrocyte sedimentation rate; chr1:25341835 chr1:25294164~25294643:- MESO cis rs3091242 0.933 rs3093584 ENSG00000224183.1 SDHDP6 4.99 6.2e-06 0.02 0.71 0.55 Erythrocyte sedimentation rate; chr1:25342223 chr1:25294164~25294643:- MESO cis rs172166 0.585 rs149963 ENSG00000216901.1 AL022393.7 4.99 6.21e-06 0.0201 0.7 0.55 Cardiac Troponin-T levels; chr6:28049354 chr6:28176188~28176674:+ MESO cis rs3091242 0.967 rs3093614 ENSG00000224183.1 SDHDP6 4.99 6.23e-06 0.0201 0.71 0.55 Erythrocyte sedimentation rate; chr1:25351353 chr1:25294164~25294643:- MESO cis rs3091242 0.967 rs1053438 ENSG00000224183.1 SDHDP6 4.99 6.23e-06 0.0201 0.71 0.55 Erythrocyte sedimentation rate; chr1:25361410 chr1:25294164~25294643:- MESO cis rs8177876 0.822 rs56166222 ENSG00000261838.4 RP11-303E16.6 4.99 6.25e-06 0.0202 1.04 0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81067920 chr16:81069854~81076598:+ MESO cis rs8177876 0.731 rs74878296 ENSG00000261838.4 RP11-303E16.6 4.99 6.25e-06 0.0202 1.04 0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81071940 chr16:81069854~81076598:+ MESO cis rs8177876 0.822 rs79926943 ENSG00000261838.4 RP11-303E16.6 4.99 6.25e-06 0.0202 1.04 0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81072005 chr16:81069854~81076598:+ MESO cis rs9322193 0.962 rs2275046 ENSG00000231760.4 RP11-350J20.5 4.99 6.25e-06 0.0202 0.77 0.55 Lung cancer; chr6:149835865 chr6:149796151~149826294:- MESO cis rs9309473 0.519 rs2421574 ENSG00000163016.8 ALMS1P -4.99 6.27e-06 0.0202 -0.89 -0.55 Metabolite levels; chr2:73681640 chr2:73644919~73685576:+ MESO cis rs2019137 0.56 rs7578633 ENSG00000274877.1 RP11-65I12.1 -4.99 6.29e-06 0.0202 -0.73 -0.55 Lymphocyte counts; chr2:113221073 chr2:113237595~113240825:+ MESO cis rs2019137 0.539 rs11123170 ENSG00000274877.1 RP11-65I12.1 -4.99 6.29e-06 0.0202 -0.73 -0.55 Lymphocyte counts; chr2:113221363 chr2:113237595~113240825:+ MESO cis rs17711722 0.522 rs4642526 ENSG00000164669.11 INTS4P1 -4.98 6.38e-06 0.0205 -0.67 -0.55 Calcium levels; chr7:65751755 chr7:65141225~65234216:+ MESO cis rs17711722 0.522 rs62469933 ENSG00000164669.11 INTS4P1 -4.98 6.38e-06 0.0205 -0.67 -0.55 Calcium levels; chr7:65800652 chr7:65141225~65234216:+ MESO cis rs17711722 0.565 rs4717276 ENSG00000164669.11 INTS4P1 -4.98 6.38e-06 0.0205 -0.67 -0.55 Calcium levels; chr7:65829754 chr7:65141225~65234216:+ MESO cis rs17711722 0.565 rs73372653 ENSG00000164669.11 INTS4P1 -4.98 6.38e-06 0.0205 -0.67 -0.55 Calcium levels; chr7:65977808 chr7:65141225~65234216:+ MESO cis rs17711722 0.565 rs4275112 ENSG00000164669.11 INTS4P1 4.98 6.38e-06 0.0205 0.67 0.55 Calcium levels; chr7:65733651 chr7:65141225~65234216:+ MESO cis rs17711722 0.523 rs313812 ENSG00000164669.11 INTS4P1 4.98 6.38e-06 0.0205 0.67 0.55 Calcium levels; chr7:66040056 chr7:65141225~65234216:+ MESO cis rs17711722 0.523 rs365896 ENSG00000164669.11 INTS4P1 4.98 6.38e-06 0.0205 0.67 0.55 Calcium levels; chr7:66045710 chr7:65141225~65234216:+ MESO cis rs4835473 0.9 rs10003922 ENSG00000251600.4 RP11-673E1.1 -4.98 6.42e-06 0.0206 -0.67 -0.55 Immature fraction of reticulocytes; chr4:143921235 chr4:143912331~143982454:+ MESO cis rs1577917 0.771 rs2842607 ENSG00000203875.9 SNHG5 -4.98 6.44e-06 0.0206 -0.73 -0.55 Response to antipsychotic treatment; chr6:85635321 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs2758847 ENSG00000203875.9 SNHG5 -4.98 6.44e-06 0.0206 -0.73 -0.55 Response to antipsychotic treatment; chr6:85639385 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs4145082 ENSG00000203875.9 SNHG5 -4.98 6.44e-06 0.0206 -0.73 -0.55 Response to antipsychotic treatment; chr6:85642298 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs9362233 ENSG00000203875.9 SNHG5 -4.98 6.44e-06 0.0206 -0.73 -0.55 Response to antipsychotic treatment; chr6:85648529 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs10944133 ENSG00000203875.9 SNHG5 -4.98 6.44e-06 0.0206 -0.73 -0.55 Response to antipsychotic treatment; chr6:85649266 chr6:85660950~85678736:- MESO cis rs1577917 0.727 rs9351065 ENSG00000203875.9 SNHG5 -4.98 6.44e-06 0.0206 -0.73 -0.55 Response to antipsychotic treatment; chr6:85650710 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs2475790 ENSG00000203875.9 SNHG5 -4.98 6.44e-06 0.0206 -0.73 -0.55 Response to antipsychotic treatment; chr6:85658350 chr6:85660950~85678736:- MESO cis rs3091242 0.933 rs11802413 ENSG00000224183.1 SDHDP6 4.98 6.47e-06 0.0207 0.72 0.55 Erythrocyte sedimentation rate; chr1:25434429 chr1:25294164~25294643:- MESO cis rs2019137 0.936 rs2305133 ENSG00000189223.12 PAX8-AS1 4.98 6.51e-06 0.0207 0.66 0.55 Lymphocyte counts; chr2:113199244 chr2:113211522~113276581:+ MESO cis rs2019137 0.936 rs12612729 ENSG00000189223.12 PAX8-AS1 4.98 6.51e-06 0.0207 0.66 0.55 Lymphocyte counts; chr2:113199471 chr2:113211522~113276581:+ MESO cis rs2019137 0.936 rs731834 ENSG00000189223.12 PAX8-AS1 4.98 6.51e-06 0.0207 0.66 0.55 Lymphocyte counts; chr2:113199621 chr2:113211522~113276581:+ MESO cis rs1577917 0.56 rs12193777 ENSG00000203875.9 SNHG5 4.98 6.52e-06 0.0207 0.71 0.55 Response to antipsychotic treatment; chr6:85536991 chr6:85660950~85678736:- MESO cis rs1577917 0.655 rs9444351 ENSG00000203875.9 SNHG5 4.98 6.52e-06 0.0207 0.71 0.55 Response to antipsychotic treatment; chr6:85538081 chr6:85660950~85678736:- MESO cis rs1577917 0.655 rs7766485 ENSG00000203875.9 SNHG5 4.98 6.52e-06 0.0207 0.71 0.55 Response to antipsychotic treatment; chr6:85553837 chr6:85660950~85678736:- MESO cis rs1577917 0.71 rs1059306 ENSG00000203875.9 SNHG5 4.98 6.53e-06 0.0208 0.69 0.55 Response to antipsychotic treatment; chr6:85678391 chr6:85660950~85678736:- MESO cis rs2019137 0.936 rs3811059 ENSG00000189223.12 PAX8-AS1 4.97 6.55e-06 0.0208 0.66 0.55 Lymphocyte counts; chr2:113204494 chr2:113211522~113276581:+ MESO cis rs2019137 0.936 rs12620738 ENSG00000189223.12 PAX8-AS1 4.97 6.55e-06 0.0208 0.66 0.55 Lymphocyte counts; chr2:113206162 chr2:113211522~113276581:+ MESO cis rs2019137 1 rs2019137 ENSG00000189223.12 PAX8-AS1 4.97 6.55e-06 0.0208 0.66 0.55 Lymphocyte counts; chr2:113216055 chr2:113211522~113276581:+ MESO cis rs2019137 0.967 rs895412 ENSG00000189223.12 PAX8-AS1 4.97 6.55e-06 0.0208 0.66 0.55 Lymphocyte counts; chr2:113216387 chr2:113211522~113276581:+ MESO cis rs80285556 1 rs55914901 ENSG00000161643.11 SIGLEC16 4.97 6.58e-06 0.0209 1.41 0.55 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50025089 chr19:49969673~49975814:+ MESO cis rs80285556 1 rs76812330 ENSG00000161643.11 SIGLEC16 4.97 6.58e-06 0.0209 1.41 0.55 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50028603 chr19:49969673~49975814:+ MESO cis rs80285556 1 rs80285556 ENSG00000161643.11 SIGLEC16 4.97 6.58e-06 0.0209 1.41 0.55 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50036913 chr19:49969673~49975814:+ MESO cis rs710913 0.618 rs6587 ENSG00000237624.1 OXCT2P1 4.97 6.62e-06 0.021 0.66 0.55 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39624273 chr1:39514956~39516490:+ MESO cis rs1577917 0.61 rs11752795 ENSG00000203875.9 SNHG5 4.97 6.63e-06 0.021 0.72 0.55 Response to antipsychotic treatment; chr6:85577411 chr6:85660950~85678736:- MESO cis rs1577917 0.655 rs9444354 ENSG00000203875.9 SNHG5 4.97 6.63e-06 0.021 0.72 0.55 Response to antipsychotic treatment; chr6:85582217 chr6:85660950~85678736:- MESO cis rs1577917 0.566 rs2842611 ENSG00000203875.9 SNHG5 -4.97 6.63e-06 0.021 -0.72 -0.55 Response to antipsychotic treatment; chr6:85592316 chr6:85660950~85678736:- MESO cis rs1577917 0.655 rs2842600 ENSG00000203875.9 SNHG5 -4.97 6.63e-06 0.021 -0.72 -0.55 Response to antipsychotic treatment; chr6:85615914 chr6:85660950~85678736:- MESO cis rs7260538 0.808 rs707265 ENSG00000267107.5 PCAT19 4.97 6.63e-06 0.021 0.79 0.55 DDT metabolite (p,p'-DDE levels); chr19:41018182 chr19:41454169~41500649:- MESO cis rs2739330 0.76 rs1002286 ENSG00000225282.1 AP000350.6 -4.97 6.63e-06 0.021 -0.63 -0.55 Liver enzyme levels (gamma-glutamyl transferase); chr22:23915150 chr22:23926900~23929574:+ MESO cis rs9322193 0.884 rs880245 ENSG00000231760.4 RP11-350J20.5 -4.97 6.64e-06 0.0211 -0.78 -0.55 Lung cancer; chr6:149846262 chr6:149796151~149826294:- MESO cis rs6558530 0.692 rs12335115 ENSG00000253982.1 CTD-2336O2.1 4.97 6.68e-06 0.0212 0.69 0.55 Systolic blood pressure; chr8:1751686 chr8:1761990~1764502:- MESO cis rs1153858 1 rs7169818 ENSG00000259520.4 CTD-2651B20.3 -4.97 6.69e-06 0.0212 -0.72 -0.55 Homoarginine levels; chr15:45347993 chr15:45251580~45279251:- MESO cis rs1153858 1 rs1145091 ENSG00000259520.4 CTD-2651B20.3 -4.97 6.69e-06 0.0212 -0.72 -0.55 Homoarginine levels; chr15:45357798 chr15:45251580~45279251:- MESO cis rs4835473 0.932 rs13147386 ENSG00000251600.4 RP11-673E1.1 4.97 6.72e-06 0.0213 0.68 0.55 Immature fraction of reticulocytes; chr4:143736586 chr4:143912331~143982454:+ MESO cis rs7617773 0.78 rs34523942 ENSG00000229759.1 MRPS18AP1 4.97 6.76e-06 0.0213 0.69 0.55 Coronary artery disease; chr3:48301179 chr3:48256350~48256938:- MESO cis rs8177876 0.658 rs75422577 ENSG00000261838.4 RP11-303E16.6 4.97 6.77e-06 0.0214 1.04 0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81054561 chr16:81069854~81076598:+ MESO cis rs8177876 0.749 rs76892049 ENSG00000261838.4 RP11-303E16.6 4.97 6.77e-06 0.0214 1.04 0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81055736 chr16:81069854~81076598:+ MESO cis rs8177876 0.749 rs79834398 ENSG00000261838.4 RP11-303E16.6 4.97 6.77e-06 0.0214 1.04 0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81057033 chr16:81069854~81076598:+ MESO cis rs4835473 0.932 rs34324222 ENSG00000251600.4 RP11-673E1.1 -4.97 6.78e-06 0.0214 -0.64 -0.55 Immature fraction of reticulocytes; chr4:143784572 chr4:143912331~143982454:+ MESO cis rs1153858 1 rs10519021 ENSG00000259520.4 CTD-2651B20.3 -4.96 6.84e-06 0.0215 -0.74 -0.55 Homoarginine levels; chr15:45339597 chr15:45251580~45279251:- MESO cis rs4835473 0.932 rs12505628 ENSG00000251600.4 RP11-673E1.1 -4.96 6.85e-06 0.0216 -0.71 -0.55 Immature fraction of reticulocytes; chr4:143758468 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs12505663 ENSG00000251600.4 RP11-673E1.1 -4.96 6.85e-06 0.0216 -0.71 -0.55 Immature fraction of reticulocytes; chr4:143758491 chr4:143912331~143982454:+ MESO cis rs4835473 0.868 rs12513078 ENSG00000251600.4 RP11-673E1.1 -4.96 6.85e-06 0.0216 -0.71 -0.55 Immature fraction of reticulocytes; chr4:143758494 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs12505665 ENSG00000251600.4 RP11-673E1.1 -4.96 6.85e-06 0.0216 -0.71 -0.55 Immature fraction of reticulocytes; chr4:143758515 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs12509716 ENSG00000251600.4 RP11-673E1.1 -4.96 6.85e-06 0.0216 -0.71 -0.55 Immature fraction of reticulocytes; chr4:143758520 chr4:143912331~143982454:+ MESO cis rs217727 0.908 rs12806111 ENSG00000232987.1 LINC01219 4.96 6.88e-06 0.0216 0.65 0.55 Breast cancer; chr11:1987136 chr11:1991096~1993469:+ MESO cis rs3018712 0.532 rs2510398 ENSG00000212093.1 AP000807.1 -4.96 6.9e-06 0.0216 -0.69 -0.55 Total body bone mineral density; chr11:68653948 chr11:68506083~68506166:- MESO cis rs8091660 0.893 rs1567656 ENSG00000278983.1 RP11-426J5.3 -4.96 6.92e-06 0.0217 -0.62 -0.55 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48568420 chr18:48564795~48568342:+ MESO cis rs2117029 0.521 rs1056875 ENSG00000258017.1 RP11-386G11.10 -4.96 6.94e-06 0.0217 -0.69 -0.55 Intelligence (multi-trait analysis); chr12:49186397 chr12:49127782~49147869:+ MESO cis rs6964833 1 rs13227433 ENSG00000123965.13 PMS2P5 4.96 6.99e-06 0.0219 0.95 0.55 Menarche (age at onset); chr7:74680386 chr7:74894116~74897835:+ MESO cis rs6964833 1 rs6967152 ENSG00000123965.13 PMS2P5 4.96 6.99e-06 0.0219 0.95 0.55 Menarche (age at onset); chr7:74684983 chr7:74894116~74897835:+ MESO cis rs6964833 1 rs6964833 ENSG00000123965.13 PMS2P5 4.96 6.99e-06 0.0219 0.95 0.55 Menarche (age at onset); chr7:74687575 chr7:74894116~74897835:+ MESO cis rs6964833 1 rs35203738 ENSG00000123965.13 PMS2P5 4.96 6.99e-06 0.0219 0.95 0.55 Menarche (age at onset); chr7:74690864 chr7:74894116~74897835:+ MESO cis rs6964833 1 rs2301907 ENSG00000123965.13 PMS2P5 4.96 6.99e-06 0.0219 0.95 0.55 Menarche (age at onset); chr7:74700517 chr7:74894116~74897835:+ MESO cis rs6964833 0.935 rs7795281 ENSG00000123965.13 PMS2P5 4.96 6.99e-06 0.0219 0.95 0.55 Menarche (age at onset); chr7:74708523 chr7:74894116~74897835:+ MESO cis rs6964833 0.935 rs7795282 ENSG00000123965.13 PMS2P5 4.96 6.99e-06 0.0219 0.95 0.55 Menarche (age at onset); chr7:74708526 chr7:74894116~74897835:+ MESO cis rs4835473 0.932 rs4835279 ENSG00000251600.4 RP11-673E1.1 -4.96 6.99e-06 0.0219 -0.66 -0.55 Immature fraction of reticulocytes; chr4:143788917 chr4:143912331~143982454:+ MESO cis rs1153858 1 rs1980288 ENSG00000259520.4 CTD-2651B20.3 -4.95 7.04e-06 0.022 -0.74 -0.55 Homoarginine levels; chr15:45328414 chr15:45251580~45279251:- MESO cis rs1789 0.903 rs4453929 ENSG00000273133.1 RP11-799M12.2 -4.95 7.06e-06 0.022 -0.77 -0.55 Blood protein levels; chr4:15670550 chr4:15563698~15564253:- MESO cis rs1789 0.903 rs4616746 ENSG00000273133.1 RP11-799M12.2 -4.95 7.06e-06 0.022 -0.77 -0.55 Blood protein levels; chr4:15671475 chr4:15563698~15564253:- MESO cis rs1789 0.868 rs4631041 ENSG00000273133.1 RP11-799M12.2 -4.95 7.06e-06 0.022 -0.77 -0.55 Blood protein levels; chr4:15671772 chr4:15563698~15564253:- MESO cis rs1789 0.903 rs4470622 ENSG00000273133.1 RP11-799M12.2 -4.95 7.06e-06 0.022 -0.77 -0.55 Blood protein levels; chr4:15672552 chr4:15563698~15564253:- MESO cis rs1789 0.903 rs6850422 ENSG00000273133.1 RP11-799M12.2 -4.95 7.06e-06 0.022 -0.77 -0.55 Blood protein levels; chr4:15680814 chr4:15563698~15564253:- MESO cis rs710913 0.738 rs755247 ENSG00000237624.1 OXCT2P1 -4.95 7.07e-06 0.022 -0.67 -0.55 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39528873 chr1:39514956~39516490:+ MESO cis rs4835473 0.932 rs1973608 ENSG00000251600.4 RP11-673E1.1 4.95 7.07e-06 0.022 0.66 0.55 Immature fraction of reticulocytes; chr4:143913057 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs6813011 ENSG00000251600.4 RP11-673E1.1 4.95 7.07e-06 0.022 0.66 0.55 Immature fraction of reticulocytes; chr4:143914496 chr4:143912331~143982454:+ MESO cis rs710913 0.587 rs6690413 ENSG00000237624.1 OXCT2P1 4.95 7.07e-06 0.0221 0.66 0.55 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39620620 chr1:39514956~39516490:+ MESO cis rs710913 0.618 rs12030495 ENSG00000237624.1 OXCT2P1 4.95 7.07e-06 0.0221 0.66 0.55 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39623923 chr1:39514956~39516490:+ MESO cis rs73086581 1 rs3746665 ENSG00000229539.1 RP11-119B16.2 -4.95 7.07e-06 0.0221 -0.72 -0.55 Response to antidepressants in depression; chr20:3929759 chr20:3888239~3888868:- MESO cis rs1577917 0.74 rs9344542 ENSG00000203875.9 SNHG5 4.95 7.1e-06 0.0221 0.7 0.55 Response to antipsychotic treatment; chr6:85684187 chr6:85660950~85678736:- MESO cis rs4964805 0.594 rs4964830 ENSG00000257681.1 RP11-341G23.4 -4.95 7.1e-06 0.0221 -0.81 -0.55 Attention deficit hyperactivity disorder; chr12:103775130 chr12:103746315~103768858:- MESO cis rs950027 1 rs950027 ENSG00000259520.4 CTD-2651B20.3 4.95 7.16e-06 0.0223 0.64 0.55 Response to fenofibrate (adiponectin levels); chr15:45508837 chr15:45251580~45279251:- MESO cis rs853679 0.567 rs7774981 ENSG00000216901.1 AL022393.7 4.95 7.2e-06 0.0224 0.91 0.55 Depression; chr6:28379133 chr6:28176188~28176674:+ MESO cis rs853679 0.567 rs7754960 ENSG00000216901.1 AL022393.7 4.95 7.2e-06 0.0224 0.91 0.55 Depression; chr6:28379168 chr6:28176188~28176674:+ MESO cis rs853679 0.567 rs3799499 ENSG00000216901.1 AL022393.7 4.95 7.2e-06 0.0224 0.91 0.55 Depression; chr6:28386473 chr6:28176188~28176674:+ MESO cis rs853679 0.567 rs2232427 ENSG00000216901.1 AL022393.7 4.95 7.2e-06 0.0224 0.91 0.55 Depression; chr6:28391932 chr6:28176188~28176674:+ MESO cis rs975739 1 rs1279675 ENSG00000236051.5 MYCBP2-AS1 -4.95 7.21e-06 0.0224 -0.68 -0.55 Hair color; chr13:77815558 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1279674 ENSG00000236051.5 MYCBP2-AS1 -4.95 7.21e-06 0.0224 -0.68 -0.55 Hair color; chr13:77815691 chr13:77075514~77129717:+ MESO cis rs975739 1 rs750192 ENSG00000236051.5 MYCBP2-AS1 -4.95 7.21e-06 0.0224 -0.68 -0.55 Hair color; chr13:77816608 chr13:77075514~77129717:+ MESO cis rs975739 0.966 rs1279403 ENSG00000236051.5 MYCBP2-AS1 -4.95 7.21e-06 0.0224 -0.68 -0.55 Hair color; chr13:77817622 chr13:77075514~77129717:+ MESO cis rs975739 0.933 rs9544609 ENSG00000236051.5 MYCBP2-AS1 -4.95 7.21e-06 0.0224 -0.68 -0.55 Hair color; chr13:77818521 chr13:77075514~77129717:+ MESO cis rs875971 0.66 rs2191268 ENSG00000226824.5 RP4-756H11.3 -4.95 7.22e-06 0.0224 -0.69 -0.55 Aortic root size; chr7:66645237 chr7:66654538~66669855:+ MESO cis rs9309473 0.606 rs78941213 ENSG00000163016.8 ALMS1P 4.95 7.22e-06 0.0224 0.96 0.55 Metabolite levels; chr2:73658010 chr2:73644919~73685576:+ MESO cis rs9309473 0.606 rs77962988 ENSG00000163016.8 ALMS1P 4.95 7.22e-06 0.0224 0.96 0.55 Metabolite levels; chr2:73658963 chr2:73644919~73685576:+ MESO cis rs3018712 0.532 rs61889616 ENSG00000212093.1 AP000807.1 -4.95 7.24e-06 0.0225 -0.67 -0.55 Total body bone mineral density; chr11:68644538 chr11:68506083~68506166:- MESO cis rs3018712 0.505 rs7102308 ENSG00000212093.1 AP000807.1 -4.95 7.24e-06 0.0225 -0.67 -0.55 Total body bone mineral density; chr11:68645762 chr11:68506083~68506166:- MESO cis rs4835473 0.9 rs3856989 ENSG00000251600.4 RP11-673E1.1 4.95 7.24e-06 0.0225 0.65 0.55 Immature fraction of reticulocytes; chr4:143921752 chr4:143912331~143982454:+ MESO cis rs853679 0.527 rs1997660 ENSG00000216901.1 AL022393.7 4.95 7.26e-06 0.0225 0.78 0.55 Depression; chr6:28301886 chr6:28176188~28176674:+ MESO cis rs853679 0.527 rs9468333 ENSG00000216901.1 AL022393.7 4.95 7.26e-06 0.0225 0.78 0.55 Depression; chr6:28303421 chr6:28176188~28176674:+ MESO cis rs6903823 0.527 rs4713158 ENSG00000216901.1 AL022393.7 4.95 7.26e-06 0.0225 0.78 0.55 Pulmonary function; chr6:28309994 chr6:28176188~28176674:+ MESO cis rs853679 0.527 rs853690 ENSG00000216901.1 AL022393.7 4.95 7.26e-06 0.0225 0.78 0.55 Depression; chr6:28317705 chr6:28176188~28176674:+ MESO cis rs3091242 0.933 rs7541095 ENSG00000224183.1 SDHDP6 -4.95 7.28e-06 0.0226 -0.72 -0.55 Erythrocyte sedimentation rate; chr1:25434800 chr1:25294164~25294643:- MESO cis rs10256972 0.552 rs6953538 ENSG00000229043.2 AC091729.9 -4.94 7.31e-06 0.0226 -0.65 -0.55 Endometriosis;Longevity; chr7:1157338 chr7:1160374~1165267:+ MESO cis rs494459 0.838 rs632124 ENSG00000278376.1 RP11-158I9.8 -4.94 7.35e-06 0.0227 -0.58 -0.55 Height; chr11:118742526 chr11:118791254~118793137:+ MESO cis rs494459 0.838 rs607125 ENSG00000278376.1 RP11-158I9.8 -4.94 7.35e-06 0.0227 -0.58 -0.55 Height; chr11:118746590 chr11:118791254~118793137:+ MESO cis rs7208859 0.673 rs9903862 ENSG00000263531.1 RP13-753N3.1 4.94 7.36e-06 0.0228 1.21 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30879415 chr17:30863921~30864940:- MESO cis rs7617773 0.817 rs936427 ENSG00000229759.1 MRPS18AP1 -4.94 7.36e-06 0.0228 -0.68 -0.55 Coronary artery disease; chr3:48259584 chr3:48256350~48256938:- MESO cis rs7617773 0.78 rs7653152 ENSG00000229759.1 MRPS18AP1 4.94 7.36e-06 0.0228 0.7 0.55 Coronary artery disease; chr3:48320607 chr3:48256350~48256938:- MESO cis rs7301826 0.651 rs1554807 ENSG00000256250.1 RP11-989F5.1 4.94 7.38e-06 0.0228 0.71 0.55 Plasma plasminogen activator levels; chr12:130795872 chr12:130810606~130812438:+ MESO cis rs975739 1 rs1759975 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.38e-06 0.0228 -0.68 -0.55 Hair color; chr13:77811023 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1759977 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.38e-06 0.0228 -0.68 -0.55 Hair color; chr13:77811073 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1668619 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.38e-06 0.0228 -0.68 -0.55 Hair color; chr13:77811615 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1668618 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.38e-06 0.0228 -0.68 -0.55 Hair color; chr13:77812002 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1158097 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.38e-06 0.0228 -0.68 -0.55 Hair color; chr13:77812240 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1759979 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.38e-06 0.0228 -0.68 -0.55 Hair color; chr13:77812719 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1766345 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.38e-06 0.0228 -0.68 -0.55 Hair color; chr13:77812990 chr13:77075514~77129717:+ MESO cis rs975739 0.933 rs1766348 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.38e-06 0.0228 -0.68 -0.55 Hair color; chr13:77813874 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1766350 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.38e-06 0.0228 -0.68 -0.55 Hair color; chr13:77814254 chr13:77075514~77129717:+ MESO cis rs975739 0.966 rs2787661 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.38e-06 0.0228 -0.68 -0.55 Hair color; chr13:77814645 chr13:77075514~77129717:+ MESO cis rs875971 0.862 rs778720 ENSG00000226824.5 RP4-756H11.3 4.94 7.4e-06 0.0229 0.76 0.55 Aortic root size; chr7:66381288 chr7:66654538~66669855:+ MESO cis rs2019137 0.936 rs902696 ENSG00000189223.12 PAX8-AS1 -4.94 7.42e-06 0.0229 -0.65 -0.55 Lymphocyte counts; chr2:113197302 chr2:113211522~113276581:+ MESO cis rs2019137 0.905 rs2276561 ENSG00000189223.12 PAX8-AS1 4.94 7.42e-06 0.0229 0.65 0.55 Lymphocyte counts; chr2:113198794 chr2:113211522~113276581:+ MESO cis rs7208859 0.623 rs56325146 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824006 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs3752019 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30824687 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs73271869 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825203 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs73271872 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30825210 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs55724095 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826040 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs56146117 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30826307 chr17:30863921~30864940:- MESO cis rs17826219 0.568 rs9903854 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Body mass index; chr17:30826980 chr17:30863921~30864940:- MESO cis rs17826219 0.568 rs9907834 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Body mass index; chr17:30826995 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs80355557 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827403 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs9911173 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827732 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs73271887 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30827917 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs9898858 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829193 chr17:30863921~30864940:- MESO cis rs7208859 0.673 rs55658077 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829501 chr17:30863921~30864940:- MESO cis rs7208859 0.623 rs9899692 ENSG00000263531.1 RP13-753N3.1 4.94 7.46e-06 0.023 1.06 0.55 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30829921 chr17:30863921~30864940:- MESO cis rs9326248 0.53 rs7122944 ENSG00000254851.1 RP11-109L13.1 -4.94 7.5e-06 0.0231 -1.09 -0.55 Blood protein levels; chr11:117163903 chr11:117135528~117138582:+ MESO cis rs7115242 0.514 rs4936367 ENSG00000254851.1 RP11-109L13.1 -4.94 7.5e-06 0.0231 -1.09 -0.55 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117171661 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs4604928 ENSG00000254851.1 RP11-109L13.1 -4.94 7.5e-06 0.0231 -1.09 -0.55 Blood protein levels; chr11:117173487 chr11:117135528~117138582:+ MESO cis rs2019137 0.936 rs4849169 ENSG00000189223.12 PAX8-AS1 4.94 7.51e-06 0.0231 0.65 0.55 Lymphocyte counts; chr2:113196080 chr2:113211522~113276581:+ MESO cis rs2019137 0.836 rs4848318 ENSG00000189223.12 PAX8-AS1 4.94 7.51e-06 0.0231 0.65 0.55 Lymphocyte counts; chr2:113196375 chr2:113211522~113276581:+ MESO cis rs2019137 0.936 rs2241978 ENSG00000189223.12 PAX8-AS1 4.94 7.51e-06 0.0231 0.65 0.55 Lymphocyte counts; chr2:113196429 chr2:113211522~113276581:+ MESO cis rs2019137 0.936 rs3828188 ENSG00000189223.12 PAX8-AS1 4.94 7.51e-06 0.0231 0.65 0.55 Lymphocyte counts; chr2:113196670 chr2:113211522~113276581:+ MESO cis rs2019137 0.936 rs3828189 ENSG00000189223.12 PAX8-AS1 4.94 7.51e-06 0.0231 0.65 0.55 Lymphocyte counts; chr2:113196919 chr2:113211522~113276581:+ MESO cis rs875971 0.508 rs10950045 ENSG00000226824.5 RP4-756H11.3 4.94 7.52e-06 0.0231 0.8 0.55 Aortic root size; chr7:66601386 chr7:66654538~66669855:+ MESO cis rs8177876 0.658 rs79603321 ENSG00000261838.4 RP11-303E16.6 4.94 7.53e-06 0.0231 1.04 0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81039139 chr16:81069854~81076598:+ MESO cis rs8177876 0.749 rs2549891 ENSG00000261838.4 RP11-303E16.6 -4.94 7.53e-06 0.0231 -1.04 -0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81046761 chr16:81069854~81076598:+ MESO cis rs8177876 0.686 rs804897 ENSG00000261838.4 RP11-303E16.6 -4.94 7.53e-06 0.0231 -1.04 -0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81067590 chr16:81069854~81076598:+ MESO cis rs10083777 0.551 rs79378252 ENSG00000261838.4 RP11-303E16.6 4.94 7.54e-06 0.0231 0.96 0.55 Metabolite levels (small molecules and protein measures); chr16:81014554 chr16:81069854~81076598:+ MESO cis rs975739 1 rs9574111 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.54e-06 0.0231 -0.67 -0.55 Hair color; chr13:77821561 chr13:77075514~77129717:+ MESO cis rs975739 1 rs9544611 ENSG00000236051.5 MYCBP2-AS1 -4.94 7.54e-06 0.0231 -0.67 -0.55 Hair color; chr13:77826482 chr13:77075514~77129717:+ MESO cis rs6443245 0.591 rs2542364 ENSG00000227110.5 LMCD1-AS1 4.94 7.55e-06 0.0231 0.69 0.55 Daytime sleep phenotypes; chr3:9578384 chr3:7952805~8611924:- MESO cis rs6443245 0.539 rs2542368 ENSG00000227110.5 LMCD1-AS1 4.94 7.55e-06 0.0231 0.69 0.55 Daytime sleep phenotypes; chr3:9578957 chr3:7952805~8611924:- MESO cis rs6443245 0.591 rs2648382 ENSG00000227110.5 LMCD1-AS1 4.94 7.55e-06 0.0231 0.69 0.55 Daytime sleep phenotypes; chr3:9579992 chr3:7952805~8611924:- MESO cis rs6443245 0.591 rs2648381 ENSG00000227110.5 LMCD1-AS1 4.94 7.55e-06 0.0231 0.69 0.55 Daytime sleep phenotypes; chr3:9580993 chr3:7952805~8611924:- MESO cis rs6443245 0.611 rs2648380 ENSG00000227110.5 LMCD1-AS1 4.94 7.55e-06 0.0231 0.69 0.55 Daytime sleep phenotypes; chr3:9583370 chr3:7952805~8611924:- MESO cis rs6443245 0.611 rs2648379 ENSG00000227110.5 LMCD1-AS1 4.94 7.55e-06 0.0231 0.69 0.55 Daytime sleep phenotypes; chr3:9583458 chr3:7952805~8611924:- MESO cis rs6443245 0.611 rs2648378 ENSG00000227110.5 LMCD1-AS1 4.94 7.55e-06 0.0231 0.69 0.55 Daytime sleep phenotypes; chr3:9583889 chr3:7952805~8611924:- MESO cis rs6443245 0.611 rs2648377 ENSG00000227110.5 LMCD1-AS1 4.94 7.55e-06 0.0231 0.69 0.55 Daytime sleep phenotypes; chr3:9583985 chr3:7952805~8611924:- MESO cis rs6443245 0.611 rs7640402 ENSG00000227110.5 LMCD1-AS1 4.94 7.55e-06 0.0231 0.69 0.55 Daytime sleep phenotypes; chr3:9585399 chr3:7952805~8611924:- MESO cis rs2851682 0.611 rs2072114 ENSG00000257058.1 RP11-864I4.4 -4.93 7.57e-06 0.0232 -0.87 -0.55 Gestational age at birth (child effect);Trans fatty acid levels; chr11:61837743 chr11:62545999~62547699:+ MESO cis rs2117029 0.782 rs6580699 ENSG00000258017.1 RP11-386G11.10 4.93 7.58e-06 0.0232 0.65 0.55 Intelligence (multi-trait analysis); chr12:49085029 chr12:49127782~49147869:+ MESO cis rs7044106 0.791 rs10739572 ENSG00000226752.6 PSMD5-AS1 -4.93 7.59e-06 0.0232 -0.77 -0.55 Hip circumference adjusted for BMI; chr9:120727537 chr9:120824828~120854385:+ MESO cis rs1150668 0.699 rs1531681 ENSG00000216901.1 AL022393.7 4.93 7.61e-06 0.0233 0.7 0.55 Pubertal anthropometrics; chr6:28259100 chr6:28176188~28176674:+ MESO cis rs9326248 0.53 rs72645460 ENSG00000254851.1 RP11-109L13.1 4.93 7.64e-06 0.0234 1.13 0.55 Blood protein levels; chr11:116900659 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs17120139 ENSG00000254851.1 RP11-109L13.1 4.93 7.64e-06 0.0234 1.13 0.55 Blood protein levels; chr11:116903485 chr11:117135528~117138582:+ MESO cis rs710913 0.717 rs1180349 ENSG00000237624.1 OXCT2P1 -4.93 7.67e-06 0.0234 -0.66 -0.55 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39540380 chr1:39514956~39516490:+ MESO cis rs710913 0.691 rs1180351 ENSG00000237624.1 OXCT2P1 -4.93 7.67e-06 0.0234 -0.66 -0.55 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39541605 chr1:39514956~39516490:+ MESO cis rs710913 0.717 rs1180352 ENSG00000237624.1 OXCT2P1 -4.93 7.67e-06 0.0234 -0.66 -0.55 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39542157 chr1:39514956~39516490:+ MESO cis rs710913 0.745 rs1180334 ENSG00000237624.1 OXCT2P1 -4.93 7.67e-06 0.0234 -0.66 -0.55 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39555972 chr1:39514956~39516490:+ MESO cis rs1789 0.786 rs6414768 ENSG00000273133.1 RP11-799M12.2 -4.93 7.71e-06 0.0235 -0.81 -0.55 Blood protein levels; chr4:15693740 chr4:15563698~15564253:- MESO cis rs1577917 0.771 rs4351223 ENSG00000203875.9 SNHG5 4.93 7.72e-06 0.0235 0.73 0.55 Response to antipsychotic treatment; chr6:85528079 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs7452605 ENSG00000203875.9 SNHG5 4.93 7.72e-06 0.0235 0.73 0.55 Response to antipsychotic treatment; chr6:85531233 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs9294337 ENSG00000203875.9 SNHG5 4.93 7.72e-06 0.0235 0.73 0.55 Response to antipsychotic treatment; chr6:85538742 chr6:85660950~85678736:- MESO cis rs1577917 0.74 rs6926049 ENSG00000203875.9 SNHG5 4.93 7.72e-06 0.0235 0.73 0.55 Response to antipsychotic treatment; chr6:85556415 chr6:85660950~85678736:- MESO cis rs494459 0.688 rs1048040 ENSG00000278376.1 RP11-158I9.8 -4.93 7.72e-06 0.0235 -0.59 -0.55 Height; chr11:118747911 chr11:118791254~118793137:+ MESO cis rs2117029 0.586 rs6580701 ENSG00000258017.1 RP11-386G11.10 -4.93 7.81e-06 0.0237 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49163482 chr12:49127782~49147869:+ MESO cis rs6108491 0.503 rs11087009 ENSG00000224961.1 RP1-278O22.1 -4.93 7.82e-06 0.0237 -0.75 -0.55 Psychosis proneness (hypomanic personality scale and revised social anhedonia scale); chr20:10339835 chr20:10753090~10753966:+ MESO cis rs6108491 0.503 rs6133872 ENSG00000224961.1 RP1-278O22.1 -4.93 7.82e-06 0.0237 -0.75 -0.55 Psychosis proneness (hypomanic personality scale and revised social anhedonia scale); chr20:10341860 chr20:10753090~10753966:+ MESO cis rs6108491 0.503 rs2327270 ENSG00000224961.1 RP1-278O22.1 -4.93 7.82e-06 0.0237 -0.75 -0.55 Psychosis proneness (hypomanic personality scale and revised social anhedonia scale); chr20:10342028 chr20:10753090~10753966:+ MESO cis rs6108491 0.503 rs7508963 ENSG00000224961.1 RP1-278O22.1 -4.93 7.82e-06 0.0237 -0.75 -0.55 Psychosis proneness (hypomanic personality scale and revised social anhedonia scale); chr20:10342511 chr20:10753090~10753966:+ MESO cis rs494459 0.838 rs1784543 ENSG00000278376.1 RP11-158I9.8 -4.93 7.83e-06 0.0237 -0.57 -0.55 Height; chr11:118760944 chr11:118791254~118793137:+ MESO cis rs494459 0.838 rs581045 ENSG00000278376.1 RP11-158I9.8 -4.93 7.83e-06 0.0237 -0.57 -0.55 Height; chr11:118761813 chr11:118791254~118793137:+ MESO cis rs494459 0.657 rs614554 ENSG00000278376.1 RP11-158I9.8 -4.93 7.83e-06 0.0237 -0.57 -0.55 Height; chr11:118764443 chr11:118791254~118793137:+ MESO cis rs494459 0.838 rs2510897 ENSG00000278376.1 RP11-158I9.8 -4.93 7.83e-06 0.0237 -0.57 -0.55 Height; chr11:118773873 chr11:118791254~118793137:+ MESO cis rs7560272 0.723 rs4346412 ENSG00000163016.8 ALMS1P 4.92 7.84e-06 0.0237 0.86 0.55 Schizophrenia; chr2:73616444 chr2:73644919~73685576:+ MESO cis rs1150668 0.796 rs2531825 ENSG00000216901.1 AL022393.7 4.92 7.84e-06 0.0237 0.71 0.55 Pubertal anthropometrics; chr6:28381487 chr6:28176188~28176674:+ MESO cis rs1150668 0.796 rs213237 ENSG00000216901.1 AL022393.7 4.92 7.85e-06 0.0237 0.72 0.55 Pubertal anthropometrics; chr6:28356161 chr6:28176188~28176674:+ MESO cis rs2729354 0.953 rs2649650 ENSG00000265566.2 RN7SL605P -4.92 7.93e-06 0.0239 -0.66 -0.55 Blood protein levels; chr11:57560094 chr11:57528085~57528365:- MESO cis rs8091660 0.929 rs3744827 ENSG00000278983.1 RP11-426J5.3 -4.92 7.96e-06 0.024 -0.62 -0.55 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48569572 chr18:48564795~48568342:+ MESO cis rs3091242 0.933 rs28530483 ENSG00000224183.1 SDHDP6 -4.92 7.97e-06 0.024 -0.71 -0.55 Erythrocyte sedimentation rate; chr1:25414356 chr1:25294164~25294643:- MESO cis rs6443245 0.591 rs2542365 ENSG00000227110.5 LMCD1-AS1 4.92 7.98e-06 0.024 0.69 0.55 Daytime sleep phenotypes; chr3:9578664 chr3:7952805~8611924:- MESO cis rs7044106 0.791 rs735109 ENSG00000226752.6 PSMD5-AS1 -4.92 8.01e-06 0.0241 -0.73 -0.55 Hip circumference adjusted for BMI; chr9:120726601 chr9:120824828~120854385:+ MESO cis rs7044106 0.791 rs735110 ENSG00000226752.6 PSMD5-AS1 -4.92 8.01e-06 0.0241 -0.73 -0.55 Hip circumference adjusted for BMI; chr9:120726662 chr9:120824828~120854385:+ MESO cis rs55794721 0.509 rs2982358 ENSG00000224183.1 SDHDP6 -4.92 8.04e-06 0.0242 -0.71 -0.55 Mean corpuscular volume;Plateletcrit; chr1:25418713 chr1:25294164~25294643:- MESO cis rs8081395 0.502 rs12947232 ENSG00000266992.1 DHX40P1 -4.92 8.05e-06 0.0242 -0.6 -0.55 White blood cell count; chr17:59714483 chr17:59976009~60002384:- MESO cis rs801193 0.773 rs801207 ENSG00000226824.5 RP4-756H11.3 4.92 8.06e-06 0.0242 0.79 0.55 Aortic root size; chr7:66555603 chr7:66654538~66669855:+ MESO cis rs875971 0.543 rs801191 ENSG00000226824.5 RP4-756H11.3 4.92 8.06e-06 0.0242 0.79 0.55 Aortic root size; chr7:66567968 chr7:66654538~66669855:+ MESO cis rs875971 0.508 rs6947808 ENSG00000226824.5 RP4-756H11.3 4.92 8.06e-06 0.0242 0.79 0.55 Aortic root size; chr7:66580095 chr7:66654538~66669855:+ MESO cis rs875971 0.508 rs10242423 ENSG00000226824.5 RP4-756H11.3 4.92 8.06e-06 0.0242 0.79 0.55 Aortic root size; chr7:66594188 chr7:66654538~66669855:+ MESO cis rs875971 0.508 rs10253883 ENSG00000226824.5 RP4-756H11.3 4.92 8.06e-06 0.0242 0.79 0.55 Aortic root size; chr7:66596151 chr7:66654538~66669855:+ MESO cis rs1577917 0.771 rs12199873 ENSG00000203875.9 SNHG5 -4.92 8.08e-06 0.0242 -0.74 -0.55 Response to antipsychotic treatment; chr6:85585229 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs2842608 ENSG00000203875.9 SNHG5 -4.92 8.08e-06 0.0242 -0.74 -0.55 Response to antipsychotic treatment; chr6:85586140 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs2842609 ENSG00000203875.9 SNHG5 -4.92 8.08e-06 0.0242 -0.74 -0.55 Response to antipsychotic treatment; chr6:85587070 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs2842612 ENSG00000203875.9 SNHG5 -4.92 8.08e-06 0.0242 -0.74 -0.55 Response to antipsychotic treatment; chr6:85593373 chr6:85660950~85678736:- MESO cis rs1577917 0.727 rs2758840 ENSG00000203875.9 SNHG5 -4.92 8.08e-06 0.0242 -0.74 -0.55 Response to antipsychotic treatment; chr6:85594907 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs9362230 ENSG00000203875.9 SNHG5 -4.92 8.08e-06 0.0242 -0.74 -0.55 Response to antipsychotic treatment; chr6:85595295 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs2758844 ENSG00000203875.9 SNHG5 -4.92 8.08e-06 0.0242 -0.74 -0.55 Response to antipsychotic treatment; chr6:85620397 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs2842601 ENSG00000203875.9 SNHG5 -4.92 8.08e-06 0.0242 -0.74 -0.55 Response to antipsychotic treatment; chr6:85620415 chr6:85660950~85678736:- MESO cis rs9532669 0.511 rs3783164 ENSG00000168852.11 TPTE2P5 -4.92 8.1e-06 0.0243 -0.75 -0.55 Cervical cancer; chr13:40806227 chr13:40822296~40921749:- MESO cis rs1150668 0.699 rs1736895 ENSG00000216901.1 AL022393.7 4.91 8.12e-06 0.0243 0.71 0.55 Pubertal anthropometrics; chr6:28252048 chr6:28176188~28176674:+ MESO cis rs11723261 0.621 rs61794960 ENSG00000275426.1 CH17-262A2.1 4.91 8.13e-06 0.0244 0.86 0.55 Immune response to smallpox vaccine (IL-6); chr4:156661 chr4:149738~150317:+ MESO cis rs8177876 0.658 rs16954505 ENSG00000261838.4 RP11-303E16.6 4.91 8.17e-06 0.0244 1.05 0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81040555 chr16:81069854~81076598:+ MESO cis rs8177876 0.749 rs2278025 ENSG00000261838.4 RP11-303E16.6 -4.91 8.17e-06 0.0244 -1.05 -0.55 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81045636 chr16:81069854~81076598:+ MESO cis rs494459 0.964 rs576283 ENSG00000278376.1 RP11-158I9.8 -4.91 8.22e-06 0.0245 -0.57 -0.55 Height; chr11:118703185 chr11:118791254~118793137:+ MESO cis rs494459 0.929 rs627391 ENSG00000278376.1 RP11-158I9.8 -4.91 8.22e-06 0.0245 -0.57 -0.55 Height; chr11:118703207 chr11:118791254~118793137:+ MESO cis rs507080 0.524 rs524409 ENSG00000278376.1 RP11-158I9.8 -4.91 8.22e-06 0.0245 -0.57 -0.55 Serum metabolite levels; chr11:118703602 chr11:118791254~118793137:+ MESO cis rs507080 0.501 rs625735 ENSG00000278376.1 RP11-158I9.8 -4.91 8.22e-06 0.0245 -0.57 -0.55 Serum metabolite levels; chr11:118704710 chr11:118791254~118793137:+ MESO cis rs507080 0.501 rs637563 ENSG00000278376.1 RP11-158I9.8 -4.91 8.22e-06 0.0245 -0.57 -0.55 Serum metabolite levels; chr11:118704770 chr11:118791254~118793137:+ MESO cis rs80285556 1 rs17311679 ENSG00000161643.11 SIGLEC16 -4.91 8.24e-06 0.0246 -1.39 -0.55 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50018074 chr19:49969673~49975814:+ MESO cis rs80285556 0.655 rs17311832 ENSG00000161643.11 SIGLEC16 4.91 8.24e-06 0.0246 1.39 0.55 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50022059 chr19:49969673~49975814:+ MESO cis rs80285556 1 rs80314222 ENSG00000161643.11 SIGLEC16 4.91 8.24e-06 0.0246 1.39 0.55 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50022257 chr19:49969673~49975814:+ MESO cis rs80285556 1 rs79602855 ENSG00000161643.11 SIGLEC16 4.91 8.24e-06 0.0246 1.39 0.55 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50022468 chr19:49969673~49975814:+ MESO cis rs80285556 1 rs17661933 ENSG00000161643.11 SIGLEC16 -4.91 8.24e-06 0.0246 -1.39 -0.55 antipsychotic drug dosage in schizophrenia or schizoaffective disorder; chr19:50031263 chr19:49969673~49975814:+ MESO cis rs10256972 0.577 rs4999286 ENSG00000229043.2 AC091729.9 -4.91 8.27e-06 0.0246 -0.65 -0.55 Endometriosis;Longevity; chr7:1159870 chr7:1160374~1165267:+ MESO cis rs10256972 0.552 rs2960830 ENSG00000229043.2 AC091729.9 -4.91 8.27e-06 0.0246 -0.65 -0.55 Endometriosis;Longevity; chr7:1161005 chr7:1160374~1165267:+ MESO cis rs10256972 0.552 rs2960831 ENSG00000229043.2 AC091729.9 -4.91 8.27e-06 0.0246 -0.65 -0.55 Endometriosis;Longevity; chr7:1161556 chr7:1160374~1165267:+ MESO cis rs10256972 0.552 rs2949195 ENSG00000229043.2 AC091729.9 -4.91 8.27e-06 0.0246 -0.65 -0.55 Endometriosis;Longevity; chr7:1163069 chr7:1160374~1165267:+ MESO cis rs10256972 0.552 rs2949192 ENSG00000229043.2 AC091729.9 -4.91 8.27e-06 0.0246 -0.65 -0.55 Endometriosis;Longevity; chr7:1164205 chr7:1160374~1165267:+ MESO cis rs10256972 0.552 rs2960837 ENSG00000229043.2 AC091729.9 -4.91 8.27e-06 0.0246 -0.65 -0.55 Endometriosis;Longevity; chr7:1164321 chr7:1160374~1165267:+ MESO cis rs1153858 1 rs4775911 ENSG00000259520.4 CTD-2651B20.3 4.91 8.27e-06 0.0246 0.73 0.55 Homoarginine levels; chr15:45357589 chr15:45251580~45279251:- MESO cis rs801193 0.844 rs732465 ENSG00000226824.5 RP4-756H11.3 -4.91 8.27e-06 0.0246 -0.79 -0.55 Aortic root size; chr7:66533463 chr7:66654538~66669855:+ MESO cis rs4835473 0.932 rs1597445 ENSG00000251600.4 RP11-673E1.1 -4.91 8.31e-06 0.0247 -0.7 -0.55 Immature fraction of reticulocytes; chr4:143768543 chr4:143912331~143982454:+ MESO cis rs26868 0.69 rs26835 ENSG00000266643.1 MIR3677 4.91 8.32e-06 0.0248 0.6 0.55 Height; chr16:2187548 chr16:2270713~2270772:+ MESO cis rs2117029 0.555 rs9788140 ENSG00000258017.1 RP11-386G11.10 -4.91 8.33e-06 0.0248 -0.72 -0.55 Intelligence (multi-trait analysis); chr12:49126738 chr12:49127782~49147869:+ MESO cis rs2117029 0.555 rs9788139 ENSG00000258017.1 RP11-386G11.10 -4.91 8.33e-06 0.0248 -0.72 -0.55 Intelligence (multi-trait analysis); chr12:49126886 chr12:49127782~49147869:+ MESO cis rs1930961 1 rs6004673 ENSG00000272977.1 CTA-390C10.10 -4.91 8.39e-06 0.0249 -1.24 -0.55 Bipolar disorder with mood-incongruent psychosis; chr22:25489386 chr22:25476218~25479971:+ MESO cis rs1150668 0.83 rs2859365 ENSG00000216901.1 AL022393.7 -4.9 8.44e-06 0.025 -0.72 -0.55 Pubertal anthropometrics; chr6:28423688 chr6:28176188~28176674:+ MESO cis rs1150668 0.796 rs2247002 ENSG00000216901.1 AL022393.7 4.9 8.44e-06 0.025 0.72 0.55 Pubertal anthropometrics; chr6:28430174 chr6:28176188~28176674:+ MESO cis rs6964833 1 rs17515241 ENSG00000123965.13 PMS2P5 -4.9 8.48e-06 0.0251 -0.93 -0.55 Menarche (age at onset); chr7:74717695 chr7:74894116~74897835:+ MESO cis rs6964833 1 rs34324835 ENSG00000123965.13 PMS2P5 4.9 8.48e-06 0.0251 0.93 0.55 Menarche (age at onset); chr7:74717986 chr7:74894116~74897835:+ MESO cis rs1577917 0.561 rs3087978 ENSG00000203875.9 SNHG5 4.9 8.48e-06 0.0251 0.68 0.55 Response to antipsychotic treatment; chr6:85678505 chr6:85660950~85678736:- MESO cis rs7684253 0.548 rs62308071 ENSG00000269949.1 RP11-738E22.3 -4.9 8.49e-06 0.0251 -0.75 -0.55 Migraine; chr4:56850720 chr4:56960927~56961373:- MESO cis rs7684253 0.548 rs922570 ENSG00000269949.1 RP11-738E22.3 -4.9 8.49e-06 0.0251 -0.75 -0.55 Migraine; chr4:56851192 chr4:56960927~56961373:- MESO cis rs950027 0.62 rs1145084 ENSG00000259520.4 CTD-2651B20.3 -4.9 8.52e-06 0.0251 -0.72 -0.55 Response to fenofibrate (adiponectin levels); chr15:45383242 chr15:45251580~45279251:- MESO cis rs6443245 0.511 rs2542366 ENSG00000227110.5 LMCD1-AS1 4.9 8.53e-06 0.0251 0.69 0.55 Daytime sleep phenotypes; chr3:9578671 chr3:7952805~8611924:- MESO cis rs7617773 0.743 rs6804986 ENSG00000229759.1 MRPS18AP1 4.9 8.63e-06 0.0254 0.69 0.55 Coronary artery disease; chr3:48322105 chr3:48256350~48256938:- MESO cis rs7044106 0.762 rs3904197 ENSG00000226752.6 PSMD5-AS1 -4.9 8.65e-06 0.0254 -0.77 -0.55 Hip circumference adjusted for BMI; chr9:120718100 chr9:120824828~120854385:+ MESO cis rs1577917 0.771 rs7742201 ENSG00000203875.9 SNHG5 -4.9 8.67e-06 0.0254 -0.68 -0.55 Response to antipsychotic treatment; chr6:85723212 chr6:85660950~85678736:- MESO cis rs1153858 1 rs1145074 ENSG00000259520.4 CTD-2651B20.3 -4.9 8.69e-06 0.0255 -0.75 -0.55 Homoarginine levels; chr15:45411626 chr15:45251580~45279251:- MESO cis rs6700559 0.873 rs7524025 ENSG00000260088.1 RP11-92G12.3 -4.9 8.69e-06 0.0255 -0.59 -0.55 Coronary artery disease; chr1:200687859 chr1:200669507~200694250:+ MESO cis rs6700559 0.683 rs7548530 ENSG00000260088.1 RP11-92G12.3 -4.9 8.69e-06 0.0255 -0.59 -0.55 Coronary artery disease; chr1:200687904 chr1:200669507~200694250:+ MESO cis rs6700559 0.683 rs7526136 ENSG00000260088.1 RP11-92G12.3 -4.9 8.69e-06 0.0255 -0.59 -0.55 Coronary artery disease; chr1:200687911 chr1:200669507~200694250:+ MESO cis rs6700559 0.733 rs7526265 ENSG00000260088.1 RP11-92G12.3 -4.9 8.69e-06 0.0255 -0.59 -0.55 Coronary artery disease; chr1:200687916 chr1:200669507~200694250:+ MESO cis rs11673344 0.566 rs1545755 ENSG00000226686.6 LINC01535 4.9 8.7e-06 0.0255 0.6 0.55 Obesity-related traits; chr19:37490607 chr19:37251912~37265535:+ MESO cis rs11673344 0.583 rs7247090 ENSG00000226686.6 LINC01535 4.9 8.7e-06 0.0255 0.6 0.55 Obesity-related traits; chr19:37522509 chr19:37251912~37265535:+ MESO cis rs10885396 1 rs10885396 ENSG00000233547.1 RP11-57H14.2 -4.9 8.7e-06 0.0255 -0.66 -0.55 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112951996 chr10:112950646~112951875:- MESO cis rs10885396 0.967 rs7094871 ENSG00000233547.1 RP11-57H14.2 -4.9 8.7e-06 0.0255 -0.66 -0.55 Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells; chr10:112952395 chr10:112950646~112951875:- MESO cis rs7044106 0.762 rs10760115 ENSG00000226752.6 PSMD5-AS1 -4.89 8.74e-06 0.0256 -0.8 -0.55 Hip circumference adjusted for BMI; chr9:120714674 chr9:120824828~120854385:+ MESO cis rs73086581 0.947 rs73084523 ENSG00000229539.1 RP11-119B16.2 4.89 8.79e-06 0.0257 0.72 0.55 Response to antidepressants in depression; chr20:3894979 chr20:3888239~3888868:- MESO cis rs9918079 0.56 rs4270584 ENSG00000273133.1 RP11-799M12.2 4.89 8.85e-06 0.0258 0.74 0.55 Obesity-related traits; chr4:15599176 chr4:15563698~15564253:- MESO cis rs9918079 0.542 rs12499412 ENSG00000273133.1 RP11-799M12.2 4.89 8.85e-06 0.0258 0.74 0.55 Obesity-related traits; chr4:15600629 chr4:15563698~15564253:- MESO cis rs2117029 0.653 rs1476137 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49129930 chr12:49127782~49147869:+ MESO cis rs2117029 0.553 rs731350 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49130804 chr12:49127782~49147869:+ MESO cis rs2117029 0.619 rs9325145 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49132101 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs10783307 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49135822 chr12:49127782~49147869:+ MESO cis rs2117029 0.554 rs12306494 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49136998 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs10783308 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49137675 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs11168884 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49146109 chr12:49127782~49147869:+ MESO cis rs11168854 0.719 rs11168890 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Body mass index; chr12:49150130 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs7954521 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49151857 chr12:49127782~49147869:+ MESO cis rs2117029 0.553 rs2162644 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49154407 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs2114846 ENSG00000258017.1 RP11-386G11.10 -4.89 8.96e-06 0.0261 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49154493 chr12:49127782~49147869:+ MESO cis rs9309473 0.519 rs35421685 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Metabolite levels; chr2:73683011 chr2:73644919~73685576:+ MESO cis rs7560272 0.588 rs4852965 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73684042 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs4852972 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73689545 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs13000788 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73691185 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs2421575 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73692395 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs13014700 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73692994 chr2:73644919~73685576:+ MESO cis rs7560272 0.512 rs13015885 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73693355 chr2:73644919~73685576:+ MESO cis rs7560272 0.502 rs4513320 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73693614 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs12619258 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73708788 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs4852976 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73709195 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs11126415 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73709373 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs12053242 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73710041 chr2:73644919~73685576:+ MESO cis rs7560272 0.513 rs7558546 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73710605 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs7599453 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73710774 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs4852977 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73711168 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs4241257 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73711480 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs3980695 ENSG00000163016.8 ALMS1P -4.89 8.98e-06 0.0261 -0.86 -0.55 Schizophrenia; chr2:73712425 chr2:73644919~73685576:+ MESO cis rs7560272 0.538 rs12052539 ENSG00000163016.8 ALMS1P 4.89 8.98e-06 0.0261 0.86 0.55 Schizophrenia; chr2:73710026 chr2:73644919~73685576:+ MESO cis rs9322193 0.847 rs868375 ENSG00000231760.4 RP11-350J20.5 4.89 8.98e-06 0.0261 0.79 0.55 Lung cancer; chr6:149844905 chr6:149796151~149826294:- MESO cis rs9322193 0.847 rs880246 ENSG00000231760.4 RP11-350J20.5 4.89 9e-06 0.0262 0.8 0.55 Lung cancer; chr6:149845972 chr6:149796151~149826294:- MESO cis rs1150668 0.699 rs12214383 ENSG00000216901.1 AL022393.7 -4.89 9e-06 0.0262 -0.71 -0.55 Pubertal anthropometrics; chr6:28255953 chr6:28176188~28176674:+ MESO cis rs1577917 0.74 rs2758845 ENSG00000203875.9 SNHG5 -4.89 9.02e-06 0.0262 -0.75 -0.55 Response to antipsychotic treatment; chr6:85625130 chr6:85660950~85678736:- MESO cis rs1577917 0.696 rs2842603 ENSG00000203875.9 SNHG5 -4.89 9.02e-06 0.0262 -0.75 -0.55 Response to antipsychotic treatment; chr6:85626619 chr6:85660950~85678736:- MESO cis rs1577917 0.74 rs12212560 ENSG00000203875.9 SNHG5 -4.89 9.02e-06 0.0262 -0.75 -0.55 Response to antipsychotic treatment; chr6:85632961 chr6:85660950~85678736:- MESO cis rs1153858 1 rs12909158 ENSG00000259520.4 CTD-2651B20.3 -4.89 9.02e-06 0.0262 -0.73 -0.55 Homoarginine levels; chr15:45328976 chr15:45251580~45279251:- MESO cis rs380904 0.552 rs10099003 ENSG00000254859.1 RP11-661A12.5 -4.88 9.06e-06 0.0263 -0.7 -0.55 Venous thromboembolism (SNP x SNP interaction); chr8:143563290 chr8:143541973~143549729:- MESO cis rs73086581 0.898 rs11906452 ENSG00000229539.1 RP11-119B16.2 4.88 9.07e-06 0.0263 0.72 0.55 Response to antidepressants in depression; chr20:4000912 chr20:3888239~3888868:- MESO cis rs1961649 0.75 rs1912861 ENSG00000280088.1 RP11-135F9.3 4.88 9.1e-06 0.0264 0.95 0.55 Metabolite levels (HVA/5-HIAA ratio); chr12:99498982 chr12:100032325~100034074:- MESO cis rs9660180 0.62 rs34298494 ENSG00000268575.1 RP1-283E3.8 4.88 9.11e-06 0.0264 0.56 0.55 Body mass index; chr1:1731963 chr1:1702736~1737688:- MESO cis rs9322193 0.884 rs7769115 ENSG00000231760.4 RP11-350J20.5 4.88 9.12e-06 0.0264 0.77 0.55 Lung cancer; chr6:149848796 chr6:149796151~149826294:- MESO cis rs9322193 0.772 rs7738696 ENSG00000231760.4 RP11-350J20.5 4.88 9.12e-06 0.0264 0.77 0.55 Lung cancer; chr6:149848985 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs7743823 ENSG00000231760.4 RP11-350J20.5 4.88 9.12e-06 0.0264 0.77 0.55 Lung cancer; chr6:149849744 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs1108889 ENSG00000231760.4 RP11-350J20.5 4.88 9.16e-06 0.0265 0.81 0.55 Lung cancer; chr6:149845433 chr6:149796151~149826294:- MESO cis rs7044106 0.791 rs10985009 ENSG00000226752.6 PSMD5-AS1 4.88 9.21e-06 0.0266 0.74 0.55 Hip circumference adjusted for BMI; chr9:120730761 chr9:120824828~120854385:+ MESO cis rs8091660 0.929 rs2175564 ENSG00000278983.1 RP11-426J5.3 4.88 9.22e-06 0.0266 0.61 0.55 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48570838 chr18:48564795~48568342:+ MESO cis rs9326248 0.516 rs6589577 ENSG00000254851.1 RP11-109L13.1 -4.88 9.25e-06 0.0267 -1.12 -0.55 Blood protein levels; chr11:116879261 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs7124741 ENSG00000254851.1 RP11-109L13.1 -4.88 9.25e-06 0.0267 -1.12 -0.55 Blood protein levels; chr11:116881503 chr11:117135528~117138582:+ MESO cis rs11723261 0.564 rs60994255 ENSG00000275426.1 CH17-262A2.1 4.88 9.35e-06 0.0269 0.9 0.55 Immune response to smallpox vaccine (IL-6); chr4:77554 chr4:149738~150317:+ MESO cis rs1577917 0.771 rs2484355 ENSG00000203875.9 SNHG5 -4.87 9.38e-06 0.027 -0.68 -0.55 Response to antipsychotic treatment; chr6:85684685 chr6:85660950~85678736:- MESO cis rs1577917 0.785 rs1885607 ENSG00000203875.9 SNHG5 4.87 9.38e-06 0.027 0.68 0.55 Response to antipsychotic treatment; chr6:85685187 chr6:85660950~85678736:- MESO cis rs6546847 0.531 rs2567602 ENSG00000163016.8 ALMS1P 4.87 9.39e-06 0.027 1 0.55 Urinary metabolites (H-NMR features); chr2:73758409 chr2:73644919~73685576:+ MESO cis rs6546847 0.531 rs2567603 ENSG00000163016.8 ALMS1P 4.87 9.39e-06 0.027 1 0.55 Urinary metabolites (H-NMR features); chr2:73758998 chr2:73644919~73685576:+ MESO cis rs9322193 0.923 rs7769101 ENSG00000231760.4 RP11-350J20.5 4.87 9.43e-06 0.0271 0.74 0.55 Lung cancer; chr6:149848768 chr6:149796151~149826294:- MESO cis rs975739 0.843 rs1041619 ENSG00000236051.5 MYCBP2-AS1 -4.87 9.44e-06 0.0271 -0.63 -0.55 Hair color; chr13:77835015 chr13:77075514~77129717:+ MESO cis rs8100891 0.537 rs4805754 ENSG00000267213.4 AC007773.2 -4.87 9.48e-06 0.0272 -0.99 -0.55 Neuroticism; chr19:32346260 chr19:32390050~32405560:- MESO cis rs801193 0.839 rs6968619 ENSG00000226824.5 RP4-756H11.3 4.87 9.53e-06 0.0273 0.79 0.55 Aortic root size; chr7:66603880 chr7:66654538~66669855:+ MESO cis rs801193 0.839 rs12534943 ENSG00000226824.5 RP4-756H11.3 4.87 9.53e-06 0.0273 0.79 0.55 Aortic root size; chr7:66605533 chr7:66654538~66669855:+ MESO cis rs801193 0.805 rs12532355 ENSG00000226824.5 RP4-756H11.3 4.87 9.53e-06 0.0273 0.79 0.55 Aortic root size; chr7:66605597 chr7:66654538~66669855:+ MESO cis rs6443245 0.611 rs67854857 ENSG00000227110.5 LMCD1-AS1 4.87 9.53e-06 0.0273 0.69 0.55 Daytime sleep phenotypes; chr3:9585850 chr3:7952805~8611924:- MESO cis rs73086581 0.568 rs6084541 ENSG00000229539.1 RP11-119B16.2 -4.87 9.58e-06 0.0275 -0.69 -0.55 Response to antidepressants in depression; chr20:3982084 chr20:3888239~3888868:- MESO cis rs4835473 0.932 rs4305468 ENSG00000251600.4 RP11-673E1.1 -4.87 9.58e-06 0.0275 -0.65 -0.55 Immature fraction of reticulocytes; chr4:143987315 chr4:143912331~143982454:+ MESO cis rs2117029 0.619 rs2753 ENSG00000258017.1 RP11-386G11.10 -4.87 9.59e-06 0.0275 -0.68 -0.55 Intelligence (multi-trait analysis); chr12:49127889 chr12:49127782~49147869:+ MESO cis rs6964833 1 rs3846966 ENSG00000123965.13 PMS2P5 4.87 9.64e-06 0.0276 0.94 0.55 Menarche (age at onset); chr7:74698811 chr7:74894116~74897835:+ MESO cis rs975739 1 rs975739 ENSG00000236051.5 MYCBP2-AS1 4.87 9.68e-06 0.0277 0.69 0.55 Hair color; chr13:77807011 chr13:77075514~77129717:+ MESO cis rs7044106 0.5 rs56725168 ENSG00000226752.6 PSMD5-AS1 -4.86 9.71e-06 0.0278 -0.75 -0.55 Hip circumference adjusted for BMI; chr9:120730298 chr9:120824828~120854385:+ MESO cis rs7044106 0.791 rs10985008 ENSG00000226752.6 PSMD5-AS1 -4.86 9.71e-06 0.0278 -0.75 -0.55 Hip circumference adjusted for BMI; chr9:120730682 chr9:120824828~120854385:+ MESO cis rs6443245 0.611 rs2648371 ENSG00000227110.5 LMCD1-AS1 -4.86 9.75e-06 0.0279 -0.69 -0.54 Daytime sleep phenotypes; chr3:9586691 chr3:7952805~8611924:- MESO cis rs11083475 1 rs979972 ENSG00000269486.2 CTC-360G5.9 4.86 9.81e-06 0.028 0.87 0.54 Heart rate; chr19:38653527 chr19:38935297~38938632:- MESO cis rs1153858 0.945 rs1974981 ENSG00000259520.4 CTD-2651B20.3 4.86 9.84e-06 0.0281 0.75 0.54 Homoarginine levels; chr15:45436925 chr15:45251580~45279251:- MESO cis rs9322193 0.886 rs4870055 ENSG00000231760.4 RP11-350J20.5 4.86 9.88e-06 0.0282 0.75 0.54 Lung cancer; chr6:149848433 chr6:149796151~149826294:- MESO cis rs7927592 0.956 rs2510384 ENSG00000212093.1 AP000807.1 4.86 9.9e-06 0.0282 0.54 0.54 Total body bone mineral density; chr11:68624369 chr11:68506083~68506166:- MESO cis rs11083475 1 rs883433 ENSG00000269486.2 CTC-360G5.9 -4.86 9.92e-06 0.0282 -0.9 -0.54 Heart rate; chr19:38715648 chr19:38935297~38938632:- MESO cis rs7044106 0.791 rs4617229 ENSG00000226752.6 PSMD5-AS1 -4.86 9.93e-06 0.0283 -0.77 -0.54 Hip circumference adjusted for BMI; chr9:120718418 chr9:120824828~120854385:+ MESO cis rs11083475 0.967 rs55876653 ENSG00000269486.2 CTC-360G5.9 4.86 9.99e-06 0.0284 0.87 0.54 Heart rate; chr19:38656140 chr19:38935297~38938632:- MESO cis rs1153858 1 rs1153849 ENSG00000259520.4 CTD-2651B20.3 -4.86 1e-05 0.0284 -0.75 -0.54 Homoarginine levels; chr15:45403497 chr15:45251580~45279251:- MESO cis rs1153858 0.945 rs2467854 ENSG00000259520.4 CTD-2651B20.3 -4.86 1e-05 0.0284 -0.75 -0.54 Homoarginine levels; chr15:45409399 chr15:45251580~45279251:- MESO cis rs1153858 1 rs2461701 ENSG00000259520.4 CTD-2651B20.3 -4.86 1e-05 0.0284 -0.75 -0.54 Homoarginine levels; chr15:45411193 chr15:45251580~45279251:- MESO cis rs1153858 1 rs2467858 ENSG00000259520.4 CTD-2651B20.3 -4.86 1e-05 0.0284 -0.75 -0.54 Homoarginine levels; chr15:45419294 chr15:45251580~45279251:- MESO cis rs6565653 1 rs6565653 ENSG00000262580.4 RP11-334C17.5 4.86 1e-05 0.0285 0.53 0.54 Ischemic stroke; chr17:80227984 chr17:80200673~80205949:- MESO cis rs860295 0.651 rs6677385 ENSG00000228264.1 PSMD8P1 4.85 1.01e-05 0.0286 0.81 0.54 Body mass index; chr1:155334790 chr1:154414369~154415137:- MESO cis rs8177876 0.658 rs12456 ENSG00000261838.4 RP11-303E16.6 4.85 1.01e-05 0.0287 1 0.54 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81031454 chr16:81069854~81076598:+ MESO cis rs7044106 0.791 rs7036196 ENSG00000226752.6 PSMD5-AS1 -4.85 1.01e-05 0.0287 -0.77 -0.54 Hip circumference adjusted for BMI; chr9:120717179 chr9:120824828~120854385:+ MESO cis rs7044106 0.791 rs2416799 ENSG00000226752.6 PSMD5-AS1 -4.85 1.01e-05 0.0287 -0.77 -0.54 Hip circumference adjusted for BMI; chr9:120718588 chr9:120824828~120854385:+ MESO cis rs7044106 0.791 rs10984998 ENSG00000226752.6 PSMD5-AS1 -4.85 1.01e-05 0.0287 -0.77 -0.54 Hip circumference adjusted for BMI; chr9:120719238 chr9:120824828~120854385:+ MESO cis rs710913 0.816 rs1727098 ENSG00000237624.1 OXCT2P1 -4.85 1.01e-05 0.0287 -0.66 -0.54 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39523655 chr1:39514956~39516490:+ MESO cis rs8091660 0.929 rs12606093 ENSG00000278983.1 RP11-426J5.3 4.85 1.02e-05 0.0287 0.63 0.54 Response to carboplatin in ovarian cancer (MTT IC50); chr18:48550924 chr18:48564795~48568342:+ MESO cis rs11083475 1 rs56365761 ENSG00000269486.2 CTC-360G5.9 4.85 1.02e-05 0.0289 0.87 0.54 Heart rate; chr19:38657463 chr19:38935297~38938632:- MESO cis rs10256972 0.567 rs2960850 ENSG00000229043.2 AC091729.9 -4.85 1.03e-05 0.029 -0.67 -0.54 Endometriosis;Longevity; chr7:1172013 chr7:1160374~1165267:+ MESO cis rs2283792 0.687 rs381849 ENSG00000224086.5 LL22NC03-86G7.1 -4.85 1.03e-05 0.029 -0.66 -0.54 Multiple sclerosis; chr22:21951341 chr22:21938293~21977632:+ MESO cis rs7617773 0.78 rs13084616 ENSG00000229759.1 MRPS18AP1 -4.85 1.03e-05 0.0292 -0.67 -0.54 Coronary artery disease; chr3:48298209 chr3:48256350~48256938:- MESO cis rs1577917 0.655 rs9444352 ENSG00000203875.9 SNHG5 4.85 1.04e-05 0.0293 0.7 0.54 Response to antipsychotic treatment; chr6:85547817 chr6:85660950~85678736:- MESO cis rs7626444 0.625 rs1718410 ENSG00000272359.1 U4 -4.84 1.04e-05 0.0294 -0.62 -0.54 Monocyte count; chr3:196750789 chr3:196747192~196747324:- MESO cis rs9322193 0.607 rs9383941 ENSG00000231760.4 RP11-350J20.5 -4.84 1.04e-05 0.0294 -0.73 -0.54 Lung cancer; chr6:149912100 chr6:149796151~149826294:- MESO cis rs11123170 0.65 rs2289897 ENSG00000189223.12 PAX8-AS1 -4.84 1.05e-05 0.0295 -0.72 -0.54 Renal function-related traits (BUN); chr2:113219877 chr2:113211522~113276581:+ MESO cis rs1789 0.786 rs6449161 ENSG00000273133.1 RP11-799M12.2 -4.84 1.05e-05 0.0296 -0.79 -0.54 Blood protein levels; chr4:15691331 chr4:15563698~15564253:- MESO cis rs26868 0.591 rs26831 ENSG00000266643.1 MIR3677 4.84 1.06e-05 0.0298 0.62 0.54 Height; chr16:2191483 chr16:2270713~2270772:+ MESO cis rs6964833 0.935 rs13238996 ENSG00000277053.3 GTF2IP1 -4.84 1.06e-05 0.0299 -0.7 -0.54 Menarche (age at onset); chr7:74655318 chr7:75185385~75237696:- MESO cis rs975739 0.966 rs9544612 ENSG00000236051.5 MYCBP2-AS1 -4.84 1.06e-05 0.0299 -0.65 -0.54 Hair color; chr13:77830706 chr13:77075514~77129717:+ MESO cis rs950027 0.967 rs2643718 ENSG00000259520.4 CTD-2651B20.3 -4.84 1.07e-05 0.03 -0.63 -0.54 Response to fenofibrate (adiponectin levels); chr15:45502464 chr15:45251580~45279251:- MESO cis rs9326248 0.569 rs652455 ENSG00000254851.1 RP11-109L13.1 -4.84 1.07e-05 0.03 -0.98 -0.54 Blood protein levels; chr11:117200733 chr11:117135528~117138582:+ MESO cis rs2117029 0.554 rs2334931 ENSG00000258017.1 RP11-386G11.10 -4.84 1.07e-05 0.03 -0.68 -0.54 Intelligence (multi-trait analysis); chr12:49174130 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs10875929 ENSG00000258017.1 RP11-386G11.10 -4.84 1.07e-05 0.03 -0.68 -0.54 Intelligence (multi-trait analysis); chr12:49174605 chr12:49127782~49147869:+ MESO cis rs2117029 0.554 rs2334930 ENSG00000258017.1 RP11-386G11.10 -4.84 1.07e-05 0.03 -0.68 -0.54 Intelligence (multi-trait analysis); chr12:49175528 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs11168904 ENSG00000258017.1 RP11-386G11.10 -4.84 1.07e-05 0.03 -0.68 -0.54 Intelligence (multi-trait analysis); chr12:49177234 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs10875931 ENSG00000258017.1 RP11-386G11.10 -4.84 1.07e-05 0.03 -0.68 -0.54 Intelligence (multi-trait analysis); chr12:49179513 chr12:49127782~49147869:+ MESO cis rs2117029 0.554 rs7954530 ENSG00000258017.1 RP11-386G11.10 -4.84 1.07e-05 0.03 -0.68 -0.54 Intelligence (multi-trait analysis); chr12:49179742 chr12:49127782~49147869:+ MESO cis rs2117029 0.586 rs7957998 ENSG00000258017.1 RP11-386G11.10 -4.84 1.07e-05 0.03 -0.68 -0.54 Intelligence (multi-trait analysis); chr12:49180240 chr12:49127782~49147869:+ MESO cis rs2117029 0.553 rs11168909 ENSG00000258017.1 RP11-386G11.10 -4.84 1.07e-05 0.03 -0.68 -0.54 Intelligence (multi-trait analysis); chr12:49183092 chr12:49127782~49147869:+ MESO cis rs1061377 0.965 rs7690465 ENSG00000249207.1 RP11-360F5.1 -4.84 1.07e-05 0.03 -0.63 -0.54 Uric acid levels; chr4:39147015 chr4:39112677~39126818:- MESO cis rs1153858 1 rs59889118 ENSG00000259520.4 CTD-2651B20.3 -4.84 1.07e-05 0.0301 -0.73 -0.54 Homoarginine levels; chr15:45326532 chr15:45251580~45279251:- MESO cis rs508487 0.537 rs5072 ENSG00000254851.1 RP11-109L13.1 -4.84 1.07e-05 0.0301 -1.2 -0.54 Cardiovascular disease risk factors;Triglyceride levels; chr11:116836867 chr11:117135528~117138582:+ MESO cis rs1150668 0.764 rs9368565 ENSG00000216901.1 AL022393.7 -4.84 1.08e-05 0.0301 -0.7 -0.54 Pubertal anthropometrics; chr6:28377433 chr6:28176188~28176674:+ MESO cis rs1150668 0.796 rs1052215 ENSG00000216901.1 AL022393.7 -4.84 1.08e-05 0.0301 -0.7 -0.54 Pubertal anthropometrics; chr6:28380381 chr6:28176188~28176674:+ MESO cis rs9326248 0.53 rs1351452 ENSG00000254851.1 RP11-109L13.1 4.83 1.08e-05 0.0301 1.1 0.54 Blood protein levels; chr11:117072638 chr11:117135528~117138582:+ MESO cis rs7115242 0.669 rs1241658 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116948901 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs511676 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Blood protein levels; chr11:116954168 chr11:117135528~117138582:+ MESO cis rs7115242 0.8 rs493134 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116962963 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs588918 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Blood protein levels; chr11:116985926 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs7121347 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Blood protein levels; chr11:116996493 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs7114963 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Blood protein levels; chr11:117005267 chr11:117135528~117138582:+ MESO cis rs7115242 0.72 rs10790169 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117006443 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs7950364 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Blood protein levels; chr11:117028170 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs2155583 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Blood protein levels; chr11:117044501 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs2000615 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Blood protein levels; chr11:117045103 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs10790172 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Blood protein levels; chr11:117057024 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs6589589 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Blood protein levels; chr11:117061712 chr11:117135528~117138582:+ MESO cis rs7115242 0.8 rs10736487 ENSG00000254851.1 RP11-109L13.1 -4.83 1.08e-05 0.0301 -1.1 -0.54 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117079516 chr11:117135528~117138582:+ MESO cis rs7174755 0.772 rs75395345 ENSG00000260657.2 RP11-315D16.4 4.83 1.09e-05 0.0303 0.6 0.54 Major depressive disorder; chr15:68081380 chr15:68267792~68277994:- MESO cis rs11723261 0.621 rs57013142 ENSG00000275426.1 CH17-262A2.1 4.83 1.09e-05 0.0303 0.85 0.54 Immune response to smallpox vaccine (IL-6); chr4:141956 chr4:149738~150317:+ MESO cis rs11723261 0.564 rs61792258 ENSG00000275426.1 CH17-262A2.1 4.83 1.09e-05 0.0303 0.85 0.54 Immune response to smallpox vaccine (IL-6); chr4:143482 chr4:149738~150317:+ MESO cis rs11723261 0.621 rs11733385 ENSG00000275426.1 CH17-262A2.1 4.83 1.09e-05 0.0303 0.85 0.54 Immune response to smallpox vaccine (IL-6); chr4:146677 chr4:149738~150317:+ MESO cis rs11723261 0.546 rs4315728 ENSG00000275426.1 CH17-262A2.1 4.83 1.09e-05 0.0303 0.85 0.54 Immune response to smallpox vaccine (IL-6); chr4:147237 chr4:149738~150317:+ MESO cis rs10510102 0.872 rs7906271 ENSG00000273891.1 RP11-500G22.5 -4.83 1.09e-05 0.0303 -0.82 -0.54 Breast cancer; chr10:121948207 chr10:121965764~121967700:+ MESO cis rs10510102 0.872 rs10887032 ENSG00000273891.1 RP11-500G22.5 -4.83 1.09e-05 0.0303 -0.82 -0.54 Breast cancer; chr10:121955887 chr10:121965764~121967700:+ MESO cis rs4835473 0.9 rs71612420 ENSG00000251600.4 RP11-673E1.1 -4.83 1.09e-05 0.0304 -0.66 -0.54 Immature fraction of reticulocytes; chr4:143779107 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs13134869 ENSG00000251600.4 RP11-673E1.1 -4.83 1.09e-05 0.0304 -0.66 -0.54 Immature fraction of reticulocytes; chr4:143782301 chr4:143912331~143982454:+ MESO cis rs7044106 0.791 rs3904196 ENSG00000226752.6 PSMD5-AS1 -4.83 1.09e-05 0.0305 -0.77 -0.54 Hip circumference adjusted for BMI; chr9:120718091 chr9:120824828~120854385:+ MESO cis rs4835473 0.9 rs7689374 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143769567 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs6537183 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143770441 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs12512202 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143771248 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs6843671 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143772041 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs35395070 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143772283 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs34614750 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143772369 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs35002497 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143772952 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs13119630 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143773901 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1450233 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143774710 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs4308330 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143774761 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs11725708 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143775683 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs17762299 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143777196 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs17694797 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143778812 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs35947975 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143778969 chr4:143912331~143982454:+ MESO cis rs4835473 0.778 rs75562808 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143779065 chr4:143912331~143982454:+ MESO cis rs4835473 0.669 rs75704080 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143779066 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1375987 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143779622 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs7687151 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143781681 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs1450236 ENSG00000251600.4 RP11-673E1.1 -4.83 1.1e-05 0.0306 -0.67 -0.54 Immature fraction of reticulocytes; chr4:143783069 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs13152209 ENSG00000251600.4 RP11-673E1.1 4.83 1.1e-05 0.0306 0.67 0.54 Immature fraction of reticulocytes; chr4:143776088 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs10016223 ENSG00000251600.4 RP11-673E1.1 4.83 1.1e-05 0.0306 0.67 0.54 Immature fraction of reticulocytes; chr4:143777429 chr4:143912331~143982454:+ MESO cis rs6565653 0.967 rs6565652 ENSG00000262580.4 RP11-334C17.5 4.83 1.1e-05 0.0307 0.53 0.54 Ischemic stroke; chr17:80227755 chr17:80200673~80205949:- MESO cis rs3931020 0.745 rs1969111 ENSG00000272864.1 RP11-17E13.2 4.83 1.11e-05 0.0307 0.74 0.54 Resistin levels; chr1:74797801 chr1:74698769~74699333:- MESO cis rs3931020 0.72 rs1327090 ENSG00000272864.1 RP11-17E13.2 -4.83 1.11e-05 0.0307 -0.74 -0.54 Resistin levels; chr1:74800795 chr1:74698769~74699333:- MESO cis rs977987 0.669 rs1001861 ENSG00000261783.1 RP11-252K23.2 -4.83 1.11e-05 0.0307 -0.68 -0.54 Dupuytren's disease; chr16:75272557 chr16:75379818~75381260:- MESO cis rs6452524 0.508 rs40214 ENSG00000249664.1 CTD-2227C6.2 -4.83 1.11e-05 0.0309 -0.74 -0.54 Hypertension (SNP x SNP interaction); chr5:83000359 chr5:83012285~83013109:- MESO cis rs7309 1 rs7309 ENSG00000227403.1 AC009299.3 -4.82 1.12e-05 0.031 -0.63 -0.54 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161236129 chr2:161244739~161249050:+ MESO cis rs12821008 1 rs12821008 ENSG00000258017.1 RP11-386G11.10 -4.82 1.12e-05 0.031 -0.7 -0.54 Bone mineral density; chr12:49080822 chr12:49127782~49147869:+ MESO cis rs860295 0.776 rs11264362 ENSG00000271380.1 RP11-307C12.12 4.82 1.12e-05 0.0311 0.66 0.54 Body mass index; chr1:155345824 chr1:154961825~154962623:+ MESO cis rs1577917 0.739 rs9344532 ENSG00000203875.9 SNHG5 4.82 1.12e-05 0.0311 0.73 0.54 Response to antipsychotic treatment; chr6:85524352 chr6:85660950~85678736:- MESO cis rs975739 1 rs914912 ENSG00000236051.5 MYCBP2-AS1 -4.82 1.12e-05 0.0311 -0.7 -0.54 Hair color; chr13:77807467 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1279402 ENSG00000236051.5 MYCBP2-AS1 -4.82 1.12e-05 0.0311 -0.7 -0.54 Hair color; chr13:77808369 chr13:77075514~77129717:+ MESO cis rs975739 0.966 rs1823554 ENSG00000236051.5 MYCBP2-AS1 -4.82 1.12e-05 0.0311 -0.7 -0.54 Hair color; chr13:77808570 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1759973 ENSG00000236051.5 MYCBP2-AS1 -4.82 1.12e-05 0.0311 -0.7 -0.54 Hair color; chr13:77809779 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1668621 ENSG00000236051.5 MYCBP2-AS1 -4.82 1.12e-05 0.0311 -0.7 -0.54 Hair color; chr13:77810308 chr13:77075514~77129717:+ MESO cis rs26868 0.746 rs27381 ENSG00000266643.1 MIR3677 4.82 1.13e-05 0.0311 0.6 0.54 Height; chr16:2189401 chr16:2270713~2270772:+ MESO cis rs507080 0.501 rs516503 ENSG00000278376.1 RP11-158I9.8 -4.82 1.14e-05 0.0313 -0.56 -0.54 Serum metabolite levels; chr11:118709639 chr11:118791254~118793137:+ MESO cis rs9326248 0.53 rs10732856 ENSG00000254851.1 RP11-109L13.1 -4.82 1.14e-05 0.0314 -1.08 -0.54 Blood protein levels; chr11:117036397 chr11:117135528~117138582:+ MESO cis rs3960554 0.529 rs6955911 ENSG00000127957.15 PMS2P3 -4.82 1.15e-05 0.0316 -0.64 -0.54 Eotaxin levels; chr7:76267148 chr7:75502930~75528148:- MESO cis rs73086581 0.524 rs2253977 ENSG00000229539.1 RP11-119B16.2 -4.82 1.15e-05 0.0316 -0.66 -0.54 Response to antidepressants in depression; chr20:3958493 chr20:3888239~3888868:- MESO cis rs9322193 0.884 rs9397036 ENSG00000231760.4 RP11-350J20.5 4.82 1.15e-05 0.0316 0.76 0.54 Lung cancer; chr6:149851787 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs9383864 ENSG00000231760.4 RP11-350J20.5 4.82 1.15e-05 0.0316 0.76 0.54 Lung cancer; chr6:149851969 chr6:149796151~149826294:- MESO cis rs9322193 0.884 rs9383865 ENSG00000231760.4 RP11-350J20.5 4.82 1.15e-05 0.0316 0.76 0.54 Lung cancer; chr6:149852043 chr6:149796151~149826294:- MESO cis rs6443245 0.611 rs2648385 ENSG00000227110.5 LMCD1-AS1 4.82 1.15e-05 0.0316 0.68 0.54 Daytime sleep phenotypes; chr3:9577083 chr3:7952805~8611924:- MESO cis rs11673344 0.566 rs11666708 ENSG00000226686.6 LINC01535 -4.82 1.15e-05 0.0316 -0.6 -0.54 Obesity-related traits; chr19:37396208 chr19:37251912~37265535:+ MESO cis rs6452524 0.508 rs256795 ENSG00000249664.1 CTD-2227C6.2 -4.82 1.15e-05 0.0316 -0.74 -0.54 Hypertension (SNP x SNP interaction); chr5:83001543 chr5:83012285~83013109:- MESO cis rs11867129 1 rs4786271 ENSG00000260132.1 LA16c-312E8.2 4.82 1.16e-05 0.0317 1.22 0.54 RR interval (tricyclic/tetracyclic antidepressant use interaction); chr16:2318141 chr16:1408834~1412248:+ MESO cis rs801193 0.569 rs10950050 ENSG00000226824.5 RP4-756H11.3 -4.81 1.16e-05 0.0318 -0.68 -0.54 Aortic root size; chr7:66774601 chr7:66654538~66669855:+ MESO cis rs9309473 0.95 rs13431529 ENSG00000163016.8 ALMS1P 4.81 1.16e-05 0.0318 0.89 0.54 Metabolite levels; chr2:73648914 chr2:73644919~73685576:+ MESO cis rs9309473 0.95 rs10189885 ENSG00000163016.8 ALMS1P 4.81 1.16e-05 0.0318 0.89 0.54 Metabolite levels; chr2:73649928 chr2:73644919~73685576:+ MESO cis rs7115242 0.844 rs645258 ENSG00000254851.1 RP11-109L13.1 -4.81 1.17e-05 0.0319 -1.13 -0.54 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:116930485 chr11:117135528~117138582:+ MESO cis rs7115242 1 rs7115242 ENSG00000254851.1 RP11-109L13.1 4.81 1.17e-05 0.0319 1.13 0.54 Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes; chr11:117037567 chr11:117135528~117138582:+ MESO cis rs1440410 0.83 rs10519678 ENSG00000251600.4 RP11-673E1.1 -4.81 1.17e-05 0.032 -0.71 -0.54 Ischemic stroke; chr4:143260920 chr4:143912331~143982454:+ MESO cis rs73086581 0.68 rs11908158 ENSG00000229539.1 RP11-119B16.2 4.81 1.17e-05 0.032 0.72 0.54 Response to antidepressants in depression; chr20:3956025 chr20:3888239~3888868:- MESO cis rs1153858 1 rs4775895 ENSG00000259520.4 CTD-2651B20.3 -4.81 1.18e-05 0.0323 -0.73 -0.54 Homoarginine levels; chr15:45325759 chr15:45251580~45279251:- MESO cis rs26868 0.596 rs26828 ENSG00000266643.1 MIR3677 4.81 1.19e-05 0.0325 0.61 0.54 Height; chr16:2194530 chr16:2270713~2270772:+ MESO cis rs7617773 0.817 rs936426 ENSG00000229759.1 MRPS18AP1 4.81 1.19e-05 0.0325 0.62 0.54 Coronary artery disease; chr3:48173763 chr3:48256350~48256938:- MESO cis rs975739 1 rs765377 ENSG00000236051.5 MYCBP2-AS1 4.81 1.19e-05 0.0325 0.67 0.54 Hair color; chr13:77803699 chr13:77075514~77129717:+ MESO cis rs6108491 0.503 rs6133870 ENSG00000224961.1 RP1-278O22.1 -4.81 1.2e-05 0.0325 -0.75 -0.54 Psychosis proneness (hypomanic personality scale and revised social anhedonia scale); chr20:10339712 chr20:10753090~10753966:+ MESO cis rs975739 0.966 rs1279388 ENSG00000236051.5 MYCBP2-AS1 -4.8 1.2e-05 0.0327 -0.68 -0.54 Hair color; chr13:77800203 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1279389 ENSG00000236051.5 MYCBP2-AS1 -4.8 1.2e-05 0.0327 -0.68 -0.54 Hair color; chr13:77801177 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1279390 ENSG00000236051.5 MYCBP2-AS1 -4.8 1.2e-05 0.0327 -0.68 -0.54 Hair color; chr13:77802061 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1279391 ENSG00000236051.5 MYCBP2-AS1 -4.8 1.2e-05 0.0327 -0.68 -0.54 Hair color; chr13:77802821 chr13:77075514~77129717:+ MESO cis rs975739 1 rs1279392 ENSG00000236051.5 MYCBP2-AS1 -4.8 1.2e-05 0.0327 -0.68 -0.54 Hair color; chr13:77803384 chr13:77075514~77129717:+ MESO cis rs9326248 0.53 rs9919599 ENSG00000254851.1 RP11-109L13.1 -4.8 1.21e-05 0.0328 -1.11 -0.54 Blood protein levels; chr11:116874768 chr11:117135528~117138582:+ MESO cis rs2117029 0.521 rs12229524 ENSG00000258017.1 RP11-386G11.10 -4.8 1.21e-05 0.0329 -0.73 -0.54 Intelligence (multi-trait analysis); chr12:49191570 chr12:49127782~49147869:+ MESO cis rs9322193 0.923 rs4869750 ENSG00000231760.4 RP11-350J20.5 4.8 1.22e-05 0.0331 0.71 0.54 Lung cancer; chr6:149855996 chr6:149796151~149826294:- MESO cis rs7617773 0.78 rs13090538 ENSG00000229759.1 MRPS18AP1 4.8 1.22e-05 0.0331 0.63 0.54 Coronary artery disease; chr3:48329279 chr3:48256350~48256938:- MESO cis rs7044106 0.791 rs10985004 ENSG00000226752.6 PSMD5-AS1 -4.8 1.23e-05 0.0334 -0.76 -0.54 Hip circumference adjusted for BMI; chr9:120722659 chr9:120824828~120854385:+ MESO cis rs860295 0.812 rs11264363 ENSG00000271380.1 RP11-307C12.12 -4.8 1.23e-05 0.0335 -0.66 -0.54 Body mass index; chr1:155348517 chr1:154961825~154962623:+ MESO cis rs26868 0.816 rs26871 ENSG00000266643.1 MIR3677 4.8 1.24e-05 0.0335 0.6 0.54 Height; chr16:2198132 chr16:2270713~2270772:+ MESO cis rs1150668 0.796 rs213236 ENSG00000216901.1 AL022393.7 4.79 1.25e-05 0.0338 0.69 0.54 Pubertal anthropometrics; chr6:28356620 chr6:28176188~28176674:+ MESO cis rs11723261 0.582 rs61792238 ENSG00000275426.1 CH17-262A2.1 4.79 1.26e-05 0.0341 0.92 0.54 Immune response to smallpox vaccine (IL-6); chr4:112398 chr4:149738~150317:+ MESO cis rs11723261 0.621 rs11721745 ENSG00000275426.1 CH17-262A2.1 4.79 1.26e-05 0.0341 0.92 0.54 Immune response to smallpox vaccine (IL-6); chr4:115052 chr4:149738~150317:+ MESO cis rs73086581 0.735 rs6037730 ENSG00000229539.1 RP11-119B16.2 4.79 1.27e-05 0.0342 0.7 0.54 Response to antidepressants in depression; chr20:4046171 chr20:3888239~3888868:- MESO cis rs73086581 0.838 rs6052265 ENSG00000229539.1 RP11-119B16.2 4.79 1.27e-05 0.0342 0.7 0.54 Response to antidepressants in depression; chr20:4046188 chr20:3888239~3888868:- MESO cis rs73086581 0.838 rs11906481 ENSG00000229539.1 RP11-119B16.2 4.79 1.27e-05 0.0342 0.7 0.54 Response to antidepressants in depression; chr20:4048059 chr20:3888239~3888868:- MESO cis rs1961649 0.75 rs11109871 ENSG00000280088.1 RP11-135F9.3 4.79 1.27e-05 0.0343 0.98 0.54 Metabolite levels (HVA/5-HIAA ratio); chr12:99498406 chr12:100032325~100034074:- MESO cis rs172166 0.61 rs156737 ENSG00000216901.1 AL022393.7 4.79 1.28e-05 0.0345 0.68 0.54 Cardiac Troponin-T levels; chr6:27927435 chr6:28176188~28176674:+ MESO cis rs172166 0.61 rs276369 ENSG00000216901.1 AL022393.7 4.79 1.28e-05 0.0345 0.68 0.54 Cardiac Troponin-T levels; chr6:27951465 chr6:28176188~28176674:+ MESO cis rs6921919 0.583 rs9468355 ENSG00000216901.1 AL022393.7 4.79 1.29e-05 0.0346 0.82 0.54 Autism spectrum disorder or schizophrenia; chr6:28374100 chr6:28176188~28176674:+ MESO cis rs6565653 0.901 rs7216510 ENSG00000262580.4 RP11-334C17.5 4.78 1.29e-05 0.0346 0.54 0.54 Ischemic stroke; chr17:80226111 chr17:80200673~80205949:- MESO cis rs6565653 0.934 rs7209632 ENSG00000262580.4 RP11-334C17.5 4.78 1.29e-05 0.0346 0.54 0.54 Ischemic stroke; chr17:80226114 chr17:80200673~80205949:- MESO cis rs6565653 0.967 rs9891253 ENSG00000262580.4 RP11-334C17.5 4.78 1.29e-05 0.0346 0.54 0.54 Ischemic stroke; chr17:80226377 chr17:80200673~80205949:- MESO cis rs11083475 0.792 rs10426809 ENSG00000275132.1 Metazoa_SRP -4.78 1.29e-05 0.0347 -0.63 -0.54 Heart rate; chr19:38696310 chr19:38200234~38200532:+ MESO cis rs35160687 0.862 rs12476706 ENSG00000273080.1 RP11-301O19.1 4.78 1.3e-05 0.035 0.7 0.54 Night sleep phenotypes; chr2:86301247 chr2:86195590~86196049:+ MESO cis rs7044106 0.708 rs10984992 ENSG00000226752.6 PSMD5-AS1 -4.78 1.31e-05 0.0351 -0.78 -0.54 Hip circumference adjusted for BMI; chr9:120711138 chr9:120824828~120854385:+ MESO cis rs7044106 0.708 rs10760113 ENSG00000226752.6 PSMD5-AS1 -4.78 1.31e-05 0.0351 -0.78 -0.54 Hip circumference adjusted for BMI; chr9:120711772 chr9:120824828~120854385:+ MESO cis rs1577917 0.682 rs6909767 ENSG00000203875.9 SNHG5 4.78 1.31e-05 0.0351 0.72 0.54 Response to antipsychotic treatment; chr6:85518391 chr6:85660950~85678736:- MESO cis rs26868 0.816 rs26872 ENSG00000266643.1 MIR3677 4.78 1.31e-05 0.0351 0.6 0.54 Height; chr16:2197643 chr16:2270713~2270772:+ MESO cis rs1577917 0.727 rs9444361 ENSG00000203875.9 SNHG5 4.78 1.32e-05 0.0353 0.67 0.54 Response to antipsychotic treatment; chr6:85691182 chr6:85660950~85678736:- MESO cis rs860295 0.58 rs6672284 ENSG00000228264.1 PSMD8P1 4.78 1.32e-05 0.0354 0.81 0.54 Body mass index; chr1:155308172 chr1:154414369~154415137:- MESO cis rs860295 0.58 rs2297480 ENSG00000228264.1 PSMD8P1 4.78 1.32e-05 0.0354 0.81 0.54 Body mass index; chr1:155309691 chr1:154414369~154415137:- MESO cis rs860295 0.58 rs11264358 ENSG00000228264.1 PSMD8P1 4.78 1.32e-05 0.0354 0.81 0.54 Body mass index; chr1:155310373 chr1:154414369~154415137:- MESO cis rs9309473 0.5 rs4286298 ENSG00000163016.8 ALMS1P -4.78 1.32e-05 0.0354 -0.81 -0.54 Metabolite levels; chr2:73654981 chr2:73644919~73685576:+ MESO cis rs9309473 0.5 rs2421668 ENSG00000163016.8 ALMS1P -4.78 1.32e-05 0.0354 -0.81 -0.54 Metabolite levels; chr2:73657969 chr2:73644919~73685576:+ MESO cis rs9309473 0.519 rs2421670 ENSG00000163016.8 ALMS1P -4.78 1.32e-05 0.0354 -0.81 -0.54 Metabolite levels; chr2:73659534 chr2:73644919~73685576:+ MESO cis rs9309473 0.519 rs12618600 ENSG00000163016.8 ALMS1P -4.78 1.32e-05 0.0354 -0.81 -0.54 Metabolite levels; chr2:73663555 chr2:73644919~73685576:+ MESO cis rs875971 0.54 rs781152 ENSG00000226824.5 RP4-756H11.3 -4.78 1.33e-05 0.0355 -0.73 -0.54 Aortic root size; chr7:66014585 chr7:66654538~66669855:+ MESO cis rs17711722 0.727 rs781151 ENSG00000226824.5 RP4-756H11.3 -4.78 1.33e-05 0.0355 -0.73 -0.54 Calcium levels; chr7:66014891 chr7:66654538~66669855:+ MESO cis rs2117029 0.638 rs7296288 ENSG00000258017.1 RP11-386G11.10 -4.78 1.33e-05 0.0355 -0.65 -0.54 Intelligence (multi-trait analysis); chr12:49086185 chr12:49127782~49147869:+ MESO cis rs2739330 0.76 rs5751761 ENSG00000273295.1 AP000350.5 -4.78 1.33e-05 0.0356 -0.68 -0.54 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23901432~23907068:- MESO cis rs9309473 0.5 rs4852952 ENSG00000163016.8 ALMS1P -4.77 1.33e-05 0.0356 -0.83 -0.54 Metabolite levels; chr2:73642780 chr2:73644919~73685576:+ MESO cis rs9309473 0.5 rs4852953 ENSG00000163016.8 ALMS1P -4.77 1.33e-05 0.0356 -0.83 -0.54 Metabolite levels; chr2:73642781 chr2:73644919~73685576:+ MESO cis rs2117029 0.556 rs1057725 ENSG00000258017.1 RP11-386G11.10 -4.77 1.34e-05 0.0357 -0.68 -0.54 Intelligence (multi-trait analysis); chr12:49128795 chr12:49127782~49147869:+ MESO cis rs1577917 0.958 rs11755642 ENSG00000203875.9 SNHG5 -4.77 1.34e-05 0.0358 -0.73 -0.54 Response to antipsychotic treatment; chr6:85740348 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs34765423 ENSG00000203875.9 SNHG5 -4.77 1.34e-05 0.0358 -0.73 -0.54 Response to antipsychotic treatment; chr6:85774730 chr6:85660950~85678736:- MESO cis rs1577917 0.917 rs2197651 ENSG00000203875.9 SNHG5 -4.77 1.34e-05 0.0358 -0.73 -0.54 Response to antipsychotic treatment; chr6:85785724 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs12213331 ENSG00000203875.9 SNHG5 -4.77 1.34e-05 0.0358 -0.73 -0.54 Response to antipsychotic treatment; chr6:85795079 chr6:85660950~85678736:- MESO cis rs2560966 0.656 rs875765 ENSG00000268061.4 NAPA-AS1 4.77 1.35e-05 0.036 0.99 0.54 Intelligence; chr19:48038467 chr19:47484282~47501597:+ MESO cis rs1153858 1 rs7171577 ENSG00000259520.4 CTD-2651B20.3 -4.77 1.35e-05 0.036 -0.73 -0.54 Homoarginine levels; chr15:45335781 chr15:45251580~45279251:- MESO cis rs997154 0.655 rs8015121 ENSG00000279656.1 RP11-298I3.6 4.77 1.36e-05 0.0362 0.87 0.54 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22906042 chr14:23023083~23024217:- MESO cis rs975739 0.868 rs11149080 ENSG00000236051.5 MYCBP2-AS1 -4.77 1.37e-05 0.0364 -0.66 -0.54 Hair color; chr13:77893625 chr13:77075514~77129717:+ MESO cis rs7626444 0.584 rs844542 ENSG00000272359.1 U4 -4.77 1.37e-05 0.0364 -0.62 -0.54 Monocyte count; chr3:196752432 chr3:196747192~196747324:- MESO cis rs7626444 0.543 rs843528 ENSG00000272359.1 U4 -4.77 1.37e-05 0.0364 -0.62 -0.54 Monocyte count; chr3:196753464 chr3:196747192~196747324:- MESO cis rs2117029 0.586 rs1874908 ENSG00000258017.1 RP11-386G11.10 -4.77 1.37e-05 0.0365 -0.69 -0.54 Intelligence (multi-trait analysis); chr12:49190247 chr12:49127782~49147869:+ MESO cis rs2739330 0.796 rs1006771 ENSG00000225282.1 AP000350.6 4.76 1.38e-05 0.0368 0.58 0.54 Liver enzyme levels (gamma-glutamyl transferase); chr22:23971817 chr22:23926900~23929574:+ MESO cis rs12935418 0.733 rs12448615 ENSG00000261838.4 RP11-303E16.6 4.76 1.39e-05 0.0368 0.94 0.54 Mean corpuscular volume; chr16:80947132 chr16:81069854~81076598:+ MESO cis rs6964833 1 rs17515241 ENSG00000277053.3 GTF2IP1 4.76 1.39e-05 0.0368 0.69 0.54 Menarche (age at onset); chr7:74717695 chr7:75185385~75237696:- MESO cis rs6964833 1 rs34324835 ENSG00000277053.3 GTF2IP1 -4.76 1.39e-05 0.0368 -0.69 -0.54 Menarche (age at onset); chr7:74717986 chr7:75185385~75237696:- MESO cis rs6443245 0.611 rs2648585 ENSG00000227110.5 LMCD1-AS1 4.76 1.4e-05 0.0371 0.7 0.54 Daytime sleep phenotypes; chr3:9588574 chr3:7952805~8611924:- MESO cis rs6443245 0.532 rs2648584 ENSG00000227110.5 LMCD1-AS1 4.76 1.4e-05 0.0371 0.7 0.54 Daytime sleep phenotypes; chr3:9588662 chr3:7952805~8611924:- MESO cis rs6443245 0.611 rs2648578 ENSG00000227110.5 LMCD1-AS1 4.76 1.4e-05 0.0371 0.7 0.54 Daytime sleep phenotypes; chr3:9591145 chr3:7952805~8611924:- MESO cis rs2280018 0.526 rs2966129 ENSG00000260735.1 RP11-72I8.1 4.76 1.4e-05 0.0371 0.56 0.54 Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid); chr16:15059070 chr16:15094411~15109197:+ MESO cis rs1153858 1 rs7402650 ENSG00000259520.4 CTD-2651B20.3 -4.76 1.41e-05 0.0373 -0.73 -0.54 Homoarginine levels; chr15:45409697 chr15:45251580~45279251:- MESO cis rs1153858 0.943 rs7402632 ENSG00000259520.4 CTD-2651B20.3 -4.76 1.41e-05 0.0373 -0.73 -0.54 Homoarginine levels; chr15:45409715 chr15:45251580~45279251:- MESO cis rs1153858 1 rs8042786 ENSG00000259520.4 CTD-2651B20.3 -4.76 1.41e-05 0.0373 -0.73 -0.54 Homoarginine levels; chr15:45411341 chr15:45251580~45279251:- MESO cis rs1153858 1 rs12440038 ENSG00000259520.4 CTD-2651B20.3 -4.76 1.41e-05 0.0373 -0.73 -0.54 Homoarginine levels; chr15:45414541 chr15:45251580~45279251:- MESO cis rs1153858 1 rs60476496 ENSG00000259520.4 CTD-2651B20.3 -4.76 1.41e-05 0.0373 -0.73 -0.54 Homoarginine levels; chr15:45421603 chr15:45251580~45279251:- MESO cis rs2739330 0.76 rs5751760 ENSG00000225282.1 AP000350.6 4.76 1.42e-05 0.0376 0.64 0.54 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23926900~23929574:+ MESO cis rs4835473 0.932 rs5016160 ENSG00000251600.4 RP11-673E1.1 4.76 1.43e-05 0.0378 0.66 0.54 Immature fraction of reticulocytes; chr4:143738305 chr4:143912331~143982454:+ MESO cis rs11083475 1 rs16972767 ENSG00000269486.2 CTC-360G5.9 4.75 1.44e-05 0.0381 0.86 0.54 Heart rate; chr19:38662404 chr19:38935297~38938632:- MESO cis rs2283792 0.812 rs240064 ENSG00000224086.5 LL22NC03-86G7.1 4.75 1.44e-05 0.0381 0.64 0.54 Multiple sclerosis; chr22:21927265 chr22:21938293~21977632:+ MESO cis rs9309473 0.519 rs1815027 ENSG00000163016.8 ALMS1P -4.75 1.45e-05 0.0383 -0.85 -0.54 Metabolite levels; chr2:73604713 chr2:73644919~73685576:+ MESO cis rs9309473 0.5 rs4852308 ENSG00000163016.8 ALMS1P -4.75 1.45e-05 0.0383 -0.85 -0.54 Metabolite levels; chr2:73606908 chr2:73644919~73685576:+ MESO cis rs9309473 0.519 rs13017182 ENSG00000163016.8 ALMS1P -4.75 1.45e-05 0.0384 -0.8 -0.54 Metabolite levels; chr2:73663877 chr2:73644919~73685576:+ MESO cis rs10256972 0.591 rs11766651 ENSG00000229043.2 AC091729.9 -4.75 1.46e-05 0.0384 -0.62 -0.54 Endometriosis;Longevity; chr7:1122010 chr7:1160374~1165267:+ MESO cis rs1153858 1 rs4774577 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45352487 chr15:45251580~45279251:- MESO cis rs1153858 1 rs11070453 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45352956 chr15:45251580~45279251:- MESO cis rs1153858 1 rs4774578 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45353853 chr15:45251580~45279251:- MESO cis rs61524473 1 rs61524473 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Metabolite levels (small molecules and protein measures); chr15:45354085 chr15:45251580~45279251:- MESO cis rs1153858 1 rs12593230 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45354770 chr15:45251580~45279251:- MESO cis rs1153858 1 rs10444821 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45355038 chr15:45251580~45279251:- MESO cis rs1153858 1 rs72623915 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45355235 chr15:45251580~45279251:- MESO cis rs1153858 1 rs66714503 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45355840 chr15:45251580~45279251:- MESO cis rs1153858 1 rs67831559 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45357109 chr15:45251580~45279251:- MESO cis rs1153858 1 rs2066090 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45357820 chr15:45251580~45279251:- MESO cis rs1153858 1 rs61365925 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45358113 chr15:45251580~45279251:- MESO cis rs1153858 1 rs16952714 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45358160 chr15:45251580~45279251:- MESO cis rs1153858 1 rs12101539 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45358468 chr15:45251580~45279251:- MESO cis rs1153858 1 rs8032904 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45359111 chr15:45251580~45279251:- MESO cis rs1153858 0.943 rs8038342 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45359339 chr15:45251580~45279251:- MESO cis rs1153858 1 rs4774579 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45359605 chr15:45251580~45279251:- MESO cis rs1153858 0.943 rs4774580 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45359888 chr15:45251580~45279251:- MESO cis rs1153858 1 rs4271549 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45360532 chr15:45251580~45279251:- MESO cis rs1153858 1 rs4627277 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45360570 chr15:45251580~45279251:- MESO cis rs1153858 1 rs4625670 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45360728 chr15:45251580~45279251:- MESO cis rs1153858 1 rs4534782 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45360735 chr15:45251580~45279251:- MESO cis rs1153858 1 rs1049503 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45361509 chr15:45251580~45279251:- MESO cis rs1153858 1 rs12595087 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45363034 chr15:45251580~45279251:- MESO cis rs1153858 1 rs3759899 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45363705 chr15:45251580~45279251:- MESO cis rs1153858 1 rs1890565 ENSG00000259520.4 CTD-2651B20.3 -4.75 1.46e-05 0.0384 -0.72 -0.54 Homoarginine levels; chr15:45371101 chr15:45251580~45279251:- MESO cis rs6921919 0.583 rs6908137 ENSG00000216901.1 AL022393.7 4.75 1.46e-05 0.0384 0.86 0.54 Autism spectrum disorder or schizophrenia; chr6:28402616 chr6:28176188~28176674:+ MESO cis rs7044106 0.791 rs10984995 ENSG00000226752.6 PSMD5-AS1 -4.75 1.46e-05 0.0385 -0.77 -0.54 Hip circumference adjusted for BMI; chr9:120716932 chr9:120824828~120854385:+ MESO cis rs1577917 0.958 rs12193904 ENSG00000203875.9 SNHG5 -4.75 1.46e-05 0.0385 -0.74 -0.54 Response to antipsychotic treatment; chr6:85742985 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs10944137 ENSG00000203875.9 SNHG5 -4.75 1.46e-05 0.0385 -0.74 -0.54 Response to antipsychotic treatment; chr6:85744596 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs11754330 ENSG00000203875.9 SNHG5 -4.75 1.46e-05 0.0385 -0.74 -0.54 Response to antipsychotic treatment; chr6:85745352 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs34622605 ENSG00000203875.9 SNHG5 -4.75 1.46e-05 0.0385 -0.74 -0.54 Response to antipsychotic treatment; chr6:85746801 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs12212480 ENSG00000203875.9 SNHG5 -4.75 1.46e-05 0.0385 -0.74 -0.54 Response to antipsychotic treatment; chr6:85749059 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs1335442 ENSG00000203875.9 SNHG5 -4.75 1.46e-05 0.0385 -0.74 -0.54 Response to antipsychotic treatment; chr6:85756974 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs13213899 ENSG00000203875.9 SNHG5 -4.75 1.46e-05 0.0385 -0.74 -0.54 Response to antipsychotic treatment; chr6:85763422 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs10806337 ENSG00000203875.9 SNHG5 -4.75 1.46e-05 0.0385 -0.74 -0.54 Response to antipsychotic treatment; chr6:85764531 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs12205492 ENSG00000203875.9 SNHG5 -4.75 1.46e-05 0.0385 -0.74 -0.54 Response to antipsychotic treatment; chr6:85766258 chr6:85660950~85678736:- MESO cis rs9309473 0.519 rs13022145 ENSG00000163016.8 ALMS1P -4.75 1.46e-05 0.0386 -0.82 -0.54 Metabolite levels; chr2:73636346 chr2:73644919~73685576:+ MESO cis rs9309473 0.519 rs4852950 ENSG00000163016.8 ALMS1P -4.75 1.46e-05 0.0386 -0.82 -0.54 Metabolite levels; chr2:73637543 chr2:73644919~73685576:+ MESO cis rs2729354 0.768 rs2848640 ENSG00000265566.2 RN7SL605P -4.75 1.47e-05 0.0387 -0.73 -0.54 Blood protein levels; chr11:57495207 chr11:57528085~57528365:- MESO cis rs2729354 0.768 rs1001956 ENSG00000265566.2 RN7SL605P -4.75 1.47e-05 0.0387 -0.73 -0.54 Blood protein levels; chr11:57499476 chr11:57528085~57528365:- MESO cis rs2729354 0.903 rs2729371 ENSG00000265566.2 RN7SL605P -4.75 1.47e-05 0.0388 -0.64 -0.54 Blood protein levels; chr11:57553849 chr11:57528085~57528365:- MESO cis rs35160687 0.64 rs13015186 ENSG00000273080.1 RP11-301O19.1 4.75 1.47e-05 0.0388 0.7 0.54 Night sleep phenotypes; chr2:86258455 chr2:86195590~86196049:+ MESO cis rs35160687 0.862 rs17737955 ENSG00000273080.1 RP11-301O19.1 4.75 1.47e-05 0.0388 0.7 0.54 Night sleep phenotypes; chr2:86280891 chr2:86195590~86196049:+ MESO cis rs35160687 0.862 rs13024964 ENSG00000273080.1 RP11-301O19.1 4.75 1.47e-05 0.0388 0.7 0.54 Night sleep phenotypes; chr2:86284745 chr2:86195590~86196049:+ MESO cis rs7560272 0.501 rs12624267 ENSG00000163016.8 ALMS1P -4.75 1.48e-05 0.0388 -0.86 -0.54 Schizophrenia; chr2:73759804 chr2:73644919~73685576:+ MESO cis rs2019137 0.901 rs4849176 ENSG00000274877.1 RP11-65I12.1 4.74 1.48e-05 0.0389 0.66 0.54 Lymphocyte counts; chr2:113220359 chr2:113237595~113240825:+ MESO cis rs9322193 0.607 rs6557165 ENSG00000231760.4 RP11-350J20.5 -4.74 1.48e-05 0.0389 -0.8 -0.54 Lung cancer; chr6:149906883 chr6:149796151~149826294:- MESO cis rs2117029 0.587 rs1865157 ENSG00000258017.1 RP11-386G11.10 -4.74 1.49e-05 0.0391 -0.67 -0.54 Intelligence (multi-trait analysis); chr12:49129003 chr12:49127782~49147869:+ MESO cis rs2111504 0.583 rs1008425 ENSG00000267213.4 AC007773.2 4.74 1.5e-05 0.0392 0.85 0.54 Bipolar disorder; chr19:32361239 chr19:32390050~32405560:- MESO cis rs2111504 0.559 rs12460112 ENSG00000267213.4 AC007773.2 4.74 1.5e-05 0.0392 0.85 0.54 Bipolar disorder; chr19:32363928 chr19:32390050~32405560:- MESO cis rs2111504 0.583 rs2868082 ENSG00000267213.4 AC007773.2 4.74 1.5e-05 0.0392 0.85 0.54 Bipolar disorder; chr19:32368475 chr19:32390050~32405560:- MESO cis rs2111504 0.583 rs8104714 ENSG00000267213.4 AC007773.2 4.74 1.5e-05 0.0392 0.85 0.54 Bipolar disorder; chr19:32381203 chr19:32390050~32405560:- MESO cis rs2111504 0.583 rs2111503 ENSG00000267213.4 AC007773.2 4.74 1.5e-05 0.0392 0.85 0.54 Bipolar disorder; chr19:32383819 chr19:32390050~32405560:- MESO cis rs2111504 0.583 rs1015839 ENSG00000267213.4 AC007773.2 4.74 1.5e-05 0.0392 0.85 0.54 Bipolar disorder; chr19:32390365 chr19:32390050~32405560:- MESO cis rs7626444 0.625 rs843530 ENSG00000272359.1 U4 -4.74 1.5e-05 0.0392 -0.62 -0.54 Monocyte count; chr3:196754153 chr3:196747192~196747324:- MESO cis rs4835473 0.897 rs11723113 ENSG00000251600.4 RP11-673E1.1 4.74 1.5e-05 0.0393 0.67 0.54 Immature fraction of reticulocytes; chr4:143707283 chr4:143912331~143982454:+ MESO cis rs9890032 1 rs3764419 ENSG00000263531.1 RP13-753N3.1 4.74 1.51e-05 0.0394 0.68 0.54 Hip circumference adjusted for BMI; chr17:30837005 chr17:30863921~30864940:- MESO cis rs975739 0.843 rs9544608 ENSG00000236051.5 MYCBP2-AS1 -4.74 1.51e-05 0.0394 -0.62 -0.54 Hair color; chr13:77818405 chr13:77075514~77129717:+ MESO cis rs2019137 0.868 rs3748916 ENSG00000274877.1 RP11-65I12.1 4.74 1.51e-05 0.0394 0.66 0.54 Lymphocyte counts; chr2:113226456 chr2:113237595~113240825:+ MESO cis rs1150668 0.768 rs1150709 ENSG00000216901.1 AL022393.7 -4.74 1.52e-05 0.0396 -0.8 -0.53 Pubertal anthropometrics; chr6:28239585 chr6:28176188~28176674:+ MESO cis rs7044106 0.791 rs7043969 ENSG00000226752.6 PSMD5-AS1 -4.74 1.52e-05 0.0397 -0.74 -0.53 Hip circumference adjusted for BMI; chr9:120731711 chr9:120824828~120854385:+ MESO cis rs2739330 0.76 rs5751760 ENSG00000231271.1 AP000350.8 4.74 1.53e-05 0.0398 0.7 0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901386 chr22:23949918~23954042:+ MESO cis rs6565180 0.525 rs1132812 ENSG00000183604.13 SMG1P5 4.74 1.53e-05 0.0398 0.49 0.53 Tonsillectomy; chr16:30186830 chr16:30267553~30335374:- MESO cis rs7396835 0.551 rs10750098 ENSG00000254851.1 RP11-109L13.1 -4.74 1.53e-05 0.0398 -1.14 -0.53 Quantitative traits; chr11:116834852 chr11:117135528~117138582:+ MESO cis rs801193 0.613 rs2016325 ENSG00000226824.5 RP4-756H11.3 4.74 1.53e-05 0.0399 0.75 0.53 Aortic root size; chr7:66858513 chr7:66654538~66669855:+ MESO cis rs6964833 0.935 rs13238996 ENSG00000123965.13 PMS2P5 4.73 1.54e-05 0.04 0.92 0.53 Menarche (age at onset); chr7:74655318 chr7:74894116~74897835:+ MESO cis rs4835473 0.932 rs13117421 ENSG00000251600.4 RP11-673E1.1 -4.73 1.55e-05 0.0403 -0.63 -0.53 Immature fraction of reticulocytes; chr4:143769405 chr4:143912331~143982454:+ MESO cis rs4835473 0.838 rs34521499 ENSG00000251600.4 RP11-673E1.1 -4.73 1.55e-05 0.0403 -0.63 -0.53 Immature fraction of reticulocytes; chr4:143777628 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs34264936 ENSG00000251600.4 RP11-673E1.1 -4.73 1.55e-05 0.0403 -0.63 -0.53 Immature fraction of reticulocytes; chr4:143780294 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs13140028 ENSG00000251600.4 RP11-673E1.1 -4.73 1.55e-05 0.0403 -0.63 -0.53 Immature fraction of reticulocytes; chr4:143782195 chr4:143912331~143982454:+ MESO cis rs710913 0.745 rs67563067 ENSG00000237624.1 OXCT2P1 -4.73 1.55e-05 0.0404 -0.64 -0.53 Peripheral arterial disease (traffic-related air pollution interaction); chr1:39581323 chr1:39514956~39516490:+ MESO cis rs9309473 0.95 rs13408433 ENSG00000163016.8 ALMS1P 4.73 1.56e-05 0.0406 0.89 0.53 Metabolite levels; chr2:73655945 chr2:73644919~73685576:+ MESO cis rs9309473 0.95 rs11126412 ENSG00000163016.8 ALMS1P 4.73 1.56e-05 0.0406 0.89 0.53 Metabolite levels; chr2:73660507 chr2:73644919~73685576:+ MESO cis rs1961649 0.75 rs7133069 ENSG00000280088.1 RP11-135F9.3 4.73 1.57e-05 0.0406 0.93 0.53 Metabolite levels (HVA/5-HIAA ratio); chr12:99502148 chr12:100032325~100034074:- MESO cis rs7044106 0.708 rs959558 ENSG00000226752.6 PSMD5-AS1 -4.73 1.58e-05 0.0408 -0.74 -0.53 Hip circumference adjusted for BMI; chr9:120606633 chr9:120824828~120854385:+ MESO cis rs7044106 0.708 rs991121 ENSG00000226752.6 PSMD5-AS1 -4.73 1.58e-05 0.0408 -0.74 -0.53 Hip circumference adjusted for BMI; chr9:120608067 chr9:120824828~120854385:+ MESO cis rs7044106 0.708 rs2416760 ENSG00000226752.6 PSMD5-AS1 -4.73 1.58e-05 0.0408 -0.74 -0.53 Hip circumference adjusted for BMI; chr9:120612361 chr9:120824828~120854385:+ MESO cis rs6964833 1 rs36044436 ENSG00000277053.3 GTF2IP1 -4.73 1.58e-05 0.0408 -0.69 -0.53 Menarche (age at onset); chr7:74675495 chr7:75185385~75237696:- MESO cis rs6921919 0.583 rs9468370 ENSG00000216901.1 AL022393.7 4.73 1.58e-05 0.0409 0.84 0.53 Autism spectrum disorder or schizophrenia; chr6:28401163 chr6:28176188~28176674:+ MESO cis rs26868 0.712 rs26832 ENSG00000266643.1 MIR3677 4.72 1.59e-05 0.0411 0.6 0.53 Height; chr16:2188336 chr16:2270713~2270772:+ MESO cis rs4835473 0.897 rs4835333 ENSG00000251600.4 RP11-673E1.1 -4.72 1.6e-05 0.0413 -0.62 -0.53 Immature fraction of reticulocytes; chr4:143703174 chr4:143912331~143982454:+ MESO cis rs1577917 0.74 rs9450302 ENSG00000203875.9 SNHG5 4.72 1.6e-05 0.0413 0.73 0.53 Response to antipsychotic treatment; chr6:85579955 chr6:85660950~85678736:- MESO cis rs67079557 1 rs67079557 ENSG00000274515.1 CTD-2026K11.5 -4.72 1.61e-05 0.0414 -0.78 -0.53 Breast cancer; chr15:75637966 chr15:75645020~75645442:+ MESO cis rs7184046 0.797 rs13737 ENSG00000274515.1 CTD-2026K11.5 -4.72 1.61e-05 0.0414 -0.78 -0.53 Height; chr15:75639788 chr15:75645020~75645442:+ MESO cis rs1961649 0.696 rs1875289 ENSG00000280088.1 RP11-135F9.3 4.72 1.61e-05 0.0415 0.97 0.53 Metabolite levels (HVA/5-HIAA ratio); chr12:99497302 chr12:100032325~100034074:- MESO cis rs2283792 0.812 rs94194 ENSG00000224086.5 LL22NC03-86G7.1 -4.72 1.61e-05 0.0415 -0.68 -0.53 Multiple sclerosis; chr22:21933937 chr22:21938293~21977632:+ MESO cis rs2283792 0.812 rs5995269 ENSG00000224086.5 LL22NC03-86G7.1 -4.72 1.61e-05 0.0415 -0.68 -0.53 Multiple sclerosis; chr22:21935025 chr22:21938293~21977632:+ MESO cis rs2283792 0.718 rs239918 ENSG00000224086.5 LL22NC03-86G7.1 -4.72 1.62e-05 0.0417 -0.66 -0.53 Multiple sclerosis; chr22:21959457 chr22:21938293~21977632:+ MESO cis rs1577917 0.771 rs9362237 ENSG00000203875.9 SNHG5 4.72 1.62e-05 0.0418 0.66 0.53 Response to antipsychotic treatment; chr6:85699346 chr6:85660950~85678736:- MESO cis rs7626444 0.625 rs1104375 ENSG00000272359.1 U4 -4.72 1.63e-05 0.0418 -0.62 -0.53 Monocyte count; chr3:196749172 chr3:196747192~196747324:- MESO cis rs1577917 0.771 rs4441928 ENSG00000203875.9 SNHG5 4.72 1.64e-05 0.042 0.7 0.53 Response to antipsychotic treatment; chr6:85532176 chr6:85660950~85678736:- MESO cis rs113835537 0.529 rs17495838 ENSG00000255517.5 CTD-3074O7.5 -4.72 1.64e-05 0.0421 -0.73 -0.53 Airway imaging phenotypes; chr11:66428794 chr11:66473490~66480233:- MESO cis rs113835537 0.529 rs116867234 ENSG00000255517.5 CTD-3074O7.5 -4.72 1.64e-05 0.0421 -0.73 -0.53 Airway imaging phenotypes; chr11:66441553 chr11:66473490~66480233:- MESO cis rs113835537 0.529 rs17580784 ENSG00000255517.5 CTD-3074O7.5 -4.72 1.64e-05 0.0421 -0.73 -0.53 Airway imaging phenotypes; chr11:66447388 chr11:66473490~66480233:- MESO cis rs113835537 0.529 rs60358007 ENSG00000255517.5 CTD-3074O7.5 -4.72 1.64e-05 0.0421 -0.73 -0.53 Airway imaging phenotypes; chr11:66454882 chr11:66473490~66480233:- MESO cis rs113835537 0.529 rs75685325 ENSG00000255517.5 CTD-3074O7.5 -4.72 1.64e-05 0.0421 -0.73 -0.53 Airway imaging phenotypes; chr11:66467771 chr11:66473490~66480233:- MESO cis rs113835537 0.529 rs57724777 ENSG00000255517.5 CTD-3074O7.5 -4.72 1.64e-05 0.0421 -0.73 -0.53 Airway imaging phenotypes; chr11:66468960 chr11:66473490~66480233:- MESO cis rs2117029 0.587 rs57853986 ENSG00000258017.1 RP11-386G11.10 -4.72 1.65e-05 0.0422 -0.69 -0.53 Intelligence (multi-trait analysis); chr12:49124612 chr12:49127782~49147869:+ MESO cis rs8100891 0.537 rs58591218 ENSG00000267213.4 AC007773.2 -4.72 1.65e-05 0.0422 -0.97 -0.53 Neuroticism; chr19:32399876 chr19:32390050~32405560:- MESO cis rs9326248 0.53 rs7112513 ENSG00000254851.1 RP11-109L13.1 -4.71 1.65e-05 0.0423 -1.05 -0.53 Blood protein levels; chr11:117166645 chr11:117135528~117138582:+ MESO cis rs1961649 0.75 rs1398085 ENSG00000280088.1 RP11-135F9.3 4.71 1.66e-05 0.0424 0.98 0.53 Metabolite levels (HVA/5-HIAA ratio); chr12:99499908 chr12:100032325~100034074:- MESO cis rs4964805 1 rs1866295 ENSG00000257681.1 RP11-341G23.4 4.71 1.66e-05 0.0426 0.82 0.53 Attention deficit hyperactivity disorder; chr12:103793168 chr12:103746315~103768858:- MESO cis rs6921919 0.583 rs6907950 ENSG00000216901.1 AL022393.7 4.71 1.66e-05 0.0426 0.85 0.53 Autism spectrum disorder or schizophrenia; chr6:28402469 chr6:28176188~28176674:+ MESO cis rs2019137 0.776 rs4849183 ENSG00000274877.1 RP11-65I12.1 -4.71 1.66e-05 0.0426 -0.68 -0.53 Lymphocyte counts; chr2:113234797 chr2:113237595~113240825:+ MESO cis rs7684446 1 rs7684446 ENSG00000273133.1 RP11-799M12.2 4.71 1.67e-05 0.0427 0.74 0.53 Red blood cell count; chr4:15591241 chr4:15563698~15564253:- MESO cis rs1789 0.653 rs13142069 ENSG00000273133.1 RP11-799M12.2 4.71 1.67e-05 0.0427 0.74 0.53 Blood protein levels; chr4:15592069 chr4:15563698~15564253:- MESO cis rs4835473 0.897 rs11728121 ENSG00000251600.4 RP11-673E1.1 4.71 1.68e-05 0.043 0.62 0.53 Immature fraction of reticulocytes; chr4:143707079 chr4:143912331~143982454:+ MESO cis rs5760092 0.572 rs738806 ENSG00000218537.1 MIF-AS1 4.71 1.7e-05 0.0434 0.68 0.53 Urinary 1,3-butadiene metabolite levels in smokers; chr22:23891985 chr22:23894426~23898930:- MESO cis rs9326248 0.569 rs10047459 ENSG00000254851.1 RP11-109L13.1 -4.7 1.71e-05 0.0435 -1.04 -0.53 Blood protein levels; chr11:116851110 chr11:117135528~117138582:+ MESO cis rs4835473 0.9 rs35670120 ENSG00000251600.4 RP11-673E1.1 -4.7 1.71e-05 0.0436 -0.65 -0.53 Immature fraction of reticulocytes; chr4:143787041 chr4:143912331~143982454:+ MESO cis rs4835473 0.9 rs4054634 ENSG00000251600.4 RP11-673E1.1 -4.7 1.71e-05 0.0436 -0.65 -0.53 Immature fraction of reticulocytes; chr4:143787045 chr4:143912331~143982454:+ MESO cis rs7626444 0.625 rs843535 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196746193 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs1798634 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196747416 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs1798635 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196747418 chr3:196747192~196747324:- MESO cis rs7626444 0.585 rs860050 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196747576 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs843539 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196747985 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs2686596 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196748248 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs2686595 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196748271 chr3:196747192~196747324:- MESO cis rs7626444 0.647 rs844546 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196748403 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs843540 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196748442 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs843541 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196748879 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs1798636 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196749733 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs1798637 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196749768 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs2931210 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196749805 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs7638090 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196749965 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs2669637 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196750498 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs2669638 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196750527 chr3:196747192~196747324:- MESO cis rs7626444 0.625 rs2686593 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196750530 chr3:196747192~196747324:- MESO cis rs7626444 0.627 rs5021326 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196750757 chr3:196747192~196747324:- MESO cis rs7626444 0.626 rs5021325 ENSG00000272359.1 U4 -4.7 1.72e-05 0.0436 -0.62 -0.53 Monocyte count; chr3:196750758 chr3:196747192~196747324:- MESO cis rs1153858 1 rs28679834 ENSG00000259520.4 CTD-2651B20.3 -4.7 1.72e-05 0.0436 -0.74 -0.53 Homoarginine levels; chr15:45324008 chr15:45251580~45279251:- MESO cis rs853679 0.567 rs13196606 ENSG00000216901.1 AL022393.7 4.7 1.73e-05 0.0439 0.89 0.53 Depression; chr6:28402301 chr6:28176188~28176674:+ MESO cis rs9322193 0.884 rs7744105 ENSG00000231760.4 RP11-350J20.5 4.7 1.73e-05 0.044 0.7 0.53 Lung cancer; chr6:149849308 chr6:149796151~149826294:- MESO cis rs1577917 0.958 rs12195776 ENSG00000203875.9 SNHG5 -4.7 1.75e-05 0.0443 -0.71 -0.53 Response to antipsychotic treatment; chr6:85778881 chr6:85660950~85678736:- MESO cis rs26868 0.66 rs258291 ENSG00000266643.1 MIR3677 4.7 1.75e-05 0.0444 0.6 0.53 Height; chr16:2195284 chr16:2270713~2270772:+ MESO cis rs1577917 0.739 rs9450318 ENSG00000203875.9 SNHG5 4.7 1.76e-05 0.0445 0.66 0.53 Response to antipsychotic treatment; chr6:85717459 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs9450319 ENSG00000203875.9 SNHG5 4.7 1.76e-05 0.0445 0.66 0.53 Response to antipsychotic treatment; chr6:85717607 chr6:85660950~85678736:- MESO cis rs1577917 0.771 rs4383777 ENSG00000203875.9 SNHG5 4.7 1.76e-05 0.0445 0.66 0.53 Response to antipsychotic treatment; chr6:85726242 chr6:85660950~85678736:- MESO cis rs9890032 1 rs28539246 ENSG00000263531.1 RP13-753N3.1 4.7 1.76e-05 0.0446 0.69 0.53 Hip circumference adjusted for BMI; chr17:30899612 chr17:30863921~30864940:- MESO cis rs9890032 0.967 rs9897628 ENSG00000263531.1 RP13-753N3.1 4.7 1.76e-05 0.0446 0.69 0.53 Hip circumference adjusted for BMI; chr17:30899634 chr17:30863921~30864940:- MESO cis rs9309473 0.558 rs11679042 ENSG00000163016.8 ALMS1P 4.69 1.77e-05 0.0449 0.95 0.53 Metabolite levels; chr2:73680184 chr2:73644919~73685576:+ MESO cis rs2019137 0.868 rs6755639 ENSG00000274877.1 RP11-65I12.1 -4.69 1.81e-05 0.0457 -0.67 -0.53 Lymphocyte counts; chr2:113224233 chr2:113237595~113240825:+ MESO cis rs7927592 0.83 rs11228240 ENSG00000212093.1 AP000807.1 4.69 1.82e-05 0.0459 0.53 0.53 Total body bone mineral density; chr11:68450822 chr11:68506083~68506166:- MESO cis rs26868 0.816 rs26873 ENSG00000266643.1 MIR3677 4.69 1.82e-05 0.046 0.58 0.53 Height; chr16:2197361 chr16:2270713~2270772:+ MESO cis rs57502260 0.834 rs3736228 ENSG00000212093.1 AP000807.1 -4.68 1.83e-05 0.0462 -0.67 -0.53 Total body bone mineral density (age 45-60); chr11:68433827 chr11:68506083~68506166:- MESO cis rs1153858 1 rs1613559 ENSG00000259520.4 CTD-2651B20.3 -4.68 1.84e-05 0.0463 -0.71 -0.53 Homoarginine levels; chr15:45329918 chr15:45251580~45279251:- MESO cis rs1153858 1 rs1618874 ENSG00000259520.4 CTD-2651B20.3 -4.68 1.84e-05 0.0463 -0.71 -0.53 Homoarginine levels; chr15:45330588 chr15:45251580~45279251:- MESO cis rs7044106 0.791 rs7036766 ENSG00000226752.6 PSMD5-AS1 -4.68 1.85e-05 0.0463 -0.76 -0.53 Hip circumference adjusted for BMI; chr9:120717343 chr9:120824828~120854385:+ MESO cis rs7104764 0.879 rs511744 ENSG00000277290.1 RP11-326C3.16 -4.68 1.85e-05 0.0463 -0.69 -0.53 Menarche (age at onset); chr11:219089 chr11:243099~243483:- MESO cis rs9309473 0.519 rs13027816 ENSG00000163016.8 ALMS1P -4.68 1.85e-05 0.0463 -0.83 -0.53 Metabolite levels; chr2:73670564 chr2:73644919~73685576:+ MESO cis rs9309473 0.5 rs2421582 ENSG00000163016.8 ALMS1P -4.68 1.85e-05 0.0463 -0.83 -0.53 Metabolite levels; chr2:73671293 chr2:73644919~73685576:+ MESO cis rs9309473 0.519 rs2421583 ENSG00000163016.8 ALMS1P -4.68 1.85e-05 0.0463 -0.83 -0.53 Metabolite levels; chr2:73671658 chr2:73644919~73685576:+ MESO cis rs9309473 0.519 rs2421584 ENSG00000163016.8 ALMS1P -4.68 1.85e-05 0.0463 -0.83 -0.53 Metabolite levels; chr2:73671725 chr2:73644919~73685576:+ MESO cis rs9309473 0.519 rs2421586 ENSG00000163016.8 ALMS1P -4.68 1.85e-05 0.0463 -0.83 -0.53 Metabolite levels; chr2:73672592 chr2:73644919~73685576:+ MESO cis rs7309 0.935 rs6432674 ENSG00000227403.1 AC009299.3 -4.68 1.85e-05 0.0463 -0.62 -0.53 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161168811 chr2:161244739~161249050:+ MESO cis rs7309 0.81 rs11684253 ENSG00000227403.1 AC009299.3 -4.68 1.85e-05 0.0463 -0.62 -0.53 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161178025 chr2:161244739~161249050:+ MESO cis rs7309 0.935 rs1921309 ENSG00000227403.1 AC009299.3 -4.68 1.85e-05 0.0463 -0.62 -0.53 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161192464 chr2:161244739~161249050:+ MESO cis rs7309 0.935 rs11884495 ENSG00000227403.1 AC009299.3 -4.68 1.85e-05 0.0463 -0.62 -0.53 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161203458 chr2:161244739~161249050:+ MESO cis rs7309 0.935 rs10930013 ENSG00000227403.1 AC009299.3 -4.68 1.85e-05 0.0463 -0.62 -0.53 Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis); chr2:161213814 chr2:161244739~161249050:+ MESO cis rs11083475 1 rs10415219 ENSG00000269486.2 CTC-360G5.9 4.68 1.86e-05 0.0463 0.82 0.53 Heart rate; chr19:38659595 chr19:38935297~38938632:- MESO cis rs9326248 0.53 rs562179 ENSG00000254851.1 RP11-109L13.1 -4.68 1.86e-05 0.0463 -1.09 -0.53 Blood protein levels; chr11:116934488 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs2513095 ENSG00000254851.1 RP11-109L13.1 -4.68 1.86e-05 0.0463 -1.09 -0.53 Blood protein levels; chr11:116935553 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs2513093 ENSG00000254851.1 RP11-109L13.1 -4.68 1.86e-05 0.0463 -1.09 -0.53 Blood protein levels; chr11:116935971 chr11:117135528~117138582:+ MESO cis rs9326248 0.53 rs510988 ENSG00000254851.1 RP11-109L13.1 -4.68 1.86e-05 0.0463 -1.09 -0.53 Blood protein levels; chr11:116943088 chr11:117135528~117138582:+ MESO cis rs2739330 0.76 rs5751761 ENSG00000218537.1 MIF-AS1 -4.68 1.87e-05 0.0463 -0.74 -0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:23901549 chr22:23894426~23898930:- MESO cis rs8100891 0.537 rs10415145 ENSG00000267213.4 AC007773.2 4.68 1.88e-05 0.0463 0.96 0.53 Neuroticism; chr19:32350147 chr19:32390050~32405560:- MESO cis rs8100891 0.537 rs113427979 ENSG00000267213.4 AC007773.2 -4.68 1.88e-05 0.0463 -0.96 -0.53 Neuroticism; chr19:32364502 chr19:32390050~32405560:- MESO cis rs8100891 0.506 rs4804992 ENSG00000267213.4 AC007773.2 -4.68 1.88e-05 0.0463 -0.96 -0.53 Neuroticism; chr19:32367885 chr19:32390050~32405560:- MESO cis rs2111504 0.945 rs1861780 ENSG00000267213.4 AC007773.2 -4.68 1.88e-05 0.0463 -0.96 -0.53 Bipolar disorder; chr19:32372138 chr19:32390050~32405560:- MESO cis rs8100891 0.537 rs4805758 ENSG00000267213.4 AC007773.2 -4.68 1.88e-05 0.0463 -0.96 -0.53 Neuroticism; chr19:32375518 chr19:32390050~32405560:- MESO cis rs8100891 0.537 rs10409835 ENSG00000267213.4 AC007773.2 -4.68 1.88e-05 0.0463 -0.96 -0.53 Neuroticism; chr19:32397754 chr19:32390050~32405560:- MESO cis rs8100891 0.537 rs10417152 ENSG00000267213.4 AC007773.2 -4.68 1.88e-05 0.0463 -0.96 -0.53 Neuroticism; chr19:32397994 chr19:32390050~32405560:- MESO cis rs1150668 0.799 rs1150705 ENSG00000216901.1 AL022393.7 4.68 1.88e-05 0.0463 0.69 0.53 Pubertal anthropometrics; chr6:28226008 chr6:28176188~28176674:+ MESO cis rs1153858 1 rs9788780 ENSG00000259520.4 CTD-2651B20.3 -4.68 1.89e-05 0.0465 -0.72 -0.53 Homoarginine levels; chr15:45393289 chr15:45251580~45279251:- MESO cis rs1153858 1 rs7181167 ENSG00000259520.4 CTD-2651B20.3 -4.68 1.89e-05 0.0465 -0.72 -0.53 Homoarginine levels; chr15:45394038 chr15:45251580~45279251:- MESO cis rs1153858 1 rs11070456 ENSG00000259520.4 CTD-2651B20.3 -4.68 1.89e-05 0.0465 -0.72 -0.53 Homoarginine levels; chr15:45394637 chr15:45251580~45279251:- MESO cis rs1153858 1 rs11070457 ENSG00000259520.4 CTD-2651B20.3 -4.68 1.89e-05 0.0465 -0.72 -0.53 Homoarginine levels; chr15:45394745 chr15:45251580~45279251:- MESO cis rs1153858 1 rs3809472 ENSG00000259520.4 CTD-2651B20.3 -4.68 1.89e-05 0.0465 -0.72 -0.53 Homoarginine levels; chr15:45402120 chr15:45251580~45279251:- MESO cis rs1153858 1 rs1820518 ENSG00000259520.4 CTD-2651B20.3 -4.68 1.89e-05 0.0465 -0.72 -0.53 Homoarginine levels; chr15:45402381 chr15:45251580~45279251:- MESO cis rs1153858 1 rs1365610 ENSG00000259520.4 CTD-2651B20.3 -4.68 1.89e-05 0.0465 -0.72 -0.53 Homoarginine levels; chr15:45402412 chr15:45251580~45279251:- MESO cis rs1961649 0.75 rs7974411 ENSG00000280088.1 RP11-135F9.3 4.68 1.89e-05 0.0465 0.94 0.53 Metabolite levels (HVA/5-HIAA ratio); chr12:99521087 chr12:100032325~100034074:- MESO cis rs1961649 0.633 rs10860455 ENSG00000280088.1 RP11-135F9.3 4.68 1.89e-05 0.0465 0.94 0.53 Metabolite levels (HVA/5-HIAA ratio); chr12:99522311 chr12:100032325~100034074:- MESO cis rs1961649 0.75 rs11109894 ENSG00000280088.1 RP11-135F9.3 4.68 1.89e-05 0.0465 0.94 0.53 Metabolite levels (HVA/5-HIAA ratio); chr12:99523973 chr12:100032325~100034074:- MESO cis rs1961649 0.75 rs11109895 ENSG00000280088.1 RP11-135F9.3 4.68 1.89e-05 0.0465 0.94 0.53 Metabolite levels (HVA/5-HIAA ratio); chr12:99524232 chr12:100032325~100034074:- MESO cis rs860295 0.651 rs6692183 ENSG00000228264.1 PSMD8P1 4.68 1.89e-05 0.0466 0.78 0.53 Body mass index; chr1:155334536 chr1:154414369~154415137:- MESO cis rs113835537 0.529 rs79798028 ENSG00000255517.5 CTD-3074O7.5 -4.68 1.89e-05 0.0466 -0.73 -0.53 Airway imaging phenotypes; chr11:66431891 chr11:66473490~66480233:- MESO cis rs113835537 0.529 rs2279865 ENSG00000255517.5 CTD-3074O7.5 -4.68 1.89e-05 0.0466 -0.73 -0.53 Airway imaging phenotypes; chr11:66435554 chr11:66473490~66480233:- MESO cis rs113835537 0.502 rs7104378 ENSG00000255517.5 CTD-3074O7.5 -4.68 1.89e-05 0.0466 -0.73 -0.53 Airway imaging phenotypes; chr11:66449204 chr11:66473490~66480233:- MESO cis rs113835537 0.529 rs12099041 ENSG00000255517.5 CTD-3074O7.5 -4.68 1.89e-05 0.0466 -0.73 -0.53 Airway imaging phenotypes; chr11:66465302 chr11:66473490~66480233:- MESO cis rs113835537 0.529 rs7928882 ENSG00000255517.5 CTD-3074O7.5 -4.68 1.89e-05 0.0466 -0.73 -0.53 Airway imaging phenotypes; chr11:66467294 chr11:66473490~66480233:- MESO cis rs113835537 0.529 rs57691879 ENSG00000255517.5 CTD-3074O7.5 -4.68 1.89e-05 0.0466 -0.73 -0.53 Airway imaging phenotypes; chr11:66469133 chr11:66473490~66480233:- MESO cis rs7626444 0.625 rs7648479 ENSG00000272359.1 U4 -4.67 1.9e-05 0.0467 -0.63 -0.53 Monocyte count; chr3:196750342 chr3:196747192~196747324:- MESO cis rs10935480 0.904 rs13065271 ENSG00000239445.4 ST3GAL6-AS1 -4.67 1.9e-05 0.0467 -0.66 -0.53 Blood protein levels; chr3:98715649 chr3:98714330~98732651:- MESO cis rs10256972 0.553 rs4236381 ENSG00000229043.2 AC091729.9 -4.67 1.91e-05 0.0469 -0.62 -0.53 Endometriosis;Longevity; chr7:1126087 chr7:1160374~1165267:+ MESO cis rs10256972 0.591 rs6968988 ENSG00000229043.2 AC091729.9 -4.67 1.91e-05 0.0469 -0.62 -0.53 Endometriosis;Longevity; chr7:1129983 chr7:1160374~1165267:+ MESO cis rs1153858 0.943 rs12439575 ENSG00000259520.4 CTD-2651B20.3 -4.67 1.91e-05 0.0469 -0.73 -0.53 Homoarginine levels; chr15:45392618 chr15:45251580~45279251:- MESO cis rs1153858 1 rs2668747 ENSG00000259520.4 CTD-2651B20.3 -4.67 1.93e-05 0.0474 -0.71 -0.53 Homoarginine levels; chr15:45325018 chr15:45251580~45279251:- MESO cis rs6964833 1 rs36044436 ENSG00000123965.13 PMS2P5 4.67 1.93e-05 0.0474 0.92 0.53 Menarche (age at onset); chr7:74675495 chr7:74894116~74897835:+ MESO cis rs8100891 0.537 rs3746016 ENSG00000267213.4 AC007773.2 -4.67 1.93e-05 0.0475 -0.96 -0.53 Neuroticism; chr19:32386353 chr19:32390050~32405560:- MESO cis rs832540 0.866 rs252894 ENSG00000226221.1 RPL26P19 4.67 1.94e-05 0.0476 0.62 0.53 Coronary artery disease; chr5:56928512 chr5:56504635~56505072:- MESO cis rs8177876 0.584 rs13185 ENSG00000261838.4 RP11-303E16.6 -4.67 1.95e-05 0.0478 -0.97 -0.53 Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid); chr16:81046036 chr16:81069854~81076598:+ MESO cis rs8100891 0.537 rs4805755 ENSG00000267213.4 AC007773.2 4.67 1.96e-05 0.048 0.96 0.53 Neuroticism; chr19:32363564 chr19:32390050~32405560:- MESO cis rs1577917 0.958 rs72907388 ENSG00000203875.9 SNHG5 -4.66 1.97e-05 0.0482 -0.68 -0.53 Response to antipsychotic treatment; chr6:85730489 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs2225754 ENSG00000203875.9 SNHG5 -4.66 1.97e-05 0.0482 -0.68 -0.53 Response to antipsychotic treatment; chr6:85739980 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs1591438 ENSG00000203875.9 SNHG5 -4.66 1.97e-05 0.0482 -0.68 -0.53 Response to antipsychotic treatment; chr6:85815496 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs1591437 ENSG00000203875.9 SNHG5 -4.66 1.97e-05 0.0482 -0.68 -0.53 Response to antipsychotic treatment; chr6:85815587 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs12198876 ENSG00000203875.9 SNHG5 -4.66 1.97e-05 0.0482 -0.68 -0.53 Response to antipsychotic treatment; chr6:85815758 chr6:85660950~85678736:- MESO cis rs1577917 0.876 rs66986937 ENSG00000203875.9 SNHG5 -4.66 1.97e-05 0.0482 -0.68 -0.53 Response to antipsychotic treatment; chr6:85822473 chr6:85660950~85678736:- MESO cis rs1577917 0.958 rs10944144 ENSG00000203875.9 SNHG5 -4.66 1.97e-05 0.0482 -0.68 -0.53 Response to antipsychotic treatment; chr6:85828037 chr6:85660950~85678736:- MESO cis rs1961649 0.75 rs7299293 ENSG00000280088.1 RP11-135F9.3 4.66 1.98e-05 0.0483 0.88 0.53 Metabolite levels (HVA/5-HIAA ratio); chr12:99510048 chr12:100032325~100034074:- MESO cis rs1961649 0.784 rs7309073 ENSG00000280088.1 RP11-135F9.3 4.66 1.98e-05 0.0483 0.88 0.53 Metabolite levels (HVA/5-HIAA ratio); chr12:99512911 chr12:100032325~100034074:- MESO cis rs494459 0.838 rs567680 ENSG00000278376.1 RP11-158I9.8 -4.66 1.98e-05 0.0484 -0.53 -0.53 Height; chr11:118737823 chr11:118791254~118793137:+ MESO cis rs494459 0.838 rs566733 ENSG00000278376.1 RP11-158I9.8 -4.66 1.98e-05 0.0484 -0.53 -0.53 Height; chr11:118737916 chr11:118791254~118793137:+ MESO cis rs4964805 0.626 rs869993 ENSG00000257681.1 RP11-341G23.4 4.66 1.98e-05 0.0484 0.88 0.53 Attention deficit hyperactivity disorder; chr12:103781360 chr12:103746315~103768858:- MESO cis rs7044106 0.791 rs10760116 ENSG00000226752.6 PSMD5-AS1 -4.66 2e-05 0.0487 -0.72 -0.53 Hip circumference adjusted for BMI; chr9:120732403 chr9:120824828~120854385:+ MESO cis rs4835473 0.714 rs10013005 ENSG00000251600.4 RP11-673E1.1 4.66 2.01e-05 0.0487 0.64 0.53 Immature fraction of reticulocytes; chr4:143711351 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs6835827 ENSG00000251600.4 RP11-673E1.1 4.66 2.01e-05 0.0487 0.64 0.53 Immature fraction of reticulocytes; chr4:143712803 chr4:143912331~143982454:+ MESO cis rs4835473 0.897 rs1553070 ENSG00000251600.4 RP11-673E1.1 4.66 2.01e-05 0.0487 0.64 0.53 Immature fraction of reticulocytes; chr4:143715981 chr4:143912331~143982454:+ MESO cis rs75920871 0.702 rs11216162 ENSG00000254851.1 RP11-109L13.1 -4.66 2.01e-05 0.0488 -0.93 -0.53 Subjective well-being; chr11:116857561 chr11:117135528~117138582:+ MESO cis rs1153858 1 rs1719247 ENSG00000259520.4 CTD-2651B20.3 -4.66 2.02e-05 0.0489 -0.7 -0.53 Homoarginine levels; chr15:45328787 chr15:45251580~45279251:- MESO cis rs7829975 0.533 rs1039917 ENSG00000233609.3 RP11-62H7.2 4.66 2.02e-05 0.0489 0.76 0.53 Mood instability; chr8:8861340 chr8:8961200~8979025:+ MESO cis rs4713118 0.505 rs156740 ENSG00000216901.1 AL022393.7 4.66 2.02e-05 0.049 0.67 0.53 Parkinson's disease; chr6:27992657 chr6:28176188~28176674:+ MESO cis rs7301826 0.58 rs12821464 ENSG00000256250.1 RP11-989F5.1 4.66 2.03e-05 0.0491 0.66 0.53 Plasma plasminogen activator levels; chr12:130838174 chr12:130810606~130812438:+ MESO cis rs7208859 0.573 rs216443 ENSG00000263531.1 RP13-753N3.1 4.66 2.03e-05 0.0492 1.12 0.53 Mean corpuscular hemoglobin;Mean corpuscular volume; chr17:30604853 chr17:30863921~30864940:- MESO cis rs2739330 0.731 rs4822450 ENSG00000231271.1 AP000350.8 4.65 2.03e-05 0.0492 0.69 0.53 Liver enzyme levels (gamma-glutamyl transferase); chr22:23900700 chr22:23949918~23954042:+ MESO cis rs11083475 0.792 rs11083473 ENSG00000275132.1 Metazoa_SRP -4.65 2.04e-05 0.0494 -0.6 -0.53 Heart rate; chr19:38689294 chr19:38200234~38200532:+ MESO cis rs3931020 0.745 rs1980851 ENSG00000272864.1 RP11-17E13.2 -4.65 2.05e-05 0.0495 -0.71 -0.53 Resistin levels; chr1:74803287 chr1:74698769~74699333:- MESO cis rs7812879 0.564 rs12114115 ENSG00000227888.4 FAM66A 4.65 2.05e-05 0.0495 0.94 0.53 Systemic lupus erythematosus; chr8:11441097 chr8:12362019~12388296:+ MESO cis rs4835473 0.932 rs1450250 ENSG00000251600.4 RP11-673E1.1 4.65 2.06e-05 0.0497 0.68 0.53 Immature fraction of reticulocytes; chr4:143731873 chr4:143912331~143982454:+ MESO cis rs4835473 0.932 rs7664248 ENSG00000251600.4 RP11-673E1.1 4.65 2.06e-05 0.0497 0.68 0.53 Immature fraction of reticulocytes; chr4:143732554 chr4:143912331~143982454:+ MESO cis rs997154 0.608 rs8007089 ENSG00000279656.1 RP11-298I3.6 4.65 2.06e-05 0.0499 0.86 0.53 Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth); chr14:22922704 chr14:23023083~23024217:- MESO trans rs7949030 0.626 rs7930896 ENSG00000186676.3 EEF1GP1 14.8 5.23e-21 1.72e-11 1.15 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62557800 chr7:125033453~125035301:+ MESO trans rs7949030 0.626 rs11231144 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62560566 chr7:125033453~125035301:+ MESO trans rs7949030 0.626 rs7943191 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561079 chr7:125033453~125035301:+ MESO trans rs7949030 0.626 rs11231145 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561382 chr7:125033453~125035301:+ MESO trans rs7949030 0.626 rs71490390 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62561713 chr7:125033453~125035301:+ MESO trans rs7949030 0.626 rs7124057 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62566624 chr7:125033453~125035301:+ MESO trans rs7949030 0.626 rs1061093 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62567436 chr7:125033453~125035301:+ MESO trans rs7949030 0.59 rs12225213 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62582776 chr7:125033453~125035301:+ MESO trans rs7949030 0.626 rs72927213 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62583726 chr7:125033453~125035301:+ MESO trans rs7949030 0.626 rs11231154 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62594821 chr7:125033453~125035301:+ MESO trans rs7949030 0.591 rs11231156 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598982 chr7:125033453~125035301:+ MESO trans rs7949030 0.591 rs12049914 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62601964 chr7:125033453~125035301:+ MESO trans rs7949030 0.591 rs35156678 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602409 chr7:125033453~125035301:+ MESO trans rs7949030 0.591 rs35880596 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602412 chr7:125033453~125035301:+ MESO trans rs7949030 0.596 rs71490394 ENSG00000186676.3 EEF1GP1 14.77 5.83e-21 1.72e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62602683 chr7:125033453~125035301:+ MESO trans rs7949030 0.626 rs11231141 ENSG00000186676.3 EEF1GP1 14.64 8.48e-21 2.38e-11 1.16 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62558793 chr7:125033453~125035301:+ MESO trans rs916888 0.61 rs199529 ENSG00000263503.1 RP11-707O23.5 14.62 9e-21 2.41e-11 1.1 0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45600869~45602340:- MESO trans rs7949030 0.626 rs61296092 ENSG00000186676.3 EEF1GP1 14.6 9.5e-21 2.44e-11 1.15 0.89 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62553366 chr7:125033453~125035301:+ MESO trans rs916888 0.821 rs199504 ENSG00000263503.1 RP11-707O23.5 -14.49 1.34e-20 3.28e-11 -1.1 -0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs1378358 ENSG00000263503.1 RP11-707O23.5 14.37 1.97e-20 3.49e-11 1.15 0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs538628 ENSG00000263503.1 RP11-707O23.5 14.37 1.97e-20 3.49e-11 1.15 0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs169201 ENSG00000263503.1 RP11-707O23.5 14.37 1.97e-20 3.49e-11 1.15 0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs199439 ENSG00000263503.1 RP11-707O23.5 14.37 1.97e-20 3.49e-11 1.15 0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs199457 ENSG00000263503.1 RP11-707O23.5 14.37 1.97e-20 3.49e-11 1.15 0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45600869~45602340:- MESO trans rs916888 0.687 rs199456 ENSG00000263503.1 RP11-707O23.5 14.37 1.97e-20 3.49e-11 1.15 0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs199451 ENSG00000263503.1 RP11-707O23.5 14.37 1.97e-20 3.49e-11 1.15 0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs199513 ENSG00000263503.1 RP11-707O23.5 -14.37 1.97e-20 3.49e-11 -1.15 -0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs199535 ENSG00000263503.1 RP11-707O23.5 14.36 2.01e-20 3.49e-11 1.14 0.89 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45600869~45602340:- MESO trans rs6477998 0.603 rs10117451 ENSG00000238072.1 RP11-305M3.2 14.22 3.13e-20 5.13e-11 1.26 0.88 Hematology traits; chr9:113273610 chr7:129410113~129410370:- MESO trans rs6477998 0.58 rs9299214 ENSG00000238072.1 RP11-305M3.2 14.05 5.29e-20 8.43e-11 1.27 0.88 Hematology traits; chr9:113273416 chr7:129410113~129410370:- MESO trans rs916888 0.602 rs199508 ENSG00000263503.1 RP11-707O23.5 -13.98 6.48e-20 1.01e-10 -1.07 -0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781472 chr17:45600869~45602340:- MESO trans rs7949030 0.596 rs11231138 ENSG00000186676.3 EEF1GP1 13.96 6.93e-20 1.05e-10 1.15 0.88 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62548723 chr7:125033453~125035301:+ MESO trans rs916888 0.697 rs199516 ENSG00000263503.1 RP11-707O23.5 -13.79 1.2e-19 1.16e-10 -1.09 -0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs199514 ENSG00000263503.1 RP11-707O23.5 -13.79 1.2e-19 1.16e-10 -1.09 -0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs199512 ENSG00000263503.1 RP11-707O23.5 -13.79 1.2e-19 1.16e-10 -1.09 -0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs199509 ENSG00000263503.1 RP11-707O23.5 -13.79 1.2e-19 1.16e-10 -1.09 -0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs199507 ENSG00000263503.1 RP11-707O23.5 -13.79 1.2e-19 1.16e-10 -1.09 -0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs415430 ENSG00000263503.1 RP11-707O23.5 -13.79 1.2e-19 1.16e-10 -1.09 -0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45600869~45602340:- MESO trans rs916888 0.779 rs430685 ENSG00000263503.1 RP11-707O23.5 -13.79 1.2e-19 1.16e-10 -1.09 -0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs199505 ENSG00000263503.1 RP11-707O23.5 -13.79 1.2e-19 1.16e-10 -1.09 -0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs70602 ENSG00000263503.1 RP11-707O23.5 -13.79 1.2e-19 1.16e-10 -1.09 -0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs199448 ENSG00000263503.1 RP11-707O23.5 13.79 1.2e-19 1.16e-10 1.09 0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs199447 ENSG00000263503.1 RP11-707O23.5 13.79 1.2e-19 1.16e-10 1.09 0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs199445 ENSG00000263503.1 RP11-707O23.5 13.79 1.2e-19 1.16e-10 1.09 0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs199443 ENSG00000263503.1 RP11-707O23.5 13.79 1.2e-19 1.16e-10 1.09 0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs199534 ENSG00000263503.1 RP11-707O23.5 13.79 1.2e-19 1.16e-10 1.09 0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs9896243 ENSG00000263503.1 RP11-707O23.5 13.79 1.2e-19 1.16e-10 1.09 0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45600869~45602340:- MESO trans rs916888 0.773 rs199533 ENSG00000263503.1 RP11-707O23.5 13.79 1.2e-19 1.16e-10 1.09 0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45600869~45602340:- MESO trans rs916888 0.779 rs199528 ENSG00000263503.1 RP11-707O23.5 13.79 1.2e-19 1.16e-10 1.09 0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs199525 ENSG00000263503.1 RP11-707O23.5 13.79 1.2e-19 1.16e-10 1.09 0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs70600 ENSG00000263503.1 RP11-707O23.5 13.79 1.2e-19 1.16e-10 1.09 0.88 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45600869~45602340:- MESO trans rs13177918 0.677 rs3857421 ENSG00000213058.3 RP4-765C7.2 -13.48 3.2e-19 2.86e-10 -1.15 -0.87 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr1:178411616~178411972:+ MESO trans rs7949030 0.688 rs11231155 ENSG00000186676.3 EEF1GP1 13.39 4.2e-19 3.65e-10 1.15 0.87 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598147 chr7:125033453~125035301:+ MESO trans rs7949030 0.653 rs17773169 ENSG00000186676.3 EEF1GP1 13.34 4.96e-19 4.06e-10 1.14 0.87 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62551058 chr7:125033453~125035301:+ MESO trans rs928391 0.681 rs12145743 ENSG00000227183.3 HDGFP1 13.3 5.61e-19 4.37e-10 1.26 0.87 Platelet count; chr1:156730859 chrX:131646639~131646890:+ MESO trans rs7949030 0.688 rs2849031 ENSG00000186676.3 EEF1GP1 -13.3 5.63e-19 4.37e-10 -1.14 -0.87 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62598193 chr7:125033453~125035301:+ MESO trans rs7949030 0.653 rs2849030 ENSG00000186676.3 EEF1GP1 -13.3 5.63e-19 4.37e-10 -1.14 -0.87 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62599514 chr7:125033453~125035301:+ MESO trans rs7949030 0.653 rs2516634 ENSG00000186676.3 EEF1GP1 -13.3 5.63e-19 4.37e-10 -1.14 -0.87 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62599714 chr7:125033453~125035301:+ MESO trans rs7949030 0.62 rs2428551 ENSG00000186676.3 EEF1GP1 13.28 6.04e-19 4.63e-10 1.14 0.87 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62562286 chr7:125033453~125035301:+ MESO trans rs916888 0.738 rs199515 ENSG00000263503.1 RP11-707O23.5 -13.24 6.77e-19 5.09e-10 -1.08 -0.87 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45600869~45602340:- MESO trans rs928391 0.681 rs12161427 ENSG00000227183.3 HDGFP1 13.21 7.51e-19 5.09e-10 1.26 0.87 Platelet count; chr1:156736030 chrX:131646639~131646890:+ MESO trans rs928391 0.681 rs3806417 ENSG00000227183.3 HDGFP1 13.21 7.51e-19 5.09e-10 1.26 0.87 Platelet count; chr1:156741831 chrX:131646639~131646890:+ MESO trans rs928391 0.624 rs4399146 ENSG00000227183.3 HDGFP1 13.21 7.51e-19 5.09e-10 1.26 0.87 Platelet count; chr1:156743766 chrX:131646639~131646890:+ MESO trans rs928391 0.681 rs4501833 ENSG00000227183.3 HDGFP1 13.21 7.51e-19 5.09e-10 1.26 0.87 Platelet count; chr1:156746806 chrX:131646639~131646890:+ MESO trans rs928391 0.681 rs11264533 ENSG00000227183.3 HDGFP1 13.21 7.51e-19 5.09e-10 1.26 0.87 Platelet count; chr1:156748656 chrX:131646639~131646890:+ MESO trans rs928391 0.681 rs11264535 ENSG00000227183.3 HDGFP1 13.21 7.51e-19 5.09e-10 1.26 0.87 Platelet count; chr1:156752632 chrX:131646639~131646890:+ MESO trans rs1816752 1 rs1816752 ENSG00000237917.1 PARP4P1 13.1 1.07e-18 7.19e-10 1.08 0.87 Obesity-related traits; chr13:24406811 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs4770666 ENSG00000237917.1 PARP4P1 13.02 1.4e-18 9.07e-10 1.05 0.87 Obesity-related traits; chr13:24414891 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs7400631 ENSG00000237917.1 PARP4P1 13.02 1.4e-18 9.07e-10 1.05 0.87 Obesity-related traits; chr13:24415927 chrY:26594851~26634652:- MESO trans rs916888 0.61 rs199452 ENSG00000263503.1 RP11-707O23.5 12.92 1.91e-18 1.2e-09 1.04 0.87 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:45600869~45602340:- MESO trans rs916888 0.61 rs199530 ENSG00000263503.1 RP11-707O23.5 -12.92 1.91e-18 1.2e-09 -1.04 -0.87 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:45600869~45602340:- MESO trans rs916888 0.821 rs199506 ENSG00000263503.1 RP11-707O23.5 -12.74 3.5e-18 2.15e-09 -1.08 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45600869~45602340:- MESO trans rs928391 0.681 rs11264534 ENSG00000227183.3 HDGFP1 12.66 4.61e-18 2.72e-09 1.24 0.86 Platelet count; chr1:156750758 chrX:131646639~131646890:+ MESO trans rs928391 0.652 rs12030654 ENSG00000227183.3 HDGFP1 12.66 4.61e-18 2.72e-09 1.24 0.86 Platelet count; chr1:156751240 chrX:131646639~131646890:+ MESO trans rs1816752 0.819 rs4770665 ENSG00000237917.1 PARP4P1 12.6 5.63e-18 3.15e-09 1.08 0.86 Obesity-related traits; chr13:24414810 chrY:26594851~26634652:- MESO trans rs1816752 0.749 rs77832754 ENSG00000237917.1 PARP4P1 12.6 5.63e-18 3.15e-09 1.08 0.86 Obesity-related traits; chr13:24416016 chrY:26594851~26634652:- MESO trans rs916888 0.531 rs183211 ENSG00000263503.1 RP11-707O23.5 12.58 5.99e-18 3.15e-09 0.99 0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:45600869~45602340:- MESO trans rs916888 0.61 rs199438 ENSG00000263503.1 RP11-707O23.5 12.58 5.99e-18 3.15e-09 0.99 0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:45600869~45602340:- MESO trans rs916888 0.61 rs199453 ENSG00000263503.1 RP11-707O23.5 12.58 5.99e-18 3.15e-09 0.99 0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:45600869~45602340:- MESO trans rs916888 0.61 rs199436 ENSG00000263503.1 RP11-707O23.5 -12.58 5.99e-18 3.15e-09 -0.99 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:45600869~45602340:- MESO trans rs916888 0.61 rs199454 ENSG00000263503.1 RP11-707O23.5 -12.58 5.99e-18 3.15e-09 -0.99 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:45600869~45602340:- MESO trans rs1816752 0.721 rs7399656 ENSG00000237917.1 PARP4P1 12.56 6.25e-18 3.15e-09 1.07 0.86 Obesity-related traits; chr13:24415708 chrY:26594851~26634652:- MESO trans rs916888 0.647 rs199524 ENSG00000263503.1 RP11-707O23.5 -12.54 6.84e-18 3.15e-09 -0.98 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:45600869~45602340:- MESO trans rs916888 0.647 rs199523 ENSG00000263503.1 RP11-707O23.5 -12.54 6.84e-18 3.15e-09 -0.98 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:45600869~45602340:- MESO trans rs916888 0.647 rs199520 ENSG00000263503.1 RP11-707O23.5 -12.54 6.84e-18 3.15e-09 -0.98 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776506 chr17:45600869~45602340:- MESO trans rs916888 0.647 rs199519 ENSG00000263503.1 RP11-707O23.5 -12.54 6.84e-18 3.15e-09 -0.98 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776558 chr17:45600869~45602340:- MESO trans rs7224296 0.709 rs199518 ENSG00000263503.1 RP11-707O23.5 -12.54 6.84e-18 3.15e-09 -0.98 -0.86 Intelligence (multi-trait analysis); chr17:46777214 chr17:45600869~45602340:- MESO trans rs916888 0.647 rs199517 ENSG00000263503.1 RP11-707O23.5 -12.54 6.84e-18 3.15e-09 -0.98 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46777221 chr17:45600869~45602340:- MESO trans rs13177918 0.75 rs58256223 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442456 chr1:178411616~178411972:+ MESO trans rs13177918 0.75 rs59354956 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442457 chr1:178411616~178411972:+ MESO trans rs13177918 0.686 rs12654827 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs13160685 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs13161099 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr1:178411616~178411972:+ MESO trans rs13177918 0.629 rs13161261 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs13161417 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs13161156 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs13181401 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs4541646 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs3900644 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs2070844 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs2073472 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr1:178411616~178411972:+ MESO trans rs13177918 0.629 rs2070842 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs13171800 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs2070841 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs13177951 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs13177970 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs13164105 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs4841 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446963 chr1:178411616~178411972:+ MESO trans rs13177918 0.677 rs13183077 ENSG00000213058.3 RP4-765C7.2 12.49 7.97e-18 3.15e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447009 chr1:178411616~178411972:+ MESO trans rs13177918 0.581 rs2245384 ENSG00000213058.3 RP4-765C7.2 12.44 9.38e-18 3.64e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150437705 chr1:178411616~178411972:+ MESO trans rs916888 0.61 rs142167 ENSG00000263503.1 RP11-707O23.5 -12.4 1.09e-17 4.21e-09 -0.97 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:45600869~45602340:- MESO trans rs13177918 0.677 rs57890152 ENSG00000213058.3 RP4-765C7.2 12.37 1.19e-17 4.53e-09 1.14 0.86 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr1:178411616~178411972:+ MESO trans rs916888 0.647 rs199449 ENSG00000263503.1 RP11-707O23.5 12.35 1.25e-17 4.58e-09 0.95 0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:45600869~45602340:- MESO trans rs916888 0.61 rs199444 ENSG00000263503.1 RP11-707O23.5 12.35 1.25e-17 4.58e-09 0.95 0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:45600869~45602340:- MESO trans rs916888 0.61 rs199442 ENSG00000263503.1 RP11-707O23.5 12.35 1.25e-17 4.58e-09 0.95 0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:45600869~45602340:- MESO trans rs916888 0.61 rs199446 ENSG00000263503.1 RP11-707O23.5 -12.35 1.25e-17 4.58e-09 -0.95 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:45600869~45602340:- MESO trans rs916888 0.61 rs199536 ENSG00000263503.1 RP11-707O23.5 -12.35 1.25e-17 4.58e-09 -0.95 -0.86 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:45600869~45602340:- MESO trans rs13177918 0.677 rs3797622 ENSG00000213058.3 RP4-765C7.2 12.31 1.46e-17 5.31e-09 1.14 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr1:178411616~178411972:+ MESO trans rs1816752 0.905 rs2000153 ENSG00000237917.1 PARP4P1 12.26 1.71e-17 5.99e-09 1.03 0.85 Obesity-related traits; chr13:24405752 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs1348110 ENSG00000237917.1 PARP4P1 12.26 1.71e-17 5.99e-09 1.03 0.85 Obesity-related traits; chr13:24406537 chrY:26594851~26634652:- MESO trans rs1816752 0.837 rs7139748 ENSG00000237917.1 PARP4P1 12.26 1.71e-17 5.99e-09 1.03 0.85 Obesity-related traits; chr13:24411531 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs9511264 ENSG00000237917.1 PARP4P1 -12.21 2.03e-17 7.04e-09 -1.04 -0.85 Obesity-related traits; chr13:24438079 chrY:26594851~26634652:- MESO trans rs7949030 1 rs10897289 ENSG00000186676.3 EEF1GP1 12.19 2.16e-17 7.45e-09 1.13 0.85 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62632544 chr7:125033453~125035301:+ MESO trans rs1816752 0.905 rs8002309 ENSG00000237917.1 PARP4P1 12.19 2.21e-17 7.47e-09 1.02 0.85 Obesity-related traits; chr13:24402217 chrY:26594851~26634652:- MESO trans rs7949030 0.754 rs36104523 ENSG00000186676.3 EEF1GP1 -12.17 2.3e-17 7.5e-09 -1.13 -0.85 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62628268 chr7:125033453~125035301:+ MESO trans rs1816752 0.87 rs7320102 ENSG00000237917.1 PARP4P1 12.07 3.26e-17 1.03e-08 1.05 0.85 Obesity-related traits; chr13:24437435 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs7339140 ENSG00000237917.1 PARP4P1 12.07 3.26e-17 1.03e-08 1.05 0.85 Obesity-related traits; chr13:24437764 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs9511261 ENSG00000237917.1 PARP4P1 12.07 3.26e-17 1.03e-08 1.05 0.85 Obesity-related traits; chr13:24437880 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs9511262 ENSG00000237917.1 PARP4P1 12.07 3.26e-17 1.03e-08 1.05 0.85 Obesity-related traits; chr13:24437885 chrY:26594851~26634652:- MESO trans rs1816752 0.712 rs2862898 ENSG00000237917.1 PARP4P1 12.04 3.56e-17 1.1e-08 1.06 0.85 Obesity-related traits; chr13:24414323 chrY:26594851~26634652:- MESO trans rs1816752 0.652 rs2902356 ENSG00000237917.1 PARP4P1 12.04 3.56e-17 1.1e-08 1.06 0.85 Obesity-related traits; chr13:24414333 chrY:26594851~26634652:- MESO trans rs1816752 0.819 rs4770664 ENSG00000237917.1 PARP4P1 12.04 3.56e-17 1.1e-08 1.06 0.85 Obesity-related traits; chr13:24414695 chrY:26594851~26634652:- MESO trans rs7949030 1 rs2956993 ENSG00000186676.3 EEF1GP1 -12.02 3.82e-17 1.18e-08 -1.14 -0.85 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62638690 chr7:125033453~125035301:+ MESO trans rs1816752 0.905 rs8002215 ENSG00000237917.1 PARP4P1 11.98 4.43e-17 1.36e-08 1.04 0.85 Obesity-related traits; chr13:24416229 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs9511266 ENSG00000237917.1 PARP4P1 11.96 4.77e-17 1.44e-08 1.06 0.85 Obesity-related traits; chr13:24438366 chrY:26594851~26634652:- MESO trans rs1816752 0.817 rs7985394 ENSG00000237917.1 PARP4P1 11.96 4.77e-17 1.44e-08 1.06 0.85 Obesity-related traits; chr13:24438714 chrY:26594851~26634652:- MESO trans rs1816752 0.789 rs7986037 ENSG00000237917.1 PARP4P1 11.96 4.77e-17 1.44e-08 1.06 0.85 Obesity-related traits; chr13:24438715 chrY:26594851~26634652:- MESO trans rs1816752 0.755 rs1981277 ENSG00000237917.1 PARP4P1 11.93 5.23e-17 1.51e-08 1.05 0.85 Obesity-related traits; chr13:24409375 chrY:26594851~26634652:- MESO trans rs1816752 0.712 rs9507335 ENSG00000237917.1 PARP4P1 11.93 5.23e-17 1.51e-08 1.05 0.85 Obesity-related traits; chr13:24409766 chrY:26594851~26634652:- MESO trans rs1816752 0.774 rs2862895 ENSG00000237917.1 PARP4P1 11.93 5.23e-17 1.51e-08 1.05 0.85 Obesity-related traits; chr13:24410328 chrY:26594851~26634652:- MESO trans rs1816752 0.811 rs9507337 ENSG00000237917.1 PARP4P1 11.93 5.23e-17 1.51e-08 1.05 0.85 Obesity-related traits; chr13:24410807 chrY:26594851~26634652:- MESO trans rs1816752 0.819 rs7316961 ENSG00000237917.1 PARP4P1 11.93 5.23e-17 1.51e-08 1.05 0.85 Obesity-related traits; chr13:24411039 chrY:26594851~26634652:- MESO trans rs916888 0.686 rs199501 ENSG00000263503.1 RP11-707O23.5 -11.9 5.88e-17 1.69e-08 -0.95 -0.85 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46785247 chr17:45600869~45602340:- MESO trans rs1816752 1 rs9511265 ENSG00000237917.1 PARP4P1 11.86 6.61e-17 1.89e-08 1.04 0.85 Obesity-related traits; chr13:24438221 chrY:26594851~26634652:- MESO trans rs13177918 0.626 rs2748240 ENSG00000213058.3 RP4-765C7.2 11.83 7.26e-17 2.05e-08 1.12 0.85 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr1:178411616~178411972:+ MESO trans rs1816752 0.875 rs8001187 ENSG00000237917.1 PARP4P1 11.83 7.36e-17 2.05e-08 1.04 0.85 Obesity-related traits; chr13:24402276 chrY:26594851~26634652:- MESO trans rs1816752 0.783 rs9507333 ENSG00000237917.1 PARP4P1 11.83 7.36e-17 2.05e-08 1.04 0.85 Obesity-related traits; chr13:24404172 chrY:26594851~26634652:- MESO trans rs13177918 0.626 rs3819332 ENSG00000213058.3 RP4-765C7.2 11.8 8e-17 2.16e-08 1.12 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr1:178411616~178411972:+ MESO trans rs13177918 0.626 rs13170300 ENSG00000213058.3 RP4-765C7.2 11.8 8e-17 2.16e-08 1.12 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr1:178411616~178411972:+ MESO trans rs1816752 0.748 rs6490912 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24408941 chrY:26594851~26634652:- MESO trans rs1816752 0.819 rs1981276 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24409361 chrY:26594851~26634652:- MESO trans rs1816752 0.837 rs57052031 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24409730 chrY:26594851~26634652:- MESO trans rs1816752 0.783 rs7317439 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24410939 chrY:26594851~26634652:- MESO trans rs1816752 0.819 rs7317504 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24411287 chrY:26594851~26634652:- MESO trans rs1816752 0.783 rs7317712 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24411365 chrY:26594851~26634652:- MESO trans rs1816752 0.783 rs7139527 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24411374 chrY:26594851~26634652:- MESO trans rs1816752 0.819 rs9511240 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24411768 chrY:26594851~26634652:- MESO trans rs1816752 0.819 rs7988388 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24412675 chrY:26594851~26634652:- MESO trans rs1816752 0.875 rs7993132 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24412903 chrY:26594851~26634652:- MESO trans rs1816752 0.792 rs7330956 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24413174 chrY:26594851~26634652:- MESO trans rs1816752 0.777 rs6490915 ENSG00000237917.1 PARP4P1 11.78 8.63e-17 2.16e-08 1.05 0.84 Obesity-related traits; chr13:24413724 chrY:26594851~26634652:- MESO trans rs13177918 0.651 rs13184111 ENSG00000213058.3 RP4-765C7.2 11.78 8.65e-17 2.16e-08 1.12 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150434649 chr1:178411616~178411972:+ MESO trans rs13177918 0.626 rs12186649 ENSG00000213058.3 RP4-765C7.2 11.78 8.65e-17 2.16e-08 1.12 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150438963 chr1:178411616~178411972:+ MESO trans rs13177918 0.581 rs2748244 ENSG00000213058.3 RP4-765C7.2 11.78 8.72e-17 2.16e-08 1.13 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150436487 chr1:178411616~178411972:+ MESO trans rs13177918 0.559 rs3901731 ENSG00000213058.3 RP4-765C7.2 11.78 8.72e-17 2.16e-08 1.13 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150437405 chr1:178411616~178411972:+ MESO trans rs1816752 0.719 rs11843470 ENSG00000237917.1 PARP4P1 11.75 9.7e-17 2.37e-08 1.04 0.84 Obesity-related traits; chr13:24423561 chrY:26594851~26634652:- MESO trans rs1816752 0.819 rs7400583 ENSG00000237917.1 PARP4P1 11.7 1.13e-16 2.74e-08 1.06 0.84 Obesity-related traits; chr13:24415916 chrY:26594851~26634652:- MESO trans rs13177918 0.557 rs12520101 ENSG00000213058.3 RP4-765C7.2 11.69 1.19e-16 2.88e-08 1.08 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr1:178411616~178411972:+ MESO trans rs13177918 0.603 rs2748241 ENSG00000213058.3 RP4-765C7.2 11.67 1.26e-16 3.04e-08 1.12 0.84 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr1:178411616~178411972:+ MESO trans rs1816752 0.719 rs11841989 ENSG00000237917.1 PARP4P1 11.62 1.52e-16 3.5e-08 1.04 0.84 Obesity-related traits; chr13:24423560 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs1050112 ENSG00000237917.1 PARP4P1 11.62 1.52e-16 3.5e-08 1.04 0.84 Obesity-related traits; chr13:24435159 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs13428 ENSG00000237917.1 PARP4P1 11.62 1.52e-16 3.5e-08 1.04 0.84 Obesity-related traits; chr13:24435303 chrY:26594851~26634652:- MESO trans rs1816752 0.875 rs1050110 ENSG00000237917.1 PARP4P1 11.62 1.52e-16 3.5e-08 1.04 0.84 Obesity-related traits; chr13:24435347 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs8000215 ENSG00000237917.1 PARP4P1 11.62 1.52e-16 3.5e-08 1.04 0.84 Obesity-related traits; chr13:24435648 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs11839006 ENSG00000237917.1 PARP4P1 11.62 1.52e-16 3.5e-08 1.04 0.84 Obesity-related traits; chr13:24435893 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs2033955 ENSG00000237917.1 PARP4P1 11.62 1.52e-16 3.5e-08 1.04 0.84 Obesity-related traits; chr13:24436406 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs2033954 ENSG00000237917.1 PARP4P1 11.62 1.52e-16 3.5e-08 1.04 0.84 Obesity-related traits; chr13:24436429 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs9511260 ENSG00000237917.1 PARP4P1 11.62 1.52e-16 3.5e-08 1.04 0.84 Obesity-related traits; chr13:24437038 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs4769348 ENSG00000237917.1 PARP4P1 11.6 1.61e-16 3.68e-08 1.02 0.84 Obesity-related traits; chr13:24400975 chrY:26594851~26634652:- MESO trans rs916888 0.779 rs199526 ENSG00000263503.1 RP11-707O23.5 -11.57 1.8e-16 4.07e-08 -0.96 -0.84 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770341 chr17:45600869~45602340:- MESO trans rs1816752 1 rs7999554 ENSG00000237917.1 PARP4P1 11.56 1.83e-16 4.07e-08 1.03 0.84 Obesity-related traits; chr13:24435631 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs7995492 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24438885 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs7995909 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24439159 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs6490927 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24439802 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs6490928 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24439921 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs6490929 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24440114 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs3825449 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24440303 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs7998797 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24440850 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs7981337 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24440915 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs7981480 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24440966 chrY:26594851~26634652:- MESO trans rs1816752 0.837 rs4769355 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24441059 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs4770680 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24441110 chrY:26594851~26634652:- MESO trans rs1816752 0.805 rs61614647 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24441829 chrY:26594851~26634652:- MESO trans rs1816752 0.774 rs55888616 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24441954 chrY:26594851~26634652:- MESO trans rs1816752 0.806 rs3816218 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24443033 chrY:26594851~26634652:- MESO trans rs1816752 0.666 rs7994022 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24443092 chrY:26594851~26634652:- MESO trans rs1816752 0.776 rs7998843 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24443147 chrY:26594851~26634652:- MESO trans rs1816752 0.712 rs6490932 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24443313 chrY:26594851~26634652:- MESO trans rs1816752 0.713 rs7336357 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24443452 chrY:26594851~26634652:- MESO trans rs1816752 0.683 rs7330532 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24443453 chrY:26594851~26634652:- MESO trans rs1816752 0.59 rs61947036 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24443544 chrY:26594851~26634652:- MESO trans rs1816752 0.746 rs9511270 ENSG00000237917.1 PARP4P1 11.54 1.99e-16 4.07e-08 1.04 0.84 Obesity-related traits; chr13:24444542 chrY:26594851~26634652:- MESO trans rs1816752 0.633 rs8002387 ENSG00000237917.1 PARP4P1 11.5 2.27e-16 4.56e-08 1.07 0.84 Obesity-related traits; chr13:24416306 chrY:26594851~26634652:- MESO trans rs928391 0.681 rs9427242 ENSG00000227183.3 HDGFP1 -11.49 2.37e-16 4.71e-08 -1.2 -0.84 Platelet count; chr1:156755209 chrX:131646639~131646890:+ MESO trans rs1816752 0.905 rs9511242 ENSG00000237917.1 PARP4P1 11.48 2.41e-16 4.74e-08 1.04 0.84 Obesity-related traits; chr13:24419261 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs7317850 ENSG00000237917.1 PARP4P1 11.48 2.41e-16 4.74e-08 1.04 0.84 Obesity-related traits; chr13:24419899 chrY:26594851~26634652:- MESO trans rs7949030 1 rs7949030 ENSG00000186676.3 EEF1GP1 11.45 2.67e-16 5.07e-08 1.09 0.84 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62627409 chr7:125033453~125035301:+ MESO trans rs1816752 0.935 rs3816219 ENSG00000237917.1 PARP4P1 11.44 2.83e-16 5.07e-08 1.03 0.84 Obesity-related traits; chr13:24442995 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs9581026 ENSG00000237917.1 PARP4P1 11.34 3.91e-16 6.49e-08 1.04 0.83 Obesity-related traits; chr13:24423788 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs7571 ENSG00000237917.1 PARP4P1 11.34 3.91e-16 6.49e-08 1.04 0.83 Obesity-related traits; chr13:24426479 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs9581025 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24423687 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs9581027 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24423790 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs9318529 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24424190 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs73469543 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24424832 chrY:26594851~26634652:- MESO trans rs1816752 0.633 rs9578729 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24425106 chrY:26594851~26634652:- MESO trans rs1816752 0.87 rs9581029 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24425147 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs9511249 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24425457 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs7991450 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24425898 chrY:26594851~26634652:- MESO trans rs1816752 0.774 rs7986162 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24425941 chrY:26594851~26634652:- MESO trans rs1816752 0.905 rs4769352 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24426237 chrY:26594851~26634652:- MESO trans rs1816752 0.805 rs4769353 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24426318 chrY:26594851~26634652:- MESO trans rs1816752 0.837 rs7324645 ENSG00000237917.1 PARP4P1 11.34 3.98e-16 6.49e-08 1.03 0.83 Obesity-related traits; chr13:24426717 chrY:26594851~26634652:- MESO trans rs13177918 0.75 rs58256223 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442456 chr1:206695837~206696269:- MESO trans rs13177918 0.75 rs59354956 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442457 chr1:206695837~206696269:- MESO trans rs13177918 0.686 rs12654827 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs13160685 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs13161099 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr1:206695837~206696269:- MESO trans rs13177918 0.629 rs13161261 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs13161417 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs13161156 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs13181401 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs4541646 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs3900644 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs2070844 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs2073472 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr1:206695837~206696269:- MESO trans rs13177918 0.629 rs2070842 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs13171800 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs2070841 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs13177951 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs13177970 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs13164105 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs4841 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446963 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs13183077 ENSG00000224114.1 RP11-343H5.4 11.3 4.49e-16 6.76e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447009 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs57890152 ENSG00000224114.1 RP11-343H5.4 11.29 4.63e-16 6.91e-08 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr1:206695837~206696269:- MESO trans rs1816752 0.935 rs4770676 ENSG00000237917.1 PARP4P1 11.29 4.69e-16 6.91e-08 1.03 0.83 Obesity-related traits; chr13:24429745 chrY:26594851~26634652:- MESO trans rs1816752 1 rs7326932 ENSG00000237917.1 PARP4P1 11.29 4.69e-16 6.91e-08 1.03 0.83 Obesity-related traits; chr13:24430355 chrY:26594851~26634652:- MESO trans rs1816752 0.776 rs9511268 ENSG00000237917.1 PARP4P1 11.26 5.24e-16 7.52e-08 1.06 0.83 Obesity-related traits; chr13:24444182 chrY:26594851~26634652:- MESO trans rs916888 0.558 rs199521 ENSG00000263503.1 RP11-707O23.5 -11.24 5.67e-16 8.07e-08 -0.96 -0.83 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776090 chr17:45600869~45602340:- MESO trans rs1816752 1 rs7988810 ENSG00000237917.1 PARP4P1 11.17 7.06e-16 8.75e-08 1.02 0.83 Obesity-related traits; chr13:24444958 chrY:26594851~26634652:- MESO trans rs13177918 0.75 rs58256223 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442456 chr5:116562562~116562930:+ MESO trans rs13177918 0.75 rs59354956 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442457 chr5:116562562~116562930:+ MESO trans rs13177918 0.686 rs12654827 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442527 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs13160685 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442768 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs13161099 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442799 chr5:116562562~116562930:+ MESO trans rs13177918 0.629 rs13161261 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442844 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs13161417 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150442937 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs13161156 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443023 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs13181401 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443033 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs4541646 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443355 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs3900644 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443359 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs2070844 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444222 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs2073472 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444504 chr5:116562562~116562930:+ MESO trans rs13177918 0.629 rs2070842 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444660 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs13171800 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444792 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs2070841 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150444908 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs13177951 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446376 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs13177970 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446447 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs13164105 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446503 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs4841 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150446963 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs13183077 ENSG00000239528.1 RPS14P8 11.17 7.07e-16 8.75e-08 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447009 chr5:116562562~116562930:+ MESO trans rs13177918 0.677 rs57890152 ENSG00000239528.1 RPS14P8 11.06 1.04e-15 1.26e-07 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150441909 chr5:116562562~116562930:+ MESO trans rs916888 0.779 rs199498 ENSG00000263503.1 RP11-707O23.5 11.06 1.05e-15 1.28e-07 0.99 0.83 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:45600869~45602340:- MESO trans rs13177918 0.651 rs13184111 ENSG00000224114.1 RP11-343H5.4 11.03 1.16e-15 1.4e-07 1.16 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150434649 chr1:206695837~206696269:- MESO trans rs13177918 0.626 rs12186649 ENSG00000224114.1 RP11-343H5.4 11.03 1.16e-15 1.4e-07 1.16 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150438963 chr1:206695837~206696269:- MESO trans rs1816752 0.819 rs7985478 ENSG00000237917.1 PARP4P1 11.01 1.26e-15 1.51e-07 1.07 0.83 Obesity-related traits; chr13:24417135 chrY:26594851~26634652:- MESO trans rs13177918 0.677 rs3797622 ENSG00000224114.1 RP11-343H5.4 11.01 1.26e-15 1.51e-07 1.17 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs3797622 ENSG00000239528.1 RPS14P8 10.99 1.32e-15 1.59e-07 1.19 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447535 chr5:116562562~116562930:+ MESO trans rs13177918 0.626 rs13175436 ENSG00000213058.3 RP4-765C7.2 10.99 1.34e-15 1.6e-07 1.11 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150450974 chr1:178411616~178411972:+ MESO trans rs13177918 0.603 rs13175992 ENSG00000213058.3 RP4-765C7.2 10.99 1.34e-15 1.6e-07 1.11 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150451026 chr1:178411616~178411972:+ MESO trans rs13177918 0.626 rs67026795 ENSG00000213058.3 RP4-765C7.2 10.99 1.34e-15 1.6e-07 1.11 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452097 chr1:178411616~178411972:+ MESO trans rs13177918 0.578 rs35919198 ENSG00000213058.3 RP4-765C7.2 10.99 1.34e-15 1.6e-07 1.11 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452428 chr1:178411616~178411972:+ MESO trans rs13177918 0.603 rs10447222 ENSG00000213058.3 RP4-765C7.2 10.99 1.34e-15 1.6e-07 1.11 0.83 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150453104 chr1:178411616~178411972:+ MESO trans rs1816752 0.819 rs6490917 ENSG00000237917.1 PARP4P1 10.94 1.6e-15 1.79e-07 1.05 0.83 Obesity-related traits; chr13:24423119 chrY:26594851~26634652:- MESO trans rs13177918 0.512 rs34113080 ENSG00000213058.3 RP4-765C7.2 10.92 1.73e-15 1.91e-07 1.08 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150429201 chr1:178411616~178411972:+ MESO trans rs1816752 0.638 rs9578730 ENSG00000237917.1 PARP4P1 10.86 2.1e-15 2.28e-07 1.03 0.82 Obesity-related traits; chr13:24425545 chrY:26594851~26634652:- MESO trans rs12291225 0.679 rs11238 ENSG00000236360.2 RP11-334A14.2 -10.82 2.47e-15 2.58e-07 -1.28 -0.82 Sense of smell; chr11:14266582 chr1:52993201~52993702:- MESO trans rs12291225 0.645 rs3763950 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14256503 chr1:52993201~52993702:- MESO trans rs12291225 0.679 rs4756786 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14264354 chr1:52993201~52993702:- MESO trans rs12291225 0.679 rs11369 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14266550 chr1:52993201~52993702:- MESO trans rs12291225 0.679 rs1043237 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14267507 chr1:52993201~52993702:- MESO trans rs12291225 0.679 rs11605531 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14270048 chr1:52993201~52993702:- MESO trans rs12291225 0.639 rs61883858 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14273162 chr1:52993201~52993702:- MESO trans rs12291225 0.679 rs11023170 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14273363 chr1:52993201~52993702:- MESO trans rs12291225 0.679 rs11023172 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14273821 chr1:52993201~52993702:- MESO trans rs12291225 0.679 rs4757245 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14276326 chr1:52993201~52993702:- MESO trans rs12291225 0.637 rs8570 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14279213 chr1:52993201~52993702:- MESO trans rs12291225 0.753 rs1431374 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14282429 chr1:52993201~52993702:- MESO trans rs12291225 0.679 rs10832240 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14283198 chr1:52993201~52993702:- MESO trans rs12291225 0.679 rs7934671 ENSG00000236360.2 RP11-334A14.2 10.82 2.47e-15 2.58e-07 1.28 0.82 Sense of smell; chr11:14283555 chr1:52993201~52993702:- MESO trans rs13177918 0.603 rs2343806 ENSG00000213058.3 RP4-765C7.2 10.81 2.48e-15 2.59e-07 1.12 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr1:178411616~178411972:+ MESO trans rs13177918 0.581 rs2245384 ENSG00000239528.1 RPS14P8 10.78 2.83e-15 2.91e-07 1.18 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150437705 chr5:116562562~116562930:+ MESO trans rs13177918 0.651 rs13184111 ENSG00000239528.1 RPS14P8 10.77 2.95e-15 3.01e-07 1.17 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150434649 chr5:116562562~116562930:+ MESO trans rs13177918 0.626 rs12186649 ENSG00000239528.1 RPS14P8 10.77 2.95e-15 3.01e-07 1.17 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150438963 chr5:116562562~116562930:+ MESO trans rs13177918 0.581 rs2245384 ENSG00000224114.1 RP11-343H5.4 10.73 3.36e-15 3.41e-07 1.16 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150437705 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs3857421 ENSG00000239528.1 RPS14P8 -10.68 4.01e-15 4.06e-07 -1.16 -0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr5:116562562~116562930:+ MESO trans rs7121616 0.576 rs4936767 ENSG00000234176.1 HSPA8P1 10.64 4.54e-15 4.56e-07 1.09 0.82 Breast cancer; chr11:123047451 chrX:121203182~121205014:- MESO trans rs6477998 0.535 rs3750535 ENSG00000238072.1 RP11-305M3.2 10.62 5e-15 5.01e-07 1.23 0.82 Hematology traits; chr9:113297453 chr7:129410113~129410370:- MESO trans rs13177918 0.557 rs12520101 ENSG00000239528.1 RPS14P8 10.59 5.49e-15 5.49e-07 1.12 0.82 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr5:116562562~116562930:+ MESO trans rs6477998 0.58 rs12343629 ENSG00000238072.1 RP11-305M3.2 10.56 6.13e-15 6.1e-07 1.15 0.82 Hematology traits; chr9:113279301 chr7:129410113~129410370:- MESO trans rs7121616 0.563 rs4936770 ENSG00000234176.1 HSPA8P1 10.53 6.71e-15 6.67e-07 1.12 0.82 Breast cancer; chr11:123058167 chrX:121203182~121205014:- MESO trans rs13177918 0.557 rs12520101 ENSG00000224114.1 RP11-343H5.4 10.48 8.07e-15 7.97e-07 1.1 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150431360 chr1:206695837~206696269:- MESO trans rs13177918 0.677 rs3857421 ENSG00000224114.1 RP11-343H5.4 -10.47 8.33e-15 8.14e-07 -1.13 -0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150443584 chr1:206695837~206696269:- MESO trans rs7121616 0.563 rs1461494 ENSG00000234176.1 HSPA8P1 10.41 1.03e-14 9.74e-07 1.07 0.81 Breast cancer; chr11:123055777 chrX:121203182~121205014:- MESO trans rs7121616 0.576 rs4802 ENSG00000234176.1 HSPA8P1 10.41 1.03e-14 9.74e-07 1.07 0.81 Breast cancer; chr11:123057914 chrX:121203182~121205014:- MESO trans rs12291225 0.679 rs11023178 ENSG00000236360.2 RP11-334A14.2 10.37 1.22e-14 1.15e-06 1.26 0.81 Sense of smell; chr11:14288736 chr1:52993201~52993702:- MESO trans rs12291225 0.679 rs34238445 ENSG00000236360.2 RP11-334A14.2 10.37 1.22e-14 1.15e-06 1.26 0.81 Sense of smell; chr11:14294369 chr1:52993201~52993702:- MESO trans rs1816752 0.837 rs9318530 ENSG00000237917.1 PARP4P1 -10.35 1.27e-14 1.2e-06 -1.02 -0.81 Obesity-related traits; chr13:24424419 chrY:26594851~26634652:- MESO trans rs13177918 0.626 rs3819332 ENSG00000224114.1 RP11-343H5.4 10.34 1.34e-14 1.25e-06 1.14 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr1:206695837~206696269:- MESO trans rs13177918 0.626 rs13170300 ENSG00000224114.1 RP11-343H5.4 10.34 1.34e-14 1.25e-06 1.14 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr1:206695837~206696269:- MESO trans rs1816752 1 rs9507341 ENSG00000237917.1 PARP4P1 -10.28 1.69e-14 1.56e-06 -1.07 -0.81 Obesity-related traits; chr13:24432440 chrY:26594851~26634652:- MESO trans rs1816752 0.875 rs3783076 ENSG00000237917.1 PARP4P1 10.26 1.76e-14 1.62e-06 0.98 0.81 Obesity-related traits; chr13:24490319 chrY:26594851~26634652:- MESO trans rs6477998 0.58 rs10981715 ENSG00000238072.1 RP11-305M3.2 10.2 2.19e-14 2.01e-06 1.16 0.81 Hematology traits; chr9:113287218 chr7:129410113~129410370:- MESO trans rs6477998 0.58 rs10759638 ENSG00000238072.1 RP11-305M3.2 -10.2 2.19e-14 2.01e-06 -1.16 -0.81 Hematology traits; chr9:113280212 chr7:129410113~129410370:- MESO trans rs13177918 0.581 rs2748244 ENSG00000224114.1 RP11-343H5.4 10.19 2.32e-14 2.12e-06 1.14 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150436487 chr1:206695837~206696269:- MESO trans rs13177918 0.559 rs3901731 ENSG00000224114.1 RP11-343H5.4 10.19 2.32e-14 2.12e-06 1.14 0.81 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150437405 chr1:206695837~206696269:- MESO trans rs1816752 1 rs9511272 ENSG00000237917.1 PARP4P1 10.18 2.36e-14 2.16e-06 1 0.81 Obesity-related traits; chr13:24446495 chrY:26594851~26634652:- MESO trans rs6477998 0.58 rs2296073 ENSG00000238072.1 RP11-305M3.2 10.17 2.49e-14 2.26e-06 1.18 0.81 Hematology traits; chr9:113299348 chr7:129410113~129410370:- MESO trans rs6477998 0.58 rs7027833 ENSG00000238072.1 RP11-305M3.2 10.17 2.49e-14 2.26e-06 1.18 0.81 Hematology traits; chr9:113301377 chr7:129410113~129410370:- MESO trans rs1816752 0.905 rs3818938 ENSG00000237917.1 PARP4P1 10.12 2.96e-14 2.68e-06 0.96 0.8 Obesity-related traits; chr13:24454945 chrY:26594851~26634652:- MESO trans rs13177918 0.798 rs12516161 ENSG00000213058.3 RP4-765C7.2 10.1 3.18e-14 2.84e-06 1.13 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150461098 chr1:178411616~178411972:+ MESO trans rs13177918 0.581 rs2748244 ENSG00000239528.1 RPS14P8 10.07 3.58e-14 3.19e-06 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150436487 chr5:116562562~116562930:+ MESO trans rs13177918 0.559 rs3901731 ENSG00000239528.1 RPS14P8 10.07 3.58e-14 3.19e-06 1.16 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150437405 chr5:116562562~116562930:+ MESO trans rs13177918 0.626 rs13175436 ENSG00000224114.1 RP11-343H5.4 10.06 3.65e-14 3.22e-06 1.14 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150450974 chr1:206695837~206696269:- MESO trans rs13177918 0.603 rs13175992 ENSG00000224114.1 RP11-343H5.4 10.06 3.65e-14 3.22e-06 1.14 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150451026 chr1:206695837~206696269:- MESO trans rs13177918 0.626 rs67026795 ENSG00000224114.1 RP11-343H5.4 10.06 3.65e-14 3.22e-06 1.14 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452097 chr1:206695837~206696269:- MESO trans rs13177918 0.578 rs35919198 ENSG00000224114.1 RP11-343H5.4 10.06 3.65e-14 3.22e-06 1.14 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452428 chr1:206695837~206696269:- MESO trans rs13177918 0.603 rs10447222 ENSG00000224114.1 RP11-343H5.4 10.06 3.65e-14 3.22e-06 1.14 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150453104 chr1:206695837~206696269:- MESO trans rs13177918 0.626 rs3819332 ENSG00000239528.1 RPS14P8 10 4.5e-14 3.94e-06 1.14 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449187 chr5:116562562~116562930:+ MESO trans rs13177918 0.626 rs13170300 ENSG00000239528.1 RPS14P8 10 4.5e-14 3.94e-06 1.14 0.8 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449748 chr5:116562562~116562930:+ MESO trans rs3749237 0.595 rs6784820 ENSG00000197582.5 GPX1P1 -9.99 4.77e-14 4.17e-06 -1 -0.8 Resting heart rate; chr3:49413431 chrX:13378735~13379340:- MESO trans rs1816752 0.819 rs4769349 ENSG00000237917.1 PARP4P1 -9.9 6.55e-14 5.63e-06 -1.08 -0.8 Obesity-related traits; chr13:24408694 chrY:26594851~26634652:- MESO trans rs6477998 0.58 rs11552582 ENSG00000238072.1 RP11-305M3.2 9.89 6.82e-14 5.83e-06 1.14 0.8 Hematology traits; chr9:113282718 chr7:129410113~129410370:- MESO trans rs6477998 0.58 rs4979231 ENSG00000238072.1 RP11-305M3.2 9.89 6.82e-14 5.83e-06 1.14 0.8 Hematology traits; chr9:113286475 chr7:129410113~129410370:- MESO trans rs13253073 0.723 rs12548542 ENSG00000260318.1 COX6CP1 9.87 7.35e-14 6.23e-06 1.57 0.8 Glucose homeostasis traits; chr8:99890167 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs35429753 ENSG00000260318.1 COX6CP1 9.87 7.35e-14 6.23e-06 1.57 0.8 Glucose homeostasis traits; chr8:99891015 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs1130474 ENSG00000260318.1 COX6CP1 9.87 7.35e-14 6.23e-06 1.57 0.8 Glucose homeostasis traits; chr8:99892049 chr16:11903923~11904137:- MESO trans rs13253073 0.657 rs35135010 ENSG00000260318.1 COX6CP1 9.83 8.56e-14 7.18e-06 1.56 0.8 Glucose homeostasis traits; chr8:99864209 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs34830464 ENSG00000260318.1 COX6CP1 9.83 8.56e-14 7.18e-06 1.56 0.8 Glucose homeostasis traits; chr8:99866638 chr16:11903923~11904137:- MESO trans rs7121616 0.562 rs2061602 ENSG00000234176.1 HSPA8P1 9.79 9.69e-14 8.05e-06 1.06 0.79 Breast cancer; chr11:123065079 chrX:121203182~121205014:- MESO trans rs7121616 0.562 rs7131452 ENSG00000234176.1 HSPA8P1 9.79 9.69e-14 8.05e-06 1.06 0.79 Breast cancer; chr11:123065314 chrX:121203182~121205014:- MESO trans rs13177918 0.603 rs2748241 ENSG00000224114.1 RP11-343H5.4 9.78 1.03e-13 8.51e-06 1.12 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr1:206695837~206696269:- MESO trans rs13177918 0.626 rs2748240 ENSG00000224114.1 RP11-343H5.4 9.77 1.06e-13 8.72e-06 1.11 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr1:206695837~206696269:- MESO trans rs13253073 0.662 rs4434590 ENSG00000260318.1 COX6CP1 9.76 1.11e-13 9.06e-06 1.54 0.79 Glucose homeostasis traits; chr8:99848429 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs7157 ENSG00000260318.1 COX6CP1 9.72 1.25e-13 9.94e-06 1.55 0.79 Glucose homeostasis traits; chr8:99877449 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs4626565 ENSG00000260318.1 COX6CP1 9.72 1.25e-13 9.94e-06 1.55 0.79 Glucose homeostasis traits; chr8:99878314 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs7844439 ENSG00000260318.1 COX6CP1 9.72 1.25e-13 9.94e-06 1.55 0.79 Glucose homeostasis traits; chr8:99878567 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs7813557 ENSG00000260318.1 COX6CP1 9.72 1.25e-13 9.94e-06 1.55 0.79 Glucose homeostasis traits; chr8:99878665 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs4510829 ENSG00000260318.1 COX6CP1 9.72 1.25e-13 9.94e-06 1.55 0.79 Glucose homeostasis traits; chr8:99878982 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs7828241 ENSG00000260318.1 COX6CP1 9.72 1.25e-13 9.94e-06 1.55 0.79 Glucose homeostasis traits; chr8:99880417 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs7812991 ENSG00000260318.1 COX6CP1 9.72 1.25e-13 9.94e-06 1.55 0.79 Glucose homeostasis traits; chr8:99884095 chr16:11903923~11904137:- MESO trans rs13253073 0.76 rs62534633 ENSG00000260318.1 COX6CP1 9.72 1.25e-13 9.94e-06 1.55 0.79 Glucose homeostasis traits; chr8:99884533 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs12548840 ENSG00000260318.1 COX6CP1 9.72 1.25e-13 9.94e-06 1.55 0.79 Glucose homeostasis traits; chr8:99885580 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs1130569 ENSG00000260318.1 COX6CP1 9.72 1.25e-13 9.94e-06 1.55 0.79 Glucose homeostasis traits; chr8:99887565 chr16:11903923~11904137:- MESO trans rs7121616 0.595 rs7949414 ENSG00000234176.1 HSPA8P1 9.7 1.37e-13 1.09e-05 1.06 0.79 Breast cancer; chr11:123072787 chrX:121203182~121205014:- MESO trans rs13177918 0.603 rs2748241 ENSG00000239528.1 RPS14P8 9.68 1.46e-13 1.16e-05 1.14 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150447931 chr5:116562562~116562930:+ MESO trans rs13177918 0.626 rs13175436 ENSG00000239528.1 RPS14P8 9.68 1.49e-13 1.17e-05 1.15 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150450974 chr5:116562562~116562930:+ MESO trans rs13177918 0.603 rs13175992 ENSG00000239528.1 RPS14P8 9.68 1.49e-13 1.17e-05 1.15 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150451026 chr5:116562562~116562930:+ MESO trans rs13177918 0.626 rs67026795 ENSG00000239528.1 RPS14P8 9.68 1.49e-13 1.17e-05 1.15 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452097 chr5:116562562~116562930:+ MESO trans rs13177918 0.578 rs35919198 ENSG00000239528.1 RPS14P8 9.68 1.49e-13 1.17e-05 1.15 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452428 chr5:116562562~116562930:+ MESO trans rs13177918 0.603 rs10447222 ENSG00000239528.1 RPS14P8 9.68 1.49e-13 1.17e-05 1.15 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150453104 chr5:116562562~116562930:+ MESO trans rs13177918 0.512 rs34113080 ENSG00000239528.1 RPS14P8 9.66 1.59e-13 1.25e-05 1.11 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150429201 chr5:116562562~116562930:+ MESO trans rs3749237 0.595 rs17595772 ENSG00000197582.5 GPX1P1 9.62 1.81e-13 1.38e-05 0.98 0.79 Resting heart rate; chr3:49372271 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs7621003 ENSG00000197582.5 GPX1P1 9.62 1.81e-13 1.38e-05 0.98 0.79 Resting heart rate; chr3:49373971 chrX:13378735~13379340:- MESO trans rs3749237 0.555 rs2117939 ENSG00000197582.5 GPX1P1 9.62 1.81e-13 1.38e-05 0.98 0.79 Resting heart rate; chr3:49377746 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs4955412 ENSG00000197582.5 GPX1P1 9.62 1.81e-13 1.38e-05 0.98 0.79 Resting heart rate; chr3:49380735 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs6797765 ENSG00000197582.5 GPX1P1 9.62 1.81e-13 1.38e-05 0.98 0.79 Resting heart rate; chr3:49386543 chrX:13378735~13379340:- MESO trans rs3749237 0.557 rs7631908 ENSG00000197582.5 GPX1P1 9.62 1.81e-13 1.38e-05 0.98 0.79 Resting heart rate; chr3:49388274 chrX:13378735~13379340:- MESO trans rs3749237 0.615 rs6792911 ENSG00000197582.5 GPX1P1 9.62 1.81e-13 1.38e-05 0.98 0.79 Resting heart rate; chr3:49392423 chrX:13378735~13379340:- MESO trans rs3749237 0.615 rs55957735 ENSG00000197582.5 GPX1P1 9.62 1.81e-13 1.38e-05 0.98 0.79 Resting heart rate; chr3:49400725 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs4855877 ENSG00000197582.5 GPX1P1 9.62 1.81e-13 1.38e-05 0.98 0.79 Resting heart rate; chr3:49411094 chrX:13378735~13379340:- MESO trans rs6477998 0.557 rs11789755 ENSG00000238072.1 RP11-305M3.2 9.57 2.23e-13 1.68e-05 1.13 0.79 Hematology traits; chr9:113292796 chr7:129410113~129410370:- MESO trans rs13177918 0.798 rs12514700 ENSG00000213058.3 RP4-765C7.2 9.56 2.26e-13 1.71e-05 1.09 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466096 chr1:178411616~178411972:+ MESO trans rs3749237 0.576 rs4241406 ENSG00000197582.5 GPX1P1 9.55 2.32e-13 1.75e-05 0.98 0.79 Resting heart rate; chr3:49562993 chrX:13378735~13379340:- MESO trans rs13177918 0.717 rs6874318 ENSG00000213058.3 RP4-765C7.2 -9.54 2.42e-13 1.81e-05 -1.08 -0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr1:178411616~178411972:+ MESO trans rs13177918 0.626 rs2748240 ENSG00000239528.1 RPS14P8 9.49 2.91e-13 2.17e-05 1.12 0.79 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150449305 chr5:116562562~116562930:+ MESO trans rs13253073 1 rs12544943 ENSG00000260318.1 COX6CP1 9.49 2.96e-13 2.2e-05 1.6 0.79 Glucose homeostasis traits; chr8:99891662 chr16:11903923~11904137:- MESO trans rs13177918 0.734 rs6579790 ENSG00000213058.3 RP4-765C7.2 9.45 3.35e-13 2.48e-05 1.07 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464379 chr1:178411616~178411972:+ MESO trans rs3749237 0.595 rs2878298 ENSG00000197582.5 GPX1P1 9.4 4.03e-13 2.98e-05 0.97 0.78 Resting heart rate; chr3:49368647 chrX:13378735~13379340:- MESO trans rs13177918 0.512 rs34113080 ENSG00000224114.1 RP11-343H5.4 9.36 4.76e-13 3.48e-05 1.08 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150429201 chr1:206695837~206696269:- MESO trans rs1816752 0.875 rs59686377 ENSG00000237917.1 PARP4P1 9.35 4.85e-13 3.54e-05 0.87 0.78 Obesity-related traits; chr13:24475869 chrY:26594851~26634652:- MESO trans rs13253073 1 rs13259066 ENSG00000260318.1 COX6CP1 9.35 4.89e-13 3.56e-05 1.58 0.78 Glucose homeostasis traits; chr8:99889455 chr16:11903923~11904137:- MESO trans rs13253073 1 rs34029308 ENSG00000260318.1 COX6CP1 9.35 4.89e-13 3.56e-05 1.58 0.78 Glucose homeostasis traits; chr8:99892425 chr16:11903923~11904137:- MESO trans rs7121616 0.595 rs7941144 ENSG00000234176.1 HSPA8P1 9.34 5.07e-13 3.65e-05 1.06 0.78 Breast cancer; chr11:123079805 chrX:121203182~121205014:- MESO trans rs3749237 0.595 rs12489092 ENSG00000197582.5 GPX1P1 9.34 5.09e-13 3.65e-05 0.97 0.78 Resting heart rate; chr3:49513481 chrX:13378735~13379340:- MESO trans rs3749237 0.555 rs7637665 ENSG00000197582.5 GPX1P1 9.34 5.09e-13 3.65e-05 0.97 0.78 Resting heart rate; chr3:49514862 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs3870337 ENSG00000197582.5 GPX1P1 9.34 5.09e-13 3.65e-05 0.97 0.78 Resting heart rate; chr3:49519662 chrX:13378735~13379340:- MESO trans rs3749237 0.615 rs11130202 ENSG00000197582.5 GPX1P1 9.34 5.09e-13 3.65e-05 0.97 0.78 Resting heart rate; chr3:49529282 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs11720264 ENSG00000197582.5 GPX1P1 9.34 5.09e-13 3.65e-05 0.97 0.78 Resting heart rate; chr3:49542914 chrX:13378735~13379340:- MESO trans rs13253073 0.723 rs7831963 ENSG00000260318.1 COX6CP1 9.33 5.22e-13 3.71e-05 1.56 0.78 Glucose homeostasis traits; chr8:99853014 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs7832488 ENSG00000260318.1 COX6CP1 9.33 5.22e-13 3.71e-05 1.56 0.78 Glucose homeostasis traits; chr8:99853185 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs6468695 ENSG00000260318.1 COX6CP1 9.33 5.22e-13 3.71e-05 1.56 0.78 Glucose homeostasis traits; chr8:99857123 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs6468696 ENSG00000260318.1 COX6CP1 9.33 5.22e-13 3.71e-05 1.56 0.78 Glucose homeostasis traits; chr8:99857130 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs13274441 ENSG00000260318.1 COX6CP1 9.33 5.22e-13 3.71e-05 1.56 0.78 Glucose homeostasis traits; chr8:99861038 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs62534626 ENSG00000260318.1 COX6CP1 9.33 5.22e-13 3.71e-05 1.56 0.78 Glucose homeostasis traits; chr8:99866119 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs7840626 ENSG00000260318.1 COX6CP1 9.33 5.22e-13 3.71e-05 1.56 0.78 Glucose homeostasis traits; chr8:99867598 chr16:11903923~11904137:- MESO trans rs13253073 0.662 rs34513504 ENSG00000260318.1 COX6CP1 9.32 5.6e-13 3.97e-05 1.55 0.78 Glucose homeostasis traits; chr8:99848918 chr16:11903923~11904137:- MESO trans rs3749237 0.595 rs3870338 ENSG00000197582.5 GPX1P1 9.29 6.14e-13 4.33e-05 0.94 0.78 Resting heart rate; chr3:49519618 chrX:13378735~13379340:- MESO trans rs13177918 0.734 rs6579791 ENSG00000213058.3 RP4-765C7.2 9.29 6.22e-13 4.38e-05 1.08 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464440 chr1:178411616~178411972:+ MESO trans rs13177918 0.603 rs2343806 ENSG00000224114.1 RP11-343H5.4 9.28 6.39e-13 4.49e-05 1.12 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr1:206695837~206696269:- MESO trans rs7121616 0.576 rs11218967 ENSG00000234176.1 HSPA8P1 9.24 7.32e-13 5.11e-05 1.04 0.78 Breast cancer; chr11:123087551 chrX:121203182~121205014:- MESO trans rs13253073 0.723 rs12548344 ENSG00000260318.1 COX6CP1 9.21 8.13e-13 5.63e-05 1.55 0.78 Glucose homeostasis traits; chr8:99868676 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs7009713 ENSG00000260318.1 COX6CP1 9.21 8.13e-13 5.63e-05 1.55 0.78 Glucose homeostasis traits; chr8:99869626 chr16:11903923~11904137:- MESO trans rs13253073 0.723 rs12546882 ENSG00000260318.1 COX6CP1 9.21 8.13e-13 5.63e-05 1.55 0.78 Glucose homeostasis traits; chr8:99869919 chr16:11903923~11904137:- MESO trans rs13177918 0.501 rs2545345 ENSG00000213058.3 RP4-765C7.2 9.19 8.74e-13 6.01e-05 1.02 0.78 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464080 chr1:178411616~178411972:+ MESO trans rs13253073 0.723 rs1135382 ENSG00000260318.1 COX6CP1 9.16 9.83e-13 6.73e-05 1.55 0.77 Glucose homeostasis traits; chr8:99879402 chr16:11903923~11904137:- MESO trans rs13253073 1 rs35935983 ENSG00000260318.1 COX6CP1 9.11 1.21e-12 8.07e-05 1.57 0.77 Glucose homeostasis traits; chr8:99888966 chr16:11903923~11904137:- MESO trans rs3749237 0.595 rs1464568 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49420833 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs4855873 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49421681 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs1464566 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49421943 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs11130192 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49429773 chrX:13378735~13379340:- MESO trans rs3749237 0.537 rs4459909 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49431784 chrX:13378735~13379340:- MESO trans rs13096760 1 rs13096760 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Intelligence (multi-trait analysis); chr3:49439373 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs11130196 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49452716 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs885592 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49460450 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs10865955 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49462396 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs4855839 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49470414 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs35701831 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49477567 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs1568661 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49483525 chrX:13378735~13379340:- MESO trans rs3749237 0.636 rs1568662 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49483830 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs4855864 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49484541 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs3924462 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49486803 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs4855861 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49488529 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs4855859 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49488867 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs7643845 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49493278 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs7637999 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49497682 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs11130199 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49501366 chrX:13378735~13379340:- MESO trans rs3749237 0.576 rs3877784 ENSG00000197582.5 GPX1P1 9.1 1.23e-12 8.07e-05 0.96 0.77 Resting heart rate; chr3:49501984 chrX:13378735~13379340:- MESO trans rs3749237 0.595 rs1464567 ENSG00000197582.5 GPX1P1 -9.1 1.23e-12 8.07e-05 -0.96 -0.77 Resting heart rate; chr3:49421819 chrX:13378735~13379340:- MESO trans rs13253073 1 rs13273257 ENSG00000260318.1 COX6CP1 9.08 1.34e-12 8.74e-05 1.54 0.77 Glucose homeostasis traits; chr8:99852468 chr16:11903923~11904137:- MESO trans rs13253073 0.941 rs4076509 ENSG00000260318.1 COX6CP1 9.06 1.43e-12 9.32e-05 1.53 0.77 Glucose homeostasis traits; chr8:99842928 chr16:11903923~11904137:- MESO trans rs13253073 0.941 rs13264726 ENSG00000260318.1 COX6CP1 9.06 1.43e-12 9.32e-05 1.53 0.77 Glucose homeostasis traits; chr8:99851139 chr16:11903923~11904137:- MESO trans rs1816752 0.875 rs59531061 ENSG00000237917.1 PARP4P1 9.04 1.55e-12 0.000101 0.88 0.77 Obesity-related traits; chr13:24507297 chrY:26594851~26634652:- MESO trans rs13177918 0.603 rs2343806 ENSG00000239528.1 RPS14P8 9.04 1.56e-12 0.000101 1.13 0.77 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150452422 chr5:116562562~116562930:+ MESO trans rs7943191 0.768 rs34065644 ENSG00000186676.3 EEF1GP1 9.03 1.62e-12 0.000105 1.02 0.77 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62604466 chr7:125033453~125035301:+ MESO trans rs7949030 0.523 rs67308910 ENSG00000186676.3 EEF1GP1 9.03 1.62e-12 0.000105 1.02 0.77 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62609887 chr7:125033453~125035301:+ MESO trans rs916888 0.738 rs199515 ENSG00000264070.1 DND1P1 -8.98 1.92e-12 0.000123 -1.05 -0.77 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779275 chr17:45585871~45586929:+ MESO trans rs13253073 1 rs4480092 ENSG00000260318.1 COX6CP1 8.97 2.01e-12 0.000128 1.53 0.77 Glucose homeostasis traits; chr8:99873372 chr16:11903923~11904137:- MESO trans rs13253073 1 rs4409375 ENSG00000260318.1 COX6CP1 8.97 2.01e-12 0.000128 1.53 0.77 Glucose homeostasis traits; chr8:99877759 chr16:11903923~11904137:- MESO trans rs13253073 1 rs13252579 ENSG00000260318.1 COX6CP1 8.97 2.01e-12 0.000128 1.53 0.77 Glucose homeostasis traits; chr8:99885073 chr16:11903923~11904137:- MESO trans rs13253073 1 rs13253073 ENSG00000260318.1 COX6CP1 8.97 2.01e-12 0.000128 1.53 0.77 Glucose homeostasis traits; chr8:99885155 chr16:11903923~11904137:- MESO trans rs13253073 1 rs10955222 ENSG00000260318.1 COX6CP1 -8.97 2.01e-12 0.000128 -1.53 -0.77 Glucose homeostasis traits; chr8:99875122 chr16:11903923~11904137:- MESO trans rs6477998 0.58 rs4979233 ENSG00000238072.1 RP11-305M3.2 8.96 2.06e-12 0.00013 1.14 0.77 Hematology traits; chr9:113295501 chr7:129410113~129410370:- MESO trans rs941207 0.756 rs2958153 ENSG00000121089.4 NACA3P 8.94 2.24e-12 0.000138 1.12 0.77 Platelet count; chr12:56687733 chr4:164943290~164943937:+ MESO trans rs1816752 0.875 rs17384871 ENSG00000237917.1 PARP4P1 8.92 2.44e-12 0.00015 0.86 0.77 Obesity-related traits; chr13:24484959 chrY:26594851~26634652:- MESO trans rs6477998 0.535 rs4979232 ENSG00000238072.1 RP11-305M3.2 -8.91 2.54e-12 0.000156 -1.14 -0.77 Hematology traits; chr9:113286594 chr7:129410113~129410370:- MESO trans rs13177918 0.501 rs10055975 ENSG00000213058.3 RP4-765C7.2 8.87 2.95e-12 0.000176 1.01 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466825 chr1:178411616~178411972:+ MESO trans rs7121616 0.545 rs116414356 ENSG00000234176.1 HSPA8P1 8.82 3.49e-12 0.000206 1.03 0.76 Breast cancer; chr11:123082611 chrX:121203182~121205014:- MESO trans rs2657294 0.796 rs2804535 ENSG00000172974.11 AC007318.5 -8.82 3.58e-12 0.00021 -0.91 -0.76 Pneumonia; chr10:75212086 chr2:65205108~65205988:+ MESO trans rs2657294 0.726 rs4746275 ENSG00000172974.11 AC007318.5 8.82 3.58e-12 0.00021 0.91 0.76 Pneumonia; chr10:75214940 chr2:65205108~65205988:+ MESO trans rs2657294 0.761 rs1259498 ENSG00000172974.11 AC007318.5 8.82 3.58e-12 0.00021 0.91 0.76 Pneumonia; chr10:75226983 chr2:65205108~65205988:+ MESO trans rs2657294 0.796 rs1259499 ENSG00000172974.11 AC007318.5 8.82 3.58e-12 0.00021 0.91 0.76 Pneumonia; chr10:75228308 chr2:65205108~65205988:+ MESO trans rs2657294 0.796 rs1259501 ENSG00000172974.11 AC007318.5 8.82 3.58e-12 0.00021 0.91 0.76 Pneumonia; chr10:75230427 chr2:65205108~65205988:+ MESO trans rs7943191 0.81 rs7942154 ENSG00000186676.3 EEF1GP1 8.81 3.65e-12 0.000212 1.02 0.76 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62569691 chr7:125033453~125035301:+ MESO trans rs7949030 0.523 rs12223627 ENSG00000186676.3 EEF1GP1 8.81 3.65e-12 0.000212 1.02 0.76 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62601085 chr7:125033453~125035301:+ MESO trans rs7943191 0.805 rs12226821 ENSG00000186676.3 EEF1GP1 8.81 3.65e-12 0.000212 1.02 0.76 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62601546 chr7:125033453~125035301:+ MESO trans rs7943191 0.81 rs7942991 ENSG00000186676.3 EEF1GP1 -8.81 3.65e-12 0.000212 -1.02 -0.76 Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index; chr11:62569731 chr7:125033453~125035301:+ MESO trans rs7811142 0.83 rs6955367 ENSG00000228546.2 CTA-313A17.3 8.8 3.87e-12 0.000224 1.17 0.76 Platelet count; chr7:100363571 chr7:102337316~102339115:+ MESO trans rs916888 0.773 rs1378358 ENSG00000264070.1 DND1P1 8.76 4.45e-12 0.000255 1.09 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709946 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs538628 ENSG00000264070.1 DND1P1 8.76 4.45e-12 0.000255 1.09 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46709947 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs169201 ENSG00000264070.1 DND1P1 8.76 4.45e-12 0.000255 1.09 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46712837 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs199439 ENSG00000264070.1 DND1P1 8.76 4.45e-12 0.000255 1.09 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46716137 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs199457 ENSG00000264070.1 DND1P1 8.76 4.45e-12 0.000255 1.09 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46718103 chr17:45585871~45586929:+ MESO trans rs916888 0.687 rs199456 ENSG00000264070.1 DND1P1 8.76 4.45e-12 0.000255 1.09 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46720553 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs199451 ENSG00000264070.1 DND1P1 8.76 4.45e-12 0.000255 1.09 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46724418 chr17:45585871~45586929:+ MESO trans rs916888 0.821 rs199513 ENSG00000264070.1 DND1P1 -8.76 4.45e-12 0.000255 -1.09 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779566 chr17:45585871~45586929:+ MESO trans rs2657294 0.73 rs1259505 ENSG00000172974.11 AC007318.5 8.75 4.6e-12 0.000262 0.91 0.76 Pneumonia; chr10:75237183 chr2:65205108~65205988:+ MESO trans rs2657294 0.73 rs1259508 ENSG00000172974.11 AC007318.5 8.75 4.6e-12 0.000262 0.91 0.76 Pneumonia; chr10:75238334 chr2:65205108~65205988:+ MESO trans rs4699052 0.507 rs6533085 ENSG00000231131.5 LINC01468 8.74 4.83e-12 0.000274 0.93 0.76 Testicular germ cell tumor; chr4:103360429 chr10:52450874~52470533:- MESO trans rs941207 0.756 rs2950388 ENSG00000121089.4 NACA3P -8.71 5.35e-12 0.000303 -1.09 -0.76 Platelet count; chr12:56639569 chr4:164943290~164943937:+ MESO trans rs941207 0.756 rs7315472 ENSG00000121089.4 NACA3P -8.71 5.35e-12 0.000303 -1.09 -0.76 Platelet count; chr12:56648276 chr4:164943290~164943937:+ MESO trans rs941207 0.756 rs67046307 ENSG00000121089.4 NACA3P -8.71 5.35e-12 0.000303 -1.09 -0.76 Platelet count; chr12:56651152 chr4:164943290~164943937:+ MESO trans rs941207 0.756 rs10876915 ENSG00000121089.4 NACA3P -8.71 5.35e-12 0.000303 -1.09 -0.76 Platelet count; chr12:56655280 chr4:164943290~164943937:+ MESO trans rs916888 0.61 rs199529 ENSG00000264070.1 DND1P1 8.71 5.36e-12 0.000303 1.03 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759851 chr17:45585871~45586929:+ MESO trans rs13177918 0.559 rs10447224 ENSG00000213058.3 RP4-765C7.2 8.7 5.56e-12 0.000312 1.03 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr1:178411616~178411972:+ MESO trans rs13177918 0.559 rs10447225 ENSG00000213058.3 RP4-765C7.2 8.7 5.56e-12 0.000312 1.03 0.76 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr1:178411616~178411972:+ MESO trans rs9611565 0.659 rs4822035 ENSG00000268568.1 AC007228.9 8.67 6.29e-12 0.000348 1.03 0.76 Vitiligo; chr22:41539908 chr19:56672574~56673901:- MESO trans rs941207 0.756 rs9634246 ENSG00000121089.4 NACA3P -8.66 6.38e-12 0.000351 -1.08 -0.76 Platelet count; chr12:56640604 chr4:164943290~164943937:+ MESO trans rs941207 0.756 rs2950394 ENSG00000121089.4 NACA3P -8.66 6.38e-12 0.000351 -1.08 -0.76 Platelet count; chr12:56644548 chr4:164943290~164943937:+ MESO trans rs941207 0.756 rs1465081 ENSG00000121089.4 NACA3P -8.66 6.38e-12 0.000351 -1.08 -0.76 Platelet count; chr12:56656390 chr4:164943290~164943937:+ MESO trans rs916888 0.821 rs199504 ENSG00000264070.1 DND1P1 -8.63 7.1e-12 0.00039 -1.03 -0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46783637 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs199535 ENSG00000264070.1 DND1P1 8.63 7.14e-12 0.000392 1.07 0.76 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45585871~45586929:+ MESO trans rs7121616 0.961 rs11218976 ENSG00000234176.1 HSPA8P1 8.63 7.17e-12 0.000393 1 0.76 Breast cancer; chr11:123090950 chrX:121203182~121205014:- MESO trans rs13253073 0.941 rs12548827 ENSG00000260318.1 COX6CP1 8.59 8.25e-12 0.00045 1.53 0.75 Glucose homeostasis traits; chr8:99841495 chr16:11903923~11904137:- MESO trans rs941207 0.789 rs2958145 ENSG00000121089.4 NACA3P -8.59 8.27e-12 0.00045 -1.08 -0.75 Platelet count; chr12:56662290 chr4:164943290~164943937:+ MESO trans rs13253073 1 rs6468694 ENSG00000260318.1 COX6CP1 8.55 9.86e-12 0.000533 1.53 0.75 Glucose homeostasis traits; chr8:99853608 chr16:11903923~11904137:- MESO trans rs13253073 1 rs6986006 ENSG00000260318.1 COX6CP1 8.55 9.86e-12 0.000533 1.53 0.75 Glucose homeostasis traits; chr8:99857251 chr16:11903923~11904137:- MESO trans rs1816752 0.669 rs7984513 ENSG00000237917.1 PARP4P1 -8.53 1.05e-11 0.000564 -0.99 -0.75 Obesity-related traits; chr13:24445117 chrY:26594851~26634652:- MESO trans rs7949030 0.504 rs2516633 ENSG00000186676.3 EEF1GP1 -8.52 1.1e-11 0.00059 -1.01 -0.75 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62604301 chr7:125033453~125035301:+ MESO trans rs3749237 0.595 rs1050088 ENSG00000197582.5 GPX1P1 -8.5 1.17e-11 0.000626 -0.91 -0.75 Resting heart rate; chr3:49533449 chrX:13378735~13379340:- MESO trans rs7949030 0.626 rs35587183 ENSG00000186676.3 EEF1GP1 8.48 1.27e-11 0.000678 1.01 0.75 Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction); chr11:62551184 chr7:125033453~125035301:+ MESO trans rs916888 0.773 rs199448 ENSG00000264070.1 DND1P1 8.46 1.36e-11 0.000712 1.02 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs199447 ENSG00000264070.1 DND1P1 8.46 1.36e-11 0.000712 1.02 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs199445 ENSG00000264070.1 DND1P1 8.46 1.36e-11 0.000712 1.02 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs199443 ENSG00000264070.1 DND1P1 8.46 1.36e-11 0.000712 1.02 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs199534 ENSG00000264070.1 DND1P1 8.46 1.36e-11 0.000712 1.02 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs9896243 ENSG00000264070.1 DND1P1 8.46 1.36e-11 0.000712 1.02 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45585871~45586929:+ MESO trans rs916888 0.773 rs199533 ENSG00000264070.1 DND1P1 8.46 1.36e-11 0.000712 1.02 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45585871~45586929:+ MESO trans rs916888 0.779 rs199528 ENSG00000264070.1 DND1P1 8.46 1.36e-11 0.000712 1.02 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45585871~45586929:+ MESO trans rs916888 0.821 rs199525 ENSG00000264070.1 DND1P1 8.46 1.36e-11 0.000712 1.02 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45585871~45586929:+ MESO trans rs916888 0.821 rs70600 ENSG00000264070.1 DND1P1 8.46 1.36e-11 0.000712 1.02 0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45585871~45586929:+ MESO trans rs916888 0.697 rs199516 ENSG00000264070.1 DND1P1 -8.46 1.36e-11 0.000712 -1.02 -0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45585871~45586929:+ MESO trans rs916888 0.821 rs199514 ENSG00000264070.1 DND1P1 -8.46 1.36e-11 0.000712 -1.02 -0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45585871~45586929:+ MESO trans rs916888 0.821 rs199512 ENSG00000264070.1 DND1P1 -8.46 1.36e-11 0.000712 -1.02 -0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45585871~45586929:+ MESO trans rs916888 0.821 rs199509 ENSG00000264070.1 DND1P1 -8.46 1.36e-11 0.000712 -1.02 -0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45585871~45586929:+ MESO trans rs916888 0.821 rs199507 ENSG00000264070.1 DND1P1 -8.46 1.36e-11 0.000712 -1.02 -0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45585871~45586929:+ MESO trans rs916888 0.821 rs415430 ENSG00000264070.1 DND1P1 -8.46 1.36e-11 0.000712 -1.02 -0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45585871~45586929:+ MESO trans rs916888 0.779 rs430685 ENSG00000264070.1 DND1P1 -8.46 1.36e-11 0.000712 -1.02 -0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45585871~45586929:+ MESO trans rs916888 0.821 rs199505 ENSG00000264070.1 DND1P1 -8.46 1.36e-11 0.000712 -1.02 -0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45585871~45586929:+ MESO trans rs916888 0.821 rs70602 ENSG00000264070.1 DND1P1 -8.46 1.36e-11 0.000712 -1.02 -0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45585871~45586929:+ MESO trans rs1816752 0.583 rs6490918 ENSG00000237917.1 PARP4P1 -8.45 1.43e-11 0.000745 -0.95 -0.75 Obesity-related traits; chr13:24427977 chrY:26594851~26634652:- MESO trans rs1816752 0.74 rs6490924 ENSG00000237917.1 PARP4P1 -8.45 1.43e-11 0.000745 -0.95 -0.75 Obesity-related traits; chr13:24432914 chrY:26594851~26634652:- MESO trans rs4699052 0.507 rs10005997 ENSG00000231131.5 LINC01468 8.44 1.45e-11 0.000752 0.93 0.75 Testicular germ cell tumor; chr4:103380554 chr10:52450874~52470533:- MESO trans rs916888 0.602 rs199508 ENSG00000264070.1 DND1P1 -8.41 1.62e-11 0.000833 -0.99 -0.75 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781472 chr17:45585871~45586929:+ MESO trans rs6477998 0.557 rs3750534 ENSG00000238072.1 RP11-305M3.2 8.34 2.12e-11 0.00107 1.06 0.74 Hematology traits; chr9:113297844 chr7:129410113~129410370:- MESO trans rs6477998 0.58 rs3750533 ENSG00000238072.1 RP11-305M3.2 8.34 2.12e-11 0.00107 1.06 0.74 Hematology traits; chr9:113297941 chr7:129410113~129410370:- MESO trans rs6477998 0.58 rs3750532 ENSG00000238072.1 RP11-305M3.2 8.34 2.12e-11 0.00107 1.06 0.74 Hematology traits; chr9:113298207 chr7:129410113~129410370:- MESO trans rs7121616 0.92 rs7109445 ENSG00000234176.1 HSPA8P1 8.25 3.05e-11 0.00153 0.96 0.74 Breast cancer; chr11:123094779 chrX:121203182~121205014:- MESO trans rs13177918 0.559 rs12109637 ENSG00000213058.3 RP4-765C7.2 8.25 3.06e-11 0.00153 1.02 0.74 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150455155 chr1:178411616~178411972:+ MESO trans rs916888 0.821 rs199506 ENSG00000264070.1 DND1P1 -8.24 3.12e-11 0.00156 -1.02 -0.74 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45585871~45586929:+ MESO trans rs941207 0.756 rs7978685 ENSG00000121089.4 NACA3P 8.23 3.3e-11 0.00165 1.11 0.74 Platelet count; chr12:56709370 chr4:164943290~164943937:+ MESO trans rs941207 0.724 rs4788 ENSG00000121089.4 NACA3P 8.23 3.3e-11 0.00165 1.11 0.74 Platelet count; chr12:56712876 chr4:164943290~164943937:+ MESO trans rs941207 0.756 rs2958149 ENSG00000121089.4 NACA3P 8.23 3.3e-11 0.00165 1.11 0.74 Platelet count; chr12:56716008 chr4:164943290~164943937:+ MESO trans rs941207 0.724 rs1979325 ENSG00000121089.4 NACA3P 8.23 3.3e-11 0.00165 1.11 0.74 Platelet count; chr12:56728152 chr4:164943290~164943937:+ MESO trans rs6477998 0.513 rs10981720 ENSG00000238072.1 RP11-305M3.2 8.2 3.69e-11 0.00184 1.1 0.74 Hematology traits; chr9:113293831 chr7:129410113~129410370:- MESO trans rs1816752 0.716 rs9553289 ENSG00000237917.1 PARP4P1 -8.16 4.2e-11 0.00208 -0.94 -0.74 Obesity-related traits; chr13:24400640 chrY:26594851~26634652:- MESO trans rs6477998 0.535 rs10981712 ENSG00000238072.1 RP11-305M3.2 8.15 4.37e-11 0.00215 1.1 0.74 Hematology traits; chr9:113283846 chr7:129410113~129410370:- MESO trans rs6477998 0.535 rs10817475 ENSG00000238072.1 RP11-305M3.2 8.15 4.37e-11 0.00215 1.1 0.74 Hematology traits; chr9:113296774 chr7:129410113~129410370:- MESO trans rs7811142 0.83 rs28495773 ENSG00000228546.2 CTA-313A17.3 8.15 4.4e-11 0.00216 1.2 0.74 Platelet count; chr7:100345960 chr7:102337316~102339115:+ MESO trans rs9611565 0.729 rs137831 ENSG00000268568.1 AC007228.9 -8.13 4.78e-11 0.00235 -1.02 -0.74 Vitiligo; chr22:41507809 chr19:56672574~56673901:- MESO trans rs7121616 1 rs7121616 ENSG00000234176.1 HSPA8P1 8.09 5.52e-11 0.00269 0.95 0.73 Breast cancer; chr11:123095918 chrX:121203182~121205014:- MESO trans rs7121616 0.96 rs7122306 ENSG00000234176.1 HSPA8P1 8.09 5.52e-11 0.00269 0.95 0.73 Breast cancer; chr11:123096254 chrX:121203182~121205014:- MESO trans rs916888 0.61 rs142167 ENSG00000264070.1 DND1P1 -8.07 5.96e-11 0.0029 -0.91 -0.73 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46717868 chr17:45585871~45586929:+ MESO trans rs7811142 0.775 rs1059129 ENSG00000228546.2 CTA-313A17.3 8.03 7.03e-11 0.00335 1.17 0.73 Platelet count; chr7:100328899 chr7:102337316~102339115:+ MESO trans rs7811142 0.562 rs7786844 ENSG00000228546.2 CTA-313A17.3 8.03 7.03e-11 0.00335 1.17 0.73 Platelet count; chr7:100336385 chr7:102337316~102339115:+ MESO trans rs7811142 0.667 rs3873746 ENSG00000228546.2 CTA-313A17.3 8.03 7.03e-11 0.00335 1.17 0.73 Platelet count; chr7:100337474 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs6979910 ENSG00000228546.2 CTA-313A17.3 8.03 7.03e-11 0.00335 1.17 0.73 Platelet count; chr7:100343007 chr7:102337316~102339115:+ MESO trans rs13177918 0.717 rs6874318 ENSG00000224114.1 RP11-343H5.4 -7.98 8.3e-11 0.00393 -1.06 -0.73 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr1:206695837~206696269:- MESO trans rs7811142 0.83 rs6948685 ENSG00000228546.2 CTA-313A17.3 7.98 8.33e-11 0.00394 1.19 0.73 Platelet count; chr7:100372565 chr7:102337316~102339115:+ MESO trans rs2657294 0.796 rs2657290 ENSG00000172974.11 AC007318.5 7.97 8.54e-11 0.00403 0.89 0.73 Pneumonia; chr10:75207404 chr2:65205108~65205988:+ MESO trans rs2657294 0.765 rs2804533 ENSG00000172974.11 AC007318.5 7.97 8.54e-11 0.00403 0.89 0.73 Pneumonia; chr10:75207723 chr2:65205108~65205988:+ MESO trans rs2657294 0.796 rs4746272 ENSG00000172974.11 AC007318.5 7.97 8.59e-11 0.00405 0.89 0.73 Pneumonia; chr10:75203869 chr2:65205108~65205988:+ MESO trans rs941207 0.756 rs2926743 ENSG00000121089.4 NACA3P 7.97 8.62e-11 0.00406 1.09 0.73 Platelet count; chr12:56720316 chr4:164943290~164943937:+ MESO trans rs7121616 1 rs7123187 ENSG00000234176.1 HSPA8P1 7.97 8.74e-11 0.00411 0.95 0.73 Breast cancer; chr11:123090915 chrX:121203182~121205014:- MESO trans rs9611565 0.625 rs2076199 ENSG00000268568.1 AC007228.9 -7.96 9.16e-11 0.00429 -1.02 -0.73 Vitiligo; chr22:41507739 chr19:56672574~56673901:- MESO trans rs9611565 0.729 rs203320 ENSG00000268568.1 AC007228.9 -7.96 9.16e-11 0.00429 -1.02 -0.73 Vitiligo; chr22:41517473 chr19:56672574~56673901:- MESO trans rs7811142 0.775 rs1636980 ENSG00000228546.2 CTA-313A17.3 -7.93 9.95e-11 0.00452 -1.16 -0.73 Platelet count; chr7:100341241 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs1063945 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100332824 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs11761253 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100341698 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs11771936 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100345660 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs75636500 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100350034 chr7:102337316~102339115:+ MESO trans rs7811142 0.779 rs77370288 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100350274 chr7:102337316~102339115:+ MESO trans rs7811142 0.72 rs7795656 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100352674 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs7341507 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100353692 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs76798830 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100355205 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs78256546 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100355347 chr7:102337316~102339115:+ MESO trans rs7811142 0.775 rs6946768 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100356770 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs41280971 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100356834 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs3087502 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100357741 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs61735533 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100358243 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs11761426 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100359270 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs77861211 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100364473 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs11769057 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100367038 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs11765869 ENSG00000228546.2 CTA-313A17.3 7.93 9.95e-11 0.00452 1.16 0.73 Platelet count; chr7:100367166 chr7:102337316~102339115:+ MESO trans rs12291225 0.546 rs12795545 ENSG00000236360.2 RP11-334A14.2 7.9 1.11e-10 0.00504 1.09 0.73 Sense of smell; chr11:14334018 chr1:52993201~52993702:- MESO trans rs9611565 0.729 rs2413646 ENSG00000268568.1 AC007228.9 -7.89 1.19e-10 0.00529 -1.01 -0.73 Vitiligo; chr22:41510321 chr19:56672574~56673901:- MESO trans rs9611565 0.729 rs2413647 ENSG00000268568.1 AC007228.9 -7.89 1.19e-10 0.00529 -1.01 -0.73 Vitiligo; chr22:41511144 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs9611602 ENSG00000268568.1 AC007228.9 -7.89 1.19e-10 0.00529 -1.01 -0.73 Vitiligo; chr22:41512401 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs1569516 ENSG00000268568.1 AC007228.9 -7.89 1.19e-10 0.00529 -1.01 -0.73 Vitiligo; chr22:41514240 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs9611603 ENSG00000268568.1 AC007228.9 -7.89 1.19e-10 0.00529 -1.01 -0.73 Vitiligo; chr22:41516746 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs17367716 ENSG00000268568.1 AC007228.9 -7.89 1.19e-10 0.00529 -1.01 -0.73 Vitiligo; chr22:41517840 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs11090049 ENSG00000268568.1 AC007228.9 -7.89 1.19e-10 0.00529 -1.01 -0.73 Vitiligo; chr22:41519325 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs9611604 ENSG00000268568.1 AC007228.9 -7.89 1.19e-10 0.00529 -1.01 -0.73 Vitiligo; chr22:41519997 chr19:56672574~56673901:- MESO trans rs13177918 0.734 rs6579790 ENSG00000224114.1 RP11-343H5.4 7.86 1.3e-10 0.00576 1.05 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464379 chr1:206695837~206696269:- MESO trans rs7811142 1 rs1000215 ENSG00000228546.2 CTA-313A17.3 7.86 1.31e-10 0.00579 1.14 0.72 Platelet count; chr7:100406920 chr7:102337316~102339115:+ MESO trans rs941207 0.756 rs7313074 ENSG00000121089.4 NACA3P -7.85 1.37e-10 0.00601 -1.09 -0.72 Platelet count; chr12:56760705 chr4:164943290~164943937:+ MESO trans rs13177918 0.798 rs12516161 ENSG00000224114.1 RP11-343H5.4 7.82 1.51e-10 0.00652 1.07 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150461098 chr1:206695837~206696269:- MESO trans rs9611565 0.694 rs202641 ENSG00000268568.1 AC007228.9 7.82 1.52e-10 0.00659 1.06 0.72 Vitiligo; chr22:41437112 chr19:56672574~56673901:- MESO trans rs7811142 0.83 rs11768967 ENSG00000228546.2 CTA-313A17.3 7.82 1.54e-10 0.00663 1.17 0.72 Platelet count; chr7:100370021 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs7792959 ENSG00000228546.2 CTA-313A17.3 7.82 1.54e-10 0.00663 1.17 0.72 Platelet count; chr7:100374780 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs6975660 ENSG00000228546.2 CTA-313A17.3 7.82 1.54e-10 0.00663 1.17 0.72 Platelet count; chr7:100377643 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs73401443 ENSG00000228546.2 CTA-313A17.3 7.82 1.54e-10 0.00663 1.17 0.72 Platelet count; chr7:100379959 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs10085549 ENSG00000228546.2 CTA-313A17.3 7.82 1.54e-10 0.00663 1.17 0.72 Platelet count; chr7:100385512 chr7:102337316~102339115:+ MESO trans rs202629 1 rs202629 ENSG00000268568.1 AC007228.9 7.82 1.55e-10 0.00663 1.07 0.72 Cannabis dependence symptom count; chr22:41453971 chr19:56672574~56673901:- MESO trans rs916888 0.61 rs199452 ENSG00000264070.1 DND1P1 7.81 1.56e-10 0.00663 0.95 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723974 chr17:45585871~45586929:+ MESO trans rs916888 0.61 rs199530 ENSG00000264070.1 DND1P1 -7.81 1.56e-10 0.00663 -0.95 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46759287 chr17:45585871~45586929:+ MESO trans rs916888 0.647 rs199524 ENSG00000264070.1 DND1P1 -7.81 1.58e-10 0.00663 -0.91 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771072 chr17:45585871~45586929:+ MESO trans rs916888 0.647 rs199523 ENSG00000264070.1 DND1P1 -7.81 1.58e-10 0.00663 -0.91 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46771151 chr17:45585871~45586929:+ MESO trans rs916888 0.647 rs199520 ENSG00000264070.1 DND1P1 -7.81 1.58e-10 0.00663 -0.91 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776506 chr17:45585871~45586929:+ MESO trans rs916888 0.647 rs199519 ENSG00000264070.1 DND1P1 -7.81 1.58e-10 0.00663 -0.91 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46776558 chr17:45585871~45586929:+ MESO trans rs7224296 0.709 rs199518 ENSG00000264070.1 DND1P1 -7.81 1.58e-10 0.00663 -0.91 -0.72 Intelligence (multi-trait analysis); chr17:46777214 chr17:45585871~45586929:+ MESO trans rs916888 0.647 rs199517 ENSG00000264070.1 DND1P1 -7.81 1.58e-10 0.00663 -0.91 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46777221 chr17:45585871~45586929:+ MESO trans rs9611565 0.685 rs169363 ENSG00000268568.1 AC007228.9 7.81 1.58e-10 0.00663 1.01 0.72 Vitiligo; chr22:41457113 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs202639 ENSG00000268568.1 AC007228.9 7.81 1.58e-10 0.00663 1.01 0.72 Vitiligo; chr22:41460133 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs5751107 ENSG00000268568.1 AC007228.9 7.81 1.58e-10 0.00663 1.01 0.72 Vitiligo; chr22:41461808 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs5751108 ENSG00000268568.1 AC007228.9 7.81 1.58e-10 0.00663 1.01 0.72 Vitiligo; chr22:41462031 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs5758365 ENSG00000268568.1 AC007228.9 7.81 1.58e-10 0.00663 1.01 0.72 Vitiligo; chr22:41462653 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs79009 ENSG00000268568.1 AC007228.9 7.81 1.58e-10 0.00663 1.01 0.72 Vitiligo; chr22:41464860 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs202631 ENSG00000268568.1 AC007228.9 7.81 1.58e-10 0.00663 1.01 0.72 Vitiligo; chr22:41467419 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs19573 ENSG00000268568.1 AC007228.9 7.81 1.58e-10 0.00663 1.01 0.72 Vitiligo; chr22:41469805 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs79011 ENSG00000268568.1 AC007228.9 7.81 1.58e-10 0.00663 1.01 0.72 Vitiligo; chr22:41470934 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs169361 ENSG00000268568.1 AC007228.9 7.81 1.58e-10 0.00663 1.01 0.72 Vitiligo; chr22:41481985 chr19:56672574~56673901:- MESO trans rs12291225 0.546 rs11023199 ENSG00000236360.2 RP11-334A14.2 7.81 1.6e-10 0.0067 1.08 0.72 Sense of smell; chr11:14372712 chr1:52993201~52993702:- MESO trans rs13177918 0.798 rs13182116 ENSG00000213058.3 RP4-765C7.2 -7.8 1.63e-10 0.00682 -0.97 -0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150465963 chr1:178411616~178411972:+ MESO trans rs12291225 0.546 rs12291662 ENSG00000236360.2 RP11-334A14.2 7.79 1.71e-10 0.00708 1.08 0.72 Sense of smell; chr11:14321403 chr1:52993201~52993702:- MESO trans rs12291225 0.545 rs11023187 ENSG00000236360.2 RP11-334A14.2 7.79 1.71e-10 0.00708 1.08 0.72 Sense of smell; chr11:14324013 chr1:52993201~52993702:- MESO trans rs12291225 0.585 rs11023194 ENSG00000236360.2 RP11-334A14.2 7.79 1.71e-10 0.00708 1.08 0.72 Sense of smell; chr11:14348223 chr1:52993201~52993702:- MESO trans rs9611565 0.649 rs202657 ENSG00000268568.1 AC007228.9 7.79 1.71e-10 0.00708 1.05 0.72 Vitiligo; chr22:41448782 chr19:56672574~56673901:- MESO trans rs727563 0.58 rs202626 ENSG00000268568.1 AC007228.9 7.79 1.71e-10 0.00708 1.05 0.72 Crohn's disease;Inflammatory bowel disease; chr22:41451186 chr19:56672574~56673901:- MESO trans rs9611565 0.532 rs202627 ENSG00000268568.1 AC007228.9 7.79 1.71e-10 0.00708 1.05 0.72 Vitiligo; chr22:41451363 chr19:56672574~56673901:- MESO trans rs9611565 0.625 rs12483991 ENSG00000268568.1 AC007228.9 -7.78 1.8e-10 0.00741 -1 -0.72 Vitiligo; chr22:41539281 chr19:56672574~56673901:- MESO trans rs13177918 0.501 rs2545345 ENSG00000224114.1 RP11-343H5.4 7.77 1.88e-10 0.00771 1.01 0.72 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464080 chr1:206695837~206696269:- MESO trans rs9611565 0.659 rs1810460 ENSG00000268568.1 AC007228.9 -7.74 2.1e-10 0.00852 -1.04 -0.72 Vitiligo; chr22:41531696 chr19:56672574~56673901:- MESO trans rs7811142 0.83 rs705866 ENSG00000228546.2 CTA-313A17.3 7.73 2.12e-10 0.00854 1.16 0.72 Platelet count; chr7:100367662 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs7792525 ENSG00000228546.2 CTA-313A17.3 7.73 2.12e-10 0.00854 1.16 0.72 Platelet count; chr7:100374499 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs6965458 ENSG00000228546.2 CTA-313A17.3 7.73 2.12e-10 0.00854 1.16 0.72 Platelet count; chr7:100375779 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs6945952 ENSG00000228546.2 CTA-313A17.3 7.73 2.12e-10 0.00854 1.16 0.72 Platelet count; chr7:100384152 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs73401450 ENSG00000228546.2 CTA-313A17.3 7.73 2.12e-10 0.00854 1.16 0.72 Platelet count; chr7:100384236 chr7:102337316~102339115:+ MESO trans rs7811142 0.83 rs73401451 ENSG00000228546.2 CTA-313A17.3 7.73 2.12e-10 0.00854 1.16 0.72 Platelet count; chr7:100384272 chr7:102337316~102339115:+ MESO trans rs9611565 0.592 rs5751101 ENSG00000268568.1 AC007228.9 7.72 2.24e-10 0.0089 1.07 0.72 Vitiligo; chr22:41432107 chr19:56672574~56673901:- MESO trans rs916888 0.531 rs183211 ENSG00000264070.1 DND1P1 7.71 2.28e-10 0.00899 0.91 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46710944 chr17:45585871~45586929:+ MESO trans rs916888 0.61 rs199438 ENSG00000264070.1 DND1P1 7.71 2.28e-10 0.00899 0.91 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46714277 chr17:45585871~45586929:+ MESO trans rs916888 0.61 rs199453 ENSG00000264070.1 DND1P1 7.71 2.28e-10 0.00899 0.91 0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46723580 chr17:45585871~45586929:+ MESO trans rs916888 0.61 rs199436 ENSG00000264070.1 DND1P1 -7.71 2.28e-10 0.00899 -0.91 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46711919 chr17:45585871~45586929:+ MESO trans rs916888 0.61 rs199454 ENSG00000264070.1 DND1P1 -7.71 2.28e-10 0.00899 -0.91 -0.72 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46722744 chr17:45585871~45586929:+ MESO trans rs9611565 0.659 rs12484694 ENSG00000268568.1 AC007228.9 -7.71 2.29e-10 0.00899 -1 -0.72 Vitiligo; chr22:41523326 chr19:56672574~56673901:- MESO trans rs9611565 0.579 rs73178621 ENSG00000268568.1 AC007228.9 -7.71 2.29e-10 0.00899 -1 -0.72 Vitiligo; chr22:41525661 chr19:56672574~56673901:- MESO trans rs12291225 0.585 rs12270374 ENSG00000236360.2 RP11-334A14.2 7.71 2.34e-10 0.00915 1.08 0.72 Sense of smell; chr11:14353533 chr1:52993201~52993702:- MESO trans rs12291225 0.585 rs4757250 ENSG00000236360.2 RP11-334A14.2 7.71 2.34e-10 0.00915 1.08 0.72 Sense of smell; chr11:14354137 chr1:52993201~52993702:- MESO trans rs12291225 0.585 rs10832246 ENSG00000236360.2 RP11-334A14.2 7.71 2.34e-10 0.00915 1.08 0.72 Sense of smell; chr11:14359282 chr1:52993201~52993702:- MESO trans rs12291225 0.585 rs11023197 ENSG00000236360.2 RP11-334A14.2 7.71 2.34e-10 0.00915 1.08 0.72 Sense of smell; chr11:14359452 chr1:52993201~52993702:- MESO trans rs12291225 0.585 rs4517475 ENSG00000236360.2 RP11-334A14.2 7.71 2.34e-10 0.00915 1.08 0.72 Sense of smell; chr11:14364599 chr1:52993201~52993702:- MESO trans rs7121616 1 rs7113273 ENSG00000234176.1 HSPA8P1 -7.67 2.71e-10 0.0104 -0.93 -0.72 Breast cancer; chr11:123092192 chrX:121203182~121205014:- MESO trans rs7121616 0.774 rs74693612 ENSG00000234176.1 HSPA8P1 7.67 2.71e-10 0.0104 0.93 0.72 Breast cancer; chr11:123092310 chrX:121203182~121205014:- MESO trans rs13177918 0.734 rs6579791 ENSG00000224114.1 RP11-343H5.4 7.65 2.91e-10 0.0112 1.05 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464440 chr1:206695837~206696269:- MESO trans rs9611565 0.694 rs2142505 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41424537 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs5758347 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41425015 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs202613 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41425989 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs202614 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41426146 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs202616 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41426217 chr19:56672574~56673901:- MESO trans rs9611565 0.569 rs188057 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41426301 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs202618 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41426852 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs202622 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41429338 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs202625 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41431078 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs7285041 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41433145 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs79005 ENSG00000268568.1 AC007228.9 7.64 3e-10 0.0113 1.06 0.71 Vitiligo; chr22:41439540 chr19:56672574~56673901:- MESO trans rs13177918 0.559 rs10447224 ENSG00000224114.1 RP11-343H5.4 7.62 3.31e-10 0.0124 1.03 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454802 chr1:206695837~206696269:- MESO trans rs13177918 0.559 rs10447225 ENSG00000224114.1 RP11-343H5.4 7.62 3.31e-10 0.0124 1.03 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150454891 chr1:206695837~206696269:- MESO trans rs9611565 0.694 rs4822032 ENSG00000268568.1 AC007228.9 -7.62 3.32e-10 0.0124 -1 -0.71 Vitiligo; chr22:41529531 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs1810461 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41531816 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs73178626 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41532367 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs4822034 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41535006 chr19:56672574~56673901:- MESO trans rs9611565 0.625 rs9611606 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41535070 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs116959331 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41536770 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs56319767 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41537833 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs73178632 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41538569 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs28530678 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41538957 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs4822036 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41540015 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs12483786 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41542532 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs12484228 ENSG00000268568.1 AC007228.9 -7.61 3.46e-10 0.0127 -0.98 -0.71 Vitiligo; chr22:41543735 chr19:56672574~56673901:- MESO trans rs7554547 0.765 rs6541010 ENSG00000261819.1 RP11-680G24.4 7.59 3.71e-10 0.0136 0.82 0.71 Nonsyndromic cleft lip with cleft palate; chr1:11913785 chr16:14988259~14990160:- MESO trans rs7811142 0.72 rs112622797 ENSG00000228546.2 CTA-313A17.3 7.58 3.78e-10 0.0138 1.14 0.71 Platelet count; chr7:100319793 chr7:102337316~102339115:+ MESO trans rs916888 0.61 rs199446 ENSG00000264070.1 DND1P1 -7.57 3.95e-10 0.0142 -0.87 -0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46735803 chr17:45585871~45586929:+ MESO trans rs916888 0.61 rs199536 ENSG00000264070.1 DND1P1 -7.57 3.95e-10 0.0142 -0.87 -0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46743059 chr17:45585871~45586929:+ MESO trans rs916888 0.647 rs199449 ENSG00000264070.1 DND1P1 7.57 3.95e-10 0.0142 0.87 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731536 chr17:45585871~45586929:+ MESO trans rs916888 0.61 rs199444 ENSG00000264070.1 DND1P1 7.57 3.95e-10 0.0142 0.87 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740910 chr17:45585871~45586929:+ MESO trans rs916888 0.61 rs199442 ENSG00000264070.1 DND1P1 7.57 3.95e-10 0.0142 0.87 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742756 chr17:45585871~45586929:+ MESO trans rs7811142 0.945 rs34989573 ENSG00000228546.2 CTA-313A17.3 7.57 3.98e-10 0.0143 1.15 0.71 Platelet count; chr7:100500272 chr7:102337316~102339115:+ MESO trans rs7811142 0.945 rs6974282 ENSG00000228546.2 CTA-313A17.3 7.57 3.98e-10 0.0143 1.15 0.71 Platelet count; chr7:100500672 chr7:102337316~102339115:+ MESO trans rs7811142 0.945 rs6978739 ENSG00000228546.2 CTA-313A17.3 7.57 3.98e-10 0.0143 1.15 0.71 Platelet count; chr7:100501057 chr7:102337316~102339115:+ MESO trans rs9611565 0.659 rs17367849 ENSG00000268568.1 AC007228.9 -7.57 4e-10 0.0143 -1.05 -0.71 Vitiligo; chr22:41527640 chr19:56672574~56673901:- MESO trans rs9611565 0.625 rs73178625 ENSG00000268568.1 AC007228.9 -7.57 4.02e-10 0.0144 -0.98 -0.71 Vitiligo; chr22:41532316 chr19:56672574~56673901:- MESO trans rs7554547 0.755 rs6662295 ENSG00000261819.1 RP11-680G24.4 7.56 4.05e-10 0.0145 0.84 0.71 Nonsyndromic cleft lip with cleft palate; chr1:11907848 chr16:14988259~14990160:- MESO trans rs7554547 0.739 rs7518827 ENSG00000261819.1 RP11-680G24.4 7.56 4.1e-10 0.0146 0.82 0.71 Nonsyndromic cleft lip with cleft palate; chr1:11916688 chr16:14988259~14990160:- MESO trans rs13177918 0.717 rs6874318 ENSG00000239528.1 RPS14P8 -7.56 4.11e-10 0.0146 -1.05 -0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150462836 chr5:116562562~116562930:+ MESO trans rs12291225 0.585 rs34171876 ENSG00000236360.2 RP11-334A14.2 7.55 4.2e-10 0.0149 1.07 0.71 Sense of smell; chr11:14332411 chr1:52993201~52993702:- MESO trans rs916888 0.779 rs199526 ENSG00000264070.1 DND1P1 -7.53 4.59e-10 0.0158 -0.89 -0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770341 chr17:45585871~45586929:+ MESO trans rs9611565 0.694 rs202664 ENSG00000268568.1 AC007228.9 7.53 4.6e-10 0.0158 1.12 0.71 Vitiligo; chr22:41417882 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs202665 ENSG00000268568.1 AC007228.9 7.53 4.61e-10 0.0158 1.16 0.71 Vitiligo; chr22:41418397 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs202666 ENSG00000268568.1 AC007228.9 7.53 4.61e-10 0.0158 1.16 0.71 Vitiligo; chr22:41418715 chr19:56672574~56673901:- MESO trans rs5758343 1 rs5758343 ENSG00000268568.1 AC007228.9 7.53 4.61e-10 0.0158 1.16 0.71 Allergic disease (asthma, hay fever or eczema); chr22:41420648 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs5758344 ENSG00000268568.1 AC007228.9 7.53 4.61e-10 0.0158 1.16 0.71 Vitiligo; chr22:41421681 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs202628 ENSG00000268568.1 AC007228.9 -7.53 4.68e-10 0.0161 -1.11 -0.71 Vitiligo; chr22:41453509 chr19:56672574~56673901:- MESO trans rs9611565 0.608 rs202652 ENSG00000268568.1 AC007228.9 7.5 5.09e-10 0.0172 1.04 0.71 Vitiligo; chr22:41442788 chr19:56672574~56673901:- MESO trans rs9611565 0.659 rs202653 ENSG00000268568.1 AC007228.9 7.5 5.09e-10 0.0172 1.04 0.71 Vitiligo; chr22:41444154 chr19:56672574~56673901:- MESO trans rs7121616 0.824 rs10892962 ENSG00000234176.1 HSPA8P1 7.5 5.18e-10 0.0175 0.87 0.71 Breast cancer; chr11:123101034 chrX:121203182~121205014:- MESO trans rs13177918 0.734 rs6579790 ENSG00000239528.1 RPS14P8 7.48 5.49e-10 0.0186 1.04 0.71 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464379 chr5:116562562~116562930:+ MESO trans rs9611565 0.694 rs202637 ENSG00000268568.1 AC007228.9 7.48 5.51e-10 0.0186 1.03 0.71 Vitiligo; chr22:41457924 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs202645 ENSG00000268568.1 AC007228.9 7.48 5.53e-10 0.0186 1.18 0.71 Vitiligo; chr22:41402516 chr19:56672574~56673901:- MESO trans rs916888 0.821 rs199506 ENSG00000214425.5 LRRC37A4P 7.48 5.57e-10 0.0187 0.89 0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781665 chr17:45506741~45550335:- MESO trans rs7554547 0.756 rs6684539 ENSG00000261819.1 RP11-680G24.4 7.47 5.72e-10 0.0192 0.83 0.71 Nonsyndromic cleft lip with cleft palate; chr1:11908216 chr16:14988259~14990160:- MESO trans rs7554547 0.756 rs11121840 ENSG00000261819.1 RP11-680G24.4 7.47 5.72e-10 0.0192 0.83 0.71 Nonsyndromic cleft lip with cleft palate; chr1:11908299 chr16:14988259~14990160:- MESO trans rs7554547 0.721 rs12092734 ENSG00000261819.1 RP11-680G24.4 7.47 5.72e-10 0.0192 0.83 0.71 Nonsyndromic cleft lip with cleft palate; chr1:11908349 chr16:14988259~14990160:- MESO trans rs916888 0.686 rs199501 ENSG00000264070.1 DND1P1 -7.47 5.73e-10 0.0192 -0.87 -0.71 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46785247 chr17:45585871~45586929:+ MESO trans rs9611565 0.765 rs727563 ENSG00000268568.1 AC007228.9 7.46 6e-10 0.0201 0.98 0.71 Vitiligo; chr22:41471373 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs139559 ENSG00000268568.1 AC007228.9 -7.45 6.3e-10 0.021 -1.03 -0.71 Vitiligo; chr22:41795632 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs79008 ENSG00000268568.1 AC007228.9 -7.45 6.3e-10 0.021 -1 -0.71 Vitiligo; chr22:41454496 chr19:56672574~56673901:- MESO trans rs941207 0.762 rs10450 ENSG00000121089.4 NACA3P 7.44 6.44e-10 0.0214 1.01 0.71 Platelet count; chr12:56590822 chr4:164943290~164943937:+ MESO trans rs9611565 0.694 rs202617 ENSG00000268568.1 AC007228.9 7.44 6.57e-10 0.0218 1.06 0.7 Vitiligo; chr22:41426789 chr19:56672574~56673901:- MESO trans rs9611565 0.592 rs8779 ENSG00000268568.1 AC007228.9 7.43 6.63e-10 0.0218 1.01 0.7 Vitiligo; chr22:41674272 chr19:56672574~56673901:- MESO trans rs727563 0.594 rs132807 ENSG00000268568.1 AC007228.9 7.43 6.63e-10 0.0218 1.01 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41675580 chr19:56672574~56673901:- MESO trans rs9611565 0.592 rs1811113 ENSG00000268568.1 AC007228.9 7.43 6.63e-10 0.0218 1.01 0.7 Vitiligo; chr22:41677130 chr19:56672574~56673901:- MESO trans rs727563 0.555 rs5751136 ENSG00000268568.1 AC007228.9 7.43 6.63e-10 0.0218 1.01 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41679577 chr19:56672574~56673901:- MESO trans rs727563 0.594 rs5758408 ENSG00000268568.1 AC007228.9 7.43 6.63e-10 0.0218 1.01 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41681733 chr19:56672574~56673901:- MESO trans rs9611565 0.559 rs5758412 ENSG00000268568.1 AC007228.9 7.43 6.63e-10 0.0218 1.01 0.7 Vitiligo; chr22:41684799 chr19:56672574~56673901:- MESO trans rs9611565 0.559 rs13056262 ENSG00000268568.1 AC007228.9 7.43 6.63e-10 0.0218 1.01 0.7 Vitiligo; chr22:41685917 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs4820444 ENSG00000268568.1 AC007228.9 7.43 6.63e-10 0.0218 1.05 0.7 Vitiligo; chr22:41806602 chr19:56672574~56673901:- MESO trans rs727563 0.635 rs5751141 ENSG00000268568.1 AC007228.9 7.43 6.82e-10 0.0223 1.05 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41711741 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs106860 ENSG00000268568.1 AC007228.9 -7.42 7.09e-10 0.023 -1.06 -0.7 Vitiligo; chr22:41444403 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs4822052 ENSG00000268568.1 AC007228.9 -7.41 7.24e-10 0.0233 -1.03 -0.7 Vitiligo; chr22:41797737 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs2050033 ENSG00000268568.1 AC007228.9 7.41 7.34e-10 0.0236 1.08 0.7 Vitiligo; chr22:41763225 chr19:56672574~56673901:- MESO trans rs727563 0.593 rs5758461 ENSG00000268568.1 AC007228.9 7.41 7.34e-10 0.0236 1.08 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41766185 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs2899349 ENSG00000268568.1 AC007228.9 7.41 7.34e-10 0.0236 1.08 0.7 Vitiligo; chr22:41768656 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs1983576 ENSG00000268568.1 AC007228.9 7.41 7.34e-10 0.0236 1.08 0.7 Vitiligo; chr22:41770482 chr19:56672574~56673901:- MESO trans rs13177918 0.501 rs10055975 ENSG00000224114.1 RP11-343H5.4 7.4 7.46e-10 0.024 0.98 0.7 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150466825 chr1:206695837~206696269:- MESO trans rs72627509 0.523 rs12650282 ENSG00000271993.1 RP11-285J16.1 -7.4 7.63e-10 0.0245 -0.92 -0.7 Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease); chr4:56867438 chr3:37182107~37182734:+ MESO trans rs9611565 0.729 rs203319 ENSG00000268568.1 AC007228.9 -7.39 7.76e-10 0.0249 -0.99 -0.7 Vitiligo; chr22:41518589 chr19:56672574~56673901:- MESO trans rs727563 0.636 rs2187795 ENSG00000268568.1 AC007228.9 7.38 8.09e-10 0.0257 1.01 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41696221 chr19:56672574~56673901:- MESO trans rs4822044 0.68 rs8138780 ENSG00000268568.1 AC007228.9 7.38 8.09e-10 0.0257 1.01 0.7 Cannabis dependence symptom count; chr22:41701458 chr19:56672574~56673901:- MESO trans rs7811142 1 rs68116612 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100408870 chr7:102337316~102339115:+ MESO trans rs7811142 0.943 rs28660238 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100425685 chr7:102337316~102339115:+ MESO trans rs7811142 0.943 rs67196635 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100427941 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs6962151 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100430861 chr7:102337316~102339115:+ MESO trans rs7811142 0.943 rs67483801 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100434135 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs11761784 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100442347 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs112317829 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100445550 chr7:102337316~102339115:+ MESO trans rs7811142 0.943 rs111493473 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100452119 chr7:102337316~102339115:+ MESO trans rs7811142 0.945 rs6955362 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100458543 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs6975514 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100458597 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs7811142 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100467820 chr7:102337316~102339115:+ MESO trans rs7811142 0.887 rs111972532 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100471465 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs4472444 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100473135 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs7809801 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100474408 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs11773661 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100475446 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs11766752 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100475669 chr7:102337316~102339115:+ MESO trans rs7811142 0.943 rs66958101 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100476397 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs11559117 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100478991 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs2406253 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100479650 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs4463351 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100480603 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs6972167 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100482390 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs60844404 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100482851 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs113738841 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100483683 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs11763511 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100484321 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs2897358 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100491017 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs60478351 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100491394 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs7787620 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100491611 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs11769700 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100492426 chr7:102337316~102339115:+ MESO trans rs7811142 1 rs6953107 ENSG00000228546.2 CTA-313A17.3 7.38 8.25e-10 0.0257 1.12 0.7 Platelet count; chr7:100498041 chr7:102337316~102339115:+ MESO trans rs1816752 0.716 rs9553330 ENSG00000237917.1 PARP4P1 -7.37 8.43e-10 0.0262 -0.82 -0.7 Obesity-related traits; chr13:24516018 chrY:26594851~26634652:- MESO trans rs1816752 0.646 rs7322323 ENSG00000237917.1 PARP4P1 -7.37 8.52e-10 0.0265 -0.84 -0.7 Obesity-related traits; chr13:24479189 chrY:26594851~26634652:- MESO trans rs1816752 0.646 rs7322329 ENSG00000237917.1 PARP4P1 -7.37 8.52e-10 0.0265 -0.84 -0.7 Obesity-related traits; chr13:24479193 chrY:26594851~26634652:- MESO trans rs9611565 0.559 rs739136 ENSG00000268568.1 AC007228.9 -7.36 8.79e-10 0.0272 -1 -0.7 Vitiligo; chr22:41704271 chr19:56672574~56673901:- MESO trans rs9611565 0.503 rs5996062 ENSG00000268568.1 AC007228.9 7.36 8.94e-10 0.0276 1.08 0.7 Vitiligo; chr22:41771460 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs6002474 ENSG00000268568.1 AC007228.9 7.36 8.94e-10 0.0276 1.08 0.7 Vitiligo; chr22:41772177 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs5996063 ENSG00000268568.1 AC007228.9 7.36 8.94e-10 0.0276 1.08 0.7 Vitiligo; chr22:41772763 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs139560 ENSG00000268568.1 AC007228.9 -7.35 9.05e-10 0.0279 -1.01 -0.7 Vitiligo; chr22:41798958 chr19:56672574~56673901:- MESO trans rs13177918 0.798 rs12516161 ENSG00000239528.1 RPS14P8 7.35 9.1e-10 0.028 1.06 0.7 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150461098 chr5:116562562~116562930:+ MESO trans rs12291225 0.883 rs1864658 ENSG00000236360.2 RP11-334A14.2 -7.35 9.28e-10 0.0285 -0.93 -0.7 Sense of smell; chr11:14234898 chr1:52993201~52993702:- MESO trans rs12291225 0.839 rs4757244 ENSG00000236360.2 RP11-334A14.2 -7.35 9.28e-10 0.0285 -0.93 -0.7 Sense of smell; chr11:14237109 chr1:52993201~52993702:- MESO trans rs13177918 0.734 rs6579791 ENSG00000239528.1 RPS14P8 7.34 9.4e-10 0.0288 1.04 0.7 Visceral adipose tissue/subcutaneous adipose tissue ratio; chr5:150464440 chr5:116562562~116562930:+ MESO trans rs9611565 0.649 rs2413659 ENSG00000268568.1 AC007228.9 7.32 1.02e-09 0.0307 1.08 0.7 Vitiligo; chr22:41768858 chr19:56672574~56673901:- MESO trans rs6477998 0.868 rs10513189 ENSG00000238072.1 RP11-305M3.2 7.32 1.03e-09 0.031 1.06 0.7 Hematology traits; chr9:113227941 chr7:129410113~129410370:- MESO trans rs9611565 0.659 rs12483998 ENSG00000268568.1 AC007228.9 -7.32 1.04e-09 0.0311 -1.03 -0.7 Vitiligo; chr22:41539358 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs139561 ENSG00000268568.1 AC007228.9 7.31 1.07e-09 0.032 1.05 0.7 Vitiligo; chr22:41799406 chr19:56672574~56673901:- MESO trans rs916888 0.697 rs199516 ENSG00000214425.5 LRRC37A4P 7.3 1.12e-09 0.0329 0.87 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779119 chr17:45506741~45550335:- MESO trans rs916888 0.821 rs199514 ENSG00000214425.5 LRRC37A4P 7.3 1.12e-09 0.0329 0.87 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779515 chr17:45506741~45550335:- MESO trans rs916888 0.821 rs199512 ENSG00000214425.5 LRRC37A4P 7.3 1.12e-09 0.0329 0.87 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46779986 chr17:45506741~45550335:- MESO trans rs916888 0.821 rs199509 ENSG00000214425.5 LRRC37A4P 7.3 1.12e-09 0.0329 0.87 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781362 chr17:45506741~45550335:- MESO trans rs916888 0.821 rs199507 ENSG00000214425.5 LRRC37A4P 7.3 1.12e-09 0.0329 0.87 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781489 chr17:45506741~45550335:- MESO trans rs916888 0.821 rs415430 ENSG00000214425.5 LRRC37A4P 7.3 1.12e-09 0.0329 0.87 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781778 chr17:45506741~45550335:- MESO trans rs916888 0.779 rs430685 ENSG00000214425.5 LRRC37A4P 7.3 1.12e-09 0.0329 0.87 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46781782 chr17:45506741~45550335:- MESO trans rs916888 0.821 rs199505 ENSG00000214425.5 LRRC37A4P 7.3 1.12e-09 0.0329 0.87 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782044 chr17:45506741~45550335:- MESO trans rs916888 0.821 rs70602 ENSG00000214425.5 LRRC37A4P 7.3 1.12e-09 0.0329 0.87 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782349 chr17:45506741~45550335:- MESO trans rs916888 0.773 rs199448 ENSG00000214425.5 LRRC37A4P -7.3 1.12e-09 0.0329 -0.87 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46731635 chr17:45506741~45550335:- MESO trans rs916888 0.773 rs199447 ENSG00000214425.5 LRRC37A4P -7.3 1.12e-09 0.0329 -0.87 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46734822 chr17:45506741~45550335:- MESO trans rs916888 0.773 rs199445 ENSG00000214425.5 LRRC37A4P -7.3 1.12e-09 0.0329 -0.87 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46740042 chr17:45506741~45550335:- MESO trans rs916888 0.773 rs199443 ENSG00000214425.5 LRRC37A4P -7.3 1.12e-09 0.0329 -0.87 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46742199 chr17:45506741~45550335:- MESO trans rs916888 0.773 rs199534 ENSG00000214425.5 LRRC37A4P -7.3 1.12e-09 0.0329 -0.87 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46746847 chr17:45506741~45550335:- MESO trans rs916888 0.773 rs9896243 ENSG00000214425.5 LRRC37A4P -7.3 1.12e-09 0.0329 -0.87 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46748690 chr17:45506741~45550335:- MESO trans rs916888 0.773 rs199533 ENSG00000214425.5 LRRC37A4P -7.3 1.12e-09 0.0329 -0.87 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46751565 chr17:45506741~45550335:- MESO trans rs916888 0.779 rs199528 ENSG00000214425.5 LRRC37A4P -7.3 1.12e-09 0.0329 -0.87 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46765770 chr17:45506741~45550335:- MESO trans rs916888 0.821 rs199525 ENSG00000214425.5 LRRC37A4P -7.3 1.12e-09 0.0329 -0.87 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46770468 chr17:45506741~45550335:- MESO trans rs916888 0.821 rs70600 ENSG00000214425.5 LRRC37A4P -7.3 1.12e-09 0.0329 -0.87 -0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46782655 chr17:45506741~45550335:- MESO trans rs9611565 0.512 rs9607842 ENSG00000268568.1 AC007228.9 -7.28 1.17e-09 0.0343 -1.01 -0.7 Vitiligo; chr22:41796718 chr19:56672574~56673901:- MESO trans rs9611565 0.559 rs132771 ENSG00000268568.1 AC007228.9 7.28 1.19e-09 0.0348 1.06 0.7 Vitiligo; chr22:41629346 chr19:56672574~56673901:- MESO trans rs727563 0.52 rs132773 ENSG00000268568.1 AC007228.9 7.28 1.19e-09 0.0348 1.06 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41635764 chr19:56672574~56673901:- MESO trans rs9611565 0.607 rs132792 ENSG00000268568.1 AC007228.9 7.27 1.22e-09 0.0354 1.08 0.7 Vitiligo; chr22:41666818 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs202655 ENSG00000268568.1 AC007228.9 7.27 1.23e-09 0.0356 1.02 0.7 Vitiligo; chr22:41445560 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs202656 ENSG00000268568.1 AC007228.9 7.27 1.23e-09 0.0356 1.02 0.7 Vitiligo; chr22:41446199 chr19:56672574~56673901:- MESO trans rs916888 0.779 rs199498 ENSG00000264070.1 DND1P1 7.27 1.25e-09 0.0362 0.91 0.7 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46788237 chr17:45585871~45586929:+ MESO trans rs12408261 0.525 rs1912930 ENSG00000227486.1 RP13-188A5.1 -7.26 1.27e-09 0.0367 -0.87 -0.7 Number of pregnancies; chr1:189065854 chrX:55908123~56015173:+ MESO trans rs12408261 0.525 rs10754017 ENSG00000227486.1 RP13-188A5.1 -7.26 1.27e-09 0.0367 -0.87 -0.7 Number of pregnancies; chr1:189066295 chrX:55908123~56015173:+ MESO trans rs9611565 0.592 rs5751139 ENSG00000268568.1 AC007228.9 7.26 1.28e-09 0.0368 1 0.7 Vitiligo; chr22:41703977 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs5758439 ENSG00000268568.1 AC007228.9 7.26 1.28e-09 0.0368 1 0.7 Vitiligo; chr22:41735758 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs5751145 ENSG00000268568.1 AC007228.9 7.26 1.28e-09 0.0368 1 0.7 Vitiligo; chr22:41737548 chr19:56672574~56673901:- MESO trans rs727563 0.635 rs5758444 ENSG00000268568.1 AC007228.9 7.26 1.28e-09 0.0368 1 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41737917 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs768414 ENSG00000268568.1 AC007228.9 7.26 1.28e-09 0.0368 1 0.7 Vitiligo; chr22:41739747 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs8141103 ENSG00000268568.1 AC007228.9 7.26 1.28e-09 0.0368 1 0.7 Vitiligo; chr22:41740926 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs5751148 ENSG00000268568.1 AC007228.9 7.26 1.28e-09 0.0368 1 0.7 Vitiligo; chr22:41743074 chr19:56672574~56673901:- MESO trans rs727563 0.635 rs5751149 ENSG00000268568.1 AC007228.9 7.26 1.28e-09 0.0368 1 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41743497 chr19:56672574~56673901:- MESO trans rs727563 0.638 rs5996058 ENSG00000268568.1 AC007228.9 7.26 1.28e-09 0.0368 1 0.7 Crohn's disease;Inflammatory bowel disease; chr22:41745448 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs964899 ENSG00000268568.1 AC007228.9 7.26 1.28e-09 0.0368 1 0.7 Vitiligo; chr22:41746382 chr19:56672574~56673901:- MESO trans rs9611565 0.513 rs739135 ENSG00000268568.1 AC007228.9 7.25 1.31e-09 0.0376 1.01 0.7 Vitiligo; chr22:41694065 chr19:56672574~56673901:- MESO trans rs12291225 0.585 rs10832242 ENSG00000236360.2 RP11-334A14.2 -7.25 1.36e-09 0.0388 -1.06 -0.7 Sense of smell; chr11:14318958 chr1:52993201~52993702:- MESO trans rs9611565 0.546 rs5758426 ENSG00000268568.1 AC007228.9 7.24 1.37e-09 0.0388 1.02 0.7 Vitiligo; chr22:41702759 chr19:56672574~56673901:- MESO trans rs9611565 0.592 rs5758427 ENSG00000268568.1 AC007228.9 7.24 1.37e-09 0.0388 1.02 0.7 Vitiligo; chr22:41703684 chr19:56672574~56673901:- MESO trans rs9611565 0.546 rs5758430 ENSG00000268568.1 AC007228.9 7.24 1.37e-09 0.0388 1.02 0.7 Vitiligo; chr22:41713840 chr19:56672574~56673901:- MESO trans rs9611565 0.546 rs5758431 ENSG00000268568.1 AC007228.9 7.24 1.37e-09 0.0388 1.02 0.7 Vitiligo; chr22:41713913 chr19:56672574~56673901:- MESO trans rs9611565 0.573 rs9306355 ENSG00000268568.1 AC007228.9 7.24 1.37e-09 0.0388 1.02 0.7 Vitiligo; chr22:41715892 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs5758434 ENSG00000268568.1 AC007228.9 7.24 1.37e-09 0.0388 1.02 0.7 Vitiligo; chr22:41720159 chr19:56672574~56673901:- MESO trans rs4822044 0.617 rs13054514 ENSG00000268568.1 AC007228.9 7.24 1.37e-09 0.0388 1.02 0.7 Cannabis dependence symptom count; chr22:41734379 chr19:56672574~56673901:- MESO trans rs9611565 0.568 rs5758441 ENSG00000268568.1 AC007228.9 7.24 1.37e-09 0.0388 1.02 0.7 Vitiligo; chr22:41736884 chr19:56672574~56673901:- MESO trans rs9611565 0.649 rs5758442 ENSG00000268568.1 AC007228.9 7.24 1.37e-09 0.0388 1.02 0.7 Vitiligo; chr22:41737056 chr19:56672574~56673901:- MESO trans rs9611565 0.592 rs5758405 ENSG00000268568.1 AC007228.9 7.24 1.41e-09 0.0396 1.01 0.7 Vitiligo; chr22:41680377 chr19:56672574~56673901:- MESO trans rs9611565 0.592 rs5758406 ENSG00000268568.1 AC007228.9 7.24 1.41e-09 0.0396 1.01 0.7 Vitiligo; chr22:41680637 chr19:56672574~56673901:- MESO trans rs9611565 0.592 rs6519270 ENSG00000268568.1 AC007228.9 7.24 1.41e-09 0.0396 1.01 0.7 Vitiligo; chr22:41682662 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs5758411 ENSG00000268568.1 AC007228.9 7.24 1.41e-09 0.0396 1.01 0.7 Vitiligo; chr22:41683730 chr19:56672574~56673901:- MESO trans rs9611565 0.5 rs10775759 ENSG00000268568.1 AC007228.9 7.24 1.41e-09 0.0396 1.01 0.7 Vitiligo; chr22:41692154 chr19:56672574~56673901:- MESO trans rs12291225 0.675 rs10219255 ENSG00000236360.2 RP11-334A14.2 7.23 1.44e-09 0.0403 0.94 0.69 Sense of smell; chr11:14236414 chr1:52993201~52993702:- MESO trans rs1816752 0.716 rs7995304 ENSG00000237917.1 PARP4P1 -7.22 1.49e-09 0.0414 -0.81 -0.69 Obesity-related traits; chr13:24514284 chrY:26594851~26634652:- MESO trans rs1816752 0.646 rs9511309 ENSG00000237917.1 PARP4P1 -7.21 1.54e-09 0.0425 -0.8 -0.69 Obesity-related traits; chr13:24515435 chrY:26594851~26634652:- MESO trans rs4822044 0.568 rs1883370 ENSG00000268568.1 AC007228.9 7.21 1.55e-09 0.0426 1.06 0.69 Cannabis dependence symptom count; chr22:41747736 chr19:56672574~56673901:- MESO trans rs9467773 0.595 rs13207371 ENSG00000242375.1 RP11-498P14.3 7.21 1.55e-09 0.0426 0.88 0.69 Intelligence (multi-trait analysis); chr6:26590846 chr9:97195351~97197687:- MESO trans rs9467773 0.62 rs1027203 ENSG00000242375.1 RP11-498P14.3 7.21 1.55e-09 0.0426 0.88 0.69 Intelligence (multi-trait analysis); chr6:26639104 chr9:97195351~97197687:- MESO trans rs9467773 0.595 rs2172007 ENSG00000242375.1 RP11-498P14.3 7.21 1.55e-09 0.0426 0.88 0.69 Intelligence (multi-trait analysis); chr6:26639549 chr9:97195351~97197687:- MESO trans rs9611565 0.605 rs202638 ENSG00000268568.1 AC007228.9 7.21 1.58e-09 0.0433 0.96 0.69 Vitiligo; chr22:41459454 chr19:56672574~56673901:- MESO trans rs9611565 0.729 rs505533 ENSG00000268568.1 AC007228.9 7.21 1.58e-09 0.0433 0.96 0.69 Vitiligo; chr22:41468212 chr19:56672574~56673901:- MESO trans rs4747521 0.759 rs2050975 ENSG00000204706.13 MAMDC2-AS1 7.2 1.6e-09 0.0437 0.92 0.69 Energy expenditure (24h); chr10:25447763 chr9:70033921~70175888:- MESO trans rs9611565 0.512 rs139562 ENSG00000268568.1 AC007228.9 -7.18 1.73e-09 0.0468 -1.05 -0.69 Vitiligo; chr22:41800680 chr19:56672574~56673901:- MESO trans rs9611565 0.512 rs139566 ENSG00000268568.1 AC007228.9 -7.18 1.73e-09 0.0468 -1.05 -0.69 Vitiligo; chr22:41803273 chr19:56672574~56673901:- MESO trans rs916888 0.773 rs199535 ENSG00000214425.5 LRRC37A4P -7.18 1.73e-09 0.0468 -0.9 -0.69 Cognitive function;Multiple system atrophy;Post bronchodilator FEV1;Intelligence (multi-trait analysis); chr17:46745296 chr17:45506741~45550335:- MESO trans rs9611565 0.608 rs2003816 ENSG00000268568.1 AC007228.9 7.18 1.75e-09 0.0472 1.03 0.69 Vitiligo; chr22:41699136 chr19:56672574~56673901:- MESO trans rs9611565 0.694 rs11090056 ENSG00000268568.1 AC007228.9 7.18 1.75e-09 0.0472 1.03 0.69 Vitiligo; chr22:41699900 chr19:56672574~56673901:- MESO trans rs727563 0.635 rs2899348 ENSG00000268568.1 AC007228.9 7.18 1.77e-09 0.0475 1.07 0.69 Crohn's disease;Inflammatory bowel disease; chr22:41768512 chr19:56672574~56673901:- MESO trans rs9611565 0.546 rs132793 ENSG00000268568.1 AC007228.9 7.17 1.79e-09 0.048 1.04 0.69 Vitiligo; chr22:41667677 chr19:56672574~56673901:- MESO trans rs877636 0.74 rs705702 ENSG00000227887.1 RPS26P13 -7.17 1.82e-09 0.0485 -0.99 -0.69 Cognitive function; chr12:55996852 chr1:208697369~208697698:- MESO trans rs877636 0.74 rs772920 ENSG00000227887.1 RPS26P13 7.17 1.82e-09 0.0485 0.99 0.69 Cognitive function; chr12:55996580 chr1:208697369~208697698:- MESO trans rs9467773 0.595 rs12525810 ENSG00000242375.1 RP11-498P14.3 7.17 1.84e-09 0.0492 0.88 0.69 Intelligence (multi-trait analysis); chr6:26623283 chr9:97195351~97197687:- MESO trans rs1816752 0.716 rs1441058 ENSG00000237917.1 PARP4P1 -7.16 1.88e-09 0.05 -0.79 -0.69 Obesity-related traits; chr13:24516275 chrY:26594851~26634652:-